会长寄语

Message from Chairman of PhIRDA

蒋建东

Jiang Jiandong

1998年的时候我从纽约西奈山医院回到北京工作，开始从事药物研究。记得当时我国自然科学的研究论文（SCI）在全球排在20位左右，与发达国家相比差距很大。光阴如梭，近20年的时间一晃而过，今天中国的研究论文已经排在全球第2位，被引数也是第2，仅次于美国。其中，药物研究的贡献更是浓墨重彩，从普通论文到CNS系列的文章（Cell，Nature，Science），从基础研究到临床转化，从研发到政策，从延展的创新到原始创新。2015年我国原创的抗疟疾药物青蒿素的研究获得了中国自然科学领域的第一个诺贝尔奖，我国的药物研究人员均为之振奋。

然而，新药研发需要国家综合实力的支撑，除了科学研究之外、涵盖的内容包括了一个国家的转化能力、工业基础、药品流通、医疗体制、伦理道德、国家政策，及文化传统等社会因素，是一个高度复杂的系统工程。推进这个系统不断获得整体的进步是中国药促会的主要关注所在，涉及到其中的每一个环节，需要许多同行和专家的帮助和支持。

在今后的一年中，我有幸做为药促会年度会长与大家一起致力于这项伟大事业。希望在大家的共同努力下，通过不断的创新与实践，新药创制也能成为国家新的高技术标志，走进世界前列。

I returned to Beijing from the Mount Sinai Hospital in New York in 1998, devoting myself to drug discovery. At that time, research articles from China was ranked around 20th in the world, far behind the advanced western countries. Time flies. Today, we are the 2nd in the world, next to the United States. Of the significant promotion, contribution from pharmaceutical science is really substantial and in every aspect, from regular articles to those in top journals, from laboratory to translation, from R&D to policy and from extended innovation to revolutionary ones. In 2015, artemisinin was awarded with the Nobel Price, encouraging us going for innovative drug discovery.

However, drug R&D requires comprehensive power, including not only scientific research, but also transformation, industrialization, marketing, health system, ethics, policy, as well as culture related issues. It represents a complex national system, and is highly concerned in the PhIRDA for its improvement. This system involves many aspects and needs support from different sides.

I feel honored to have a chance to work with you in the next year in serving the great goal. It is therefore our aim to build a world-class drug R&D system in China.



目　录

Contents

一 中国医药创新促进会简介/Brief Introduction of PhIRDA 001

二 中国医药创新促进会章程/Constitution of PhIRDA 003

三 机构设置/Organizational Structure of PhIRDA.....012

四 会领导介绍/Introduction of PhIRDA Leadership 013

1）第九届会员大会以来历任会长/Chairmen of PhIRDA since 9th General Assembly.....013

2）现任会领导/Current Leadership of PhIRDA 014

五 第十届会员大会第四次会议/The Fourth Meeting of 10th PhIRDA General Assembly 017

1）工作报告摘要/Summary of PhIRDA Annual Work Report.....017

2）会议纪要/Summary of the Meeting 031

六 专业委员会介绍/Introduction of Specialty Committees.....035

1）第二届药物研发专业委员会/The 2nd Drug R&D Specialty Committee 036

2）第二届药物临床研究专业委员会/The 2nd Clinical Research Specialty Committee 037

3）第二届医药政策专业委员会/The 2nd Medicinal Policy Specialty Committee 038

4）第一届医药创新投资专业委员会/The 1st Pharmaceutical Innovation Investment Specialty Committee 039

5）创新研发服务专业委员会发起人/Sponsors of Innovation R&D Services Specialty Committee 040

七 重要活动/Important Events.....041

八 第十届会员单位及其代表/Members & Representatives of PhIRDA 10th General Assembly 064

九 第十届会员单位简介/Brief Introduction of PhIRDA 10th General Assembly Members 069

十 大事记/Remarkable Events 175

中国医药创新促进会简介

中国医药创新促进会，英文名称：China Pharmaceutical Innovation and Research Development Association（PhIRDA），成立于1988年，是经国家民政部登记注册的非营利性全国性一级社会团体组织。

中国医药创新促进会（简称“中国药促会”），原名“中国医药工业科研开发促进会”，2014年10月23日经国家民政部批准更名。中国药促会秉承“创新、产业化、国际化”的宗旨，以临床需求为导向，长期致力于“产学研用”紧密结合，促进医药行业创新发展。目前，中国药促会有会长及会员单位107家，主要由五个方面成员构成：一是，专注于药品自主创新的初创型研发企业；二是，从事医药创新研发的国内一流高等院校和科研院所；三是，在新药临床研究领域具有较高水平、特别是承担“重大新药创制”科技重大专项新药临床评价研究技术平台的临床医疗机构；四是，致力于医药创新投资的金融机构；五是，在国内医药创新领域处于领先地位的民族医药企业。另外，中国药促会还成立了药物研发专业委员会、药物临床研究专业委员会、医药政策专业委员会、医药创新投资专业委员会和创新研发服务专业委员会，形成了以创新为核心，以促进创新为目标的组织构架，并通过加入国际药品制造商协会联合会 （IFPMA）继续拓展国际交流渠道。

中国药促会工作内容主要包括：一是，通过举办各种论坛、发布会、大型会议等活动，促进会员单位乃至整个医药产业的相互交流、创新发展；二是，通过与国外医药行业协会、企业、科研机构和外国驻华使馆合作，推动中外医药产业的多方位合作交流，为会员单位搭建国际交流平台；三是，开展医药政策研究，为我国医改事业、完善药物政策和医药产业发展建言献策；四是，为会员单位提供医药信息搜集、整理、评价服务，包括编辑每日《医药信息简报》、每周《国际医药产业发展动态与研发信息简报》等内部电子刊物以及中国药促会官方网站、微信公众号等服务平台；五是，践行国家创新驱动发展战略指导精神，为会员单位拓宽医药创新投融资渠道、搭建合作平台，推动社会资本加大对初创及研发型企业自主创新项目的投入。

中国药促会将围绕办会宗旨，不断拓展服务内涵和外延，做好政府与会员企业的桥梁和纽带，维护会员合法权益，加强行业自律，推动我国医药产业的创新和可持续发展，为加快我国经济社会发展、保障人民群众健康不断做出贡献！

Brief Introduction of PhIRDA

Founded in 1988, China Pharmaceutical Innovation and Research Development Association (PhIRDA) is registered as a non-profit organization by the Ministry of Civil Affairs of China at the first national level.

Formerly named China Pharmaceutical Industry Research and Development Association, the association was approved to rename into PhIRDA by Ministry of Civil Affairs on October 23, 2014. PhIRDA will exert great effort on “academia-industry collaboration”, which centers on the principle of “innovation, industrialization, internationalization”, persists in innovation to achieve unmet clinical requirements. At current stage, PhIRDA has 107 members, mainly consist of five major categories: first, start-up and R&D enterprises focusing on innovation of pharmaceutical products; second, domestic first-class universities, colleges and research institutions conducting pharmaceutical research and development; third, clinical institutions featuring high skills in applicable research on new drugs, especially those undertake “Major New Drug Innovation” technological platform for good clinical practice; fourth, financial institutions committing to pharmaceutical innovation; fifth, national pharmaceutical enterprises excelling at innovation. Moreover, PhIRDA has established Drug R&D Specialty Committee, Clinical Research Specialty Committee, Medicinal Policy Specialty Committee, Pharmaceutical Innovation Investment Specialty Committee and Innovation R&D Services Specialty Committee in order to promote the innovation as the goal of organizational structure. PhIRDA is also a member of International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) to continuously broaden channels of international collaboration.

Major work of PhIRDA includes: first, to promote communication and innovative development of our members and even the whole pharmaceutical industry through forums, press-conferences, summits, etc.; second, to make efforts to establish an international exchange platform for our members through cooperation with foreign embassies and foreign associations to stimulate communication between China and foreign countries in pharmaceutical field; third, to conduct policy researches, propose valuable suggestions on healthcare reform and the development of pharmaceutical industry; fourth, to improve the website and WeChat official account of PhIRDA and provide collecting, arranging, revising service of pharmaceutical information, which includes the following internal e-magazines such as the daily *Pharmaceutical Information Brief,* the weekly *International Pharmaceutical Development Tendency and Research Information Brief*; fifth, to practice the guiding spirits of national innovation-driven development strategy, to broaden the investment and financing channels of pharmaceutical innovation, to build the cooperation platform for our members, and to promote social capitals to pay more attention on investment in innovative projects of start-up and R&D enterprises.

PhIRDA will center on our principle, continuously expand services, build a bridge between the government and our members, maintain legitimate rights and interests of members, strengthen self-discipline, promote healthy development of Chinese pharmaceutical industry, making constant contributions to the greater economic development of the country and public health.

中国医药创新促进会章程

第一章 总 则

第一条 本团体的名称：中国医药创新促进会，英文名称：China Pharmaceutical Innovation and Research Development Association；缩写：PhIRDA。

第二条 本团体是由国内医药创新型生产企业、专注于医药创新的研发型企业、从事医药创新研发的高等院校和科研院所、在新药临床研究领域具有较高水平的药物临床研究机构和致力于医药创新投资的金融机构自愿结成的全国性、专业性、非营利性社会组织。

第三条 本团体的宗旨：高举中国特色社会主义伟大旗帜，以邓小平理论、三个代表重要思想、科学发展观为指导，贯彻国家有关方针、政策和改革精神，提高中国医药工业的科研创新能力，加强医药科研与生产的紧密结合，推动中国医药创新的国际步伐，加快中国医药及相关行业的技术进步，提高经济效益，维护会员单位的合法权益，为医药卫生事业、经济社会发展做出更大的贡献。本团体遵守宪法、法律、法规和国家政策，遵守社会道德风尚。

第四条 本团体接受业务主管单位国务院国有资产监督管理委员会和社团登记管理机关民政部的业务指导和监督管理。

第五条 本团体的住所：北京市。

第二章 业务范围

第六条 本团体的业务范围：

（一）认真贯彻执行党中央、国务院有关中国医药创新各项政策，深入研究新药研发政策和中国医药体系创新的相关问题，科学预测新药研发的走向，及时提出中国医药创新发展的政策建议，切实反映会员单位合理的愿望和要求，协助会员单位解决实际问题；

（二）组织和参加有关医药行业发展的交流活动，增强中国医药行业的创新能力。组织和参加有关学术交流，组建中国医药行业发展、创新智库，推动医药行业产学研的结合，积极开展新药科研和技术协作及科技成果的推广，组织技术转让与协作，促进医药高科技的产业化、专业化；

（三）发挥自身优势、充分利用现代化手段，搜集、整理、研究、传递医药科技研发信息，聚焦医药行业重点问题，并开展咨询服务；

（四）推动中国医药行业的国际交流，组织开展各种形式的中外医药行业信息、技术、人员的交流与合作；

（五）践行国家创新驱动发展战略指导精神，为会员单位拓宽医药创新投融资渠道、搭建合作平台，推动社会资本加大对医药创新项目的投入。

第三章 会 员

第七条 本团体的会员为单位会员。

第八条 申请加入本团体的会员，必须具备下列条件：

（一）拥护本团体的章程；

（二）有加入本团体的意愿；

（三）在本团体的业务领域内具有一定的影响。

第九条 会员入会的程序是：

（一）提交入会申请书；

（二）经会员大会讨论通过；

（三）由会员大会或会员大会授权的机构发给会员证。

第十条 会员享有下列权利：

（一）本团体的选举权、被选举权和表决权；

（二）参加本团体的活动；

（三）获得本团体服务的优先权；

（四）对本团体工作的批评建议权和监督权；

（五）按规定有获得本团体发出的信息资料和刊物权；

（六）有对本团体提出保护合法权益不受侵害的权利；

（七）入会自愿，退会自由。

第十一条 会员履行下列义务：

（一）遵守本团体章程，执行本团体决议；

（二）维护本团体合法权益；

（三）完成本团体交办的工作；

（四）按规定交纳会费；

（五）向本团体反映情况，提供有关资料。

第十二条 会员退会应书面通知本团体，并交回会员证。会员如果2年不履行义务，视为自动退会。

第十三条 会员如有严重违反本章程的行为，经会员大会表决通过，予以除名。

第四章 组织机构和负责人产生、罢免

第十四条 本团体的最高权力机构是会员大会。会员大会的职权是：

（一）制定和修改章程；

（二）选举和罢免会长、副会长和秘书长；

（三）审议本团体的工作报告和财务报告；

（四）制定并修改会费标准；

（五）决定名誉职务的设立和人选；

（六）决定办事机构、分支机构、代表机构和实体机构的设立、变更和注销；

（七）决定副秘书长、各机构主要负责人的聘任；

（八）决定本团体终止事宜；

（九）决定其他重大事宜。

第十五条 会员大会须有2／3以上的会员出席方能召开，其决议须经到会会员半数以上表决通过方能生效。

第十六条 会员大会每届5年，因特殊情况需提前或延期换届的，须经会员大会表决通过，报业务主管单位审查并经社团登记管理机关批准同意。但延期换届最长不超过1年。会员大会每两年至少召开1次。

第十七条 秘书处是会员大会的执行机构，在闭会期间领导本团体开展日常工作，对会员大会负责。

第十八条 本团体的会长、副会长、秘书长必须具备下列条件：

（一）坚持党的路线、方针、政策、政治素质好；

（二）在本团体业务领域内有较大影响；

（三）会长、副会长最高任职年龄不超过70周岁，秘书长最高任职年龄不超过60周岁且为专职；

（四）身体健康，能坚持正常工作；

（五）未受过剥夺政治权利的刑事处罚；

（六）具有完全民事行为能力。

第十九条 本团体会长、副会长、秘书长如超过最高任职年龄的，应当办理离职手续。

第二十条 本团体实行年度轮值会长制度；会长从会员中经选举产生，任期1年。副会长、秘书长每届任期5年，连任不超过两届。

第二十一条 会长为本团体法定代表人。因特殊情况，经会长委托，会员大会同意，报业务主管单位审查、社团登记管理机关批准后，可以指定一名副会长或秘书长担任法定代表人。

法定代表人代表本团体签署有关重要文件。

本团体法定代表人不兼任其他团体的法定代表人。

本团体会长、副会长、单位会员代表离开所属单位的，自动失去会长、副会长、单位会员代表资格，由原单位会员推荐新的人选，报会员大会选举备案。

第二十二条 本团体会长行使下列职权：

（一）召集和主持会员大会；

（二）检查会员大会决议的落实情况；

（三）代表本团体签署有关重要文件；

（四）会长可委托副会长或秘书长代行会长的部分职权。

第二十三条 本团体设立秘书处，秘书长行使下列职权：

（一）主持办事机构开展日常工作，组织实施年度工作计划；

（二）协调各分支机构、代表机构、实体机构开展工作；

（三）提名副秘书长以及各机构主要负责人，交会员大会决定；

（四）决定办事机构、代表机构、实体机构专职工作人员的聘用；

（五）处理其他日常事务。

第五章 资产管理、使用原则

第二十四条 本团体经费来源：

（一）会费；

（二）捐赠；

（三）政府资助；

（四）在核准的业务范围内开展活动和服务的收入；

（五）利息；

（六）其他合法收入。

第二十五条 本团体按照国家有关规定收取会员会费。

会费由秘书处负责管理，并在会员大会期间向全体会员单位公布经费使用情况。

第二十六条 本团体经费必须用于本章程规定的业务范围和事业的发展，不得在会员中分配。

第二十七条 本团体建立严格的财务管理制度，保证会计资料合法、真实、准确、完整。

第二十八条 本团体配备具有专业资格的会计人员。会计不得兼任出纳。会计人员必须进行会计核算，实行会计监督。会计人员调动工作或离职时，必须与接管人员办清交接手续。

第二十九条 本团体的资产管理必须执行国家规定的财务管理制度，接受会员大会和财政部门的监督。资产来源属于国家拨款或者社会捐赠、资助的，必须接受审计机关的监督，并将有关情况以适当方式向社会公布。

第三十条 本团体换届或更换法定代表人之前必须接受财务审计。

第三十一条 本团体的资产，任何单位、个人不得侵占、私分和挪用。

第三十二条 本团体专职工作人员的工资和保险、福利待遇，参照国家和本团体的有关规定执行。

第六章 章程的修改程序

第三十三条 对本团体章程的修改，须经会员大会审议。

第三十四条 本团体修改的章程，须在会员大会通过后15日内，报业务主管单位审查，经同意，报社团登记管理机关核准后生效。

第七章 终止程序及终止后的财产处理

第三十五条 本团体完成宗旨或自行解散或由于分立、合并等原因需要注销的，由会员大会提出终止动议。

第三十六条 本团体终止动议须经会员大会表决通过，并报业务主管单位审查同意。

第三十七条 本团体终止前，须在业务主管单位及有关机关指导下成立清算组织，清理债权债务，处理善后事宜。清算期间，不开展清算以外的活动。

第三十八条 本团体经社团登记管理机关办理注销登记手续后即为终止。

第三十九条 本团体终止后的剩余财产，在业务主管单位和社团登记管理机关的监督下，按照国家有关规定，用于发展与本团体宗旨相关的事业。

第八章 附 则

第四十条 本章程经2017年10月29日第十届会员大会第四次会议表决通过。

第四十一条 本章程的解释权属本团体的会员大会。

第四十二条 本章程自社团登记管理机关核准之日起生效。

Constitution of PhIRDA

Chapter One: General Principle

Article 1. Name of the Association: China Pharmaceutical Innovation and Research Development Association (the abbreviated name is PhIRDA).

Article 2. The Association is a nationwide, professional, non-government and non-profit industrial organization, which consists of national pharmaceutical enterprises excelling at innovation, start-up and R&D enterprises focusing on independent innovation of pharmaceutical products, domestic first-class universities, colleges and research institutions conducting pharmaceutical research and development, clinical institutions featuring high skills in applicable research on new drugs, especially those undertake “major new drug innovation” technological platform for good clinical practice and investment institutions committing to pharmaceutical innovation.

Article 3. The objectives of the Association include:
Holding the great banner of Socialism with Chinese characteristics, taking Deng Xiaoping Theory, Three Represents and Scientific Outlook of Development as our guide, to implement the relevant general and specific policies and the reform spirit of the government, enhance research and innovation capacity of China's pharmaceutical industry, strengthen the combination between the scientific research institutions and pharmaceutical enterprises, promote international cooperation on research and development of China’s pharmaceutical industry, expedite the technological development in pharmaceutical industry, enhance the economic efficiency in enterprises and provide better service for healthcare and economic developments.The Association follows the China’s related constitution, laws, regulations and policies, as well as the ethical code of the society.

Article 4. The Association undertakes administration by Ministry of Civil Affairs and State-owned Assets Supervision and Administration Commission of the State Council.

Article 5. The Association’s residence is in Beijing.

Chapter Two: Business Range

Article 6. Business range of the Association

1) To carry out and implement relevant general and specific policies on Chinese pharmaceutical industry development made by the Central Committee of CPC and the State Council, perform in-depth research on new drug development and Chinese pharmaceutical innovation system, scientifically forecast the direction of new drug development, timely propose the recommendations for development of Chinese pharmaceutical industry, reflect members’ reasonable wishes and demands, and assists members to solve practical problems.

2) To organize and participate in the relevant exchange programs to enhance Chinese pharmaceutical industry development. To organize and participate in the relevant academic exchanges, set up a think tank for Chinese pharmaceutical industry development and innovation, promote the pharmaceutical industry combination of scientific research and practices, operate the relevant research cooperation and academic-achieve promotion, and assist to industrialization and specification of the high technology.

3) Using our advantages and modern technologies to collect, study and publish the medical information, to focus on the key issues of industry and provide consultancy.

4) To promote the international communication of Chinese pharmaceutical industry, and organize different kinds of cooperation and exchanges on information, technologies and personnels.

5) To implement national innovation-driven development strategy to guide the members to broaden the channels of pharmaceutical innovation and investment, build a platform for cooperation, and promote social capital for the newly independent innovation projects of those R&D enterprises.

Chapter Three: Members

Article 7. Members of the Association: Institutional members.

Article 8. Applicant members should fulfill the following requirements:
1) Upholding the constitution of the Association;

2) Be willing to join the Association;

3) Possessing certain influences in the professional (industrial, academic) realm of our Association.

Article 9. Procedure of joining the Association
1) Submitting application;

2) Being approved through discussion on PhIRDA General Assembly;

3) PhIRDA General Assembly or authorized agency issuing certificate to approved members.

Article 10. Rights and duties of members
1) The rights of election, being elected and vote;

2) Participate in the Association activities;

3) The priorities of obtaining services from Association;

4) The rights of supervision, suggestion and criticizing the issues of Association;

5) The rights of obtaining the information and publications by Association;

6) The right of protecting legitimate rights and interests.

7) Enjoying freedom of joining and quitting the Association;

Article 11. Duties of the members
1) Follow the Constitution of PhIRDA, implement the decision of the Association;

2) Protect the legal rights and interests of the Association;

3) Complete the work entrusted by the Association;

4) Pay membership dues on time as per the stipulation;

5) Provide various information requested by the Association.

Article 12. Quitted members should notify the Association with a written statement and return the membership certificates. If members don't carry out their duties for 2 years, they are regarded as withdrawing from the Association automatically.

Article 13. Members with serious breach of the Constitution will be cancelled with their membership by vote of the PhIRDA General Assembly on the basis of consensus.

Chapter Four: Generation and Recall of Organization Leadership

Article 14. The PhIRDA General Assembly is the highest powerful organization of the Association. Functions of the PhIRDA General Assembly include:
1) Composing and revising the Constitution of the association;

2) Electing and recalling of the Chairman, Vice-President and Secretary-General;

3) Reviewing working report and financial report of this association;

4) Establishing and modifying the membership fee standard;

5) Making decision on the establishment and nomination of honorary position;

6) Deciding the establishment, alteration and cancellation of offices, branches, agencies and entities of the Association;

7) Appointing Deputy Secretary-General and other major responsible persons;

8) Deciding termination of the Association;

9) Deciding other important issues.

Article 15. The PhIRDA General Assembly should require a participation of more than two thirds of all members. The effectiveness of its decision should require acquire approval vote of more than half members.

Article 16. The PhIRDA General Assembly lasts 5 years each term. Approval from Members General Assembly, subject to the review and approval from the related registration and administration authority, Members General Assembly can be convened in advance or later under special circumstances. Members General Assembly shall not postpone one year in maximum. The PhIRDA General Assembly shall be convened at least once every two years.

Article 17. Secretariat, the executive department of Members General Assembly, shall conduct routine work of the association during the inter-sessional period.

Article 18. The Chairman, Vice-Presidents and Secretary-General of the association must meet the following requirements:
1) Persist in the CCP political direction, decisions, policies and good political qualities.

2) Strong influence in the professional work field.

3) An age of no more than 70 for the Chairman, Vice-President. An age of no more than 60 for the Secretary-General. The Secretary-General should be in full-time position.

4) Being healthy enough to do normal daily work.

5) Never deprived of political rights for criminal punishment.

(6) With ability of completing civil behavior.

Article 19. The Chairman, Vice-Presidents and Secretary-General of the association exceeds the maximum age shall conduct demission procedures.

Article 20. The Association applies system of annual Chairman rotation; the Chairman shall be elected from association members, and the term lasts for 1 year.

The Vice-President and Secretary-General are in position for a 5-year term, while their maximum tenure in office shall not surpass 2 terms.

Article 21. The Chairman is the legal representative of the Association. Under special circumstances, with the Chairman's commission and approval from Members General Assembly, subject to the review and approval from the related registration and administration authority, a Vice-President or the Secretary-General can be appointed as the legal representative.

The legal representative will represent PhIRDA to sign the relevant documents.

The legal representative is not allowed to hold a concurrent post in other associations.

The Chairman, Vice-President and members of the Association will automatically lose their representative qualification when leaving their member units, and new election from candidates for their posts will be invoked.

Article 22. Function and powers executed by the President:
1) Calling for and hosting the General Assembly.

2) Examining the implementation of decisions made by General Assembly.

3) Signing important documents on behalf of the association.

4) In the case of being authorized by the Chairman, Vice-Presidents and Secretary-General can perform parts of Chairman's responsibilities.

Article 23. The PhIRDA General Assembly establishes the Secretariat, and the functions executed by the Secretary-General include:

1) In charge and to organize administrative sectors to do routine work and implement annual work plan.

2) To coordinate the work of sub-branches, representatives and entities.

3) To nominate the Deputy Secretary-General and representatives of sub-branches for the General Assembly's approval.

4) To manage the employment of full-time working staffs for the Association.

5) In charge of executing other routine affairs.

Chapter Five: Principle of Assets Management and Utilization

Article 24. Funds resources of the Association:

1) Member annual fee;

2) Donation;

3) Government subsidies;

4) Income from approved business activities and services;

5) Interests;

6) Other income from legitimate sources.

Article 25. Members pay fees to the Association according to the relevant state regulation.

The secretariat is responsible to manage the dues and the financial revenue and expenditure will be reported to all members during the General Assembly.

Article 26. The funds of the Association shall be used in the business range and career development regulated in the constitution and shall not be distributed among members.

Article 27. The Association sets up strict financial management rules and regulations, in order to ensure that the accounting data is legitimate, true, accurate and complete.

Article 28. The Association employs accounting staff with professional qualifications. An accountant cannot be a cashier at the same time. Accountants must perform accounting and accounting supervision. If accountants leave the posts or are transferred to other work, they must go through connecting procedures with the managing staff and shifting persons.

Article 29. Management of assets of the Association shall be executed according to the financial regulations stipulated by the state, and shall accept supervision of the members' Conference and the financial department. The assets that come from the government subsidies and social contribution shall be subjected to supervision by the audit organ, and shall be also promulgated to the public by the proper means.

Article 30. Before the legal person of the Association is replaced or is at the expiration of his term of office, he must be subjected to the financial audit by the relevant registration administration organ and the professional administration unit.

Article 31. The assets of the Association cannot be embezzled, diverted and distributed in private by any unit or any person.

Article 32. The wages, insurance and welfare of full-time staffs should comply with relevant regulations for government institutions in China.

Chapter Six: Revision Procedure of the Constitution

Article 33. The right of interpreting this Constitution belongs to the General Assembly.

Article 34. The Constitution comes into force on the date when it is ratified by social registration administration organ.

Chapter Seven: Procedure of disbanding the Association and handling the Assets

Article 35. Association cancelled due to organization structure changes or other reasons will be firstly proposed by the General Assembly.

Article 36. The proposal needs to be submitted and passed by the General Assembly and approved by administration department.

Article 37. Before disbanding the Association a clearing group shall be formed, under the direction of the professional administrative unit and the relevant organ, settle claims and debts, and to deal with the aftermath. During the clearing period any activities except clearing work will not be in progress.

Article 38. The Association is terminated after cancelling its registration in Social Organization Registration Administration.

Article 39. The left assets, after the Association is terminated, will be used to develop the business concerned about the Association's aim under the supervision of the professional administrative unit and the mass organization registration administration, in accordance with the relevant state regulations.

Chapter Eight: Appendix

Article 40. This Constitution was approved by 4th Meeting of 10th PhIRDA General Assembly on October 29th, 2017.

Article 41. The right of interpreting this Constitution belongs to PhIRDA General Assembly.

Article 42. The Constitution comes into force on the date when it is approved by the authority of social organization registration & administration.

Organizational Structure of Association 机构设置



会领导介绍 | Introduction of PhIRDA Leadership

第九届会员大会以来历任会长照片
Chairmen of PhIRDA Since 9th General Assembly

桑国卫

中国药促会会长（2009–2012） 中国药促会荣誉会长（2012–2014）
十一届全国人大常委会副委员长 中国工程院院士

Sang Guowei

Chairman of PhIRDA (2009-2012) Honorary Chairman of PhIRDA (2012-2014)
Vice Chairman of the Standing Committee of Eleventh National People's Congress
Academician of Chinese Academy of Engineering

陈启宇

2012–2013年度会长
上海复星医药（集团）股份有限公司执行董事、董事长

Chen Qiyu

Annual Chairman
2012-2013
Executive Director, Chairman of the Board, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

闫希军

2013–2014年度会长
天士力控股集团
董事局主席

Yan Xijun

Annual Chairman
2013-2014
Chairman of the Board, Tasly Holding Group

孙飘扬

2014–2015年度会长
江苏恒瑞医药
股份有限公司董事长

Sun Piaoyang

Annual Chairman
2014-2015
Chairman of the Board, Jiangsu Hengrui Medicine Co., Ltd.

蒋华良

2015–2016年度会长
中国科学院
上海药物研究所所长

Jiang Hualiang

Annual Chairman
2015-2016
Director, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

丁列明

2016–2017年度会长
贝达药业股份有限公司
董事长兼CEO

Ding Lieming

Annual Chairman
2016-2017
Chairman of the Board & CEO, Betta Pharmaceutical Co., Ltd.

现任会领导
Current Leadership of PhIRDA

会长　蒋建东

中国医学科学院药物研究所所长

Jiang Jiandong, Chairman of PhIRDA

Director, Institute of Materia Medica, Chinese Academy of Medical Sciences

执行会长　宋瑞霖

中国医药创新促进会

Song Ruilin, Executive President

China Pharmaceutical Innovation and Research Development Association

副会长 陈启宇

上海复星医药（集团）股份有限公司
执行董事、董事长

Chen Qiyu, Vice President
Executive Director, Chairman of the Board, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

副会长 闫希军

天士力控股集团董事局主席

Yan Xijun, Vice President
Chairman of the Board, Tasly Holding Group

副会长 孙飘扬

江苏恒瑞医药股份有限公司董事长

Sun Piaoyang, Vice President
Chairman of the Board, Jiangsu Hengrui Medicine Co., Ltd.

副会长 蒋华良

中国科学院上海药物研究所所长

Jiang Hualiang, Vice President
Director, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

副会长 丁列明

贝达药业股份有限公司董事长兼CEO

Ding Lieming, Vice President
Chairman of the Board & CEO, Betta Pharmaceutical Co., Ltd.

副会长 张伯礼

天津中医药大学校长，中国工程院院士

Zhang Boli, Vice President
President, Tianjin University of Traditional Chinese Medicine, Academician, Chinese Academy of Engineering

副会长 蔡东晨

石药控股集团有限公司董事长

Cai Dongchen, Vice President
Chairman of the Board, China Shijiazhuang Pharmaceutical Group Co., Ltd.

副会长 任晋生

先声药业有限公司董事长

Ren Jinsheng, Vice President
Chairman of the Board, Simcere Pharmaceutical Group

副会长 邓金栋

中国医药集团总公司副总经理

Deng Jindong, Vice President
Deputy General Manager, China National Pharmaceutical Group Corporation

副会长 舒畅

上海医药集团股份有限公司副总裁

Shu Chang, Vice President
Vice President, Shanghai Pharmaceuticals Holding Co., Ltd.

副会长 柯尊洪

成都康弘药业集团股份有限公司董事长

Ke Zunhong, Vice President
Chairman of the Board, Chengdu Kanghong Pharmaceutical Group Co., Ltd.

副会长 刘殿波

绿叶制药集团有限公司董事长

Liu Dianbo, Vice President
Chairman of the Board, LUYE Pharma Group Co., Ltd.

秘书长 冯岚

中国医药创新促进会

Feng Lan, Secretary-General
China Pharmaceutical Innovation and Research Development Association

PhIRDA
中国药促会

中国医药创新促进会工作报告

2017年10月29日第十届四次会员大会

（摘要）

执行会长 宋瑞霖

第一部分 2016-2017年度的主要工作回顾

自2016年11月13日我会召开第十届三次会员大会，并在2017年2月25日会长会议扩大会议上明确2017年度工作重点以来，我会始终围绕“创新、产业化、国际化”宗旨，不断深入发挥为政府决策建言献策作用，在会员及行业服务能力、水平上不断与国际接轨，通过举办形式多元化、水平高端化的各种大型活动拓宽服务内涵，在促进医药产业创新与国际化发展方面做了开创性的一些工作，取得了行业瞩目的一些成果。2016-2017年度完成的主要工作体现在以下五个方面：

一、发挥行业智库作用，为改革完善国家医保及药品监管相关政策建言献策

（一）积极推动国家医保目录调整及相关机制完善工作

1、参与医保目录调整工作，推动创新药物进入医保目录。我会宋瑞霖执行会长作为唯一来自专业团体的咨询专家，受邀成为人力资源和社会保障部（以下简称“人社部”）新版国家医保目录调整咨询专家委员会综合专家组四位管理专家之一。在确定医保目录调入和调出备选药品名单以及谈判药品备选范围的工作中，我会积极推动将符合条件的新药和高质仿制药纳入备选名单，发挥了行业协会的重要作用。

2、分别于2017年3月、5月向人社部提交了关于医保谈判原则、完善医保目录动态调整机制等的意见和建议。针对今年人社部探索开展的医保药品谈判及医保目录动态调整工作，我会反复多次征求专委会专家及会员单位意见，整理出具有实操性、可落地的具体建议报送人社部。在医保谈判原则报告中，我会建议，应当以药品的综合价值及性价比作为主要评估依据，关注“总体费用”而非“单药价格”，并明确企业申报资料的综合评分标准；针对不同类别药品采取多元化、多类别的谈判策略等。我会大部分建议获得人社部的认可，在实际开展的医保药品谈判工作中被采纳。

3、开展创新药医保准入路径及医保支付标准形成机制的课题研究。创新药作为填补临床需求空白、打破进口原研药垄断、降低患者负担的关键要素，如何被尽快准入医保、获得合理支付价格，实现成果转化、惠及患者，是医保部门及行业内的重点关注领域。我会抓住行业热点，通过国内外文献综述、实地调研走访等方式积极开展相关课题研究，以期为医保部门建立创新药的准入机制提供契合国情的解决方案。

（二）接受CFDA委托，对《药品管理法》及药品监管体系改革提供建议

1、2016年12月初向毕井泉局长提交在我国实施知识产权保护制度改革的可行性及完善临床试验管理的相关建议。

我会对完善临床试验机构及国际多中心临床研究管理以及在中国建立药品专利链接、数据保护等制度进行了深入研究，向毕井泉局长提交了建议报告。我们在报告中提出实施临床试验机构备案制、设置区域性伦理委员会、鼓励开展国际多中心临床试验、建立中国的橘皮书制度和专利链接制度等建议，得到了CFDA主要领导的高度重视，大部分建议最终被10月8日中共中央办公厅、国务院办公厅公布的《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》所采纳。在该文件起草和协调国务院部门意见过程中，我会代表多次应邀参加征求意见会议并发表行业意见。

2、参加2017年5月19日国务院汪洋副总理在中南海主持召开的国务院部门协调会议。宋瑞霖会长作为唯一受邀的专家就药品知识产权保护制度改革发表意见建议，建议受到汪洋副总理的高度关注，为促进中央认可在我国建立药品专利链接、专利期补偿等制度可行性提供了行业参考意见。

3、接受CFDA委托，对药品管理法中涉及知识产权保护相关条款的修订进行研究。我会通过系统梳理国际主流国家相关制度运行的成熟经验，并充分考虑我国产业发展的实际状况，撰写了《药品管理法》相关知识产权条款修订建议稿及修订说明。我会研究报告与建议得到了CFDA有关司局高度评价。2017年6月9日，受CFDA法制司、药化注册司委托，我会在烟台召开了“药品专利链接及专利期补偿制度研讨会”，参会领导与企业代表就在我国建立药品专利链接及专利期补偿制度的可行性进行深入研讨论证并达成一致意见。这一成果对中办、国办《意见》中明确在我国探索专利链接制度和试点实行专利期延长制度发挥了积极作用。

二、通过各种渠道和活动宣传我国医药创新环境及成果，打造我国医药创新品牌

（一）成功举办第二届医药创新品牌系列评选活动

2016年12月，由我会与中国医学科学院、中国中医科学院、人民网共同主办的“第二届（2016）中国医药创新品牌系列评选活动”正式启动。经过由药物研发、临床界46位权威专家组成的专家评审委员会以产品对临床、经济与社会价值的贡献率作为主要衡量标准初步审核、召开评审会终审，以及开通公众网络投票，3个最具临床价值创新药，4家最具创新能力医药企业，4名最具影响力创新人物，3个最具临床替代价值仿制药的获奖项目最终于2017年3月12日晚人民日报社演播大厅的颁奖典礼被揭晓。本次评选首次设立了中国医药创新终身成就奖，中国工程院院士、国家重大新药创制科技重大专项技术总师桑国卫被评审委员会专家一致推举为首届“医药创新终身成就奖”获得者。全国人大常委会副委员长陈竺院士和国家卫计委、CFDA及农工党中央负责同志出席颁奖典礼并为获奖者颁奖。

本届创新品牌评选活动在业界获得了比首届活动更高的关注度和好评度，公众投票数、点赞人数及网站访问量均远超首届，彰显出评选活动对弘扬民族医药优质产品、提高品牌知名度、推动医药行业以品牌引领创新起到了重要的促进作用。

（二）在《Nature》刊文宣传我国医药创新现状及成果

我会在2016年受国家卫计委科教司委托开展的国家“重大新药创制”科技重大专项“十一五”、“十二五”实施绩效评估结果基础上，整理出5篇介绍中国医药创新进展的综述，今年5月在《Nature》主刊上刊登，首次在世界舞台展示了前进中的中国医药创新现状，在国内外产生了非常积极的影响，刘延东副总理特别就此批示给予肯定。

三、搭建医药创新与投融资界零距离交流对话平台，创办首届“中国医药创新与投资大会”，并积极筹备规模更大、国际化水平更高的第二届大会

去年11月14-16日，我会联合中国证券业协会在国家“重大新药创制”科技重大专项实施管理办公室（以下简称“新药专项办”）等单位的支持下，成功举办首届“中国医药创新与投资大会”（以下简称“创投大会”）。

大会吸引了医药投资界1500位代表（包括300余家医药企业与220家投资机构代表）到会交流洽谈，规模空前，社会反响热烈，受到行业和各界媒体的广泛关注与赞许。

今年由我会会同中国证券业协会、中国医疗器械行业协会和香港交易所共同举办的第二届“中国医药创新与投资大会”于10月29日-31日在苏州召开。与第一届创投大会相比较，除医药企业和投资机构参会外，部分国家驻华使领馆和医药行业相关组织也派代表团出席会议，参会人数达到2000人。本届大会设有开幕式、临床数据全球首发、医疗器械创新项目路演、国内非上市企业与上市企业路演、国际创新项目路演及创新、投资政策论坛与投资人经验分享论坛等逾18场精彩纷呈、各具特色的活动。

大会开幕式上，国家食品药品监督管理总局孙咸泽副局长，国家卫生计生委曾益新副主任，国际著名金融家、前以色列央行行长Jacob A. Frenkel，香港交易所董事总经理许正宇分别发表了致辞和演讲。国内外医药创新领域著名企业CEO以及行业领先投融资机构的重量级嘉宾出席开幕式并参与了各主题的开放式讨论。

本届大会将成为向世界宣传展示我国医药创新政策与成果、促进创新项目投资合作的高端平台，成为亚太地区促进医药创新交流与发展的重要活动品牌。

四、加入IFPMA，成为国际医药协会组织的重要成员之一，将为我国创新成果走向国际舞台发挥更积极的作用

2016年11月29日，国际药品制造商协会联合会（IFPMA）在华盛顿召开第29届理事会，表决通过了我会加入IFPMA的申请，我会成为IFPMA中唯一代表中国本土制药企业的成员组织。

（一）要求台湾地区及相关组织更名，为维护祖国统一作出应有贡献

我会在2017年6月26日的IFPMA理事会会议上严正提出应按联合国承认的名称称呼台湾地区及其相关协会组织，要求在IFPMA的网站、通信、文件等所有表述中均采用“中国台北（Chinese Taipei）”的名称。我会的倡议得到了IFPMA及相关成员单位的高度认可和国内有关部门的高度评价。2017年7月6日，IFPMA就台湾地区称谓问题回函，表示将在过往和未来的网站和文件中更改关于台湾地区的表述。

（二）受CDE委托，组建ICH相关指南修订工作组

我会受CDE委托，针对29个ICH专家工作小组向会员单位及四个专委会陆续招募专家，目前，CDE已确定有16位我会推荐的专家被纳入到10个ICH专家工作组中。

与此同时，我会通过内部筛选于2017年9月15日向IFPMA提名的9位专家全部通过审核并正式成为ICH 5个处于第一阶段的指导原则专家工作组成员。其中，我会药物研发专业委员会第一任主任委员、方恩（天津）医药发展有限公司执行董事长张丹被选为“E19-优化安全性数据的收集”专家工作组组长，将出席ICH年度会议并参与讨论；我会药物临床研究专业委员会副主任委员、北京大学第一医院临床试验中心主任崔一民被选为“M9-BCS的生物豁免（ICH M9 - Biowaivers）”工作组候补组长；北京儿童医院药剂科主任王晓玲被选为儿科外推工作组候补组长。

（三）对日本、欧洲等国家相关机构进行走访，学习国外知识产权保护、医保等政策对医药创新的促进经验

今年4月初、6月底7月初，我会由会领导及会员单位代表组成代表团，先后出访日本、瑞士、法国、德国等国家，对这些国家的部分政要、咨询机构、创新企业等进行了走访调研，获得了知识产权保护及医保准入等一系列一手资料；尤其是对世界卫生组织、世界贸易组织和世界知识产权组织总部开展的访问，获得三大国际组织高规格接待。代表团与受访机构就推动药品知识产权保护政策、开展全球创新合作等议题进行了深入磋商与交流，

对药品知识产权保护政策既要平衡药品创新与可及性，又要综合考虑国家财政、医保基金承受能力等因素达成共识。

五、召开各种学术研讨会议，推动我国临床研究质量及药学服务水平不断提高

（一）“第二届中国临床研究质量管理（GCP）暨创新药研发大会”助力临床研究及新药研发水平的提高

2017年6月10-11日，由我会与中国心血管健康联盟、中国抗血栓药物治疗联盟共同主办的“第二届中国临床研究质量管理（GCP）暨创新药研发大会”在山东省烟台市召开。CFDA、国家卫计委等相关领导以及多位重量级临床专家、国内外创新型企业代表及研发人员共计300余人出席本次会议。多位领导、专家就尽快建立符合国际标准的临床多中心药物临床试验研究体系和数据管理体系，促进我国新药临床研究水平和研究效率快速提升，与国际接轨等问题，从各专业领域不同视角为本次大会呈现了多个精彩纷呈的主题报告，并与参会代表展开了深入的研讨与互动。

（二）第八届医院药学政策论坛为药师在医保体系中的作用与定位指明方向

由我会与中国药师协会共同主办的“第八届中国医院药学政策论坛”于2017年7月21日在银川成功召开。来自人社部、两家主办单位的相关领导，以及来自全国各地药学领域的代表近400人参加了会议。与会代表针对药学人员在新医保目录调整中发挥的作用及未来药师在临床药学服务方面的能力培养等议题进行实际案例分析和深入探讨。

在会员大会闭会期间，我会通过召开会长会议及通讯表决等方式，新纳入会员14家，我会会员单位达到98家，本次会员大会提请审议11家新的会员单位入会申请。我会正在形成由行业知名创新型企业、拥有独特技术与平台的一大批初创型创新公司、国内医药行业优质企业、国内领先的研发机构、临床研究机构以及活跃于医药创新领域的各类投资金融机构组成，覆盖医药创新全产业链的会员架构。经过各会员单位和专家委员会的共同努力，会员单位的研发活动已经成为我国医药创新发展不可或缺的重要力量。

第二部分 2018年度重点工作建议

各位代表，刚刚胜利闭幕的中共第十九次代表大会，正式宣告中国特色社会主义进入了新时代，我国社会主要矛盾已经转化为人民日益增长的美好生活需要和不平衡不充分的发展之间的矛盾。在这个新时代开启的时刻，中国医药产业也迎来了历史上最为剧烈的变革，中国医药创新的春天已经到来。

我会作为国内促进医药创新的代表性行业协会，将认真学习、领会十九大会议文件精神，围绕具有里程碑意义的两办《意见》的贯彻落实，更多发挥会员单位和专委会专家的作用，为完善《意见》的具体执行措施不断深入研究，促进医药行业创新发展环境的持续改善；同时，我会将不断创新为会员单位和医药行业服务的渠道和方式，通过搭平台、促交流，提高服务业务水平，努力成长为全方位、强有力促进医药行业创新、国际化发展的社会团体。为此，2018年度将着重开展以下几项工作：

一、继续发挥行业智囊团作用，输出专家智力资源，开展各项政策、行业准则等研究与制定工作

1、配合CFDA工作，为起草完成两办《意见》配套政策文件献计献策；进一步深入开展药品专利链接、专利补偿等知识产权保护方面具体政策措施研究。

两办印发《意见》后，CFDA正在紧锣密鼓地工作，预计将出台几十个配套规章及文件，我会将积极配合CFDA有关工作，通过研究吸纳国际先进经验，结合我国国情，提出切实、可行的具体建议。

2、开展国家基本医保目录动态调整机制、创新药医保准入及医保支付标准形成机制的研究。

日前，人社部医保司已经正式委托我会就“完善医保药品目录动态调整机制”进行专题研究。我会将就医保药品目录动态调整的总体思路、基本原则，动态调整的范围和方式、规模和周期，与调整方式相适应的调整程序（专家评审、谈判准入），目录内药品退出条件和程序，药品目录管理的相关政策（支付标准衔接）等进行深入研究，为人社部提出建设性具体建议。

3、接受重大专项办委托开展重大专项“十三五”年度评估和总体评估工作。

国家新药重大专项办已明确委托我会对新药重大专项 “十三五”阶段支持的创新药物、临床急需品种和关键技术、平台等项目成果产出开展年度评价及“十三五”时期整体实施效果总体评价。我会将会充分发挥会员优势，组织力量做好相关工作。

4、推荐、组织专家参与ICH相关工作组及指南修订工作。

我会将按照ICH秘书处和CDE的需求，继续推荐相关专业领域的权威专家参与ICH技术指南的制定工作。

5、就制定“中国药促会行业伦理准则”开展研究。

为进一步推动我国医药行业伦理准则的建立和实施，加强与国际标准的接轨和融合，规范中国医药产业的市场环境，我会将制定“中国药促会医药行业伦理准则”，加强中国准则能力建设，为会员单位在国际领域的合作奠定基础。

二、与国内外相关机构建立创新研发协作机制，共同推动我国药物创新水平提高、与国际接轨

1、与美国癌症研究基金会共同搭建中美肿瘤医药创新合作平台

我会与美国癌症研究基金会已正式签署了合作备忘录，双方将共同搭建“中美肿瘤医药创新合作平台”，包括：成立中美肿瘤创新药物专家合作委员会；建立长期的“中美肿瘤医药创新合作机制”，共同推动全球多中心临床试验及试验数据的国际互认，推动国际药品监管体系改革。接下来，我会与美国癌症研究基金会将每年组织召开一次国际肿瘤创新药物大会，按照年度分别在中国和美国召开，邀请中美医药领域专家、学者和研发企业参加；同时还将召开肿瘤专科国际学术研讨会，搭建肿瘤研发与临床界、投资界的交流。

2、与港澳台地区建立四方创新合作机制。

我会与我国台湾地区生技医疗产业策进会、香港生物医药创新协会、澳门国际中药质量研究会签署了合作协议，决定建立四方医药创新合作机制，汇集两岸四地医药创新领域的专家及产业界代表参与该机制，就新药研发趋势、医药卫生领域合作等热点问题进行交流，为中国及全球生物医药界华人提供创新合作的平台与纽带。

三、继续搭建创新与资本对话交流平台，办好“第三届中国医药创新与投资大会”

我会已举办两届“中国医药创新与投资大会”，通过搭建创新与资本对话交流平台，强化科技同经济对接、创新成果同产业对接，促进资本市场对科技成果的转化，在业界取得较热烈的反响。因此，我会将继续主办“中国医药创新与投资大会”，搭建涵盖药物研发、生产、使用、流通、投资五位一体的多元化国际交流平台，将大会打造成为亚洲独具特色的专业化医药创新与投资人年度品牌会议。

四、与Nature、CFDA南方医药经济研究所及其下属医药经济报、米内网等机构、媒体开展创新宣传活动

1、与Nature合作宣传中国医药创新成果。

根据2016年10月13日我会与施普林格·自然集团签订的合作备忘录，一方面，每年通过《Nature》向全球科研读者展示我国医药创新方面已经取得的成果；推荐会员单位中的创新者代表每年接受Nature周刊采访，制作访谈特刊；另一方面，施普林格·自然集团每年将派相关学科领域资深编辑来参加我会组织的学术研讨会等活动；为每年举办的“中国医药创新与投资大会”提供相应的会前宣传与会后深度报道；同时还可以为我会会员单位提供优惠的媒体推广服务合作机会。

2、依托医药经济报、米内网等媒体宣传药品监管改革政策及成效等。

与CFDA南方医药经济研究所下属媒体医药经济报、米内网等合作，通过组织专家接受媒体访谈、撰写行业热点政策问题观点，对近期国家正如火如荼开展的深化药品审评审批等药品监管制度改革及成效等进行宣传。

3、改革“最有价值创新药”品牌评选方式，由企业自主申报改为主办方主动从数据库遴选入围品种。

与CFDA南方医药经济所合作筛选“创新品牌评选”入围品种，以客观价值评比，取代企业申报、答辩的传统模式，使评选活动更加客观、公正。

五、继续拓展与各国驻华使领馆、行业协会的合作交流活动

继续拓展与以色列、加拿大、澳大利亚等国家驻华使馆及美国、日本等国家制药商协会之间的产业合作交流形式，适时组织项目对接、出访考察等国际交流活动，为会员企业寻求海外合作机会，进一步提高中国医药企业的国际竞争力，促进我国医药产业界在贸易、投资和技术等领域与国际社会深入融合。

六、继续办好各种论坛及学术交流活动，服务医药创新关键环节

我会将继续办好每年一届的中国临床研究质量管理（GCP）大会和医院药学论坛，为提高我国临床研究质量和水平、提高医院药学工作人员助力医生合理用药等医药创新关键领域的能力作出行业协会应有的贡献。

中国药促会将不断保持自身创新意识，为会员单位提供更创新、更多元化的服务，做好企业与政府的桥梁，促进医药创新政策环境的改善，搭建更高层次的国内外合作交流平台，为医药行业的创新、可持续发展和保障人民的健康，为实现医药强国的伟大目标而不懈奋斗！

PhIRDA Annual Work Report of 2016-2017

The Fourth Meeting of the 10th General Assembly on October 29th, 2017 (Abstract)

Song Ruilin, Executive President

Section One. Review of Major Work in 2016-2017

The Third Meeting of 10th General Assembly on November 13th, 2016 and the President Board Meeting on February 25th, 2017 pointed out the key works of 2017, PhIRDA has always focused on the purpose of "Innovation, Industrialization and Internationalization", continued to play an important role in offering suggestions for government decision-making, continued to act on international convention in member and industrial service capacity and level, broadened the service connotation by holding various large-scale activities with diversified forms and high-end levels, made some groundbreaking works and obtained some industry-focused achievements in promoting innovation and internationalization development of pharmaceutical industry. In 2016-2017, the main works completed in five aspects:

I. PhIRDA played the role of industrial think tank and offered suggestions for reforming and improving relevant policies of national medical insurance and drug supervision

(I) PhIRDA actively promoted the adjustment of National Reimbursement Drug List and the improvement of relevant mechanisms.

1) PhIRDA participated in the adjustment of Reimbursement Drug List and promoted innovative drugs to be included into the Reimbursement Drug List. Song Ruilin, the Executive President of PhIRDA, as the only advisory expert from professional association, was invited to be one of the four management experts of comprehensive expert group of Experts Advisory Committee for new National Reimbursement Drug List of the Ministry of Human Resources and Social Security (hereinafter referred to as "MOHRSS"), and in determining the Alternative Drugs Adjustment List of the National Reimbursement Drug List and the range of alternative drugs which are covered by medical insurance, PhIRDA actively suggested new drugs and high-quality generic drugs that meet the conditions into the list of alternative drug, which plays an important role of industry association.

2) PhIRDA submitted comments and suggestions on medical insurance negotiation principles, improving the dynamic adjustment mechanism of Reimbursement Drug List, etc. to the MOHRSS on March and May, 2017 respectively. For the medical insurance drug negotiation and Reimbursement Drug List dynamic adjustment works carried out by MOHRSS, PhIRDA sorted out the practical and implementable specific suggestions to MOHRSS after repeatedly soliciting comments from experts of the Specialty Committees and members. In the report of medical insurance negotiation principles, PhIRDA suggests the comprehensive value and cost performance of drugs shall be taken as the primary assessment basis with focusing on the "overall fee" rather than "single drug price" and defining the comprehensive scoring standard of declaration information of enterprises; for different drugs, diversified and multi-class negotiation strategies shall be adopted, etc.. Most of PhIRDA's suggestions were recognized by MOHRSS and adopted in the medical insurance drug negotiation carried out.

3) PhIRDA carried out the research on medical insurance access for innovative drugs and the mechanism of medical insurance payment standard. For innovative drugs, which are a key factor to fill the gaps of clinical need, break the monopoly of imported brand-name drugs and reduce the burden of patients, the matter that how to get access to medical insurance as soon as possible and obtain a reasonable payment price to realize the achievement transformation and benefiting patients is a key focus area of medical insurance departments and industry. PhIRDA held the industry focus and actively carried out relevant topic researches by the study of domestic and foreign literature, field researches and visits etc. to provide a solution meeting the national demand of medical insurance departments which establish an access mechanism for innovative drugs.

(II) PhIRDA accepted the entrustment of CFDA, to provide suggestions for reforms of Pharmaceutical Administration Law and drug regulatory system.

1) At the beginning of December, 2016, PhIRDA submitted relevant suggestions on the feasibility for implementing the intellectual property protection system reform in China and improving the clinical trial management to Minister Bi Jingquan. PhIRDA conducted in-depth researches in improving the clinical trial organization and international multi-center clinical research management and establishing drug patent link, data protection and other systems in China, and submitted a suggestion report to Minister Bi Jingquan. In the report, we proposed to implement the clinical trial organization filing system, set up regional ethics committees, encourage to carry out the international multi-center clinical trial, establish China's orange book system and patent link system and other suggestions, which were highly valued by CFDA's principal leaders, and most suggestions were finally adopted by Opinions on Deepening the Review and Approval System Reform and Encouraging the Drug and Medical Device Innovation issued by the General Office of the CPC Central Committee and the General Office of the State Council on October 8th. In the process of drafting and coordinating the departmental opinions of the State Council of this document, the representatives of PhIRDA were invited to attend the consultation meeting and deliver the industrial comments for many times.

2) PhIRDA participated in the State Council departmental coordination meeting hosted by Wang Yang, the Vice-Premier of the State Council on May 19th, 2017. Executive President Song Ruilin, as the unique invited expert, gave comments and suggestions on drug intellectual property protection system reform, and the suggestions were highly focused by Wang Yang, the Vice-Premier, which provided industrial reference comments for promoting the Central Committee to recognize the feasibility of establishing drug patent link, patent term restoration and other systems.

3) PhIRDA accepted the entrustment of CFDA, to conduct researches on revision to relevant clauses in the Pharmaceutical Administration Law involving intellectual property protection. PhIRDA wrote the revised draft and revision note for relevant intellectual property clause in the Pharmaceutical Administration Law by systemically sorting out the mature experience of relevant system operations in major international countries and giving full consideration to the actual conditions of industrial development in China. The research report and suggestions of PhIRDA were highly appraised by relevant CFDA departments. On June 9th, 2017, entrusted by Legal Division and Department of Drug and Cosmetics Registration of CFDA, PhIRDA held the "Conference on drug patent link and patent term restoration system" in Yantai, and the attending leaders and enterprise representatives conducted in-depth discussions and demonstrations on establishing the drug patent link and patent term restoration system in China and reached a consensus. This achievement has played a positive role in the Opinions by the General Office of the CPC Central Committee and the General Office of the State Council in exploring the patent link system and implementing pilot patent period extension system in China.

II. PhIRDA publicized pharmaceutical innovation environment and achievements of China and built the pharmaceutical innovative brand of China through various channels and activities

(I) PhIRDA held the series activities of pharmaceutical innovative brand selection for the second time successfully.

In December, 2016, the "The 2nd (2016) Selection Activities for the Pharmaceutical Innovative Brand in China" co-hosted by PhIRDA, Chinese Academy of Medical Sciences, China Academy of Chinese Medical Sciences and People's network was started officially. Through the primary review and final review meeting by the expert review committee consisting of 46 authoritative experts in drug R&D and clinical field with the contribution rate of a product to clinical, economic and social values as the major standard, as well as public Internet voting, awarded projects such as 3 innovative drugs with most clinical values, 4 most innovative pharmaceutical enterprises, 4 most influential innovators and 3 generic drugs with most clinical alternative values were finally announced on the award ceremony at Studio Hall of People's network on the evening of March 12th, 2017. The Lifetime Achievement Award for pharmaceutical innovation in China was set up in this selection for the first time, and Sang Guowei, academician of Chinese Academy of Engineering and the General Expert Committee of National Science and Technology Major Project for Major New Drug Research and Development, was unanimously elected as the winner of the first "Lifetime Achievement Award for Pharmaceutical Innovation" by experts of the review committee. Academician Chen Zhu, the Vice Chairman of the Standing Committee of the National People's Congress, and responsible comrades from National Health and Family Planning Commission, CFDA and the Central Committee of Chinese Peasants and Workers Democratic Party attended the award ceremony and awarded prizes for the winners.

This innovative brand selection activities obtained more attentions and praises in the industry comparing to the first activities, with number of public vote, number of likes and Website traffic more than the first, which showed the selection activities played an important promoting role in carrying forward national pharmaceutical quality products, improving the brand awareness and promoting the pharmaceutical industry to lead the innovation by brand.

(II) PhIRDA publicized the current situation and achievements of pharmaceutical innovation in China in Nature.

PhIRDA, on the basis of the results of "the 11th Five-Year" and "the 12th Five-Year" implementation performance assessments of "National Key Project on Innovation and Development of Major New Drugs" entrusted by the Science and Education Division of National Health and Family Planning Commission in 2016, sorted out 5 reviews introducing the pharmaceutical innovation process in China, which was published in the main journal of Nature in March of this year, and this is the first time to demonstrate the current situation of advancing pharmaceutical innovation in China in a world stage, which had a very positive impact at home and abroad, where Vice-Premier Liu Yandong affirmed it in particular.

III. PhIRDA built the zero distance exchange and dialogue platform for pharmaceutical innovation and investment and financing communities, founded the first "China BioMed Innovation and Investment Conference" and actively prepared the second conference with larger scale and higher international level.

On November 14th-16th of the last year, PhIRDA and the Securities Association of China (SAC), under the supports of the Management Office of National Science and Technology Major Projects for Major New Drug Research and Development (hereinafter referred to as the "Office of New Drug Projects") and other units, successfully held the first "China BioMed Innovation and Investment Conference" (herein after referred to as the "CBIIC"). The Conference attracted 1,500 representatives (including representatives from more than 300 pharmaceutical enterprises and 220 investment institutions) exchanges and discussions, with an unprecedented scale and enthusiastic social response, which got general attentions and praises from the industry and Media.

In this year, the second "China BioMed Innovation and Investment Conference" co-hosted by PhIRDA, SAC, China Association for Medical Devices Industry (CAMDI) and Hong Kong Stock Exchange (HKEX) was held on October 29th-31st. Comparing to the first Innovation and Investment Conference, in addition to pharmaceutical enterprises and investment organizations, embassies and consulates in China and relevant organizations in the pharmaceutical industry of some countries also sent delegations to attend the meeting, and the attendance was up to 2,000. This Conference set up more than 18 splendid and distinctive

activities such as opening ceremony, clinical-trial data release of innovative drugs, roadshow of medical devices innovative projects, roadshow of non-listed companies and listed companies, international roadshow of innovative projects, innovation and investment policy forum and investor experience sharing forum, etc.

On the opening ceremony, Sun Xianze, the Vice-Minister of China Food and Drug Administration, Zeng Yixin, the Vice-Minister of National Health and Family Planning Commission, Jacob A. Frenkel, Chairman of JPMorgan Chase International and former Israeli Central Bank Governor, Xu Zhengyu, the Managing Director of Hong Kong Exchanges and Clearing Ltd. delivered addresses and speeches respectively. CEOs of domestic and foreign famous enterprises in pharmaceutical innovation field and powerful guests of industrial leading investment and financing organizations attended the open ceremony and participated in open-ended discussions of various topics.

This conference will become a high-end platform for publicizing pharmaceutical innovation policies and achievements in China to the world and promoting investment and cooperation for investment projects and become an important activity brand for promoting pharmaceutical innovation exchange and development in Asian-Pacific region.

IV. PhIRDA joined the IFPMA as one of the key members of international pharmaceutical association organization, which will play a more positive role in promoting China's innovative achievements to go to the international stage.

On November 29th, 2016, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) held the 29th council meeting in Washington and approved PhIRDA's application for joining the IFPMA by voting, and PhIRDA became the unique member organization on behalf of local pharmaceutical enterprises in China in IFPMA.

(I) PhIRDA required Taiwan and relevant organizations to be renamed, making due contributions to the reunification of motherland.

On the council meeting of IFPMA on June 26th, 2017, PhIRDA lodged solemn representations that Taiwan and relevant associations and organizations shall be called according to names admitted by the United Nations, requiring IFPMA's networks, communications, files and all other representations to adopt the name of "Chinese Taipei". The proposal of PhIRDA was highly recognized by IFPMA and relevant members and highly praised by relevant domestic departments. On July 6th, 2017, IFPMA replied for the appellation of Taiwan and represented that it will change representations related to Taiwan in past and future networks and files.

(II) PhIRDA was entrusted by CDE to organize the Expert Working Group for ICH relevant guidelines

PhIRDA was entrusted by CDE to recruit experts successively from members and four specialty committees for 29 ICH expert working groups, and at present, CDE has confirmed 16 experts recommended by PhIRDA to be included in 10 ICH expert working groups.

At the same time, all of 9 experts nominated by PhIRDA after internal selection to IFPMA on September 15th, 2017 passed the review and officially join 5 ICH expert working groups which is at the stage I of guidelines. Among them, Zhang Dan, the First Chairman of PhIRDA Drug R&D Specialty Committee, and the Executive President of Fountain Medical Development Ltd., was selected as the leaders of expert working group of "E19-Optimizing the Collection of Security data" and will attend the ICH annual meeting and participate in the discussion; Cui Yimin, the vice chairman of PhIRDA Clinical Research Specialty Committee and director of clinical trial center of Peking University First Hospital, was selected as the alternate leader of Working Group of ICH M9-Biowaivers"; Wang Xiaoling, the director of department of pharmacy of Beijing Children's Hospital, was selected as the alternate leader of working group for pediatric extrapolation.

(III) PhIRDA visited relevant organizations in Japan, Europe and other countries, to learn the promoting experiences to pharmaceutical innovation by foreign intellectual property protection and medical insurance and other policies.

In the beginning of April and the end of June to the beginning of July of this year, PhIRDA delegation consisting of PhIRDA's leaders and representatives of members has visited successively Japan, Switzerland, France, Germany and other countries and made visits and investigations to some politicians, advisory organizations, innovative enterprises, etc. of these countries, obtaining a series of first-hand data for intellectual property protection, medical insurance access, etc.; especially for visits to headquarters of World Health Organization, World Trade Organization and World Intellectual Property Organization have obtained high-level receptions from the three international organizations. The delegation carried out in-depth consultations and exchanges with visited organizations for promoting drug intellectual property protection policies, carrying out global innovation and operation and other topics, and reaching a consensus in that the drug intellectual property protection policy shall not only balance drug innovation and accessibility but also comprehensively consider the bearing capacity of national finance and medical insurance funds and other factors.

V. PhIRDA held various academic conferences, to promote the continuous improvement of clinical research quality and pharmacy service level in China.

(I) The 2nd China Good Clinical Practice Management (GCP) Conference improved the clinical research and new drug R&D level.

On June 10th-11th, 2017, the "2nd China Good Clinical Practice Management (GCP) Conference co-hosted by PhIRDA, China Cardiovascular Association and China Antithrombotic Therapy Association was held in Yantai, Shandong. There were more than 300 people attending this conference, including relevant leaders of CFDA, National Health and Family Planning Commission, etc., many powerful clinical experts, representatives and R&D personnel from domestic and foreign innovative enterprises. Many leaders and experts delivered a number of brilliant keynote speeches on this Conference from various professional fields and different perspectives for establishing clinical multi-center drug clinical-trial research system and data management system that meet the international standards as soon as possible, promoting the rapid improvement of new drug clinical research level and efficiency in China, acting on the international convention and other problems, and carried out in-depth discussions and interactions with attending representatives.

(II) The 8th Hospital and Pharmacy Policy Forum indicated directions for the role and position of pharmacists in the medical insurance system

The 8th Hospital and Pharmacy Policy Forum in China co-hosted by PhIRDA and Chinese Pharmacists Association was successfully held in Yinchuan on July 21st, 2017. There were nearly 400 people attending the forum, including relevant leaders from MOHRSS and two hosts and representatives in the pharmacy field from all over the country. The attending representatives carried out actual case analyses and in-depth discussions for pharmaceutical personnel's role in new Reimbursement Drug List adjustment and pharmacists' capacity in clinical pharmacy service in the future and other topics.

The meeting has approved 11 new member applications and confirmed 14 new members approved by the Presidents' meeting during intersessional meetings. So far, the number of members of PhIRDA has increased to 98. PhIRDA is forming a membership framework consisting of famous industrial innovative enterprises, a large number of start-up innovative companies with unique technologies and platforms, high-quality enterprises in domestic pharmaceutical industry, domestic leading R&D organizations, clinical research organizations and various investment and financial organizations active in the field of pharmaceutical innovation and covering the entire chain from pharmaceutical manufacturing, R&D, clinical, policy and investment. Through joint efforts of all members and specialty committee, the R&D activities of members have become an indispensable important power for the development of pharmaceutical innovation in China.

Section II Suggestions on key works in 2018

All delegates, the 19th Session of National Congress of the Communist Party of China just concluded successfully and officially declared that the socialism with Chinese characteristics has entered a new era and the main contradiction of China's society has become that between the people's ever-growing needs for a better life and the unbalanced and inadequate development. At the time when the new era starts,China's pharmaceutical

industry has also faced the most dramatic reform in the history and the spring for China's pharmaceutical innovation has already come.

PhIRDA, as a domestic representative industrial association promoting the pharmaceutical innovation, will study and understand carefully the spirit of documents of 19th Session of National Congress, focus on the implementation of Opinions by the two Offices which has a milestone significance, give more play to the role of members and specialty committee, continue to make in-depth researches for improving the specific executive measures of Opinions and promote the continuous improvement for the innovative development environment of pharmaceutical industry; at the same time, PhIRDA will continue to make innovations in service channels and ways for members and pharmaceutical industry, and strive to become a comprehensive and internationally developed social organization that strongly promotes the innovation of pharmaceutical industry through building platforms, promoting exchanges and improving the service business level. For this, in 2018, we will focus on the following aspects:

I. PhIRDA will continue to play the role of industrial think tank, output expert intellectual resources and carry out research and development works for various policies, industrial guidelines, etc.

1) PhIRDA will cooperate with CFDA, to offer advice and suggestions for drafting and completing supporting policy documents of Opinions by the General Office of Central Committee of CPC and the General Office of the State Council; we will further and in depth carry out specific policy and measure researches in drug patent link, patent term restoration and other intellectual property protections.

After the General Office of Central Committee of CPC and the General Office of the State Council issued the Opinions, CFDA has been working in full swing, with dozens of supporting regulations and files being expected to be issued, and PhIRDA will actively cooperate with CFDA on relevant works and provide practical and feasible specific suggestions through researching and absorbing international advanced experiences and combining the national conditions of China.

2) PhIRDA will carry out researches on National Reimbursement Drug List dynamic adjustment mechanism and innovative drug medial insurance access and medical insurance payment standard forming mechanism.

A few days ago, the Medical Insurance Division of MOHRSS has officially entrusted PhIRDA to conduct a special research on "improving the Reimbursement Drug List dynamic adjustment mechanism". PhIRDA will conduct in-depth researches in general idea and basic principle of reimbursement Drug List dynamic adjustment, scope, method, scale and period of dynamic adjustment, adjustment programs adapting to the adjustment method (expert review, negotiation access), withdrawal conditions and procedures for drugs within the List, relevant policies of National Drug List management (payment standard connection), etc., and propose constructive specific suggestions to MOHRSS.

3) PhIRDA will accept the entrustment of Management Office of National Science and Technology Major Project for Major New Drug Research and Development "the 13th Five-Year Plan" annual assessment and overall assessment works of major S&T projects.

The Management Office of National Science and Technology Major Project for Major New Drug Research and Development has entrusted PhIRDA to carry out annual assessment for innovative drugs, varieties under clinically urgent need and key technologies, platforms and other project achievements supported in the "13th Five-Year Plan" and overall assessment for the implementation effect during the "13th Five-Year Plan". PhIRDA will give a full play to the member advantages and organize strengths to do well at relevant works.

4) PhIRDA will recommend and organize experts to participate in ICH experts working groups and guidelines' revision works.

PhIRDA, according to the demand of ICH secretariat and CDE, will continue to recommend authoritative experts of relevant professional fields to participate in the development works of ICH technical guidance.

5) PhIRDA will carry out researches on developing the “Codes of Industrial Ethics of PhIRDA”.

In order to further promote the establishment and implementation of Codes of Pharmaceutical Industrial Ethics, strengthen the integration and fusion with international standards and standardize the market environment of pharmaceutical industry in China, PhIRDA will develop the “Codes of Pharmaceutical Industrial Ethics of PhIRDA”, to strengthen the code capacity construction in China and lay a foundation for cooperation of member units in international field.

II. PhIRDA will establish an innovation R&D collaboration mechanism with domestic and foreign relevant organizations, to jointly promote the improvement of pharmaceutical innovation in China and the international integration

1) PhIRDA will jointly build the Sino-US Innovation and cooperation platform for oncology drugs with National Foundation for Cancer Research.

PhIRDA has officially signed the Memorandum of Understanding with National Foundation for Cancer Research, and the both parties will jointly build the “Sino-US Innovation and Cooperation Platform for Oncology Drugs”, including establishing the Sino-US expert cooperation committee of anti-tumor innovative drugs; establishing a long-term “Sino-US Innovation Cooperation Mechanism for Oncology Drug”, to jointly promote the international mutual recognition for global multi-center clinical trial and trail data and promote the reform of international drug supervision system. Then, PhIRDA will organize an international conference for oncology innovative drug annually with National Foundation for Cancer Research, which will be held in China and the United States respectively according to years, and experts, scholars and R&D enterprises from China and the United States will be invited to join the Conference; at the same time, the international oncology conference will be held, to build the exchange of oncology R&D, clinical community and investment community.

2) PhIRDA will establish a four-party innovation and cooperation mechanism with Hong Kong, Macao and Taiwan regions.

PhIRDA has signed a cooperation agreement with Taiwan's Institute for Biotechnology and Medicine Industry, Hong Kong Biopharmaceutical Innovation Association, Macao International Association for Quality Research in Chinese Medicines, deciding to establish a four-party pharmaceutical innovation and cooperation mechanism, gather experts and industrial representatives in pharmaceutical innovation field from four regions to participate in this mechanism, make exchanges for new drug R&D trend, pharmaceutical and healthy fields cooperation and other hot issues and provide a platform and link of innovation and cooperation for Chinese power in bio-pharmaceutical industry in China and in the world.

III. PhIRDA will continue to build the dialogue and exchange platform for innovation and investment and hold the “3rd China BioMed Innovation and Investment Conference”

PhIRDA has held two “China BioMed Innovation and Investment Conference”, through building the dialogue and exchange platform for innovation and investment, which has strengthened the integration of technology with the economy and innovative achievements with the industry and promoted the transformation of technological achievements in the capital markets with enthusiastic response in the industry. Therefore, PhIRDA will continue to hold the “China BioMed Innovation and Investment Conference” to build a five-in-one diversified international exchange platform covering Drug R&D, production, use, circulation and investment and build the Conference into an Asia’s unique professional pharmaceutical innovation and investors annual brand meeting.

IV. PhIRDA will carry out innovative publicity activities with Nature, Southern Medicine Economic Research Institute and its subordinate Medicine Economic News, MENET and other organizations and media

1) PhIRDA will cooperate with Nature to publicize the pharmaceutical innovative achievements in China.

According to the Memorandum of Cooperation signed by PhIRDA and Springer Nature on October 13th, 2016, on the one hand, we will show the achievements of China's pharmaceutical innovation that have been achieved to the global scientific research readers through Nature annually; recommend innovators in members to receive Nature (journal) interviews annually and make special interviews; on the other hand, Springer Nature will send senior editors in relevant subjects and fields to participate in conferences organized by PhIRDA annually and other activities; provide corresponding pre-conference publicity and post-conference in-depth reporting for annual "China BioMed Innovation and Investment Conference"; at the same time, it also provides favorable media promotion service and cooperation opportunities for members of PhIRDA.

2) PhIRDA will publicize drug supervision reform policies, achievements, etc. through Medicine Economic News, MENET and other media

PhIRDA will cooperate with CFDA Southern Medicine Economic Research Institute and its subordinate Medicine Economic News, MENET and other media, to publicize drug supervision reforms, achievements, etc. such as deepening drug review and approval that was carried out in full swing in recent years through organizing experts to accept media interviews and write points of view for industry focus policy issues.

3) PhIRDA will reform the brand selection way of "Innovative Drugs with Most Values", from self-declaration by enterprises to shortlisted varieties initiatively selected by Organizers from the database.

PhIRDA will cooperate with Southern Medicine Economic Research Institute to select the shortlisted varieties of "innovative brand selection", which will be evaluated through objective values instead the traditional mode of enterprise declaration and defense, to make the selection activities more objective and just.

V. PhIRDA will continue to expand cooperation and exchange activities with the embassies and consulates in China and trade associations of all countries

PhIRDA will continue to expand industrial cooperation and exchange forms with the embassies and consulates in China of Israel, Canada, Australia and other countries and pharmaceutical manufacturers associations of the United States, Japan and other countries, and organize international exchange activities such as project integration, visits and investigations as appropriate, to seek overseas cooperation opportunities for members, further improve the international competitiveness of China's pharmaceutical enterprises and promote the deep fusion of China's pharmaceutical industrial community with international society in trade, investment, technology and other fields.

VI. PhIRDA will continue to hold various forums and academic exchange activities, to serve the key links of pharmaceutical innovation

PhIRDA will continue to hold the annual "China Cardiovascular Disease Clinical Research Quality Management Standard (GCP) Conference" and Hospital and Pharmacy Policy Forum, to make due contributions of industrial association to improving quality and level of China's clinical research, improving rational drug use and other capabilities improvement in key fields of pharmaceutical innovation of hospital pharmacy personnel and assistant doctors.

PhIRDA will continue to keep its own sense of innovation, provide more innovative and more diversified services for members, be a good bridge between enterprises and governments, promote the improvement of policy environment for pharmaceutical innovation and build a higher level of domestic and foreign cooperation and exchange platform, to make untiringly struggles for innovation and sustainable development of pharmaceutical industry, thus protecting people's health and realizing the great goal of a powerful country in pharmaceutical innovation.

中国医药创新促进会
第十届会员大会第四次会议纪要

2017年10月29日，中国医药创新促进会（以下称“中国药促会”）在苏州召开了第十届会员大会第四次会议（以下称“大会”）。大会应到会员单位109家，实到会员单位88家，符合我会章程关于“会员大会须有2/3以上会员出席方能召开”的规定。

大会由中国药促会2016-2017年度会长、贝达药业股份有限公司董事长兼首席执行官丁列明主持。国资委行业协会商会党建工作局李春梅副局长，中国工业经济联合会经济团体工作部汪富亮副主任、中国药促会88家会员单位共160余位代表参加了会议。

（一）大会审议事项

1、大会审议通过了中国药促会执行会长宋瑞霖所做的《中国药促会2016-2017年度工作总结暨2017-2018年度工作安排》报告。

2、大会审议通过了《中国药促会2016-2017年度会费收支情况报告》。

3、大会审议通过了《关于发展中国药促会会员单位的议案》。本次会议审议通过了11家单位的入会申请，并追认了会员大会闭会期间会长会议通过的14家单位的入会申请。由此，中国药促会会员单位增加至109家，形成了药品制造、研发、临床、政策、投资全链条多元化的会员组织架构。

4、大会审议通过了《关于变更副会长的议案》。

5、大会审议通过了《关于设立中国医药创新促进会创新研发服务专业委员会的议案》，创新研发服务专业委员会旨在通过推动严格遵循人用药品注册技术国际协调会（ICH）GxP及我国相关规定，完善临床前、临床研究、药品生产以及临床研究设计、执行和报告全过程的质量控制和质量保障体系建设，以保证临床研究受试者的安全性、临床试验的科学性、数据准确性和真实完整性，提高由实验工艺向生产工艺转化的研究能力，确保研究质量管理符合注册监管要求及相关管理规定，为医药行业创新提供规范及良好的服务。

6、大会审议通过了《关于修订<中国医药创新促进会章程>的议案》、《关于修订会费标准的议案》。

（二）选举2018-2019年度候任会长和副会长

本次大会按照民政部和国资委要求，以无记名投票的方式进行了候任轮值会长、副会长选举。中国药促会副会长、绿叶制药集团董事长刘殿波先生当选为中国药促会2018-2019年度轮值会长；中国医药集团总公司副总经理邓金栋先生当选中国药促会副会长。

中国药促会2017-2018年度会长、中国医学科学院药物研究所所长蒋建东对中国药促会上一年度的工作予以肯定，并提出了下一年度的设想和要求。他提出，药物研究是一个系统工程，不仅仅是单纯的技术研究，还包括转化工艺技术和行政政策、医院流通各个环节，希望今后不断推动研究工作转化成科学成就服务社会，努力将中国医药行业打造为世界标杆。

国资委行业协会商会党建工作局李春梅副局长发表讲话。她代表国务院国资委行业协会商会工作局对会议的召开表示热烈祝贺，对中国药促会的工作予以了高度肯定。同时希望中国药促会能够继续从行业发展大局出发，适应新的形势要求，进一步加强自身建设，更好地推动医药创新发展的目标落到实处，努力把中国梦落实在医药强国梦当中。

大会内容丰富，安排紧凑，圆满完成了各项议程。通过修改章程和会费标准，强化了中国药促会的领导机构建设，完善了内部治理结构，为下一年度发展方向的确定和主要任务的开展实施奠定了基础；同时新会员的加入和创新研发服务专业委员会的成立为中国药促会推动医药创新和发展注入了新的血液和动力，彰显中国药促会在医药创新领域的拓展和凝聚力的进一步增强。

二〇一七年十月二十九日

Summary of the Fourth Meeting of the 10th PhIRDA General Assembly

On October 29, 2017, China Pharmaceutical Innovation and Research Development Association (PhIRDA) held the Fourth Meeting of the 10th PhIRDA General Assembly (hereinafter referred to as the meeting) in Suzhou. The number of members supposed to attend is 109 and the actual attendance is 88, which met the "2/3 member participation requirement" of PhIRDA Constitution.

The meeting was chaired by Ding Lieming, the 2016-2017 Annual Chairman of PhIRDA and Chairman & CEO of Betta Pharmaceuticals Co., Ltd.. Li Chunmei, Deputy Director of Party Building Bureau of Federation of China Trade Associations & Chambers of Commerce, SASAC, Wang Fuliang, Deputy Director of Economic Teamwork Department of China Federation of Industrial Economics and more than 160 representatives from 88 members of PhIRDA attended the meeting.

Session One. Approving items at the meeting

1) The meeting approved 2016-2017 Annula Work Report & 2017-2018 PhIRDA's Work Plan presented by Song Ruilin, Executive President of PhIRDA.

2) The meeting approved PhIRDA's Annual Financial Report for year 2016-2017.

3) The meeting approved the Proposal on Recruiting Member Units of PhIRDA. The meeting has approved 11 new member applications and confirmed 14 new members approved by the Presidents' meeting during intersessional meetings. So far, the number of members of PhIRDA has increased to 109, covering the entire chain from pharmaceutical manufacturing, R&D, clinical, policy and investment.

4) The meeting approved the Proposal on Changing Vice Presidents.

5) The meeting approved the Proposal on Setting up Innovation and R&D Services Special Committee of the China Pharmaceutical Innovation and Research Development Association. The special committee aims at improving the system construction of quality control and quality assurance of pre-clinical, clinical research, pharmaceutical manufacturing as well as the overall process of the clinical research design, conduct and report by promoting strict abidance by GxP of International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) and related regulations of our country to guarantee the safety of the subjects of clinical research and the scientificity, the accuracy and integrity of data of clinical trial, to increase the research capacity of transforming from experimental techniques to manufacturing techniques and ensure that research quality management conforms to the requirements of registration supervision and related stipulations, thus providing standard and sound services for innovations in pharmaceutical industry.

6) The meeting approved the Proposal on Revising the Constitution of the China Pharmaceutical Innovation and Research Development Association and Proposal on Revising the Membership Fees Standard.

Session Two. Electing the president-elect and vice president-elect of 2018-2019

According to the requirement of Ministry of Civil Affairs and State-owned Assets Supervision and Administration Commission, the meeting has elected the rotating president-elect and vice president-elect through secret ballot. Mr. Liu Dianbo, Chairman of Luye Pharma Group and Vice President of PhIRDA, was elected as the 2018-2019 Annual Chairman of PhIRDA; Mr. Deng Jindong, Vice General Manager of China National Pharmaceutical Group Corporation was elected as Vice President of PhIRDA.

Jiang Jiandong, 2017-2018 Annual Chairman of PhIRDA and Director of the Institute of Materia Medica, Chinese Academy of Medical Sciences, gave praises of PhIRDA's work this year and proposed the plans and requirements for the next year. He pointed out that drug research is a systematic project which should not be confined to pure technical research but include all aspects like technology transformation, administrative policy, circulation among hospitals, and hopes that we can continuously advance the transformation of research work into scientific outcomes to serve the society and strive to become the world leader in the pharmaceutical industry.

Li Chunmei, Deputy Director of Party Building Bureau of Federation of China Trade Associations & Chambers of Commerce, SASAC gave a speech. On behalf of the Work Bureau of Federation of China Trade Associations & Chambers of Commerce, SASAC of the State Council, she extended warm congratulations on the successfully held of the General Assembly and highly commended of PhIRDA's work. In the mean time, she hopes that PhIRDA can keep on taking the whole situation into consideration, adapt to new situation requirements, and further strengthen self-construction so as to better put the goals of pharmaceutical innovation and development into place and realize the Chinese dream through leading the world in the field of pharmaceutical industry.

The meeting successfully completed all contents. All items on agenda have been completed successfully. The revision of the constitution and membership fees standard strengths the construction of PhIRDA, improves the internal governance structure and lays a solid foundation for setting the development direction and implementing the major tasks in the upcoming year. Meanwhile, PhIRDA has been injected with fresh blood and impetus by recruiting new members and setting up innovation and R&D services special committee, manifesting that the expansion and cohesive power of PhIRDA has been further enhanced in the field of pharmaceutical innovation.

October 29, 2017

专业委员会简介 | Introduction of Specialty Committees

根据工作需要，经中国医药创新促进会（以下简称“中国药促会”）第十届一次、二次、四次会员大会审议通过，批准成立药物研发、药物临床研究、医药政策、医药创新投资和创新研发服务五个专业委员会。

药物研发专业委员会旨在通过强化药物研发交流，促进中国药促会会员单位创新研发能力的提升；参与ICH及国内外相关技术指南修订，为促进行业药物研发规范性及与国际接轨提出意见和建议。

药物临床研究专业委员会旨在通过为中国药促会会员单位的临床研究活动提供指导和建议，促进会员单位临床研究能力与水平的提升。

医药政策专业委员会旨在研究国内外医药政策领域的重大理论与实践问题，为政府提供决策参考。

医药创新投资专业委员会旨在吸纳对于医药创新有经验、有实力的投资界代表加入，激发中国药促会会员单位与投资界的密切合作，提升医药创新的效率和效益，在医药领域推动投资早期介入创新的政策和生态环境的形成。

创新研发服务专业委员会包含合同研究组织（CRO）和合同开发与生产组织（CDMO），旨在通过为会员单位及国内外企业提供符合国际标准的新药研发服务，形成具有国际竞争力的新药研发核心服务商集群，助力创新成果的转化。

各专业委员会允许吸纳相关专家以个人身份加入，为中国药促会会员单位在政策、研发、技术创新、临床试验及研发服务等方面提供指导与咨询，为会员单位创新活动的开展提供切实服务。

According to the First, Second and Fourth Meeting of 10th PhIRDA General Assembly, China Pharmaceutical Innovation and Research Development Association (PhIRDA) approved the establishment of five Specialty Committees: Medicinal Policy, Drug R&D, Clinical Research, Pharmaceutical Innovation Investment and Innovation R&D Services.

Drug R&D Specialty Committee aims to enhance the innovative R&D capability of PhIRDA's members through providing suggestions and comments on their innovative R&D activities, participating in the revision of ICH and relevant technical guidelines both at home and abroad, and providing opinions and suggestions for promoting the standardization and international harmonization of drug R&D of pharmaceutical industry.

Clinical Research Specialty Committee aims to promote clinical research capability through providing guidance and suggestions, as well as other aspects of clinical research activities of PhIRDA's members.

Medicinal Policy Specialty Committee aims to research major theoretical and practical issues in medicinal policies, providing references for government.

Pharmaceutical Innovation Investment Specialty Committee aims to attract representatives from investment communities with rich experience in pharmaceutical innovation, in order to stimulate the close cooperation between investment institutions and members, enhance the efficiency and effectiveness of innovation, promote the policy environment and ecological environment of innovation investment in early intervention.

Innovation R&D Services Specialty Committee includes Contract Research Organizations (CRO) and Contract Development and Manufacturing Organizations (CDMO), aiming to providing the new drug R&D services to members with international standardization, to create an international competiveness new drug R&D service group, to enhance the transfer of innovation achievements.

Each specialty committee absorbed related experts to join personally and provide guidance and consultation on policies, R&D, technological innovation and clinical trials to provide practical services to PhIRDA's members.

第二届药物研发专业委员会

The 2nd Drug R&D Specialty Committee

名誉主任委员 蒋建东

中国医药创新促进会会长
中国医学科学院药物研究所所长

Honorary Chairman, Jiang Jiandong
Chairman of China Pharmaceutical Innovation and Research Development Association (PhIRDA)
Director of Institute of Materia Medica, Chinese Academy of Medical Science

主任委员 王印祥

北京加科思新药研发有限公司董事长

Chairman, Wang Yinxiang
Chairman of Beijing Jacobio Pharma Co., Ltd.

副主任委员 张 丹

方恩（天津）医药发展有限公司董事长兼CEO

Vice-Chairman, Zhang Dan
Chairman & CEO of Fountain Medical (Tianjin) Co., Ltd.

副主任委员 陈建峰

中国工程院院士
北京化工大学副校长

Vice-Chairman, Chen Jianfeng
Academician of the Chinese Academy of Engineering,
Vice-President, Beijing University of Chemical Technology

副主任委员 房健民

荣昌生物制药（烟台）有限公司总经理兼首席科学官

Vice-Chairman,
Fang Jianmin
General Manager &
Chief Scientist Officer of RemeGen, Ltd.

副主任委员 何 伟

浙江导明医药科技有限公司总经理

Vice-Chairman, He Wei
General Manager of DTRM Biopharma

副主任委员 鲁先平

深圳微芯生物科技有限责任公司总裁兼首席科学官

Vice-Chairman, Lu Xianping
President & Chief Scientist Officer of Shenzhen Chipscreen Biosciences Co., Ltd.

副主任委员 徐希平

深圳奥萨医药有限公司董事长

Vice-Chairman, Xu Xiping
Chairman of the Board, Shenzhen AUSA Pharmaceuticals Ltd.

副主任委员 杨大俊

江苏亚盛医药开发有限公司董事长

Vice-Chairman, Yang Dajun
Chairman of Ascentage Pharma Group Corp., Ltd.

副主任委员 俞德超

信达生物制药（苏州）有限公司董事长兼总裁

Vice-Chairman, Yu Dechao
President & Chairman of Innovent Biologics, Inc.

副主任委员 陈 力

华领医药技术（上海）有限公司总经理

Vice-Chairman, Chen Li
General Manager of Hua Medicine (Shanghai) Ltd.

副主任委员 江宁军

基石药业（苏州）有限公司首席执行官

Vice-Chairman, Jiang Ningjun
CEO of CStone Pharmaceuticals Co., Ltd.

第二届药物临床研究专业委员会

The 2nd Clinical Research Specialty Committee

名誉主任委员 孙 燕

中国工程院院士

中国医学科学院肿瘤医院国家新药临床研究中心主任

Honorary Chairman, Sun Yan
Academician of the Chinese Academy of Engineering
Director of National New Drugs Clinical Research Center, Cancer Hospital, Chinese Academy of Medical Sciences

名誉主任委员 葛均波

中国科学院院士

复旦大学附属中山医院心内科主任

Honorary Chairman, Ge Junbo
Academician of Chinese Academy of Sciences
Director of Cardiology Department, Zhongshan Hospital Fudan University

主任委员 霍 勇

北京大学第一医院心内科及心脏中心主任

Chairman, Huo Yong
Director of Cardiology and Heart Center, Peking University First Hospital

副主任委员 王拥军

首都医科大学附属北京天坛医院常务副院长

Vice-Chairman, Wang Yongjun
Executive Deputy Dean of Beijing Tiantan Hospital, Capital Medical University

副主任委员 季加孚

北京大学肿瘤医院院长

Vice-Chairman, Ji Jiafu
President of Beijing Cancer Hospital

副主任委员 石远凯

国家癌症中心副主任、中国医学科学院肿瘤医院副院长

Vice-Chairman, Shi Yuankai
Deputy Director of National Cancer Centre
Vice President of Cancer Hospital, Chinese Academy of Medical Sciences

副主任委员 侯 健

第二军医大学长征医院血液科主任、全军骨髓瘤与淋巴瘤中心主任

Vice-Chairman, Hou Jian
Director of Department of Hematology, Shanghai Changzheng Hospital
Director, Myeloma and Lymphoma Disease Center of PLA

副主任委员 王广发

北京大学第一医院呼吸科主任

Vice-Chairman, Wang Guangfa
Director of Department of Respiration, Peking University First Hospital

副主任委员 崔一民

北京大学第一医院临床试验中心主任

Vice-Chairman, Cui Yimin
Director of Clinical Trial Center, Peking University First Hospital

副主任委员 李文斌

首都医科大学附属北京世纪坛医院脑胶质瘤科主任

Vice-Chairman, Li Wenbin
Director of Brain Glioma Dept. Beijing Shijitan Hospital affiliated to Capital Medical University

第二届医药政策专业委员会

The 2nd Medicinal Policy Specialty Committee

主任委员 邵 蓉
中国药科大学研究生院常务副院长
Chairman, Shao Rong
Executive Deputy Dean of China Pharmaceutical University Graduate School

副主任委员 史录文
北京大学药学院药事管理与临床药学系主任
Vice-Chairman, Shi Luwen
Director of Department of Pharmacy Administration and Clinical Pharmacy School of Pharmaceutical Sciences, Peking University

副主任委员 张清奎
原国家知识产权局医药生物审查部部长
Vice-Chairman, Zhang Qingkui
Former Director-General of Pharmaceutical and Biotech Examination Department, State Intellectual Property Office of the P.R.C.

副主任委员 朱恒鹏
中国社会科学院经济研究所副所长
Vice-Chairman, Zhu Hengpeng
Deputy Director of Institute of Economics of Chinese Academy Social Science

副主任委员 胡 欣
北京医院药学部主任
Vice-Chairman, Hu Xin
Director of Department of Pharmacy, Beijing Hospital

副主任委员 刘军帅
山东省青岛市社会保险研究会副会长
Vice-Chairman, Liu Junshuai
Vice-President of Qingdao Social Insurance and Research Association

副主任委员 陈 川
北京华康管理咨询有限公司董事长
Vice-Chairman, Chen Chuan
Chairman of Beijing HuaKang Healthcare Consulting Co., Ltd.

副主任委员 武志昂
沈阳药科大学工商管理学院教授
Vice-Chairman, Wu Zhi'ang
Professor of School of Business Management, Shenyang Pharmaceutical University

副主任委员 陈 文
复旦大学公共卫生学院院长
Vice-Chairman, Chen Wen
Dean of School of Public Health, Fudan University

副主任委员 王 波
北京秦脉医药咨询有限责任公司董事长
Vice-Chairman, Wang Bo
Chairman of Beijing CHNMED Pharmaceutical Technology Development Co., Ltd.

副主任委员 邵 颖
上海复星医药（集团）股份有限公司副总裁兼研发中心主任
Vice-Chairman, Shao Ying
Vice President, Director of R&D Center, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

副主任委员 冯 毅
方恩（天津）医药发展有限公司中国区总裁
Vice-Chairman, Feng Yi
President of China, Fountain Medical Development Ltd.

副主任委员 宣建伟
中山大学医药经济研究所所长
Vice-Chairman, Xuan Jianwei
Director of Institute of Medicine and Economics, Sun Yat-Sen University

第一届医药创新投资专业委员

The 1st Pharmaceutical Innovation Investment Specialty Committee

主任委员 杜 莹
再鼎医药（上海）有限公司董事长兼首席执行官
Chairman, Du Ying
Chairman of the Board & CEO, ZAI Lab (Shanghai) Co., Ltd.

副主任委员 储慧斌
海捷投资控股集团首席合伙人
Vice-Chairman, Chu Huibin
Chief Partner of Hiyield Capital Holding Group

副主任委员 易诺青
高瓴资本集团合伙人
Vice-Chairman, Yi Nuoqing
Partner of Hillhouse Capital Management, Ltd.

副主任委员 李凯军
上海醴泽投资管理有限公司管理合伙人
Vice-Chairman, Li Kaijun
Managing Partner of LYZZ Capital Advisors Management, Ltd.

副主任委员 朱晋桥
深圳市倚锋投资管理企业（有限合伙）董事长
Vice-Chairman, Zhu Jinqiao
Chairman of Shenzhen EFung Capital Co., Ltd.

副主任委员 陈鹏辉
博远资本创始合伙人
Vice-Chairman, Chen Penghui
Founding Partner of Biotrack Capital

副主任委员 梁颖宇
启明维创创业投资管理（上海）有限公司
主管合伙人
Vice-Chairman, Liang Yingyu
Managing Partner of Qiming Weichuang Venture Capital Management (Shanghai) Co., Ltd.

副主任委员 田 源
深圳前海元明资产管理有限公司创始合伙人
Vice-Chairman, Tian Yuan
Founding Partner of Shenzhen Qianhai YuanMing Asset Management Co., Ltd.

创新研发服务专业委员会发起人

Sponsors of Innovation R&D Services Specialty Committee

谭凌实
缔脉生物医药科技（上海）有限公司董事长兼首席执行官
Tan Lingshi, Chairman of the Board & CEO, dMed Biopharmaceutical Co., Ltd.

张 丹
方恩（天津）医药发展有限公司董事长
Zhang Dan, Chairman of the Board, Fountain Medical (Tianjin) Co., Ltd.

洪 浩
凯莱英医药集团（天津）股份有限公司董事长兼CEO
Hong Hao, Chairman of the Board & CEO, Asymchem Laboratories (Tianjin) Co., Ltd.

陈春麟
上海美迪西生物医药股份有限公司首席执行官
Chen Chunlin, CEO, Shanghai Medicilon Inc.

闻丹忆
上海立迪生物技术股份有限公司董事长
Wen Danyi, Chairman of the Board, Shanghai LIDE Biotech Co., Ltd.

PhIRDA 中国药促会

重要活动 | Important Events

中国药促会2017年会长会议扩大会议（2017年2月25日 · 杭州）

2017 PhIRDA President Board Meeting (February 25, 2017, Hangzhou)

参会代表合影

Photograph of Representatives

药品专利链接和专利期补偿制度研讨会（2017年6月9日·烟台）

Conference on Drug Patent Linkage and Patent Term Restoration System (June 9, 2017, Yantai)

中国药促会在烟台召开了“药品专利链接和专利期补偿制度研讨会”。会议就中国引入药品专利链接制度与专利期补偿制度的可行性以及如何落地等热点问题进行了讨论。国家食品药品监督管理总局、国家知识产权局、卫生计生委等部门相关领导及会员单位代表和专业委员会专家近70人出席了会议。

PhIRDA held the “Conference on Drug Patent Linkage and Patent Term Restoration System” in Yantai, and the attending leaders and enterprise representatives conducted in-depth discussions on establishing the drug patent linkage and patent term restoration system in China. Almost 70 delegates including leaders from CFDA, SIPO, and NHFPC etc., representatives from members and experts of specialty committees attended the conference.

会议现场

Plenary Meeting

中国药促会药物研发专委会与药物临床研究专委会2016年年会（2016年12月3日·顺德）

2016 Annual Meeting of PhIRDA Drug R&D Specialty Committee and Clinical Research Specialty Committee (December 3, 2016, Shunde)

参会代表合影

Photograph of Representatives

中国药促会药物研发专业委员会换届会议暨第二届第一次工作会议（2017年6月10日·烟台）

PhIRDA Drug R&D Specialty Committee General Election and the First Meeting of 2nd General Assembly (June 10, 2017, Yantai)

会议现场

Plenary Meeting

中国药促会药物临床研究专业委员会换届会议暨第二届第一次工作会议（2017年6月10日 · 烟台）

PhIRDA Clinical Research Specialty Committee General Election and the First Meeting of 2nd General Assembly (June 10, 2017, Yantai)

会议现场

Plenary Meeting

中国药促会医药政策专业委员会换届会议暨第二届第一次工作会议（2017年6月10日·烟台）

PhIRDA Medicinal Policy Specialty Committee General Election and the First Meeting of 2nd General Assembly (June 10, 2017, Yantai)

会议现场

Plenary Meeting

第十届会员大会第四次会议（2017年10月29日 · 苏州）

The Fourth Meeting of 10th PhIRDA General Assembly

(October 29, 2017, Suzhou)

参会代表合影

Photograph of Representatives

会场全景

Plenary Meeting

2016–2017年度会长丁列明主持会议

Ding Lieming (PhIRDA Annual Chairman 2016-2017)
chaired the meeting

执行会长宋瑞霖做工作报告

PhIRDA Annual Work Report given by
Executive President Song Ruilin

新任会长蒋建东讲话

Addressed by Jiang Jiandong
(PhIRDA Annual Chairman 2017-2018)

2016–2017年度会长为2017–2018年度会长颁发证书

Ding Lieming, PhIRDA Annual Chairman 2016-2017,
presented certificate to Jiang Jiandong,
PhIRDA Annual Chairman 2017-2018

第二届（2016年）中国医药创新最具影响力品牌评选活动颁奖典礼（2017年3月12日 · 北京）

The Ceremony of the Second (2016) Most Influential Brand Selection in Chinese Pharmaceutical Industry (March 12, 2017, Beijing)

出席典礼的领导和嘉宾

The Officials and VIPs

领导、颁奖嘉宾及获奖者合影

Photograph of the Participants

“最具临床替代价值仿制药”获奖者和颁奖嘉宾合影
Photograph of the Generic Drug with Most Clinical Alternative Value

“最具临床价值创新药”获奖者和颁奖嘉宾合影
Photograph of the Innovative Products with Most Clinical Value

“中国医药创新终身成就奖”桑国卫院士与陈竺副委员长、刘谦原副主任、宋瑞霖执行会长合影
Photograph of “Lifetime Achievement Awards of China Pharmaceutical Innovation” winner Academician Sang Guowei with Vice Chairman Chen Zhu, former Deputy Director Liu Qian and Executive President Song Ruilin

“最具创新能力医药企业”获奖者和颁奖嘉宾合影
Photograph of the Most Innovative Pharmaceutical Enterprise

“最具影响力创新人物”获奖者和颁奖嘉宾合影
Photograph of the Most Influential Innovative People

第二届中国临床研究质量管理（GCP）暨创新药研发大会（2017年6月10-11日·烟台）

The Second China Cardiovascular Disease Clinical Research Quality Management Standard (GCP) Conference (June 10-11, 2017, Yantai)

由中国药促会、中国心血管健康联盟、中国抗血栓药物治疗联盟共同主办的“第二届中国临床研究质量管理（GCP）暨创新药研发大会”在山东省烟台市召开。大会围绕如何建立符合国际标准的临床多中心药物临床试验研究体系，推动国内创新药物研发与国际接轨等问题展开了深入讨论。来自药品审核查验机构、医疗机构和医药企业的多位专家，还有来自本土创新型企业和跨国医药企业的医药专家，以及临床研究机构和企业的相关工作人员共计300余人出席了会议。

The Second China Cardiovascular Disease Clinical Research Quality Management Standard (GCP) Conference was co-hosted by PhIRDA, China Cardiovascular Association and China Anti-thrombotic Drug Treatment Alliance in Yantai, Shandong Province. Representatives conduct in-depth discussions on how to establish a multi-center clinical trial system that meets the international standard and how to bring pharmaceutical innovation in China in line with international practice. More than 300 people attended this conference, including experts from inspection sectors, clinical institutions, pharmaceutical companies and R&D institutions and senior representatives from domestic and foreign innovative enterprises attended this event.

会议现场

Plenary Meeting

第八届中国医院药学政策论坛（2017年7月21日·银川）

The 8th China Hospital Pharmacy Policy Forum (July 21, 2017, Yinchuan)

中国药促会和中国药师协会共同主办的以“发挥药师服务能力，助力健康中国”为主题的第八届中国医院药学政策论坛在银川召开。来自人社部、中国药促会、中国药师协会等单位的相关领导和各医疗机构的药剂科主任、临床专家，以及来自全国各地药学领域的代表近400人参加了会议。

The 8th China Hospital Pharmacy Policy Forum co-hosted by PhIRDA and Chinese Pharmacists Association was successfully held in Yinchuan on July 21, 2017. Nearly 400 people attended the forum, including relevant leaders from MOHRSS, PhIRDA and Chinese Pharmacists Association, and pharmacy directors from medical institutions, clinical experts and representatives in pharmacy field from all over the country.

会场全景

Plenary Meeting

第二届中国医药创新与投资大会
（2017年10月29日-31日·苏州）

2017 China BioMed Innovation and Investment Conference
(October 29-31, 2017, Suzhou)

由中国药促会等协会主办的第二届“中国医药创新与投资大会”在苏州工业园区盛大开幕。大会开幕式紧紧围绕医药创新政策、投资走向、创新模式与投资的交互影响等问题展开讨论。共有9个重磅新药的最新临床研究数据在开幕式后的临床数据首发专场进行了发布。CFDA副局长孙咸泽和国家卫计委副主任曾益新等领导及来自国内外投资、医药创新企业与研究院所等700余家机构、约2000名代表出席了开幕式。

2017 China BioMed Innovation and Investment Conference was co-hosted by PhIRDA, SAC, CAMDI, and HKEX. Policies on encouraging pharmaceutical innovation, investment trend and innovative model and interactive influence of investment were the main topics and 9 new drugs released their latest clinical-trial data on the conference. Sun Xianze, the Vice Minister of China Food and Drug Administration (CFDA), Zeng Yixin, the Vice Minister of National Health and Family Planning Commission (NHFPC) and over 700 investment institutions, R&D institutes and pharmaceutical innovation companies, more than 2000 delegates participated in this event.

开幕式会场全景

Plenary Meeting of the Opening Ceremony

国家食品药品监督管理总局副局长孙咸泽致辞

Addressed by Sun Xianze, Vice Minister of China Food and Drug Administration (CFDA)

国家卫生和计划生育委员会副主任曾益新致辞

Addressed by Zeng Yixin, Vice Minister of National Health and Family Planning Commission (NHFPC)

摩根大通国际董事长Jacob A. Frenkel围绕“全球经济与央行政策”做专题报告

Jacob A. Frenkel, Chairman of JPMorgan Chase International gave speech on the Global Economy and Central Banking

中国证券业协会副会长葛伟平致辞

Addressed by Ge Weiping, Vice Chairman of Securities Association of China

中国医疗器械行业协会执行副会长姜峰致辞

Addressed by Jiang Feng, Executive Vice President of China Association for Medical Devices Industry

江苏省苏州市委常委、苏州工业园区党工委书记徐惠民致辞

Addressed by Xu Huimin, Member of the Standing Committee of CPC Suzhou Municipal Committee & Secretary of CPC SIP Working Committee

中国药促会2016-2017年度会长、贝达药业股份有限公司董事长丁列明主持开幕式第一阶段

Ding Lieming, 2016-2017 Annual Chairman of PhIRDA, Chairman of the Board & CEO of Betta Pharmaceutical Co., Ltd. chaired the 1st session of the Opening Ceremony

中国药促会执行会长宋瑞霖主持开幕式第二阶段

Song Ruilin, Executive President of PhIRDA chaired the 2nd session of the Opening Ceremony

TESARO联合创始人、总裁兼首席运营官Mary Lynne Hedley 围绕“通过分散式创新促进治疗性发现和开发”做专题报告

Mary Lynne Hedley, Co-Founder, President & Chief Operating Officer of TESARO Co., Ltd. gave speech on Driving Therapeutic Discovery and Development through Distributed Innovation

香港交易所董事总经理许正宇围绕“新经济、新金融、新医药”做专题报告

Christopher Hui, Managing Director of Hong Kong Exchange and Clearing Ltd. gave speech on New Economy, New Finance and New BioMed

中国药促会、台湾-生技医疗产业策进会、香港生物医药创新协会和澳门-国际中药质量研究会签署两岸四地生物医药创新合作协议

Cooperation Agreement on Pharmaceutical Innovation among PhIRDA (China Mainland), Institute for Biotechnology and Medicine Industry (IBMI) (Chinese Taipei), HK Bio-Med Innotech Association (Hong Kong), and International Association of Quality Research in Chinese Medicine (Macau)

中国药促会与美国癌症研究基金会签署合作备忘录

Memorandum of Understanding signed by PhIRDA and National Foundation for Cancer Research (NFCR)

“全球医药投资趋势”主题讨论

Panel on Global Pharmaceutical Investment Trends

“国际药物研发与临床研究”主题讨论

Panel on Pharmaceutical R&D and Clinical Research

开展政策研讨 积极建言献策

Making discussions on medical policies & Providing suggestions

2016-2017年度，中国药促会先后承接了国家卫计委、人社部、国家食药总局等部委及企业委托的政策研究课题十多项，并通过召开研讨会、组建研发联盟等方式不断寻求完善医药创新政策环境的方案，促进医药产业健康发展。

During 2016-2017, entrusted by NHFPC, MOHRSS, CFDA and related departments and companies, PhIRDA carried out more than 10 research projects, meanwhile, organized seminars to improve the eco-system for pharmaceutical innovation, so as to promote the healthy development of pharmaceutical industry.

重大专项办与中国药促会创新企业座谈会（2017年10月29日 · 苏州）

Seminar on Management Office of National Science and Technology Major Project for Major New Drug Research and Development and PhIRDA Innovative Enterprises (October 29, 2017, Suzhou)

外宾的会见与交流

Meetings and Exchanges with Foreign VIPs

执行会长宋瑞霖会见国际药品制药商协会联合会 (IFPMA) 副总干事Brendan Shaw（2017年5月18日 · 北京)

Executive President Song Ruilin met with Brendan Shaw, Deputy Director-General of IFPMA (May 18, 2017, Beijing)

执行会长宋瑞霖与澳大利亚生物技术协会首席执行官 Glenn Cross（2017年10月13日 · 北京）

Executive President Song Ruilin met with Glenn Cross, CEO of Australia's Biotech Organization (October 13, 2017, Beijing)

执行会长宋瑞霖会见美国癌症研究基金会主席一行 (2017年10月30日 · 苏州）

Executive President Song Ruilin met with the Chairman and Delegation of NFCR (October 30, 2017, Suzhou)

执行会长宋瑞霖、副会长刘殿波会见前厚生劳动省大臣川崎二郎（左二）（2017年4月7日 · 日本东京）

Executive President Song Ruilin and Vice President Liu Dianbo met with Jiro Kawasaki, former Minister of Health, Labour and Welfare (April 4, 2017, Tokyo, Japan)

中国药促会代表团赴欧洲考察访问
（2017年6月26日-7月4日·欧洲）

PhIRDA delegation visited Europe (June 26-July 4, 2017, Europe)

中国药促会2016-2017年度会长丁列明率团赴欧进行访问。期间，中国药促会代表团受邀出席了IFPMA会长会议和理事会会议。并先后访问了世界卫生组织总部、法国制药企业协会、法国赛诺菲公司总部、世界贸易组织、世界知识产权总部、德国研究型制药企业协会、德国拜耳公司、德国工业联合会、绿叶制药集团德国分公司等多家机构。

Led by PhIRDA Chairman 2016-2017 Ding Lieming, PhIRDA Delegation was invited to Europe to attend the President Meeting and Council Meeting of IFPMA, and successively visited the WHO headquarter, LEEM, Sanofi headquarter, WTO headquarter, WIPO headquarter, VFA, Bayer AG, BDI and Luye Pharma AG (Miesbach) etc.

代表团与世界贸易组织代表会谈现场

Meeting with WTO

代表团与世界知识产权组织代表合影

Meeting with WIPO

中国药促会2016-2017年度会长丁列明、执行会长宋瑞霖与IFPMA总干事 Thomas Cueni

2016-2017 Chairman Ding Lieming, Executive President Song Ruilin and Thomas Cueni, Director-General of IFPMA

代表团与德国研究型制药企业协会代表会谈现场

Meeting with VFA

代表团与法国制药企业协会代表会谈现场

Meeting with LEEM

代表团与德国工业联合会代表会谈现场

Meeting with BDI

IFPMA、中国药促会和RDPAC共同主办
IFPMA实践伦理准则培训会议（2017年10月10日 · 北京）

Held IFPMA Code Capacity Workshop Ethics & Business Integrity Training together with IFPMA and RDPAC (October 10, 2017, Beijing)

执行会长宋瑞霖致辞

Executive President Song Ruilin gave a speech

中国药促会与IFPMA、RDPAC高层讨论会

Photograph of the high level discussion among PhIRDA, IFPMA and RDPAC

第十届会员单位及其代表

Members & Representatives of 10th PhIRDA General Assembly

蒋建东 Jiang Jiandong	中国医学科学院药物研究所所长 Director, Institute of Materia Medica, Chinese Academy of Medical Sciences
陈启宇 Chen Qiyu	上海复星医药（集团）股份有限公司执行董事、董事长 Executive Director, Chairman of the Board, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
闫希军 Yan Xijun	天士力控股集团董事局主席 Chairman of the Board, Tasly Holding Group
孙飘扬 Sun Piaoyang	江苏恒瑞医药股份有限公司董事长 Chairman of the Board, Jiangsu Hengrui Medicine Co., Ltd.
蒋华良 Jiang Hualiang	中国科学院上海药物研究所所长，中国科学院院士 Director, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Academician of Chinese Academy of Sciences
丁列明 Ding Lieming	贝达药业股份有限公司董事长兼CEO Chairman of the Board & CEO, Betta Pharmaceutical Co., Ltd.
张伯礼 Zhang Boli	天津中医药大学校长，中国工程院院士 President, Tianjin University of Traditional Chinese Medicine, Academician, Chinese Academy of Engineering
蔡东晨 Cai Dongchen	石药控股集团有限公司董事长 Chairman of the Board, China Shijiazhuang Pharmaceutical Group Co., Ltd.
任晋生 Ren Jinsheng	先声药业有限公司董事长 Chairman of the Board, Simcere Pharmaceutical Group
邓金栋 Deng Jindong	中国医药集团总公司副总经理 Deputy General Manager, China National Pharmaceutical Group Corporation
舒　畅 Shu Chang	上海医药集团股份有限公司副总裁 Vice President, Shanghai Pharmaceuticals Holding Co., Ltd.
柯尊洪 Ke Zunhong	成都康弘药业集团股份有限公司董事长 Chairman of the Board, Chengdu Kanghong Pharmaceutical Group Co., Ltd.
刘殿波 Liu Dianbo	绿叶制药集团有限公司董事长 Chairman of the Board, LUYE Pharma Group Co., Ltd.
徐镜人 Xu Jingren	扬子江药业集团董事长 Chairman of the Board, Yangtze River Pharmaceutical Group
白礼西 Bai Lixi	太极集团有限公司董事长 Chairman of the Board, Taiji Group Co., Ltd.
胡季强 Hu Jiqiang	浙江康恩贝制药股份有限公司董事长 Chairman of the Board, Zhejiang Conba Pharmaceutical Co., Ltd.
李振江 Li Zhenjiang	神威药业集团有限公司董事长 Chairman of the Board, Shineway Pharmaceutical Group Co., Ltd.
李春波 Li Chunbo	浙江医药股份有限公司董事长 Chairman of the Board, Zhejiang Medicine Co., Ltd.
高任龙 Gao Renlong	华北制药集团有限责任公司首席科学家 Chief Scientist, North China Pharmaceutical Group Corporation
汲　涌 Ji Yong	东北制药集团股份有限公司总经理 General Manager, Northeast Pharmaceutical Group Co., Ltd.
刘革新 Liu Gexin	四川科伦药业股份有限公司董事长 Chairman of the Board, Sichuan Kelun Pharmaceutical Co., Ltd.
李　聪 Li Cong	通化东宝药业股份有限公司总经理 General Manager, Tonghua Dongbao Pharmaceutical Co., Ltd.
李安平 Li Anping	山西振东制药股份有限公司董事长 Chairman of the Board, Shanxi Zhendong Pharmaceutical Co., Ltd.

张成海 Zhang Chenghai	美罗药业股份有限公司董事长 Chairman of the Board, Merro Pharmaceutical Co., Ltd.
顾浩亮 Gu Haoliang	上海上药信谊药厂有限公司总经理 General Manager, SPH SINE Pharmaceutical Co., Ltd.
李　昕 Li Xin	华润双鹤药业股份有限公司总裁 President, China Resources Double-Crane Pharmaceutical Co., Ltd.
陶德胜 Tao Desheng	丽珠医药集团股份有限公司总裁 President, Livzon Pharmaceutical Group Inc.
郭殿武 Guo Dianwu	杭州民生药业有限公司首席科学家 Chief Scientist, Hangzhou Minsheng Pharmaceutical Co., Ltd.
董弘宇 Dong Hongyu	浙江佐力药业股份有限公司总经理 General Manager, Zhejiang Jolly Pharmaceutical Co., Ltd.
欧阳静波 Ouyang Jingbo	广西梧州中恒集团股份有限公司总裁、副董事长、党委书记 President, Vice Chairman & Party Secretary, Guangxi Wuzhou Zhongheng Group Co., Ltd.
王　勇 Wang Yong	南京圣和药业股份有限公司董事长 Chairman of the Board, Nanjing Sanhome Pharmaceutical Co., Ltd.
赵　涛 Zhao Tao	山东步长制药股份有限公司董事长 Chairman of the Board, Shandong Buchang Pharmaceutical Co., Ltd.
于伟仕 Yu Weishi	悦康药业集团有限公司董事长 Chairman of the Board, Youcare Pharmaceutical Group Co., Ltd.
陈庆才 Chen Qingcai	江苏奥赛康药业股份有限公司董事长 Chairman of the Board, Jiangsu Aosaikang Pharmaceutical Co., Ltd.
王晓琳 Wang Xiaolin	重庆植恩药业有限公司副董事长 Vice Chairman, Zein Pharmaceutical Co., Ltd.
冯　鹤 Feng He	正大青春宝药业有限公司总裁 President, Chiatai Qingchunbao Pharmaceutical Co., Ltd.
徐希平 Xu Xiping	深圳奥萨医药有限公司董事长 Chairman of the Board, Shenzhen AUSA Pharmaceuticals Ltd.
娄　竞 Lou Jing	三生制药集团董事长兼首席执行官 Chairman of the Board & CEO, 3S Pharmaceutical Group
任武贤 Ren Wuxian	亚宝药业集团股份有限公司董事长 Chairman of the Board, Yabao Pharmaceutical Group Co., Ltd.
葛啸虎 Ge Xiaohu	常州方圆制药有限公司董事长 Chairman of the Board, Changzhou Fangyuan Pharmaceutical Co., Ltd.
李伯涛 Li Botao	齐鲁制药有限公司董事长 Chairman of the Board, Qilu Pharmaceutical Co., Ltd.
鲁先平 Lu Xianping	深圳微芯生物科技有限责任公司董事、总裁、首席科学家 Director, President & Chief Scientific Officer, Shenzhen Chipscreen Biosciences, Ltd.
张海英 Zhang Haiying	青岛黄海制药有限责任公司董事长 Chairman of the Board, Qingdao Huanghai Pharmaceutical Co., Ltd.
钟慧娟 Zhong Huijuan	江苏豪森药业集团有限公司董事长 Chairman of the Board, Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
叶宇翔 Ye Yuxiang	深圳信立泰药业股份有限公司总经理 General Manager, Shenzhen Salubris Pharmaceuticals Co., Ltd.
王善春 Wang Shanchun	正大天晴药业集团股份有限公司总裁 President, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
孔　泰 Kong Tai	北京泰德制药股份有限公司总裁 President, Beijing Tide Pharmaceutical Co., Ltd.

张贵民 Zhang Guimin	鲁南制药集团股份有限公司董事长、总经理 Chairman of the Board & CEO, Lunan Pharmaceutical Group Co., Ltd.
萧　伟 Xiao Wei	江苏康缘药业股份有限公司董事长 Chairman of the Board, Jiangsu Kanion Pharmaceutical Co., Ltd.
孙　毅 Sun Yi	成都百裕制药股份有限公司董事长 Chairman of the Board, Chengdu Baiyu Pharmaceutical Co., Ltd.
陈保华 Chen Baohua	浙江华海药业股份有限公司总裁 President, Zhejiang Huahai Pharmaceutical Co., Ltd.
杨代常 Yang Daichang	武汉禾元生物科技股份有限公司董事长 Chairman of the Board, Wuhan Healthgen Biotechnology Corp.
高　帆 Gao Fan	西藏易明西雅医药科技股份有限公司董事长 Chairman of the Board, Tibet AIM Pharm. INC.
刘振腾 Liu Zhenteng	山东罗欣药业集团股份有限公司董事会执行董事 Executive Director of the Board, Luoxin Pharmaceutical Group Co., Ltd.
俞德超 Yu Dechao	信达生物制药（苏州）有限公司董事长兼总裁 Chairman of the Board & CEO, Innovent Biologics (Suzhou) Co., Ltd.
陈　力 Chen Li	华领医药技术（上海）有限公司总经理 CEO, Hua Medicine (Shanghai) Ltd.
吴劲梓 Wu Jinzi	歌礼生物科技（杭州）有限公司董事长 Chairman of the Board, Ascletis Bioscience Co., Ltd.
杨大俊 Yang Dajun	江苏亚盛医药开发有限公司董事长兼CEO Chairman of the Board & CEO, Ascentage Pharma Group Corp., Limited
杜　莹 Du Ying	再鼎医药（上海）有限公司董事长兼首席执行官 Chairman of the Board & CEO, ZAI Lab (Shanghai) Co., Ltd.
薛　群 Xue Qun	北海康成（北京）医药科技有限公司创建人、董事长及首席执行官 Founder, Chairman of the Board & CEO, CANbridge Life Sciences Ltd.
王清梅 Wang Qingmei	和记黄埔医药（上海）有限公司商务开发和战略合作资深副总裁 Senior Vice President, Business Development & Strategic Alliances, Hutchison MediPharma Limited
徐　霆 Xu Ting	苏州康宁杰瑞生物科技有限公司董事长兼CEO Chairman of the Board & CEO, Suzhou Alphamab Co., Ltd.
江宁军 Jiang Ningjun	基石药业（苏州）有限公司首席执行官 CEO, CStone Pharmaceuticals Co., Ltd.
李怡平 Li Yiping	上海药明巨诺生物科技有限公司首席执行官 CEO, JW Therapeutics (Shanghai) Co., Ltd.
王印祥 Wang Yinxiang	北京加科思新药研发有限公司董事长 Chairman of the Board, Beijing Jacobio Pharma Co., Ltd.
崔霁松 Cui Jisong	北京诺诚健华医药科技有限公司总经理 General Manager, Beijing InnoCare Pharma Tech Co., Ltd.
梁　恒 Liang Heng	百济神州（北京）生物科技有限公司首席财务官兼首席战略官 CFO & Chief Strategy Officer, BeiGene (Beijing) Co., Ltd.
谢　东 Xie Dong	前沿生物药业（南京）股份有限公司董事长 Chairman of the Board, Frontier Biotechnologies Inc.
钟黎蕴华 Zhongli Yunhua	珐博进（中国）医药技术开发有限公司执行总裁 Managing Director, FibroGen (China) Medical Technology Development Co., Ltd.
房健民 Fang Jianmin	荣昌生物制药（烟台）有限公司总经理兼首席科学官 General Manager and Chief Scientific Officer, RemeGen, Ltd.

王思振 Wang Sizhen	北京泛生子基因科技有限公司首席执行官 CEO, Genetron Health (Beijing) Co., Ltd.
赵　宏 Zhao Hong	赛生医药江苏有限公司首席执行官兼总裁 CEO & President, SciClone Pharmaceuticals (Jiangsu) Co., Ltd.
储慧斌 Chu Huibin	海捷投资控股集团首席合伙人 Chief Partner, Hiyield Investment Holding Group
易诺青 Yi Nuoqing	高瓴资本管理有限公司合伙人 Partner, Hillhouse Capital Management, Ltd.
李凯军 Li Kaijun	上海醴泽投资管理有限公司管理合伙人 Managing Partner, LYZZ Capital Advisors Management, Ltd.
朱晋桥 Zhu Jinqiao	深圳市倚锋投资管理企业（有限合伙）董事长 Chairman of the Board, Shenzhen Efung Venture Capital Co., Ltd.
陆潇波 Lu Xiaobo	红杉资本股权投资管理（天津）有限公司合伙人 Partner, Sequoia Capital Equity Investment Management (Tianjin) Co., Ltd.
梁颖宇 Liang Yingyu	启明维创创业投资管理（上海）有限公司主管合伙人 Managing Partner, Qiming Weichuang Venture Capital Management (Shanghai) Co., Ltd.
田　源 Tian Yuan	深圳前海元明资产管理有限公司创始合伙人 Founding Partner, Shenzhen Qianhai YuanMing Asset Management Co., Ltd.
易八贤 Yi Baxian	上海浦东科技投资有限公司管理合伙人兼副总裁 Managing Partner & Vice President, Shanghai Pudong Science and Technology Investment Co., Ltd.
吴　海 Wu Hai	淡马锡投资咨询（北京）有限公司中国区执行总经理 Executive General Manager of China, Temasek Investment Management
胡雪峰 Hu Xuefeng	深圳市高特佳投资集团有限公司主管合伙人 Competent Partner, Shenzhen GTJA Investment Group Co., Ltd.
苑全红 Yuan Quanhong	上海建信股权投资管理有限公司总裁 CEO, Shanghai Jianxin Capital Management Co., Ltd.
李振福 Li Zhenfu	北京德福悦安投资顾问有限公司董事长 Chairman of the Board, GL Capital Group
居伟民 Ju Weimin	中投海外直接投资有限责任公司总经理 President, CIC Capital Co., Ltd.
成建新 Cheng Jianxin	平安银行医疗健康文化旅游金融事业部总裁 President, Finance SBU of Healthcare Industries of Ping An Bank
陈　可 Chen Ke	天津博信鑫元资产管理股份有限公司总经理 General Manager, Tianjin Boxin Xinyuan Asset Management Co., Ltd.
陈鹏辉 Chen Penghui	成都博远嘉昱创业投资合伙企业（有限合伙）创始合伙人 Founding Partner, Biotrack Capital
钱庭栀 Qian Tingzhi	上海景旭创业投资有限公司总裁 President, Shanghai Prosperico Venture Co., Ltd.
祝献忠 Zhu Xianzhong	华融证券股份有限公司党委书记、董事长 Secretary of the Party Committee & Chairman of the Board, Huarong Securities Co., Ltd.
钱龙海 Qian Longhai	第一创业证券股份有限公司董事、总裁 Director and President, First Capital Securities Co., Ltd.
郑效东 Zheng Xiaodong	上海东富龙科技股份有限公司董事长 Chairman of the Board, Shanghai Tofflon Science and Technology Co., Ltd.
王锦刚 Wang Jingang	北京科信必成医药科技发展有限公司总经理 General Manager, CoSci Med-Tech Co., Ltd.
张　丹 Zhang Dan	方恩（天津）医药发展有限公司董事长 Chairman of the Board, Fountain Medical (Tianjin) Co., Ltd.
李　革 Li Ge	药明康德新药开发有限公司董事长兼首席执行官 Chairman of the Board & CEO, WuXi AppTec Co., Ltd.

李　靖 Li Jing	药渡经纬信息科技（北京）有限公司董事长 Chairman of the Board, Pharmacodia (Beijing) Co., Ltd.
谭凌实 Tan Lingshi	缔脉生物医药科技（上海）有限公司董事长兼首席执行官 Chairman of the Board & CEO, dMed Biopharmaceutical Company Limited
张天泽 Zhang Tianze	零氪科技（北京）有限公司首席执行官 CEO, LinkDoc Co., Ltd.
吴晓明 Wu Xiaoming	中国药科大学原校长 Former President, China Pharmaceutical University
高思华 Gao Sihua	北京中医药大学原校长 Former President, Beijing University of Chinese Medicine
吴春福 Wu Chunfu	沈阳药科大学党委书记 Secretary of the Party Committee, Shenyang Pharmaceutical University
刘俊义 Liu Junyi	北京大学药学院原院长 Former Dean, Peking University School of Pharmaceutical Sciences
陆伟跃 Lu Weiyue	复旦大学药学院党委书记 Secretary of the Party Committee, School of Pharmacy Fudan University
刘克良 Liu Keliang	中国人民解放军军事医学科学院毒物药物研究所原所长 Former Director, Institute of Pharmacology and Toxicology Academy of Military Medical Sciences
李卓荣 Li Zhuorong	中国医学科学院北京协和医学院医药生物技术研究所副所长 Deputy Director, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College
王拥军 Wang Yongjun	首都医科大学附属北京天坛医院常务副院长、党委副书记 Executive Deputy Dean & Deputy Secretary of the Party Committee, Beijing Tiantan Hospital, Capital Medical University
陈建峰 Chen Jianfeng	北京市纳微化结构药物工程技术研究中心，北京化工大学副校长，中国工程院院士 Beijing Nanostructured Drug Engineering & Technology Center, Vice President, Beijing University of Chemical Technology, Academician of Chinese Academy of Engineering

第十届会员单位简介（排名不分先后）

Brief Introduction of 10th PhIRDA General Assembly Members

中国医学科学院药物研究所

Institute of Materia Medica, Chinese Academy of Medical Sciences

中国医学科学院药物研究所（以下简称“药物所”）成立于1958年，隶属于中国医学科学院北京协和医学院。

药物所始终以寻找和研究防治严重危害人民健康的常见病、多发病及疑难疾病的药物为主要方向，坚持以创制具有自主知识产权的新药为重点，是国家重点药物研究机构之一，采用现代医药学理论和高新技术开展多学科综合性研究，旨在走出有中国特色的新药创制之路。药物所主要研究方向包括抗肿瘤药物、防治心脑血管疾病药物、治疗神经精神类疾病药物、抗代谢紊乱药物、抗感染药物、抗炎免疫类药物、治疗老年退行性疾病药物等。

药物所现建有1个国家重点实验室，即天然药物活性物质与功能国家重点实验室；7个省部级重点实验室和国家药物及代谢产物分析研究中心、国家新药开发工程技术研究中心、国家药物筛选中心、中国医学科学院北京协和医学院新药安全评价中心、药物所药物晶型研究中心。“十一五”以来，国家“新药创制”重大专项在药物研究所建立了包括综合大平台在内的多个技术平台,有效地增进了研究所的研究能力。自建所以来，药物所作为第一完成单位共获得国家级奖31项；持有的有效专利700余项，获得授权的国内外专利344项；共编写著作354本。近年来，药物所发表论文质量取得明显提升，2016年以第一完成单位发表SCI论文 188篇。

药物所与国内及美国、法国、日本、德国、西班牙、加拿大等国家和地区的制药公司、大学、科研机构、全球非营利性组织建立了密切的协作关系，进行了广泛的科技合作和学术交流。自1989年开始，药物所还与新疆维吾尔自治区药物研究所（简称新疆药物所）建立了横向合作关系，新疆药物所挂牌为“中国医学科学院药物研究所新疆分所”，共同为推动新疆民族医药事业的发展而努力。

药物所还负责编辑出版《药学学报》、Chinese Chemical Letters（CCL，中国化学快报）、Journal of Asian Natural Products Research（JANPR，亚洲天然产物研究）及Acta Pharmaceutica Sinica B（APSB，《药学学报》英文刊）四种学术期刊；其中CCL和JANPR为SCI收录杂志，APSB被Medline及ESCI等收录，《药学学报》成为青蒿素诺贝尔奖获奖奠基论文的发表杂志。

药物所人始终以“献身、创新、求实、协作”的精神为指引，勤奋钻研、刻苦攻关、与时俱进、继往开来，努力为我国医药卫生事业的可持续发展，为创造社会效益和增强人类健康贡献力量。

The Institute of Materia Medica (IMM) at CAMS and PUMC was founded in 1958. Its mandate is to discover and research innovative drugs for treating or preventing human diseases. IMM's scientists use the latest biomedical theories, cutting-edge technologies, and state-of-the-art clinical resources to develop drugs from botanic compounds, synthetic chemicals, and bioproducts.

Principle drug research efforts at IMM focus on cancer, cardiovascular diseases, neurodegenerative and psychiatric diseases, metabolic disorders, infectious diseases, and inflammation. IMM researchers have made significant contributions in phytochemistry, analytic chemistry, computer-aided drug design, molecular pharmacology, high-throughput screening, synthetic biology, and drug-delivery systems, and have had notable successes developing new drugs that serve patients in China and abroad.

The institute hosts a State Key Laboratory of Bioactive Substance and Function of Natural Medicines and seven Ministry-level Key Laboratories. The departments in IMM include: Synthetic Medicinal Chemistry, Natural Medicinal Chemistry, Pharmacology, Pharmaceutical Analysis, Biosynthesis, Drug Screening, Polymorphic Drugs, Drug Delivery Systems, Drug Metabolism, and New Drug Research and Development. The Comprehensive Drug Platform funded by the National Science and Technology Project for Major New Drug Innovation and Development is one of the very few state drug programs established by the central government in China. Establishment of such programs has significantly enhanced IMM's research capabilities.

The institute has 495 staff and faculty members, of whom 123 are full or associate professors and 62 are principle investigators. Five scientists are academicians of the Chinese Academy of Sciences or the Chinese Academy of Engineering. IMM is housed on the main campus of the PUMC School of Pharmacy and provides training for senior pharmaceutical professionals and postdoctoral scientists. The Ministry of Education has classified Pharmaceutical Sciences at IMM as a National Key Discipline in Medicine. IMM currently has more than 380 graduate students and has graduated 1,488 students to date, granting 782 doctoral and 706 Master's degrees.

Since the institute's establishment, its scientists have discovered or developed hundreds of new drugs and acquired 130 new drug certificates from the China FDA, including numerous innovative drugs such as butylphthalide, bicyclol and imrecoxib. IMM's contributors have won 286 awards from the government and professional societies for drug research and development, including 13 at the national level. Notably, IMM won the first prize in the 2015 National Scientific and Technological Progress Awards for its research on creating an artificial musk. IMM has published 7,777 academic papers and 349 monographs, and holds 277 approved patents.

IMM stresses translational research and development, and has two wholly owned enterprises: Beijing Union Pharmaceutical Factory and Beijing Union Second Pharmaceutical Factory. It is also the major shareholder of Beijing LianXin Pharmaceutical Co., Ltd.; Beijing Union-Genius Pharmaceutical Technology Co., Ltd.; and Beijing Collab Pharma Co., Ltd.

IMM has established extensive partnerships and collaborations with pharmaceutical companies, universities, and research institutes worldwide, including in the United States, France, Japan, Germany, Spain, and Canada.

IMM hosts the editorial offices of four scientific journals: Acta Pharmaceutica Sinica, Chinese Chemical Letters, the Journal of Asian Natural Products Research, and Acta Pharmaceutica Sinica B.

In the spirit of its motto, “Devotion, Innovation, truth-seeking, and Cooperation,” staff and faculty at IMM look forward to continuing their tradition of excellence in research, creating a sustainable future for Chinese medicine and the Chinese health care industry.

上海复星医药（集团）股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

上海复星医药（集团）股份有限公司（简称“复星医药”，股票代码：600196.SH，02196.HK）成立于1994 年，是在中国拥有领先地位的医疗健康产业集团。复星医药以促进人类健康为使命，其业务覆盖医药健康全产业链，主要包括药品制造与研发、医疗服务、医疗器械与医学诊断、医药分销与零售。复星医药拥有国家级企业技术中心及国际化的研发团队，持续专注于心血管、中枢神经系统、血液系统、代谢及消化系统、抗感染、抗肿瘤等治疗领域的创新研发。面向未来，复星医药将秉承“持续创新 乐享健康”的品牌理念，继续坚持“内生式增长、外延式扩张、整合式发展”的发展战略，致力于成为全球主流医疗健康市场的一流企业。

Established in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a leading healthcare group in the PRC. Fosun Pharma’s business covers the whole healthcare industry chain, including pharmaceutical manufacturing and R&D, healthcare services, medical diagnosis and devices, as well as pharmaceutical distribution and retail, making contribution to improving people’s health. Fosun Pharma maintains a national recognized enterprise technology center and a highly capable international R&D team, with relentless efforts exerted on innovation and research of therapeutic areas including cardiovascular system, central nervous system, blood system, metabolism and alimentary system, anti-infection and anti-tumor. Looking forward, Fosun Pharma will adhere to the brand philosophy of “Innovation for Good Health”, and will continue sticking to the development strategy of “organic growth, external expansion and integrated development”, striving to become a first-tier enterprise in the global mainstream pharmaceutical and healthcare market.

天士力控股集团
Tasly Holding Group

天士力控股集团创建于 1994 年,是以大健康产业为主线,以生物医药产业为核心,以健康保健产业和医疗康复、健康养生管理与服务产业为两翼的高科技国际化企业集团。

秉承“追求天人合一，提高生命质量”的企业理念，以“创造健康，人人共享”为使命，以“打造中药现代化、国际化领先地位，构建以大生物医药核心的大健康产业领航品牌，用科技创造健康美好生活”为企业愿景，着力打造现代中药“顶天立地”，全面推进国际化进程，为中国品牌赢得世界尊重。

秉承“追求天人合一，提高生命质量”的企业理念，以“创造健康，人人共享”为使命，以“打造中药现代化、国际化领先地位，构建以大生物医药核心的大健康产业领航品牌，用科技创造健康美好生活”为企业愿景，着力打造现代中药“顶天立地”，全面推进国际化进程，为中国品牌赢得世界尊重。

围绕消费者的健康品质生活需求，根据中医“治未病、治已病、治末病”的思想精髓，打造“六个一”品牌工程，即做好一盒药、一瓶水、一杯茶、一樽酒、一套健康管理方案、一个儿童教育平台。建立“防—治—养—管”一体化的大健康管理新模式，为全球家庭提供健康产品和服务。实现“生得优，育得好，活得长，病得少，走得安”的健康幸福人生。

Tasly Holding Group was founded in 1994, it is a technological and international enterprise that develops great health industry as its main business; biomedicine industry as its core business; health care, medical rehabilitation, health & wellness management and service industry as its supporting business.

Sticking to the corporate philosophy of ‘to pursue harmonization between human and nature, to improve life quality’; to achieve the mission of ‘to share the joy of health with all’; to follow the corporate vision of ‘take a lead in TCM modernization and internationalization, build a leading integrated health brand centered in biomedicine, create a beautiful life with technology’. Tasly is making every effort to build up an international reputation for modern TCM and Chinese brand.

Tasly has established advanced international quality standard through whole industrial chain and built up a biomedicine industrial chain value system, a brand new ecological intelligent manufacturing system has been upgraded; a harmonious development between human and environment, enterprise and society has been realized. Tasly has created an industrial cluster including biomedicine, TCM material, healthcare, medical rehabilitation and health management service, and children education.

Concentrating on consumers’ needs of quality life, based on the TCM ideology of ‘preventive treatment’, Tasly has created the ‘Six-One’ project, which includes a box of medicine, a bottle of water, a cup of tea, a glass of liquor, a health management program, a children education platform. An integrated health management model ‘prevention-treatment-wellness-management’ is established, for the goal of ‘to serve people for healthier newborn, quality well being, prolonged life, minimized sickness and pacified leave’.

江苏恒瑞医药股份有限公司

Jiangsu Hengrui Medicine Co., Ltd.

江苏恒瑞医药股份有限公司始建于 1970 年，2000 年在上海证券交易所上市。公司以“科研为本，创造健康生活”为理念，坚持“质量第一，诚信经营”为原则，目前已发展成为国内最大的抗肿瘤药、手术药物的研究和生产基地，国家“重大新药创制”专项孵化器基地、国家抗肿瘤药技术创新产学研联盟牵头单位、国内最具创新能力的制药企业之一，同时也是国家重点高新技术企业、国家高技术研究发展计划（863计划）成果产业化基地，建有国家靶向药物工程技术研究中心、国家博士后科研工作站。公司在美国、欧洲、日本和中国多地建有研发中心或分支机构，全球员工13000人，目前各类研发人员近2100人，其中有1300多名博士、硕士及50多名海归人士，有5人被列入国家“千人计划”，每年科研经费占销售额的 10%左右。近年来，公司先后承担了 4 项国家 863 计划重大科技专项项目、23 项国家“重大新药创制”专项，共申请了 200多项发明专利，其中 100多项全球专利（PCT 专利），有 2 个创新药艾瑞昔布和阿帕替尼已获批上市，另有一批创新药处于不同的临床阶段。公司注射剂和口服制剂先后通过美国 FDA和欧盟认证，在海外主流市场销售，成为唯一一家将注射剂规模化销往欧美日市场的中国制药企业。公司将继续致力于让中国老百姓以合理的价格用上国际先进品质的药品。

Jiangsu Hengrui Medicine Co., Ltd., established in 1970 and listed in Shanghai Stock Exchange in 2000, holding the idea of “create a healthy life based on science and research” and philosophy of “quality first, integrity management”, is the largest research and manufacturing base of antineoplastics and surgical medicine in China as well as the special incubator base for “New Drug Development”. Known as the lead of National Anti-tumor Medicine Production Technology Innovation Alliance, one of the most innovative pharmaceutical enterprises, Jiangsu Hengrui Medicine is also the National Key High-tech Enterprise and industrialization base of National Science and Technology Major Project (863 Project), which has a national engineering technology research center of targeted drugs and National Post-doctoral Scientific Research Workstation.

Hengrui Medicine has constituted a thorough innovation system with R&D centers and clinic departments in American, Europe, Japan and China, with 13,000 employees worldwide. Now Hengrui Medicine is equipped with a R&D team of more than 2100, among which more than 1300 professionals with phD and master degree, and 50 overseas talent., five of them belongs to Recruitment Program of Global Experts. Scientific research funds occupy more than 10% of sales every year. In recent years, Hengrui undertakes four projects of National Science and Technology Major Project (863 Project) and 23 projects has been placed to “Major New Drug Development”. About 200 patents for invention have been applied, among which 100 are global patent (PCT). The innovative drug Imrecoxib and Apatinib have been approved for marketing; two innovative drugs have been submitted for manufacturing; another eight innovative drugs are in different stages of clinical research. Over the last three years, injection drug and oral preparation has been certified by U.S. FDA and EU, and sold in overseas market. Therefore, Hengrui becomes the first national pharmaceutical enterprise which penetrates into U.S. and European markets with domestic injection products. Jiangsu Hengrui Co., Ltd will continue to devote itself to making Chinese people be available of advanced international standard drugs with reasonable price.

中国科学院上海药物研究所

Shanghai Institute of Materia Medica, Chinese Academy of Sciences

中国科学院上海药物研究所是我国历史最悠久的综合性药物研究机构。其前身是国立北平研究院药物研究所，创建于1932年，首任所长为赵承嘏。1933年南迁上海，2003年落户浦东张江高科技园区。

建所以来，上海药物所秉承着“寻找治疗疾病的新药，为人民解除病痛”的办所宗旨，共研制开发新药100余种并投入生产，创制了蒿甲醚、二巯基丁二酸、石杉碱甲等一批在国内外具有影响的创新药物。近年来又研制了现代中药丹参多酚酸盐、抗菌新药盐酸安妥沙星等新药，另有一批新药正处于临床研究阶段。

自中国科学院开展“知识创新工程”以来，上海药物所确立了“出新药”战略，瞄准国际生命科学发展的前沿领域以及药物研究的重要科学问题，开展创新药物基础和应用基础研究，发展药物研究新理论、新方法和新技术。

重点围绕治疗恶性肿瘤、心脑血管系统疾病、神经精神系统疾病、代谢性疾病、自身免疫性疾病及感染性疾病等开展新药研发，并加强现代中药的研发。

经过几代人的努力，上海药物所已发展成为学科齐全、成就卓著、人才荟萃、在国内外享有较高声誉的综合性创新药物研究机构。

Shanghai Institute of Materia Medica (hereafter referred as SIMM), Chinese Academy of Sciences (hereafter referred as CAS), has the longest history as a comprehensive research institution for drug discovery in China. SIMM was evolved from Peking Institute of Materia Medica, Academia Sinica, founded in 1932 by Professor Chenggu Zhao (T. Q. Chou). It was relocated to Wukang Road, Shanghai in 1933, then to Yueyang Road in 1953, and settled down in Zhang Jiang Hi-Tech Park, Pudong New District in 2003.

In line with the mission of “Discovering new drugs to relieve patients suffering from various diseases”, SIMM has developed and commercialized over 100 new drugs. Among them, a number of innovative drugs such as Artemether, Dimercaptosuccinic acid, and Huperzine A gained recognition both home and abroad. Recent years have witnessed the development of some novel drugs from SIMM, including Depsides salts, a modern Traditional Chinese Medicine (TCM), and Antofloxacin Hydrochloride, a novel fluoroquinolone antibacterial agent. SIMM has currently a number of candidates in clinical stages.

Since the implementation of the Knowledge Innovation Program of CAS, developing novel drugs has become a paramount research focus of SIMM in recent years. In line with frontiers in life sciences and aiming at solving key scientific problems in drug discovery, SIMM carries out both basic and applied studies and develops new theories, methods and technologies. Research priorities are given to treat major diseases, such as cancer, cardio-cerebrovascular disease, neuropsychiatric disease, metabolic disease, autoimmune disease, and infectious disease. SIMM pays also attention to the development of modern Traditional Chinese Medicine (TCM).

Through several generations’ efforts, SIMM has become one of the leading interdisciplinary centers of excellence in China. It is recognized worldwide by its outstanding achievements and distinguished research team.

贝达药业股份有限公司
Betta Pharmaceutical Co., Ltd.

贝达药业股份有限公司是一家由海归博士团队创办的、以自主知识产权创新药物研究和开发为核心，集研发、生产、营销于一体的制药企业。公司自2003年成立以来，聚焦恶性肿瘤、糖尿病和心脑血管病领域，持续开展新药的研发和生产。目前，公司现有员工900余人，其中归国博士近20位。2016年11月7日，公司在深交所创业板成功挂牌上市。公司总部在杭州，拥有GMP认证的生产车间,同时在北京设有新药研发中心，有200余名研发人员，并在全国拥有一支近400人的市场销售队伍。

经过8年多的努力，公司自主研发的国家一类新药盐酸埃克替尼（凯美纳）于2011年获国家食品药品监督管理局颁发的新药证书和生产批文，并在2014年11月，获批用于晚期非小细胞肺癌的一线治疗。2015年埃克替尼在国内市场的销量已超过跨国药企开发的同类竞争产品；2016年埃克替尼在国内市场的销售额已突破10亿人民币。

2013年，公司与美国安进公司合资成立贝达安进制药有限公司，共同推进安进公司抗癌药物帕妥木单抗在中国的市场化。2014年，贝达药业投资美国Xcovery公司，共同开发针对肺癌的新一代靶向药物X-396。2017年，公司斥资4.8亿元收购卡南吉医药科技（上海）有限公司，并与北京天广实、杭州瑞普基因、北京华昊中天等多家公司达成战略合作协议。

Betta Pharmaceuticals Co., Ltd. was founded by a group of overseas returnees and is mainly developing innovative therapeutics, including R&D, manufacturing and marketing. Since founded in 2003, Betta is focusing on developing innovative drugs in the oncology, diabetes and cardiovascular fields. Currently, Betta has more than 900 employees, including 20 Ph.D.s returned from overseas. On Nov.7, 2016, Betta was listed at the Shenzhen Stock Exchange. The company is headquartered in Hangzhou, housing a GMP-certified manufacturing facility, while set up a R&D site in Beijing, with 200 R&D team members. Betta also has a 400-member marketing and sales team throughout China.

After 8-year development, Betta has successfully marketed a oncology innovative drug–icotinib hydrochloride (Conmana®), which was approved by the China Food and Drug Administration (CFDA) in 2011. In Nov, 2014, icotinib was approved by the CFDA as the first-line treatment for the non-small cell lung cancer patients. In 2015, the sales of icotinib has surpassed that of its competitors developed by multi-national pharmaceutical companies in China; in 2016, icotinib has crossed the 1 billion RMB sale milestone.

In 2013, Betta set up a joint venture with Amgen, to commercialize Amgen's Vectibix in China. In 2014, Betta invested the U.S.-based biotech Xcovery, to co-develop its next-generation lung cancer targeted therapeutics–X396. In 2017, Betta spent 480 million RMB to acquire Anew Pharma and has set up collaborations with a few biotechs such as Beijing Mabworks, Hangzhou Repugene and Beijing Biostar Technologies.

天津中医药大学

Tianjin University of Traditional Chinese Medcine

天津中医药大学始建于1958年。学校建有中医学、中药学、中西医结合3个博士后科研流动站，中医学、中药学、中西医结合3个一级博士点，25个二级博士点和46个二级硕士点，25个本科专业。学校在校生达12000人，其中留学生达到2000人。学校拥有6所附属医院，共有4000张床位，年门诊量400余万人。

学校现拥有中医内科学和针灸推拿学国家级重点学科2个、28个省部级重点学科，2个国家级实验室，中意中医药联合实验室，23个省部级重点实验室，3个省部级工程中心。

学校以“进德修业，继承创新”为校训，以重点学科建设和中医药对外教育为特色，以科学研究为优势，以中医药学为主，医、理、文、管、工、教育等多学科协调发展。坚持“传承与创新协同，科研与服务并举，以质量求内涵，全面协调发展”方针，建设高层次、外向型、国内一流、国际知名的教学研究型中医药大学。

Tianjin University of Traditional Chinese Medicine was founded in 1958. The school has three post doctoral research stations, three primary doctoral disciplines (Chinese medicine, Chinese materia medica and integrative of Chinese and western medicine), 25 secondary doctoral disciplines, 46 secondary master disciplines and 25 undergraduate professionals. There are more than 12000 students, including about 2000 overseas students. The school also has 6 affiliated hospitals, which have 4000 beds and more than 4 million outpatient services.

The school has two national key discipline and specialties (internal medicine of TCM and acupuncture) and 28 provincial or ministerial level key discipline and specialties. There are also two national level laboratories, two Sino-Italian joint laboratories of TCM, 23 provincial or ministerial key laboratories and 3 provincial engineering centers.

The school motto is “improve the virtue and refine the achievements, inheritance and innovation”. This school takes key disciplinary building-up and education for foreign students as its characteristic and has the advantage of scientific research on TCM, Besides TCM, other disciplines including medicine, science and engineering, literature, management and education develop in phase.

石药控股集团有限公司

China Shijiazhuang Pharmaceutical Group Co., Ltd.

石药控股集团有限公司建于1938年5月，现有资产总额270亿元，员工21000人。在港上市公司（01093.HK）市值700亿港币，是香港知名医药上市企业之一，也是香港恒生红筹股指数成份股。

石药集团主要从事医药产品的开发、生产和销售。产品包括心脑血管、抗生素、维生素、解热镇痛、消化系统用药、抗肿瘤用药等七大系列近千个品种，有30多个产品单品种销售过亿元，产品销售遍及全国和世界60多个国家和地区。

石药集团是“国家级创新型企业”，新药研发实力位居全国制药企业最前列。目前集团在研新药项目180个，仅国家一类新药就有25个，涉及心脑血管、精神神经、内分泌、抗肿瘤等领域。集团成功上市的具有自主知识产权的一类新药“恩必普”是脑卒中治疗领域的全球领先药物，在全球86个国家受到专利保护。创新药的研发和快速成长推动企业实现了转型升级，原料药、成药的销售比重由原来的7:3转变为3:7，石药集团成为国内传统药企成功实现“主动转型”的典范。

为追求卓越，迈向高端，石药集团对标国际高端制药标准，持续提升产品质量的内涵。截至目前，集团旗下所有药品都通过了新版GMP认证，此外，共取得了16张CEP证书和33个DMF登记号，有21个产品顺利通过美国FDA现场检查。另一方面，企业加大了在美国、欧盟地区注册非专利药的力度，已经有盐酸曲马多片、二甲双胍片等7个产品在美国批准并上市。与此同时，石药集团在美国建立了研发实验室，多个药物正在美国开展临床试验，未来，将陆续有更多的新药产品在欧美等国际高端市场上市销售。

CSPC holding company limited has been founded from May, 1938 with total assets of 27 billion RMB, approximately 21,000 staff members. CSPC is one of HK's well known listed Pharmaceutical companies and also one of Hang Seng red-Chips Index Component stocks, whose market value over 70 billion HK dollars.

CSPC is mainly engaged in the development, production and sales of pharmaceutical products. Its key products content nearly 1,000 varieties of 7 series in cardiovascular and cerebrovascular, antibiotic, vitamin, xanthine, digest system and anti-tumor. 30 more varieties have been achieved sales volumes over 100 million RMB, meanwhile, the products are sold throughout China and over 60 countries and regions in the world.

CSPC is a “National Innovative Enterprise”. The R&D ability of new drugs is far ahead among the pharmaceutical companies in China. CSPC currently holds 180 new drug researching projects, and 25 National Class I new drugs are included, involving cardiovascular and cerebrovascular, nervous system, anti-tumor, endocrine and other fields. NBP, a successfully promoted National Class I drug, is the third with independent intellectual property rights and it is also protected in 86 countries around the world. The development and rapid growth of innovative drugs accelerate the upgrading pace of CSPC. The proportion of API and Finished product changes from original 7:3 to 3:7 and CSPC become a model of domestic pharmaceutical enterprises which is successfully realized “initiative transformation”.

In search of excellence and high-end, CSPC has been continuously improving the products quality to meet the international high standard of manufacture. Up to now, all products of CSPC group have successfully passed the new GMP certification. Besides, CSPC has obtained 16 CEP certificates and 33 DMF registration numbers, and 21 products pass the on-site inspection of FDA. On the other hand, CSPC put strength in the registrations of non-patent drugs in the US, Europe and other countries. Now, 7 products such as tramadol hydrochloride tablets and diformin tablets have been on the market in the US. Meanwhile, a new R&D lab has been set up in America and varieties of drugs have been on clinical trials. This symbolizes that products from CSPC is able to compete in the international high-end market and can be sold directly in the US pharmacies, and also symbolizes the quality of CSPC products has reached at the international advanced level.

先声药业有限公司

Simcere Pharmaceutical Group

先声药业成立于1995年，当时是仅有几十名员工、注册资金200多万元的小型药品经销公司。经过二十年的发展，先声药业已发展成为集生产、研发、销售为一体，拥有5家通过GMP认证的现代化药品生产企业，2家全国性的药品营销企业、1家药物研究院，拥有员工4200余人的新型药业集团。

目前，先声药业拥有45种以上药品的强大产品组合，重点覆盖抗肿瘤、心脑血管、感染等疾病治疗领域。并拥有“先声®”“必存®”“再林®”“英太青®”四个“中国驰名商标”。

先声药业一直致力于新药创新开发，每年将销售额的8%～12%用于新药研发，2007年以来，先声药业共计申请发明专利359项；获中国授权发明专利200多项，国外授权专利近20项，近年来承担10多项国家“重大新药创制”项目。先声药业先后获得“国家科学技术发明二等奖”和“国家科学技术进步二等奖”各1次。从2014年开始，启动“精准医疗百家汇”创新项目，旨在通过开放的商业创新模式，建立协同创新和完全市场化的开放运行机制，加快公司的创新开发。

先声药业于2003 年获准设立国家企业博士后工作站，2005 年批准成立“国家认定企业技术中心”；2008 年批准设立“江苏省抗肿瘤分子靶向药物重点实验室”；2009年各生产企业重新被认定为“国家高新技术企业”；2009 年获准设立“江苏省企业院士工作站”；2015年批准成立“转化医学与创新药物国家重点实验室”。

2010 年11 月，跨国公司百时美施贵宝与先声药业同时宣布开展抗肿瘤药领域的国际合作研发，此后先声走上了国际合作开发新药的道路。2011年先声的必奇原料和制剂产品通过欧盟GMP 认证，标志着先声质量管理水平提升到了一个新的高度。

2010年以来，先声药业有近10个一类创新药进入和即将进入临床研究阶段。先声药业近几年均被中国医药信息中心和南方所评为“中国最具创新力的企业”。

Founded in 1995, Simcere was a small medicine distribution company with just handful persons and registered capital of 2 million Yuan. 20 years later, Simcere has become a new pharmaceutical group which can manufacture, R&D and promote medicines. Simcere owns 5 GMP modern manufacturing plants, 2 national medicine promoting companies, 1 R&D institution, and over 4200 employees.

Currently Over 50 branded drugs of Simcere are in production and available on market, of which therapeutic areas focus on oncology, neuroscience, infectious diseases and rheumatoid arthritis. We have four China Well-known Trademarks: “Simcere” “Bicun” “Zailin” and “Yingtaiqing”.

Simcere has been committed to researching developing new drugs and have invested 8% to 12% of sales revenue each year for new drug research and development.Since 2007, Simcere had totally applied for 359 invention patents, have gained more than 200 Chinese invention patents and nearly 20 foreign licensing patents. In recent years, we undertook more than 10 National Major New Drug Discovery projects and obtained the Second place of both “National Science and Technology Invention Award” and “National Science and Technology Progress Award”. Since 2014, to speed up the innovation, Simcere started an innovation project called BioSciKin, in order to build an open mechanism to comply with innovation and the market though an open business innovation model.

Simcere was authorized to build National Enterprise Postdoctoral Workstation in 2003 and National Enterprise Technology Center in 2005. In 2008, we were approved to build Jiangsu Provincial Key Laboratory of Anti-tumor Molecular Targeted Drugs. In 2009, all 5 production enterprises of Simcere were assessed as National High and New Technology Enterprises and allowed to build the Jiangsu Provincial Enterprise Academician Workstation.In 2015, Our laboratory of Translational Medicine and Innovative Drug was admitted as State Key Laboratory.

In November 2010, Simcere and multinational company BMS announced to develop a R&D partnership in oncology at the same time. In 2011, Simcere's branded antidiarrheal drug Biqi API and formulation product passed the Eu-GMP inspection, which means QA of Simcere has reached a new level.

Since 2010, Simcerehas nearly 10 State Class I New Medicine enter or be about to enter the clinical research stage. And Simcere has been named as The Most Innovative Companies by China Medical Information Center and Southern Medicine Economic Research Institute.

中国医药集团总公司

China National Pharmaceutical Group Corporation

中国医药集团是由国务院国资委直接管理的中国规模最大、产业链最全、综合实力最强的医药健康产业集团。以预防治疗和诊断护理等健康相关产品的分销、零售、研发及生产为主业。旗下拥有10家全资或控股子公司和国药控股、国药股份、国药一致、天坛生物、现代制药、中国中药6家上市公司。2005－2015年，集团营业收入年平均增幅26.89%，利润总额年平均增幅35.28%，总资产年平均增幅31.16%。2015年，集团营业收入近3000亿元，是目前唯一一家进入世界500强的中国医药企业。

中国医药集团全力推进十一大业务板块——医药现代物流分销、零售连锁、生物制品、化学制药、现代中药、诊断试剂与化学试剂、科学仪器与医疗器械、医药科研与工程设计、医药国际经营与海外实业、医药会展与传媒、医疗健康产业的发展，构成了一个以医药健康产业为核心竞争力的创新型企业。

中国医药集团拥有覆盖全国31个省、自治区、直辖市的医药流通配送网络和与国际水平接轨的30个配送中心，是国内最大的生物医药研发、生产企业，承担了80%以上的国家免疫规划用疫苗的生产任务。集团建立了生物制药、麻醉精神药品、抗感染药、抗肿瘤药、心脑血管用药、呼吸系统用药等生产基地和药材基地，拥有国内实力最强的应用性医药研究机构和工程设计院。2010年，中国医药集团被评为国家创新型企业。

中国医药集团是我国医药行业与外资合作最早、最多和最成功的企业。从1980年开始先后与多个国际著名医药企业建立了中国大冢制药有限公司、华瑞制药有限公司、西安杨森制药有限公司、中美施贵宝制药有限公司、苏州胶囊有限公司等20家合资企业，与世界上100多个国家和地区建立了贸易合作关系，开展了多项国际技术合作，国际化步伐不断加快。

中国医药集团以“关爱生命、呵护健康”为企业理念，承担着国家抢险救灾药品、生物技术产品、中药材、医疗器械的中央储备、调拨和供应任务，在1976年唐山大地震、1998年抗洪抢险、2003年抗击非典的战斗中；在2008年汶川抗震救灾、2009年防控甲型H1N1流感疫情、2010年玉树和舟曲抗震救灾的现场；在2008年奥运会、2009年国庆阅兵和2010年上海世博会等重大事件医药物资储备与应急供应，2010年国家麻疹疫苗强化免疫活动，以及2013年芦山地震中，都能看到国药人紧张工作的身影，为保障人民的生命健康和社会稳定发挥了重要作用。同时，集团研发生产的疫苗出口到印度、韩国、泰国、斯里兰卡等国，为当地民众健康做出了积极贡献。

We-China National Pharmaceutical Group Corporation (Sinopharm)-are the largest Chinese medical and healthcare group directly managed by State-owned Assets Supervision and Administration Commission of the State Council (SASAC), with the most complete industrial chain coverage and strongest comprehensive competence in China. Our core businesses include distribution, retail, scientific research and manufacture of healthcare related products and we own 10 wholly-owned or holding subsidiaries, and 6 listed companies: Sinopharm Group Co., Ltd., China National Medicines Co., Ltd., Sinopharm Accord Medicines Co., Ltd., Beijing Tiantan Biological Products Co., Ltd., Shanghai Shyndec Pharmaceutical Co., Ltd. and China Traditional Chinese Medicine Co. Ltd.. Since Year 2005 to Year 2015, our annual average growth rate of revenue was 26.89%, annual average growth rate of gross profit was 35.28% and annual average growth rate of total assets was 31.16%. In 2015, our sales revenue exceeded RMB 300 billion and became the first Chinese pharmaceutical company who entered Global Top 500.

With all-out efforts, we are promoting the overall construction of five major platforms–the modern integrated distribution and logistics platform, the integrated manufacturing and R&D platform for scientific and technological innovation, the integrated globally operational platform, the health care industry platform and the highly efficient control and synergy platform and building up the five nationwide networks respectively specialized for pharmaceutical logistics and distribution, retailing pharmacy chain, anaesthetic distribution, cold-chain distribution for biological products and medical equipments and consumable materials distribution, to comprehensively fuel the joint development of the eleven core business sectors of modern pharmaceutical logistics and distribution; medicine retail; biological products; chemical pharmaceuticals; modern traditional Chinese medicines; diagnostics and chemical reagents; scientific instruments and medical equipments; medical scientific research and engineering design; pharmaceutical international trade and overseas industry, pharmaceutical exhibitions and media, and health care industry. So far, we have become an innovation-oriented pharmaceutical and healthcare enterprise.

We own a pharmaceutical and medical distribution network covering 31 provinces, autonomous regions and municipalities and 30 international standard distribution centers, and in the mean time as the largest R&D institution and manufacturer for biological products, we have taken the responsibility of manufacturing more than 80% of EPI vaccines in China. We have built up the production bases for biopharmaceutical products, anaesthetics and psychotropics, anti-infectives, anti-tumors, cardiovascular drugs and respiratory system drugs, and planting bases for medicinal herbs and have the strongest applied medical research institutions and engineering design institute. In 2010, we were elected the national innovation oriented enterprises.

In Chinese pharmaceutical industry, we are the first, the largest and the most successful enterprise to cooperated with foreign companies. We have established dozens of successful Sino-foreign pharmaceutical joint ventures since 1980's, e.g. China Otsuka Pharmaceutical Co., Ltd. Sino-Swed Pharmaceutical Co., Ltd. (SSPC), Xian Janssen Pharmaceutical Co., Ltd., Sino-American Squibb Pharmaceutical Co., Ltd. and Suzhou Capsugel Ltd.. We have built up business relations with the clients from over 100 countries and regions, and conducted many international technical collaboration programs. Our pace to go internationalization is being sped up.

Adhering to the corporate credo of 'Caring for life, attending to health', we have always undertaken the responsibility of central reserve, allocation and provision of medicines and health care products against emergencies, disasters and epidemics. Our staff could be found working hard at the emergency sites, e.g. Tangshan Earthquake in 1976, fighting against floods in 1998, prevention and treatment of SARS in 2003, earthquake relief in Wenchuan in 2008, control of influenza A H1N1 in 2009, disaster relief of Yushu Earthquake and Zhouqu Mudslide in 2010, and Lushan Earthquake in 2013. They also appeared at the scene of every significant event for the country, e.g. Beijing Olympic Games in 2008, National Day parade in 2009, Shanghai Expo 2010 and national measles supplementary immunization in 2010. We have been playing a crucial role in securing public health and social stability. With our vaccine products have been exported to India, Thailand, South Korea, Nepal, Sri Lanka, etc., we have also made great contributions to the well being of local public.

We are shooting at the goal of growing into an international pharmaceutical healthcare group, with the whole industrial chain covering business to drive the entire industry forward by 2015.

上海医药集团股份有限公司

Shanghai Pharmaceuticals Holding Co., Ltd.

上海医药集团股份有限公司是一家总部位于上海的全国性医药产业集团。公司主营业务覆盖医药研发与制造、分销与零售，2016年营业收入1208亿元， 综合排名位居全国前列，入选上证180 指数、沪深300 指数样本股，H 股入选恒生指数成分股、摩根斯坦利中国指数（MSCI）。

上海医药研发以创新为长期坚持的方向，致力于为重大疾病和慢性病提供安全有效的治疗药物，公司建立了以中央研究院为技术核心的多层次研发体系，入选十余项“重大新药创制”国家科技重大专项，累计拥有发明专利319件，公司合作完成的两个项目分获2014、2015 年国家科技进步一等奖。公司采用开放式研究模式，与各大科研院所等合作开展创新药物研发。

上海医药制造覆盖化学和生物药品、现代中药和保健品、医疗器械等领域， 产品聚焦五大治疗领域，过亿产品26 个。公司旗下拥有多个中国驰名商标。公司所有药品生产企业全部通过新版GMP 认证，并全面实施精益六西格玛管理，积极推进两化融合。公司有多个原料药或制剂通过了WHO、FDA、欧盟以及其他发达国家的质量认证。

上海医药的分销网络以华东、华北、华南三大重点区域为中心辐射全国各地，分销业务规模排名全国前三。公司的疫苗、高端耗材、DTP（高值药品直送）及SPD（医药物流管理技术）等新业务发展在国内处于领先地位，并积极拓展电商新模式。

上海医药药品零售销售规模居全国药品零售行业前列，上海华氏大药房拥有药房的数量在华东地区名列前茅，门店覆盖全国16 个省、直辖市及自治区，门店总数近1800 家。

公司倡导“创新、诚信、合作、包容、责任”的企业核心价值观，致力于持之以恒，提升民众的健康生活品质，努力打造受人尊敬、拥有行业美誉度的领先品牌药制造商和健康领域服务商。

Shanghai Pharmaceuticals Holding Co., Ltd. (referred to as “Shanghai Pharma” or “SPH”) is a state-owned pharmaceutical group headquartered in Shanghai, China. The company’s core business covers pharmaceutical R&D, manufacturing, distribution and retailing. In 2016, the company reported a total revenue of RMB 120.8 billion, making it one of the major forces in the industry in China. SPH stock is included as a sample stock of both the SSE 180 and CSI 300 indexes. Its H shares were selected into the Hang Seng Index Compositional Stocks and MSCI.

Shanghai Pharma’s Research & Development team is dedicated to providing innovative, safe and effective drugs against serious and chronic diseases. The company has set up an R&D system with a Central Research Institute as a technical core. Over ten state-level scientific and technological R&D projects are currently underway to develop major new drugs. SPH owns one state-level and ten provincial/city-level Corporate Technology Centers. In total, we have registered 319 invention patents. In 2014 and 2015, two cooperative projects won the First Class National Scientific and Technological Progress Award. SPH has adopted an open R&D philosophy. As a result, we have built strategic alliances in R&D with both research institutions and corporations, in order to develop innovative drugs.

Shanghai Pharma’s manufacturing business provides products ranging from chemicals and bio-pharms to modern Chinese medicine, healthcare products and medical devices. We are focused on five major therapeutic areas.26 products have annual sales revenues of over RMB 100 million. SPH manages a number of renowned trademarked Chinese brands. All our production lines have passed the new GMP certification. The company has implemented a Lean Management system, optimized production and conducted pilot programs to integrate information technology and industrialization. A number of our APIs and preparations have passed quality authentications from the WHO, FDA, EU and other developed countries.

Shanghai Pharma’s distribution network covers the whole Chinese territory, starting with the most developed regions (Eastern, Northern and Southern parts) and expanding to other areas. Our distribution system is the third largest in size nationwide. SPH is the leader in new business development for vaccines, high-end consumables, DTP and SPD in China.The company is currently exploring new business models based on e-commerce for the pharmaceutical industry.

Shanghai Pharma is one of the top pharmaceutical retailers in China in terms of sales revenue. Our Huashi Pharmacy is one of the largest drugstore chains in Eastern China with about 1800 locations covering 16 provinces, autonomous regions and municipalities.

With a solid foundation anchored in our core values–innovation, integrity, cooperation, inclusiveness and responsibility–Shanghai Pharma is continuously dedicated to the providing a healthier life to the general public, while striving to be recognized as a respected manufacturer of leading pharmaceutical brands, as well as a healthcare services provider with a stellar reputation.

成都康弘药业集团股份有限公司

Chengdu Kanghong Pharmaceutical Group Co., Ltd.

成都康弘药业集团股份有限公司（以下简称康弘药业）是一家致力于中成药、化学药及生物制品的研发、生产、销售及传播服务的医药集团，总部位于四川省成都市，销售网络遍布全国。

康弘药业坚持以专业、创新、国际化为核心发展战略，开创了“聚焦领域－需求导向－深入研究－专利新药－规范生产－专业营销”六位一体的独特经营模式，完成了在中枢神经系统、消化系统、眼科及其他等重点临床领域具有“康弘特色”的产品布局。

康弘药业的核心竞争力来源于长远战略布局和持续专业创新能力，研发投入远高于行业平均水平，且正向国际平均水平靠拢。依托国家认定企业技术中心、国家级博士后科研工作站以及四川省重点实验室，康弘药业建立了多个创新平台，承担了11项国家级课题；现已获授权专利100余项，其中30余项为国际专利。

2009年，商标被国家工商总局认定为“中国驰名商标”。2010年，康弘药业被国家知识产权局列入“全国企事业知识产权试点单位”；2011年，被中国化学工业协会评为“中国化学制药行业创新型企业品牌十强”；2012年，被国家科技部、国务院国资委、中华全国总工会列入国家第五批“创新型试点企业”。

康弘药业将不断努力研制专业创新的医药产品，促进人类健康事业的进步，努力成为中国最杰出的药业集团之一。

Chengdu Kanghong Pharmaceutical Group Co., Ltd. is a modern medicinal enterprise located in Chengdu, China. Kanghong’s core business is to develop, manufacture, market and promote innovative medicine including Traditional Chinese Medicine, small molecule and biologic drugs.

Kanghong, always maintaining development strategy as profession, innovation and internationalization, created a distinctive business model as core therapy areas focused, demand oriented, research in-depth, patent drug, manufacture standardized and professional marketing. Kanghong has set up a product layout of Kanghong’s own characteristics in C.N.S, digestive system, ophthalmology and others.

The core competitiveness of Kanghong is the ability of long term strategic layout and sustained professional innovation. Kanghong has established several innovative platform including the National-level Enterprise Technology Center, the National Post-doctoral Scientific Research Workstation, Key Laboratory of Sichuan Province and so on. Until now, Kanghong has authorized more than 100 patents, among which there are more than 30 foreign patents.

Since the establishment of the Kanghong, it has received wide-spread identity from various levels of government, clients and consumers from all walks of life. We are the only corporation in Sichuan province that has been awarded “National Pilot Innovative Corporation” in 2012. We are National Experimental Enterprise for Intellectual Property. The Kanghong trade mark is awarded “Famous Trade Mark of China”.

Kanghong will always focused on developing and researching innovative medicine to promote human health and to becoming one of the most outstanding Chinese pharmaceutical enterprise.

绿叶制药集团有限公司

LUYE Pharma Group Co., Ltd.

绿叶制药集团是一家以研发为基础的专业制药企业，公司成立于1994年，2014年在香港主板上市(02186.HK)。公司在中国和欧洲设有生产及研发基地，并在香港、新加坡和马来西亚设有分支机构，全球员工近4000名。

绿叶制药致力于创新药物的研发、生产和销售，30余个上市产品覆盖抗肿瘤、中枢神经系统、心血管、消化及代谢等治疗领域；业务遍及中国、美国、欧洲、澳洲、日韩等全球主要医药市场和新兴市场。绿叶制药建立了与国际接轨的研发体系，在微球、脂质体、透皮释药和皮下植入剂等新型给药系统领域处于国际先进水平。公司拥有丰富的在研产品线，多个创新制剂及创新药在海外开展不同阶段的注册临床研究，并已取得突破性进展。

以成为最受尊敬的全球领先制药企业为愿景，绿叶制药将继续以创新和国际化为方向，力争2020年成为世界100强的国际性专业制药企业。

Luye Pharma Group Ltd. is a professional pharmaceutical company based on R&D. The company was founded in 1994 and listed on the main board of the Hong Kong Stock Exchange in 2014 (02186.HK). The company has state-of-the-art production facilities and R&D centers located in China, the USA and Europe, as well as overseas branch offices in Hong Kong, Singapore and Malaysia with approximately 4,000 employees.

Luye Pharma focuses on developing, producing, marketing and selling innovative pharmaceutical products in four therapeutic areas-oncology, central nervous system, cardiovascular and metabolism. The company has a portfolio of over 30 products. The business of Luye Pharma covers global main pharmaceutical markets including China, the U.S., Europe, Australia, Japan and South Korean. Luye Pharma has established a professional R&D system of international standard, and reached international level in the area of new drug delivery system technologies such as microspheres, liposome and TDS. Currently, Luye Pharma has multiple innovative preparations and drugs that are undergoing different stages of registry clinical studies in the U.S and EU.

With the vision of to be one of the most respected leading global pharmaceutical enterprises, Luye Pharma will keep adhering to the road of innovation and internationalization, and endeavor to become one of the top 100 global pharmaceutical companies by 2020.

扬子江药业集团

Yangtze River Pharmaceutical Group

扬子江药业集团创建于1971年，是一家跨地区、产学研相结合、科工贸一体化的国家大型医药企业集团，也是科技部命名的全国首批创新型企业。集团总部位于江苏省泰州市，旗下20多家成员公司分布北京、上海、南京、广州、成都、苏州、常州等地；营销网络覆盖全国各省、市、自治区。

多年来，集团始终秉承“求索进取，护佑众生”的理念，践行“高质 惠民创新 至善”核心价值观。企业综合经济效益自1996年起，连续十多年排名江苏省和全国医药行业前列，并跻身“中国企业500强”、“中国民营企业500强”、“全国纳税500强”。据国家工信部公布的数据，扬子江药业集团有限公司主营业务收入名列2014年度中国医药工业百强榜首位。

集团坚持以创新引领发展，加快实施“三药并举”研发创新战略。依托产学研联合建成设施一流的江苏省（扬子江）新药研究院，拥有国家级企业技术中心、药物制剂新技术国家重点实验室、中药国家工程研究中心等创新研发平台。经过多年的持续积累和创新，产品体系中西药并举，覆盖10多个领域、20多种剂型、200多个品规。

集团视质量为企业的生命。现有20多个产品被评为“江苏省名牌产品”，11个产品获“中国名优产品”称号，9个产品被列入“国家中药保护品种”，2个产品获“国家科技进步二等奖”；另有4个车间（6个产品）已通过欧盟GMP认证。集团自2005年以来蝉联全国医药行业QC成果评比一等奖总数“十一连冠”，并被中国食品药品检定研究院、江苏省食品药品监督管理局指定为“实训基地”。

面向未来，奋进中的扬子江药业集团以振兴民族医药为己任，怀着科学、严谨、负责的态度，竭诚为全人类的健康服务，努力向世界一流制药企业的目标迈进。

Established in 1971, YRPG is a large cross-regional pharmaceutical group that features industry-university-institute cooperation and integrates scientific research, industrial production and sale. It is among the first group of Innovative Enterprises named by the Ministry of Science and Technology. Headquartered in Taizhou (Jiangsu Province), The sales network spans all of China. YRPG has over 20 subsidiary companies.

Since its inception, YRPG follows its philosophy of “seeking progress at all times and safeguarding all human beings” and principle of “benefiting the general public through quality products and innovation”. Since 1996, the group's overall economic strength has topped the list of pharmaceutical industry in Jiangsu as well as in China. According to figures from the Ministry of Industry and Information, YRPG's prime operating income was among the top three of the Chinese pharmaceutical companies since 2009.

YRPG upholds the principle of developing through innovation. It is now stepping up the R&D strategy of “three medicines in one go”. It has built the Jiangsu (YRPG) New Medicine Institute through industry-university-institution cooperation. Its R&D platforms include a nation-level class enterprise technological center, a key state-level laboratory of pharmaceutical preparation, and an engineering R&D center for traditional Chinese medicine. With these platforms. Through years of work, its products include both Chinese and Western medicines, encompassing over 10 fields, 20 preparations and 200 sizes for medicine.

YRPG sees quality as the life of our company. It now has over 20 products awarded “Jiangsu Well-known Brands”, 11 “Chinese Excellent Products” and 9 “National Protected TCM Medicine”. Two of YRPG's products won Second Prize for National Science and Technology Progress. More than 20 products meet the pharmacopeia standards in the U.S.A and EU., and three facilities have gained EU GMP qualification. Since 2005, it has consecutively won first-place prizes year after year from the National Pharmaceutical Industry QC. It was also designated a training center by the Chinese Food and Drug Administration and Jiangsu Food and Drug Agency.

Looking forward, YRPG will continue working to help build up the Chinese pharmaceutical industry, and serve all human beings scientifically, rigorously and responsibly.

太极集团有限公司

Taiji Group Co., Ltd.

太极集团有限公司（简称太极集团）是中国企业500强之一，中国医药工业10强。2016年3月1日前，完成 “太极实业”、“西南药业”、“桐君阁”三家上市公司整合为一。“太极”（TAIJI）为中国首批驰名商标，OTC品牌药企第一名，2016年集团销售总额达330亿元，2021年将跨越千亿大关。

太极集团拥有10000家药房、13000名员工、20多家医药商业公司、13家制药厂及太极医药研究院、重庆中药研究院两大研发机构。1998年，太极集团与国内外15所院校合作建立博士后工作站；1999年，太极集团技术中心被认定为国家级企业技术中心；2014年，获国家批准建立太极院士专家工作站，中国工程院近20位院士成为太极研发顾问。

太极集团现有中西药品种1200多个、全国独家生产品种50多个、获得国家中药保护品种50多个、国家基药品种165个，获国家专利137项、年销售额逾亿元的品种15个。

太极集团的快速发展主要得益于日益增强的科研开发能力，日益完善的国内市场网络，日益成熟的信息化管理，先进的生产装备，畅销的外贸营销渠道，一流的员工队伍和管理团队，颇具中国特色的管理经验。更为重要的是，太极员工多年受“忠诚、责任、团结、努力”的太极精神熏陶，充满了 “光大太极、振兴中华”的必胜信念。

习近平、张德江、江泽民、李鹏、温家宝、吴邦国、李源潮等党和国家领导人多次亲临太极集团视察工作，充分肯定太极集团的发展壮大之路，江泽民同志亲笔书写“太极集团”四个金光闪闪的大字予以鼓励。

阴阳互根方能相长，阴阳平衡万事万物方能和谐发展。太极集团渴望交流，期待合作，愿和您为中国医药事业走向世界而共同努力！

健康世界 太极无限

Taiji Group Co., Ltd. (short for TaiJi Group) is one of the top 500 Chinese enterprises, having 20 billion yuan assets.

We have been integrated “Taiji industry”, “Tong Jun Ge” and “Southwest Pharma Ceutical” with single company. “Tai Ji” (TAIJI) have been a well-known brand in China, In 2016,the gross sales was 33.0 billion yuan, In 2021, Taiji Group plans to reach one billion yuan in the next decade.

Taiji Group owns more than 1,200 drugs varieties, of which 50 exclusive products, 165 national base products. The enterprise has achieved 137 patens and 15 of single product sales reach one billion per year.

The great achievements we made is mainly due to the growing research and development capabilities, increasing domestic market, advanced equipment, outstanding workforce and specialized management.

More importantly, Taiji staff observe the spirit of “loyalty, responsibility, unity, and hardwork” for many years, having the notion of contributing to long-term development of the company.

Xi Jinping, Zhang Dejiang,Jiang Zeming, Li Peng, Wen Jiabao and other state leaders have been visited Taiji and totally gave affirmation to our company. Moreover, Jiang Zeming handwritten “tai ji ji tuan” four glittering characters to encourage Taiji Group.

Taiji Group longs for communication and desperately waiting for cooperation with all the excellent companies. Let’s make efforts to push traditional Chinese medicine into the international market. We are always dedicated to the health of people around the world!

浙江康恩贝制药股份有限公司

Zhejiang Conba Pharmaceutical Co., Ltd.

浙江康恩贝制药股份有限公司是一家集药品研发、生产、销售及药材种植为一体的医药上市企业。

公司前身为创建于1969年的“兰溪云山制药厂”，目前管理总部设在浙江省杭州市，公司在杭州、兰溪、金华，以及 江西、云南、内蒙古、四川等地拥有先进规范的药品生产基地，并在兰溪建有国内最大的现代植物药制造基地——康恩贝植物药产业园。公司旗下拥有浙江康恩贝中药有限公司、浙江金华康恩贝生物制药有限公司、云南希陶绿色药业股份有限公司、杭州康恩贝制药有限公司、江西天施康中药股份有限公司、上海康恩贝医药有限公司、云南康恩贝植物药有限公司、内蒙古康恩贝药业有限公司等多个颇具规模和实力的全资及控股子公司。

公司为国家高新技术企业、国家创新型企业、国家知识产权试点企业，建有国家认定企业技术中心、国家博士后科研工作站、院士工作站，并拥有一支由博士、硕士和高中级技术人员组成的实力雄厚、专注于现代植物药和特色化学药研发的团队，已建立新药研发的多个技术平台，在心脑血管系统用药、泌尿系统用药、抗糖尿病用药、呼吸道系统用药、消化系统用药和抗感染药等药物的研发，以及植物提取分离和结构改造、新型药物释放系统应用等诸多方面，研发具有自主知识产权的新药，在药材种植、植物提取、制剂生产、市场营销等各环节，已建立起规范高效的产业体系。

公司历来十分重视产品品牌和企业品牌的培育和保护，在药品多个领域建立了消费者熟知与认可的品牌，“康恩贝”、“前列康”是中国驰名商标，“天保宁”、“阿乐欣”、“金康”、“金奥康”、“希陶”、“天保康”、“天狮”等均在各自领域拥有较高的品牌知名度，在同类竞争产品中已树立起了较突出的品牌优势。

Zhejiang Conba Pharmaceutical Co., Ltd. (founded in 1969, listed in 2004, stock code 600572) is a holding subsidiary and main member enterprise of Conba Group Co., Ltd. It is a listed pharmaceutical enterprise integrating herbs planting and pharmaceutical R&D, production and sales. The company was previously known as “Lanxi Yunshan Pharmaceutical Factory” founded in 1969 and was renamed “Zhejiang Conba Pharmaceutical Co., Ltd.” in October 1999. The company was registered in Lanxi, Zhejiang Province, with head office set in Hangzhou, Zhejiang. It owns advanced and standard pharmaceutical production bases in Hangzhou, Lanxi, Jinhua as well as Jiangxi, Yunnan, Inner Mongolia and Sichuan, etc., and has built domestic largest modern herbal medicine manufacturing base, Conba Herbal Medicine Industrial Park in Lanxi. The company owns a dozen of wholly owned and holding subsidiaries of considerable size and strength including Zhejiang Conba Chinese Medicine Co., Ltd.,Zhejiang Jinhua Conba Bio-Pharm. Co., Ltd., Yunnan Xitao Green Pharmaceutical Co., Ltd., Hangzhou Conba Pharmaceutical Co., Ltd., Jiangxi Herbi-sky Co., Ltd., Zhejiang Conba Pharmaceutical R&D Co., Ltd., Zhejiang Conba Pharmaceutical Sales Co., Ltd., Shanghai Conba Pharmaceutical Sales Co., Ltd., Yunnan Conba Herbal Medicine Co., Ltd. and Inner Mongolia Conba Pharmaceutical Sales Co., Ltd., etc.

Zhejiang Conba Pharmaceutical Co., Ltd. always adheres to building its own core competitiveness. R&D and brand have always been two advantages of company.

First of all, Company has multiple new drug R&D technology platforms and an elite technical team. It has established long-term strategic partnership and strategic alliance relationship with domestic and foreign well-known research institutions, colleges and universities. In the fields of drug R&D as well as plant extraction and separation, structure modification and new drug release system application, etc., it develops new drugs with independent intellectual property right, and in the links of herbs planting, active pharmaceutical ingredients and plant extraction, new drug R&D, preparation production and marketing, etc., it has built a standard and efficient industrial system and become the only enterprise integrating national technology center, national post-doctoral research workstation, academicians workstation, national innovative enterprise and Zhejiang key enterprise research institute in traditional Chinese medicine industry in Zhejiang.

Secondly, company attaches particular importance to product brand and enterprise brand cultivation and protection, so it has built brands familiar to and recognized by consumers in several fields including urinary system and cardiovascular system, etc. Now, the company has become one of the enterprises owning the most famous trademarks and brand products, among which “Conba”, “Prostate Plus”, “Zhenshiming” are identified as famous trademark of China, while “Prostate Plus”, as the company’s leading herbal medicinal product, has become the first brand in domestic Chinese herbal medicines treating BPH; “Tianbaoning” is China's first modern herbal medicine preparation meeting international quality standards. In addition, “Alocin”, “Xitao”, “Yuanbang”, “Baby” and “Omeprazole”, etc., have considerable brand awareness in their respective fields and set up considerable brand advantages in similar competitive products.

神威药业集团有限公司

Shineway Pharmaceutical Group Co., Ltd.

神威药业集团是集研发、生产、销售于一体的大型现代医药企业集团，中国中药行业前五强，香港联合交易所主板市值最大的现代中药企业，拥有“神威”、“五福”、“神苗”三个中国驰名商标，是全国规模最大、技术水平最高、质量控制能力最强的现代中药注射剂、软胶囊、颗粒剂专业制造商，成为全国唯一的中药制剂高技术产业化示范基地，被国家科技部等五部委联合授予国家认定企业技术中心、国家技术创新示范企业、国家级知识产权优势企业。

神威拥有全国唯一的“中药注射剂新药开发技术国家地方联合工程实验室”，每年有数个国家级新药投入市场，多项科研成果获得国家、省级科学技术进步奖和国家发明专利。神威清开灵注射液、参麦注射液、舒血宁注射液为“全国百姓放心药”，占据了国内同品种70%以上市场份额，降脂通络软胶囊、舒筋通络颗粒等多个品种被列为国家中药保护品种，五福心脑清软胶囊、小儿清肺化痰颗粒、滑膜炎颗粒等知名产品畅销全国。神威主导完成的“中药注射剂全面质量控制及在清开灵、舒血宁、参麦注射液中的应用”技术获国家科技进步奖二等奖。神威与中国中医科学院、澳大利亚知名科研单位联合开发组分中药塞络通胶囊，治疗老年性痴呆，首开中药国际产学研合作模式先河。

Shineway Pharmaceutical Group is a large modern pharmaceutical enterprise in herb planting, research and development, manufacture and distribution in China, recognized as one of the top 5 enterprises in the Chinese medicine industry, the Group is the largest modern Chinese medicine enterprise listed on the Main Board of Hong Kong Stock Exchange by market value, holding 3 “China Famous Brand”-“Shineway”, “Wufu”, “Shenmiao”, it is the professional manufacturer of modern Chinese medicine injections, soft capsules, granules with the largest scale, the highest technology and the strongest quality control, and became the only modern Chinese medicine formulation high-tech industrialization demonstration base, authorized by five national ministries including the Ministry of Science and Technology as National Enterprise Technology Center, National Technology Innovation Demonstration Enterprise, and National IPR Advantageous Enterprise.

Only Shineway has the “Chinese medicine injection new drug development technology national local joint engineering laboratory”, in each year several national new drugs will be released into the market, a lot of scientific research achievements are honored with the National or Provincial Science and Technology Progress Award and the National Invention Patents. Shineway’s Qingkailing injection, Shenmai injection, Shuxuening injection are regarded as “Assured Drug”, which occupy more than 70% domestic market share in similar varieties, Jiangzhi Tongluo soft capsules, Shujin Tongluo granules and other species are listed as a national Chinese medicine protection species, Wufu Xinnaoqing soft capsules, Xiaoer Qingfei Huatan granules, Huamoyan granules are well known and sold nationwide. Shineway leads to complete the “traditional Chinese medicine injections comprehensive quality control and the application in Qingkailing Shuxuening Shenmai Injection” obtain the National Science and Technology Progress Award. Shineway combine with China Academy of Chinese Medical Sciences, Australia renowned research institutions to jointly develop components of traditional Chinese medicine SLT capsules, aiming at the treatment of senile dementia, it is a precedent to open traditional Chinese medicine international cooperative mode on industry-study-research.

浙江医药股份有限公司

Zhejiang Medicine Co., Ltd.

浙江医药股份有限公司是于1997年5月组建的大型股份制综合制药企业。1999年8月经中国证监会核准，公司向社会公开发行了人民币A股5800万股，同年10月公司股票在上海证券交易所挂牌上市。截止2015年末，注册资本9.3亿元，总资产82亿元。

浙江医药现拥有新昌制药厂、维生素厂、昌海生物分公司、浙江来益生物技术有限公司、浙江来益医药有限公司等五家主要分公司（子公司）和医药工业研究院、上海来益生物药物研究开发中心两家研发单位，为国家高新技术企业，国家创新型企业，拥有国家级企业技术中心，设有国家级博士后科研工作站。现有员工6000余名，其中各类专业技术人员2000余名，占员工总数的40%以上。

目前，浙江医药已经形成了脂溶性维生素，类维生素，喹诺酮类抗生素，抗耐药抗生素等系列产品的专业化、规模化生产。公司原料产品：维生素E产量国内最大，为全球第二大生产商；天然维生素E产量为国内最大，全球第三大生产商；β-胡萝卜素和斑蝥黄素是全国最大、全球第三大供应商；盐酸万古霉素及替考拉宁已占全球产量的40%以上；公司制剂产品：乳酸左氧氟沙星注射液（商品名“来立信”）占全国销售的20%以上，注射用盐酸万古霉素（来可信）占全国销售的30%以上，注射用替考拉宁（加立信）为国内最大供应商。

浙江医药通过认真实施“创新创业、竞争发展、科技兴企、人才强企”的发展战略，紧紧抓住产品开发这条主线，突出结构调整，整合各种资源，加强原始技术创新和优势产品技术创新，做好优势品种的DMF文件注册和FDA认证工作，大力推行清洁生产、循环经济，以全球化为立足点，构建完善的市场网络，树立良好的品牌形象，创建先进的企业文化，大力提升了企业的核心竞争力，目前，浙江医药已发展成为一家技术先进、规模庞大、实力雄厚、对全球市场具有影响力的医药企业。

Zhejiang Medicine Co., Ltd. (hereinafter referred to as “ZMC”) is a large pharmaceutical stock-shared corporation established in May 1997. After being approved by the CSRC, ZMC issued 58 million public A shares in August 1999 and was listed via Shanghai Stock Exchange in October of the same year. With a registered capital of RMB 936 million, the current corporate annual sales income is close to 5 billion yuan and its total assets, up to 8 billion yuan.

ZMC currently owns six subsidiaries (Xinchang Pharmaceutical Factory, Vitamin Factory, Changhai Biological Company, Zhejiang Health Creation Biotechnology Co., Ltd., Zhejiang Health Creation Pharmaceutical Co., Ltd. and Shanghai Vital Health Management Co., Ltd.) and two R&D units (Research Institute of Pharmaceutical Industry and Shanghai Health Creation Biological Drug Research and Development Center). It is rated as the “National High-Tech Enterprise” and “National Innovative Enterprise” having National Enterprise Technology Center and National Post-doctor Scientific Research Station at its core.

ZMC specializes in large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. The corporation has formulated a range of dominant products through in depth and extensive studies. In addition to fat soluble vitamins which include VE, natural VE, VA, Biotin, Coenzyme Q10, carotenoids likeβ-carotene, Canthaxanthin, Astaxanthin, Lycopene, Zeaxanthin and Lutein, ZMC also produces Vancomycin HCl, Teicoplanin, Levofloxacin, Miglitol, in the form of APIs and FDF. Manufacturing in ZMC’s domestically model FDF Industrial Park is the 8 other dosage forms: large-volume injections, small-volume injections, freeze dried powder injections, tablets, hard capsules, soft capsules, pills and oral solutions.

Taking globalization as its standpoint, the development strategy of ZMC encompasses innovative entrepreneurship, competitive development, scientific technology advancement and talent implementation. By focusing on developing products, highlighting structure readjustment, re-organizing and integrating various resources, and strengthening its technological innovation in methods and products, ZMC is to build a consummate market network and to build a pristine image for its branded products on top of promoting its corporate culture and competitiveness in its core business. At presence, ZMC is recognized as a large global influential pharmaceutical corporation with advanced technology, strong capital and technical strengths.

华北制药集团有限责任公司

North China Pharmaceutical Group Corporation

华北制药集团公司是中国最大的化学制药企业之一。1953年建厂，开创了中国大规模生产抗生素的历史。经过60年的发展，现拥有三十余家子公司， 5大生产基地，新头孢药物生产基地，新制剂药物生产基地，抗肿瘤药物生产基地，青霉素类药物生产基地，生物技术药物生产基地，产品涵盖了抗生素与半合成抗生素，生物技术药物，抗肿瘤药物，维生素，农兽药等600多个品种的原料和制剂。2016年华北制药实现销售收入110亿元。

华北制药新制剂分厂是华药制剂生产基地，占地面积388亩，总投资26亿元。厂房及布局设计完全按照cGMP 规范要求进行设计、施工。现有生产线25条，年生产能力粉针制剂5亿支、口服制剂159.3亿片（粒、袋）、小容量注射剂3亿支、滴眼剂4300万支。有无菌粉针制剂、小容量注射剂、滴眼剂、胶囊剂、片剂、颗粒剂等主流剂型。产品涵盖心脑血管类、免疫抑制剂类、新抗生素类、保健品类等。

华北制药生物技术分公司是华药生物技术药物生产基地，是国内规模最大、技术水平最高、工艺设备先进的中国第一家重组人血白蛋白产业化基地。厂房及布局设计完全按照国际GMP标准建造，年产吨级以上产品，质量达到国际先进水平。基因重组人血白蛋白项目是国家重大新药创制重点课题，拥有自主知识产权，截止到2016年底，重组人血白蛋白技术已获得专利20余项，比传统血源人血白蛋白具有纯度更高、无动物组分、不含病毒残留的优势，产品更安全、更可靠。加上金坦公司已建成的，华北制药已具备三个成熟的细胞表达系统，拥有丰富的生物技术产业化经验。

华北制药华民药业有限责任公司成立于2010年，是华药头孢抗生素生产基地，也是目前中国最大的头孢产品生产基地。占地面积300亩，总投资12亿元。厂房及布局设计完全按照cGMP规范要求进行设计、施工，生产过程闭环管理、生产环节自动监控、产品质量全程跟踪，立体仓库实现了自动化物流信息管理。目前有9个模块18条生产线，产品涵盖四代头孢所有主导产品，年生产能力粉针9亿支，片剂7亿片，胶囊25亿粒，颗粒剂1亿袋。形成了从药用中间体原料至制剂的完整的头孢产业链及丰富的头孢产品群。

华北制药实施“4+N”的产品战略，聚焦“抗感染、抗肿瘤、心脑血管和免疫调节”四大重点领域，以大健康和滴眼剂等为其他治疗领域，均采用国际先进的工艺技术装备。现诚邀国内外研发机构、制药企业和医药商业公司进行技术、生产及市场方面的合作。

NCPC is one of the largest pharmaceutical enterprises in China. Established in 1953, NCPC created a history of large-scale production of antibiotics. During 60 years' development, NCPC owns over 30 subsidiaries, 5 major production bases, including new cephalosporins production base, new formulation production base, antineoplastic production base, penicillins production base and biotechnology drugs production base, covering more than 600 kinds of APIs and preparations, such as antibiotics, semisynthetic antibiotics, biologicals, antineoplastic, vitamins, pesticides and veterinary etc. NCPC brand obtains the comprehensive awareness in domestic and abroad market, renowned both inside and outside the country. NCPC achieved the sales revenue of NCPC achieved the sales revenue of RMB 11.00 billion in 2016.

NCPC New Formulation Branch Factory is the production base for formulation, covers an area of 388 acres, total investment is RMB 2.6 billion. The plant and layout design are designed and constructed according to the requirements of cGMP. There are 25 production lines, the annual production capacity of 500 million vials powder for injections, 15.93 billion tablets (capsules, sachets) oral preparation, 300 million ampoules small volume injections and 43 million eye drops. Covering the main dosages of sterile powder for injection, small-volume injection, eye drops, capsules, tablets and granules etc. The products cover the therapeutic drugs of cardiovascular and cerebrovascular, immunosuppressant, new antibiotics and healthcare products etc.

NCPC Biotechnology Branch Company is a production base for biotechnology drug in NCPC, is the first industrialization base for rHSA in China, has the Largest scale, highest technology and advanced process equipments. The plant and layout design are built according to cGMP standard, the annual capacity is more than tons of products, and the quality reaches advanced international level. rHSA project is a National innovative key project for important new drug, holds proprietary intellectual property rights, up to the end of 2016, the project has obtained over 20 related patents, compared with the traditional natural human serum albumin, rHSA has the advantages of higher purity, no animal components or virus residues, the product is much more safe and reliable. Including the cell expression system that Jin Tan company has been built, NCPC has three mature cell expression system, has rich experience in the biotechnology industry.

NCPC HebeiHuamin Pharmaceutical Co., Ltd. was established in 2010, is the production base for cephalosporins in NCPC and the largest production base for cephalosporins in China. Covering an area of 388 acres,and the total investment is RMB 1.2 billion. The plant and layout design are designed and constructed according to the requirements of cGMP, the closed-loop management in the production process, the automatic monitoring at the production steps and the whole-process tracking on the product quality, and the automatic logistics information management in the stereoscopic warehouse. At present, there are 9 modules and 18 production lines, covering all of the leading products in the 4th generation cephalosporins, the annual production capacity of 900 million vials powder for injection, 700 million tablets, 2.5 billion capsules and 100 million sachets granules. The complete cephalosporin industry chain and the abundant cephalosporin products group covering from the intermediate material to formulation products have been established.

NCPC implements the product strategy of “4+N”, focusing on 4 key product areas: anti-infective drugs, anti-cancer drugs, cardiovascular system drugs and immune drugs, taking comprehensive health and eye drops as other therapeutic area, using advanced technology and equipments in the productions. Now NCPC heartly invites R&D institutes, pharmaceutical enterprises and medical commercial corporations domestic and abroad to cooperate in technology, manufacturing and marketing.

东北制药集团股份有限公司

Northeast Pharmaceutical Group Co., Ltd.

东北制药集团股份有限公司（简称“东北制药”）前身为东北制药总厂1946 年始建于佳木斯，1949 年迁至沈阳，1993 年6 月成立东北制药集团股份有限公司，并于1996 年在深交所上市。截至2016年底，东北制药总资产97.6亿元，从业人员9500人，年营业收入48亿元，年出口创汇1.15亿美元，是国有大型综合性制药企业集团。

拥有化学原料药、化学制剂、生物医药、医药商业、医药工程五大业务板块，主要生产抗生素类、维生素类、消化系统类、麻醉药品类、生物诊断试剂类等10大系列产品，400多种医药中间体、化学原料药和制剂产品。主导原料药产品VC系列、磷霉素系列、左卡尼汀系列等占国际供应市场强势地位，远销100多个国家和地区。拥有制剂产品国家批准文号366个，现有244个品规药品进入《国家基本医疗保险、工伤保险和生育保险药品目录》甲乙类目录。东北制药是国内定点麻精药品生产企业，占据国内抗艾药物统一采购近70%的市场份额,特色产品卡孕栓为全球独家。

东北制药具备完善的质量管理体系，产品质量符合新版GMP、EP8.0、USP37、JP16、BP2014、CP2010等最新质量标准。公司多个产品先后通过了EDQM、FDA、日本厚生省、BRC、HALAL、KOSHER等国际高端认证。主导产品通过了美国、欧洲、日本、巴西、俄罗斯、波兰等多个国家和地区的注册和质量审计。

东北制药设有研究院、设计公司、制造安装公司、国际贸易公司和医药商业公司，旗下东北大药房遍布东北、辐射全国。公司拥有股份公司及子公司沈阳第一制药、东瑞精细化工、辽宁生物、沈阳施德5家高新技术企业。拥有“东北”、“复美欣”两个中国驰名商标及一大批省市驰名商标。先后多年跻身中国制造业企业500强，并被确认为国家认定企业技术中心。

面向未来发展，东北制药以“一切为了健康，向未知与不可能挑战”为核心价值观实现“公司有朝气、产品有名气、员工有福气”的企业愿景，着力打造国内一流、国际知名的大型医药企业集团。

Northeast Pharmaceutical Group Co.,Ltd. (hereinafter referred to as “Northeast Pharm”) formerly known as Northeast General Pharmaceutical Factory founded in Jiamusi in 1946, then moved to Shenyang in 1949. In June 1993, Northeast Pharmaceutical Group Co.,Ltd. was established and became public company listed on the Shenzhen Exchange Stock in 1996. By the end of 2016, Northeast Pharm has total assets of RMB 9.76 billion, 9500 employees, annual revenues of RMB 4.8 billion and annual exports amount of $115 million, is the state-owned large-scale comprehensive pharmaceutical enterprise group.

Northeast Pharm have five business sectors including APIs, chemicals, bio-pharmaceuticals, pharmacy chains &medical distribution, pharmaceutical engineering, mainly focus on the production of 10 series products including antibiotics, vitamins, digestive system drugs, such as narcotic drugs, biological diagnostic reagents etc. and more than 400 kinds of pharmaceutical intermediates, chemical raw materials and finished products. Leading products including VC series, fosfomycin series, levo-carnitine series, possess strong position in the international market and are exported to more than 100 countries and regions. We have 366 preparation products national approval numbers, and 244 existing drugs are in the the national basic medical insurance, work injury insurance and maternity insurance drug list A and B class list.

Northeast Pharm has a perfect quality management system, the quality of products meet most of the latest quality standard including the new version GMP, EP8.0, USP37, JP16, BP2014, CP2010. Many products have passed the EDQM, FDA, Japan MHLW, BRC, HALAL, KOSHER and other international authorization. Leading products are either registered in or passed the quality audit of the United States, Europe, Japan, Brazil, Russia, Poland and other countries or regions.

Northeast Pharm have research institutes, design company, manufacturing and installation company, international trading companies and commercial pharmaceutical companies, pharmacies of the Northeast Pharm spread all over northeast and radiate national wide. The company has 5 subsidiaries including the ShenYang No.1 Pharmaceutical Corporation, Dong Rui Fine Chemicals Company, Liaoning Bio-Pharm Company, Shenyang ShiDe Pharmaceutical Company. We have two well-known trademark of “DONGBEI” and “FuMeiXin” and a large number of provincial famous brand in China. We have ranked among China's top 500 manufacturing enterprises for many years and were recognized as a national enterprise technology center.

Future-oriented developing, Northeast Pharm will take “All for health, we will challenge the unknown and the impossible!” as the core values, pursue the corporate vision of “Energetic Company Leading Products Happy Employees”, and take efforts to create domestic first-class, international well-known large pharmaceutical groups.

四川科伦药业股份有限公司

Sichuan Kelun Pharmaceutical Co., Ltd.

创立于1996年，历经20年发展，现已成为拥有海内外90余家企业的现代化药业集团。集团的产业板块，科伦药业(SZ002422)于2010年6月3日在深圳证券交易所成功上市，全球最大的大输液专业制造商和运营商在资本市场扬帆启航。

2016年科伦集团营业收入超过400亿元、利税超过20亿元人民币。根据商务部发布的2012年中国药品流通行业销售排序和工信部医药统计年报，科伦集团旗下的商业和产业双双进入全国前十强。

作为科伦集团旗下的产业板块，科伦药业生产和销售包括大容量注射剂(输液)、小容量注射剂(水针)、注射用无菌粉针(含分装粉针及冻干粉针)、片剂、胶囊剂、颗粒剂、口服液、腹膜透析液以及原料药、医药包材、医疗器械，以及抗生素中间体等共计588个品种978种规格的产品。其中，拥有114个品种共274种规格的输液产品、383个品种共608种规格的其它剂型医药产品、还拥有45个品种共47种规格的原料药、10个品种的抗生素中间体、32个品种的医药包材、4个品种共7种品规的医疗器械产品，是中国输液行业中品种最为齐全、包装形式最为完备的医药制造企业之一。以具体产品计，公司有117个品种纳入《国家基本药物目录》，是目前国内产业链最为完善的大型医药集团。

截至目前，科伦药业及子（分）公司共申请专利2771 项，其中已获授权专利2254 项。目前，科伦已启动针对肿瘤、细菌感染、肠外营养等多个疾病领域共330余个项目的药物研究，着力于解决重大疾病未满足的临床需求和临床用药的可及性。科伦共申报92个项目，29项为国内首家申报，截至目前获批临床49项，待批生产36项。科伦快速高效的自主研发能力，跻身中国首批研发第一方阵，业界瞩目，叹为奇迹。2015年1月，公司自主研发的可立袋®因其技术创新性突破、推动行业科技进步作用明显、经济效益和社会效益显著，获得“国家科技进步二等奖“。

多年来，公司先后被国家发展与改革委员会、科学技术部、财政部、海关总署、国家税务总局、国务院国资委、工业和信息化部、国家工商总局、中华全国总工会授予“国家认定企业技术中心”、“国家第三批创新型企业”、“国家技术创新示范企业”、“国家地方联合工程实验室”、“工业品牌培育示范企业”、“国家级信息化和工业化深度融合示范企业”、“守合同重信用企业”、“两化融合管理体系贯标试点企业”、“2015年全国工业企业质量标杆”等多种荣誉称号。

Founded in 1996, Kelun Group has developed into a modern pharmaceutical group, with more than 90 subsidiaries (branches) both at home and abroad; all this rapid development took place within just 20 years. On June 3, 2010, the bell at Shenzhen Stock Exchange rang to declare the listing of Kelun Pharmaceutical (SZ002422), the industrial segment of the Kelun Group. That memorable day marked the entrance of the biggest manufacturer and distributor of IV Solutions into the capital market.

Kelun Group´s sales revenues in 2016 exceeded RMB 40 billion, and profit tax was over RMB 2 billion. According to the 2012 Sales Ranking of Chinese Drug Circulation Industry released by the Ministry of Commerce and the Pharmaceutical Statistic Annals of the Ministry of Industry and Information Technology (MIIT), the business and industrial segments of the Kelun Group ranked within the Top 10.

As the industrial segment of the Kelun Group, Kelun Pharmaceutical is specialized in manufacture and sale of 588 different products in 978 specifications, including LVP (IV Solutions), SVP (small volume parenterals), sterile powder for injections (including dispensed & lyophilized), tablets, capsules, granules, oral solutions, dialysis solutions, APIs, pharmaceutical packaging materials, medical devices, and antibiotic intermediates, among which 274 specifications in 114 varieties belong to IV solutions; 608 specifications in 383 varieties belong to pharmaceutical products in other dosage forms; 47 specifications in 45 varieties belong to APIs; 10 varieties belong to antibiotic intermediates; 32 varieties belong to pharmaceutical packaging materials; 7 specifications in 4 varieties belong to medical devices. Kelun is the pharmaceutical manufacturing enterprise with the largest number of different products and packaging forms in the IV solution industry of China. In terms of specific products, 117 varieties of Kelun products have been included in the National Essential Drugs List. At present, the company is the largest pharmaceutical group with the most complete industrial chain in China.

So far, Kelun Pharmaceutical, including its subsidies, has applied for 2,771 patents in total, of which, 2,254 have been approved. Besides, more than 330 medicine research programs on tumor, bacterial infection, parenteral nutrition and other fields are in process, targeting at unsatisfied clinical demands and accessibility of clinic medicine for critical diseases. In the 92 projects declared by Kelun, 29 are the first of its kind in China. Data as to the present shows that 49 clinical programs are approved and 36 to be put in batch production. The speedy, high-efficient and independent R&D capacity of Kelun contributes a lot to its promotion to the 1st R&D array of the first batch in China, winning attention and admiration in the industry. In January 2015, Collapsible PP Bottle (Uniflex®), a result of its independent R&D, was awarded the “National 2nd Prize of Technological Progress” for its breakthrough in technical innovation, significance to technological progress, economic and social benefits of the industry.

For years, the Company has received numerous titles from the National Development and Reform Commission, Ministry of Science and Technology, Ministry of Finance, General Administration of Customs, State Taxation Administration, State-owned Assets Supervision and Administration Commission of the State Council, Ministry of Industry and Information Technology, State Administration of Industry and Commerce and All-China Federation of Trade Union, including “National Recognized Enterprise Technology Center”, “National 3rd Batch of Innovative Enterprise”, “National Model of Technology Innovation”, “National-Local Jointed Engineering Laboratory”, “Industrial Brand Cultivation Model”, “National Model of Deeply Integrated Information and Industrialization”, “Contract-Honoring and Credit-Valuing Enterprise”, “Pilot of Management System Standard Implementation of Information and Industrialization Integration”, and “Quality Benchmark for National Industrial Enterprises of the Year 2015”.

通化东宝药业股份有限公司

Tonghua Dongbao Pharmaceutical Co., Ltd.

通化东宝药业股份有限公司始建于1985年12月1日，1992年11月改制为股份制有限公司，1994年在上海证券交易所挂牌上市。公司最早以发展中药产业为主，研制推出的“镇脑宁胶囊”，成为中药治疗头痛的经典产品。公司从1998年开始发展生物制药，于1998年成功研制出具有中国独立知识产权的重组人胰岛素“甘舒霖”，填补了国内空白，使中国继美国、丹麦之后成为世界上第三个能生产重组人胰岛素的国家，项目获国家科技进步二等奖。人胰岛素的生产打破跨国企业对中国人胰岛素市场的垄断，经过十余年专业化的市场营销，目前东宝人胰岛素市场占有率已经超越部分跨国企业排第二位。公司秉承"坚持自主创新、创造世界品牌"的发展理念，加快胰岛素类似物产品开发，目前市场上在售的所有类似物通化东宝均已申报注册，未来通化东宝将成为胰岛素制剂最全的公司。为东宝立足于糖尿病领域的发展打下坚实基础。

通化东宝在加大产品研发同时，不断加大产能建设，到今年9月通化东宝的胰岛素生产能力从原料到制剂都能独自承担上亿中国糖尿病人的胰岛素治疗需求，成为中国糖尿病人的坚强依靠。2013年4月通化东宝年产3吨的人胰岛素原料生产线通过欧盟GMP认证，标志通化东宝成为世界一流重组人胰岛素生产企业，也是世界三大重组人胰岛素生产基地之一。通化东宝正一步一个脚印朝着一流的生物制药企业前进。

Tonghua Dongbao Pharmaceutical Co., Ltd. was founded on December 1, 1985, restructured into joint-stock Co., in November, 1992, and listed on the stock exchange of Shanghai in 1994. Initially, Tonghua Dongbao mainly focused on traditional Chinese medicine industry and produced “Zhennaoning Capsule”, which is the classic treatment to headache. The company began to develop biopharmaceuticals in 1998, and successfully produced the recombinant human insulin “Ganshulin” with Chinese independent intellectual property rights in that year, filling the blank of human insulin field in China. This breakthrough made China become the first three countries in the world that are able to produce the recombinant human insulin, ranking after the United States and Denmark. The project won the second class prize of the National Scientific and Technological Progress. Production of human insulin broke the monopoly of the multinational enterprises in Chinese market. After more than ten years of professional marketing, the market share of Dongbao human insulin has bypassed some multinational enterprises, ranking the second. The company adheres to the concept of development, “to independent innovation, create a world brand”, to accelerate the development of insulin analogue products. Currently, Tonghua Dongbao has declared to be registered on the market for sales of all analogues. In the future, Tonghua Dongbao will become the most comprehensive insulin preparations company, which will lay a solid foundation in the field of diabetes for the future development of Dongbao.

When Tonghua Dongbao increases the product research and development, we also increase the capacity of production. By September of this year, Tonghua Dongbao’s production capacity of insulin from the raw material to the preparation alone will meet the demand of hundreds of millions of diabetes insulin treatment, becoming a strong support for Chinese diabetes patients. In April 2013, Tonghua Dongbao’s production line that produces 3 tons of insulin raw materials has attained the EudraGMP approval, which made it become the world first class human recombinant insulin production enterprise. It is also one of the world’s three largest production base for recombinant human insulin. Tonghua Dongbao is walking towards the first class biological pharmaceutical enterprise by one step at a time.

山西振东制药股份有限公司

Shanxi Zhendong Pharmaceutical Co., Ltd.

振东制药股份有限公司是山西省首家登陆创业板的上市企业，为高新技术企业，拥有中药材开发公司、北京研究院、生物健康科技公司、医药物流公司和振东、泰盛、安特、开元、康远五个药品和两个饮片七大生产基地。主要生产抗肿瘤、心脑血管等八大系列 615 个品种，现已形成中药材种植、研发、生产、销售为一体的完整产业链。

振东制药长期与国内外多家科研院所进行合作。国内与中国医学科学院、中国军事医学科学院、中国中医科学院、中国药科大学等合作，进行新产品的研制开发，并承担了国家重大专项科技项目；国外与澳大利亚阿德莱德大学、美国国立卫生研究院及沃特世公司、荷兰 SU 生物医药公司等进行国际合作，旨在推动中医药走出国门，造福全球人类。

振东制药营销网络覆盖全国 400 余个城市，与全国数千家医疗单位建立了业务关系，形成了“多渠道，多模式”的销售体系，有完善的学术支持、售后服务与信息反馈渠道。

面向未来，振东制药将以“百年企业，百亿振东”为目标，以“好人好药，好药好人”为理念，全力打造“振东制药”全国知名品牌，为人类的健康事业贡献力量。

The Zhendong Pharmaceutical Co., Ltd., located in Shanxi Province, is the first listed high-tech company on the Growth Enterprise Market, which comprises Chinese Herbal Medicine Development Company, Beijing Pharmaceutical Research Institute, the Bio-health Technology Company, the Pharmaceutical Logistics Company, and also has five drugs and two Chinese herbal pieces of production basis (the Zhendong Pharmaceutical, the Taisheng Pharmaceutical, the Ante Pharmaceutical, the Kaiyuan Pharmaceutical, the Kangyuan Pharmaceutical). It has 615 kinds of products in eight medicine series for antitumor, cardiovascular and etc. A health industrial chain with the integration of Chinese herbal materials planting, researching, manufacturing and marketing has been formed completely.

The Zhendong Pharmaceutical Co., Ltd. has established a long termcooperation relations with home and abroad institutes and universities. Seeking national cooperation with institutions and university like the Chinese Academy of Medical Sciences, the Academy of Military Medical Sciences, the China Academy of Chinese Medical Sciences and the China Pharmaceutical University is dedicated to the research and development of new medical products as well as some of the national key Science and Technology Special Projects. Purpose of international cooperation with the United States National Cancer Research Center, Australia Adelaide University, the Waters Company and SU BioMedicineB.V. of the Netherlands is to promote Chinese herbal medicine abroad and benefit the global human beings.

Zhendong Pharmaceutical Co., Ltd. whose marketing network has covered more than 400 Chinese cities, has established business relations with thousands of medical institutions nationwide, and formeda marketing system of “multiple channels, and multiple modes” with its well-developed academic mechanism, after-sale service and information feedback channels.

Looking forward to the future, Zhendong Pharmaceutical Co., Ltd. will take “century-old enterprise and 10 billion yuan Zhendong” as target, establish the philosophy of “being good person for high quality drug, high quality drug from good person”, make great efforts to create the national well-known brand “Zhendong Pharmaceutical” and contribute to human’s health industry.

美罗药业股份有限公司
Merro Pharmaceutical Co., Ltd.

美罗药业是以药品研发、制造和销售为核心业务的专业化上市公司，注册资本3.5亿元，是国家级高新技术企业，拥有“国家级博士后工作站”，现已通过美国FDA认证、澳大利亚TGA认证等。

美罗拥有占地面积15.5万平方米、建筑面积13万平方米的现代化医药产业基地，包括美罗大药厂、美罗中药厂以及美罗国际药物研发中心等，一直致力于化学药制剂、生物医药、中药、植物药的研究、生产和销售，在行业内具有突出地位。美罗产品的三个方向是：国家基本药物、国际仿制药和生物医药的研发、制造，并在现有200多个产品的基础上重点发展缓控释制剂和生物制剂，还相继承担了数个国家级重点课题研究项目及重大高新技术产业化工程项目、国家十二五重大新药创制项目，在中成药开发、现代剂型创新、原生药资源利用、天然植物保健品、生物药品和生物医用材料的开发与应用等诸多研究项目中均取得重大突破。

美罗积极与国际制药公司合作，不断研发、引进新品种，全力推进国际医药市场产品、技术的广泛合作，不断提升公司创新能力，向专业化、规范化、国际化迈进，把美罗建设成为一个运用科技、服务卓越、精于变化的国际制药公司。

Merro Pharmaceutical Co., Ltd. is a public listed pharmaceutical company specializing in R&D, manufacturing and marketing of pharmaceutical products, with registered capital of 350 million yuan. Merro is a national high-tech enterprise, has a state-level post-doctoral working station. Now it had been approved by US FDA and Australia TGA Regulatory.

Merro is a modern medicine industry base which covers a land of 155,000 square meters and the build-up area is 130,000 square meters, contains Dalian Merro Pharmaceutical Factory, Dalian Merro Traditional Chinese Medicine Factory and Merro Drug Research and Development Center etc. Merro has been devoting to the development, manufacture and sales of chemical medicine, biological medicine, Chinese traditional medicine and herbal medicine, Merro is a leading company in the pharmaceutical field. Merro’s core strategies are: developing and manufacturing of National Essential Drugs, Generic drugs and Biomedicines; focusing on ER preparation and biologicals based on more than 200 products; Merro also undertakes a number of National important research projects, vital High-tech Industry demonstration projects and National twelfth five-year major new drug innovation projects, it gains a lot of major breakthrough in Chinese medicine development, modern dosage form innovation, original resource utilization and development and application of natural plant health products and biological drugs and biomedical materials.

Merro collaborates widely with international pharmaceutical companies, improving the company’s innovation capability and becoming an international pharmaceutical company with high technology, superior service and adaptability to changes.

上海上药信谊药厂有限公司

SPH SINE Pharmaceutical Co., Ltd.

上海上药信谊药厂有限公司是上海医药直属企业。信谊品牌始创于1916，是近代中国最早的民族化学制药企业之一。历经百年传承，不断发展壮大，成为集制造、销售、研发为一体的大型民族制药企业。旗下拥有九大工业生产基地，四大商业公司、一家市级研发中心。信谊具有强大的渠道和终端覆盖能力，营销网络辐射全国30多个省、市、自治区，覆盖了全国近10000 家医院终端、800余家主要经销商、150多个地级市，拥有一支1200多人的高素质、专业化的终端销售队伍。

信谊是中国化学制药企业产品最多、剂型最全的产业实体之一，拥有产品批文1114个，涉及14个治疗领域，覆盖16种剂型，有3个国家一类新药品种，其中“培菲康”是国家一类生物制品，已获得中国、美国、英国、加拿大、澳大利亚等多国专利。2012 年，“培菲康”被选为益生菌制剂“国家标准菌种”，目前正作为自主知识产权产品在申报美国FDA注册。公司在保持处方药领先的基础上，以“培菲康”为主要产品进入OTC业态，将通过未来几年的不懈努力，使之成为中国制药行业最具规模的企业之一，并始终成为引领微生态领域发展的先行者。

信谊品牌已获得“中国驰名商标”、“中国最具历史文化价值品牌”、“上海市著名商标”等多项殊荣，作为上海医药产业的重要组成部分，信谊人将秉承 “以信治厂，以谊为人”的经营理念，立足于品类发展、产业整合、品质提升、职能管控四大创新，提高企业的核心竞争力。

SINE is an affiliate of Shanghai Pharmaceuticals Holding Co., Ltd. Established in 1916, this brand is one of the first national chemical and pharmaceutical companies in modern China. With over one century of experience, we have become a large national pharmaceutical company with manufacturing, sales, and R&D capabilities. We have nine industrial production bases, four business companies, and one R&D center at municipal-level. SINE has our powerful channels and a marketing network of more than 30 provinces, cities, autonomous regions in the nation, covering nearly 10,000 hospitals, more than 800 major dealers, and more than 150 prefecture-level cities. We have a high-quality and professional sales team consisting of 1,200 employees.

SINE is one of the Chinese pharmaceutical enterprises with the largest and most comprehensive product portfolioand formulations. We have gained official approval for 1,114 products involving 14 treatment fields and covering 16 formulations, and 3 State Type I new drugs where “Bifico” is a State Type I biologicalproduct and patented in China, U.S., UK, Canada, and Australia.

SINE has been granted a “Chinese national well-known trademark,” a “Chinese brand with the greatest historical and cultural value,” and “well-known trademark of Shanghai.” Jinqiao Development ZoneCMC’s good Service philosophies and practical service initiatives provide much assistance and support for us. As an important component of the Shanghai pharmaceutical industry, SINE employees adhere to the business philosophy “Govern Factory By Trust, Be Friendly ”, and practice four innovations “Category Development, Industry Consolidation, Quality Improvement, and Competency Control &Management ” to improve our core competitiveness.

SINE R&D center focuses on independent research and development while fully utilizing the social resources and insisting on the collaborative R&D thinking. To master core technologies, we work with the domestic and overseasscientific research institutions in various professional fields to build a R&D platform for probiotics products. SINE Institute has established a good relation with Shanghai Institute of MateriaMedica, China Academy of Science, Institute of MateriaMedica, Chinese Academy of Medical Science & Peking Union Medical College, and Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences. It has also worked with East China University of Science and Technology, National Institutes for Food and Drug Control, Tongji University, Shanghai Sixth People’s Hospital Affiliated Shanghai Jiao Tong University School of Medicine, and Nanjing Drum Tomer Hospital, the Affiliated Hospital of Nanjing University Medical School to build a probiotics R&D platform. It has built a branded generics R&D platform in cooperation with Chinese Academy of Medical Science & Peking Union Medical College, National Pharmaceutical Engineering Research Center, Shanghai Institute of Pharmaceutical Industry, Second Military Medical University, and Fudan University.

华润双鹤药业股份有限公司

China Resources Double-Crane Pharmaceutical Co., Ltd.

华润双鹤药业股份有限公司拥有70余年制药历史，1997年挂牌上市【股票代码 600062】，2010年进入位列世界500强企业的华润（集团）有限 公司旗下，成为其医药板块化学药平台的支柱企业。目前拥有16家子公司，近1.4万名员工，年工业收入53.67亿元，净利润8.4亿元，是“中国驰名商标”企业和“国家高新技术企业”。经济实力、竞争活力和可持续发展能力位居 国内制药公司前列。

公司主要产品聚焦大输液、心脑血管、内分泌和儿科等领域；拥有〇号、冠爽、糖适平、儿泻康、珂立苏、压氏达等多个知名产品；销售网络深入医院、社区医疗卫生服务站、地县卫生院及药店等终端。

公司坚守“关心大众，健康民生”的企业宗旨，秉承华润集团“诚实守信、业绩导向、客户至上、感恩回报”的价值观，正向着“百亿工业”发展战略目标稳步迈进。

China Resources Double-Crane Pharmaceutical Co., Ltd. has over 70 years of history in pharmaceutical industry. The company was listed in 1997 (Share Code: 60006), acquired by China Resources (Holding)Co., Ltd. (Global 500) in 2010 and becoming one of its pillar enterprises in Chemical Pharmaceuticals. Currently, the company has 16 subsidiaries, over 14 thousand employees, Industrial annual revenue of 5.37 billion RMB, and net profit of 840 million RMB. The company is recognized as “China Top Brand” and “National High-tech Enterprise” and its economic strength, competition vitality, and development sustainability are ranked among the highest in the nation. The company’s main product focuses on four therapeutic areas: IV solution, cardiovascular and cerebrovascular diseases, endocrine diseases, and pediatric pharmaceuticals. The company has developed a wide range of well-known products including Hypertensive No.0, GuanShuang, Tangshiping, Erxiekang, Kelisu and Yashida. Sales network covers hospitals, community health service stations, county hospitals, and pharmacies. China Resources Double-Crane Pharmaceutical Co., Ltd. has been advocating tenet of the company: “Care for People and Promote Health” and adhering to the enterprise value of China Resources: “Integrity, Pursuing Excellence, Customer Come First, and Return to Community.” China Resources DoubleCrane Pharmaceutical Co., Ltd. has been moving forward steadily to achieving 10 billion-industry strategic objective.

丽珠医药集团股份有限公司

Livzon Pharmaceutical Group Inc.

丽珠医药集团股份有限公司是集医药研发、生产、销售为一体的综合性企业集团，创建于1985年1月，注册资本为4.25亿元，截止2016年，公司总资产逾100亿元人民币，年度营业收入76亿元，公司员工超过8000人。

丽珠集团拥有化学药、中成药、诊断试剂等400多个品种，有18个专利产品，21个独家产品，其中参芪扶正注射液、艾普拉唑和中药产业化项目先后荣获广东省科技进步一等奖。2016年1月，集团原研新药艾普拉唑荣获国家科技进步二等奖。1993年，丽珠A、B股相继上市；2014年，公司完成了B转H股，成为行业第一家完成A+H股的上市公司。

近几年来，公司先后获得国内多个行业荣誉：2011年被评为中国最具竞争力医药上市公司20强，2012年被评为最佳上市企业治理10强；2013年被评为上市企业投资价值TOP10强，2014至2016年连续被评为中国最具品牌价值500强企业。

2016年，集团已整体搬迁至金湾区丽珠工业园，工业园占地42.7万平方米，总投资约20亿元人民币，是按美国FDA和欧盟标准建造的国际一流的现代化制药生产基地，其过硬的硬件设备和全自动智能化运行均处于世界领先水平。

公司秉承以人为本、以精立业、以质取胜、以诚服务的经营理念，以永远致力于人类的健康事业为使命！以提供国内领先、国际一流的特色专科药为目标！以开拓和布局“精准医疗”相关领域的业务为愿景！

近几年，公司以科研创新驱动发展，成立单抗生物技术有限公司，拥有国家千人计划专家评审以及广东省领军人才为骨干成员的海外生物医药研发团队，建立了“国内领先、国际接轨”的单抗生物制药研发平台。2016年公司又紧跟国家发展步伐，布局“精准医疗”，相继成立了丽珠圣美和丽珠基因检测公司。根据公司发展战略，到2017年将实现销售100亿的战略目标。

Livzon Pharmaceutical Group Inc., founded in 1985, is a comprehensive pharmaceutical enterprise integrating development & research, production and sales of pharmaceutical products. Livzon has 9 GMP production plants located in Guangdong, Shanghai, Sichuan, Fujian, 3 plantation bases for Chinese drug preparation production located in Shanxi, Gansu, Yunan of China, with more than 5,700 employees.

Livzon has modern industrial chain and product group, operates to manufacture drug preparation, bulk medicines and intermediates, as well as diagnostic reagents and equipment, with approximate 280 products therapeutically grouped as gastrointestinal, cardio-cerebral-vascular, anti-biotic, gonadotropic hormone etc. Meanwhile, Livzon possesses production bases as leading manufacturer of Chinese drug preparation injection, and specialist bulk medicines and intermediates such as fermented antibiotics, sterile cephalosporins, and hypolipidemic “statins”.

All production lines are compliant with GMP requirements, including some DMFs, USA FDA inspection and COS approvals etc. Benefited from the regulatory compliance, an extensive overseas market is under robust development, including India, Japan, Eastern Europe for bulk medicines and intermediates, and the Philippines, Kyrgyzstan, Uzbekistan, Tajikistan, Hong Kong and Pakistan for drug preparation.

In recent years, Livzon implement the strategic transformation of R&D, focusing to antibody medicines and vaccines, and it has already established laboratories of antibody medicines and vaccine development. At the meanwhile, Livzon adjusts R&D direction of chemical pharmaceutical for carrying out transformation and upgrade. Livzon forms a complete research system. In addition, Livzon has established long-term cooperative relationship with more than 30 domestic and overseas scientific research institutes.

杭州民生药业有限公司

Hangzhou Minsheng Pharmaceutical Co., Ltd.

杭州民生药业有限公司（杭州民生药厂）创建于1926年，是中国最早的四家西药厂之一，同时也是中国最早的针剂生产厂家。90余年来，民生药业一直专注于西药制药产业，见证了中国整个西药制药的历史。2006年被商务部评为第一批"中华老字号"企业。经过多年的积累和发展，民生药业成为了一家专业化、负责任的现代化制药公司。

2013年，民生药业整体搬迁至余杭经济技术开发区，新民生工厂公司总体投资7亿多元，占地11.4万平方米，建筑面积12万平方米。新厂区包含各类针剂、输液、片剂、胶囊、眼药、外用药等生产厂房及其他各辅助设施。新工厂全部生产线均通过新版GMP认证。

90余年来，数代“民生人”艰苦奋斗，自强不息，同心同德，开拓创新，走出了具有民生特色的发展之路，打造了全国知名品牌21金维他。现阶段民生药业致力于四大生产线：以血液肿瘤为主的肿瘤药产品线、以滴眼液为主的外用药产品线、麻醉营养领域产品线、肝病领域产品线，为人们提供了健康保障，践行了“发展企业，合作共赢，贡献社会，造福员工”的企业宗旨。

民生药业以传播科学健康观为己任，不断追求卓越，致力于打造充满活力的百年企业。

Established in 1926, Hangzhou Minsheng Pharmaceutical Co.,Ltd. (former is Hangzhou Minsheng Pharmaceutical Factory) is one of the earliest four chemical pharmaceutical factories and has the longest history of injection manufacture in China. Since 1926, the company has been specializing in the chemical medicine industry, witnessing the entire history of western medicine in China. In 2006, Minsheng Pharma was awarded “China time-honored brand” in the first group by the Ministry of Commerce of the People's Republic of China. After years of development, the company has grown as an extremely professional and responsible modernized pharmaceutical company.

Minsheng Pharmaceutical Company has removed to Yuhang Economic and Technological Development Zone since 2013. 700 million yuan was allocated to the construction of the new factory, whose floor area is 114,000 m^2 and covered area is 120,000 m^2. Minsheng Pharma has abundant product lines such as injections, transfusions, tablets, capsules, ophthalmic preparations, externally applied agents. The whole production lines of the new factory have been granted GMP certificate.

For over 90 years, generations of "Min Shengers" have made their own way to unique development. They work hard and never stop fighting. They make unremitting efforts to improve themselves as well as the company. In the path to a brighter future, all “Min Shengers” have devoted themselves to creation and innovation with one heart and one mind, and have built the nationally known brand “21 Super-Vita”. At the present stage, we are devoted to four product lines: anti-cancer products mainly for hematologic tumor; externally applied medicines mainly for eye drops; production line for anaesthetics and nutraceuticals, and production line for hepatopathy. Providing safeguards for people’s well-being, Minsheng Pharma has long been practiced the enterprise purpose ---- “to develop the company, to cooperate and achieve the mutual benefits, to contribute to the society, and to benefit the employees”.

Min Shengers have regarded the philosophy of science and health as our duty. We constantly strive for excellence and commit to developing into a dynamic centennial enterprise.

浙江佐力药业股份有限公司

Zhejiang Jolly Pharmaceutical Co., Ltd.

浙江佐力药业股份有限公司发起设立于2000年1月，是一家集科研、生产、销售于一体的国家高新技术制药企业。2011年2月22日，公司成功登陆创业板（股票代码300181），成为浙江省湖州市第一家创业板上市公司。目前，公司拥有浙江佐力健康产业投资管理有限公司一家全资子公司，青海珠峰冬虫夏草药业有限公司、浙江凯欣医药有限公司、浙江百草中药饮片有限公司、浙江百草医药有限公司四家控股子公司，投资并参与了德清县第三人民医院合作办医。

公司位于风景秀丽的莫干山脚下，占地200余亩，建筑面积10万多平方米，拥有现代化的原料药、片剂、胶囊、颗粒和冻干粉针等生产流水线。公司研发中心是省级高新技术研究开发中心、浙江省企业技术中心、药用真菌制药技术国家地方联建工程实验室。

公司立足于药用真菌生物发酵技术生产中药产品，通过多年的研发、改进，实现了珍稀中药材——乌灵参的产业化生产，实现了传统中药材和现代生物技术的结合。公司利用从天然乌灵参中分离获得的菌种，运用现代生物发酵技术，实现了乌灵参发酵菌粉（乌灵菌粉）的工厂化、规模化生产。公司以市场为导向，不断加强对乌灵菌粉的深度研究，成功开发了国家一类新药乌灵胶囊，以及用于治疗更年期综合症的灵莲花颗粒和用于治疗前列腺增生的灵泽片等乌灵系列产品。通过收购控股青海珠峰冬虫夏草药业有限公司，公司在药用真菌领域又收获重磅产品--冬虫夏草发酵制剂产品百令片。

多年来，公司坚持产品创新、市场创新和管理创新，积极开拓市场，连续实现销售、利税的大幅增长，取得了快速发展。与此同时，公司也获得了诸多荣誉：“国家级火炬高新技术企业”、“国家高新技术企业”、“全国模范劳动关系和谐企业”、“全国五一劳动奖章”、“浙江省绿色企业”、“浙江省诚信守法企业”、“浙江省文明单位”、“浙江省创新型试点企业”、“浙江省优秀民营企业”、“中国驰名商标”、“浙江省著名商标”、“浙江省知名商号”、“浙江名牌产品”等。

公司在加强内生式增长的同时，通过外延式并购以及现有的资源优势，在医药制造流通、医疗服务、精准医疗领域进行了一系列的产业布局，积极布局大健康产业，拓展发展新空间。公司将始终秉承“辅佐人类身体健康，致力祖国医药发展”的使命，倡导“创新、奉献、卓越、合作、共赢”的核心理念，坚持以乌灵系列产品为起点，以药用真菌的产业化为己任，同时，结合中药饮片、配方颗粒等资源，发展中医门诊以及特色医疗服务项目，专注大健康领域，构建‘慢病及健康管理’生态系统。

Zhejiang Jolly Pharmaceutical Co., Ltd. is a national high-tech enterprise with an integration of scientific research, production and marketing which was founded in Jan, 2000. On Feb. 22nd, 2011, it successfully became a public company in the Growth Enterprises Market in Shenzhen Stock Exchange (Stoke Code:300181), which is also the first public enterprise in the Growth Enterprises Market of Huzhou. At present, the company has a wholly-owned subsidiary, Zhejiang Jolly Health Industry Investment Management Co., Ltd., two subsidiaries, Qinghai Everest Cordyceps Sinensis Pharmaceutical., Ltd and Zhejiang Kaixin Medicine., Ltd. Moreover, the company also invests and participates in Deqing No.3 People’s Hospital’s cooperating medical service.

Our company is located at the foot of the scenic Mount Mogan, covering an area of over 200 mu, and reaching an construction area of 100 thousands square meters. We have modern production lines, including raw materials, tablets, capsules, particles, frozen dry powder injection. Our R&D center is titled as “Provincial High-Tech Research and Development Center”, “Zhejiang Enterprise Technology Center” and “National & Local Co-operational Engineering Lab for Medicinal Fungi Pharmaceutical Technology”.

Based on bio-fermentation technology, our company uses medicinal fungi to produce traditional Chinese medicinal products, and with years of research and improvement, we have developed an industrialized production pattern for Wulingshen, a rare Chinese herbal medicine, which successfully combines the traditional Chinese herbal medicine and the modern biotechnology together. Applying modern bio-fermentation technology, we use Wuling strains, which come from natural Wulingshen, to develop an industrialized production pattern for Wulingshen fermentation power (Wuling Powder). By taking the market-oriented approach, our company keeps an intensive research in Wuling Powder, and has successfully developed Wuling series products, Wuling Capsule, a kind of national first class new medicine, Linglianhua Particle for menopausal syndrome treatment, Lingze Tablet for BPH treatment. With the acquisition of Qinghai Everest Cordyceps Sinensis Pharmaceutical., Ltd, we successfully own a blockbuster, the “Bailing Tablet”, a cordyceps sinensis fermented preparation which belongs to the medicinal fungi field

For years, our company keeps on product innovation, market innovation and management innovation. Thanks to the actively development of the market, we have achieved growth in sales, profits and tax payment in succession, and consequently our company is developing at an incredible speed. Meanwhile, we have also received many honors like “National Torch High-tech Enterprise”, “State High-tech Enterprise ”, “National Model Harmonious Enterprise”, “National Labor Medal ”, “Zhejiang Green Enterprise”, “Zhejiang Honest and Faithful Enterprise”, “Zhejiang Model Unit”, “Zhejiang Innovation-based Pilot Enterprise ”, “Zhejiang Excellent Private Enterprise”, “Chinese Famous Trademark”, “Zhejiang Famous Brand”, “Zhejiang Well-known Enterprise” and “Zhejiang Famous Brand product”.

We will stick to our enterprise spirit: “assist human health and attribute to the pharmaceutical development of China“, take “innovation, dedication, excellence, cooperation and win-win” as our core concepts, stick with the Wuling-series products and take the industrialization of medicinal fungi as our responsibility, and rely on “pharmaceutical manufacturing, pharmaceutical distribution, medical services “the three major platforms to construct chronic disease and health management ecosystems.

广西梧州中恒集团股份有限公司

Guangxi Wuzhou Zhongheng Group Co., Ltd.

广西梧州中恒集团股份有限公司简介（简称：中恒集团），是一家以制药为核心主导，拥有健康食品等延伸板块的多元化、现代化集团上市公司（股票代码：600252），国家级高新技术企业、中国医药制造业百强企业，华南地区最大的心脑血管中药注射剂生产企业。

中恒集团下属的梧州制药，是我国中药行业前端的一颗璀璨明珠，在近90年的创新发展中，拥有了广西医药产业工程院、广西药物提纯工程技术研究中心、广西千亿元研发中心、院士工作站等技术平台，自主创新能力处于领先地位，已成功研发了注射用血栓通、中华跌打丸、妇炎净胶囊等核心科技产品，拥有了13大类217个品种，收载于《中国药典》品种102个。尤其注射用血栓通（冻干），属国家基本药物、医保甲类品种，在上市20多年中，质量保证、疗效显著、使用安全，成为中药注射剂治疗心脑血管疾病的首选用药。

集团下属的双钱实业，是我国最大的龟苓膏健康食品生产企业，主导产品“双钱”牌是中华老字号，深得消费者喜爱。

中恒集团牢牢把握国家新一轮深化改革开放，全面建成小康社会，大力推进“一带一路”战略，以及中国—东盟自贸区开放带来的历史性机遇，以医药医疗健康领域的传承与创新，提升人类生命质量体验为使命，以中药产业链为主体，以消费者健康为延伸，以特色化学药为补充，以研发、营销、资本为核心抓手，致力于培育“品质、创新、包容、卓越”的核心价值观，塑造“执行、分享、创造、成长”的企业团队精神，打造全球医药健康价值链的服务运营商，成为医药健康产业综合性企业集团，为助力健康中国再立新功。

Guangxi Wuzhou Zhongheng Group Co., Ltd. (short for Zhongheng Group), is a diversified and modernized listed group enterprise (stock code: 600252) with pharmaceuticals as the business core and healthy food as one of the business extensions, which receives reputations as National High-tech Enterprise, Top 100 of Chinese Pharmaceutical Enterprises and the Largest TCM injection manufacturer for cardio-cerebrovascular diseases in Southern China.

Wuzhou Pharmaceutical, a subsidiary of Zhongheng Group, is a splendid pearl at the leading edge of TCM industry. In nearly 9 decades' innovative development, Wuzhou Pharmaceutical has possessed technology platforms such as Guangxi Pharmaceutical Industrial Academy of Engineering, Guangxi Technological Research Center of Purification Engineering, Guangxi Hundred-billion Yuan R&D Center and Academician Workstation, successfully developed core technology products includes Xueshuantong for Injection, Zhonghua Dieda Pill and Fuyanjing Capsule, and developed 217 varieties of medicine in 13 categories, among which 102 varieties are collected into Chinese Pharmacopoeia. Specially the Xueshuantong for Injection (lyophilized), the national essential drugs and the catalog A medicine in medical insurance, during the 20 years marketing history, with assuring quality, significant efficacy and safe usability, has become the preferred drug to cure cardio-cerebrovascular diseases among TCM injections.

Wuzhou Double Coins, another subsidiary of Zhongheng Group, has been Chinese biggest manufacturing enterprise of Guiling Gao healthy food. The 'Double Coins' Guiling Gao is the leading product, which is the Chinese time-honored brand and deeply praised by the customers.

Zhongheng Group firmly grasps the historical opportunities brought by the policy of China's deepening reform and opening-up, comprehensive construction of moderately prosperous society, vigorous promotion of 'One Belt, One Road' strategy and the opening-up of ASEAN-China Free Trade Area, closely embraces the mission of inheritance and innovation in Medical & Health Care area and improving human life quality. Taking TCM industrial chain as the main, customers' health as the intension, characteristic chemical medicine as the supplement and R&D, marketing and capital as the key points, Zhongheng Group strives to cultivate the core values of 'Innovation, Quality, Inclusiveness and Excellence', shape the team spirit of 'Execution, Sharing, Creation and Development', create a service provider of worldwide Health and Medicine value chain, so as to become a comprehensive enterprise group in Health and Medicine industry and give more contribution for building healthy China.

南京圣和药业股份有限公司

Nanjing Sanhome Pharmaceutical Co., Ltd.

南京圣和药业股份有限公司始建于1996年，是一家集新药研发、药品生产和市场营销为一体的国家重点高新技术企业。

圣和人以“让更多的人享受健康的快乐”为使命，努力提高新产品的科技含量，致力于新产品的科技开发，迄今已获新药证书近百本，拥有国家发明专利及国际专利数十项。通过自有技术、独立开发的中西药品种中有国家一类新药，有国家重点新产品，有国家中药保护品种，有全国独家产品。公司承担了包括国家863计划、重大新药创制专项、国家创新基金、国家高技术产业化专项、国家火炬计划在内的国家和省级重点科研项目。新产品的开发不仅为企业的建设增添了经济实力，还为企业可持续发展蕴藏了生机。2008年，国家人力资源和社会保障部批准设立“博士后科研工作站”；圣和还设有省级工程技术研究中心、省级企业技术中心、省级企业院士工作站以及国家级创新药物孵化平台等。

圣和药业目前拥有片剂、颗粒剂、胶囊剂、冻干粉针剂、粉针剂、软膏剂、大容量注射剂、小容量注射剂等十多种剂型生产线，多达30余种的药品行销国内市场，其中“圣诺安”、“圣诺灵”、“消癌平”、“优诺安”等多个主导产品分别被国家、省、市认定为“高新技术产品”。现有20个创新药处在不同的研发阶段，2个1.1类创新药已获得临床批件，2个1.1类创新药正在申报临床阶段。未来公司将不断推出疗效好、市场前景广阔的新品上市，形成了本企业科技创新的特色。

公司建立二十年来，一步一个脚印走出自己发展的路子。2004年，中华全国总工会授予本公司“五一劳动奖状”荣誉称号，公司还先后被国家、省市有关部门评定为“国家重点高新技术企业”、“中国优秀民营科技企业”、“中国化学制药工业企业百强”、“中华全国工商业联合会科技进步奖”、“江苏省科学技术进步一等奖”、“江苏省优秀民营科技企业”、“江苏省质量信用等级A级企业”、“中国专利优秀奖”和“中国医药制造业守法诚信企业”等荣誉称号。

Nanjing Sanhome Pharmaceutical Co., Ltd. was founded in 1996, and it is a State Key High-tech Enterprise integrating new drug development, production and marketing.

Sanhome’s corporate values are to help more people enjoy the healthy life, so we are motivated to improve the novelty and technology of the drug product. So far, we have been granted almost one hundred new drug certificates by the CFDA, and dozens of China invention patents as well as international patents. There are National New Products, National Protected Traditional Medicines and exclusive drug products in our pipeline. Sanhome also undertakes many national and provincial key programs, including National High-tech R&D Program of China (863 Program), National Science and Technology Major Projects for “Major New Drugs Innovation and Development”, National Fund for Innovation, National Industrialized High-technology Program, and National Torch Project. In 2008, the Ministry of Human Resources and Social Security of the People's Republic of China granted Sanhome to set up a “Post-doctoral Research Center”. In addition, Sanhome is also granted to set up several R&D centers by the government, including Provincial Engineering Technology Research Center, Provincial Enterprise Technology Center, Provincial Enterprise Academician Workstation and National Incubator for Innovative Drugs.

Sanhome is capable to manufacture multiple drug formulations such as tablets, granules, capsules, freeze-dried powder injection, powder injection, ointment, large and small volume injections. More than 30 types drugs are distributed in China, and “Sheng Nuo An”, “Sheng Nuo Ling”, “Xiao Ai Ping” as well as “You Nuo An” are designated as the High-tech Products by the government. At present, we have 20 new molecular entities (NME) in the pipeline. Two of them are Type 1.1 New Drug and their IND applications have been approved by the CFDA. Another two NME is in progress for IND. Sanhome will keep bringing out new drug products with good efficacy and safety to the drug market.

During the past 20 years, Sanhome has proven itself as an innovative pharmaceutical company. Sanhome has been awarded “the National May 1 Labour Medal”, “State Key High-tech Enterprise”, “Top 100 Enterprises of Chemical and Pharmaceutical Industry in China”, “All China Federation of Industry and Commerce (ACFIC) Award for Progress in Science and Technology”, “the First Prize Winner of Jiangsu Science and Technology Progress Award”, “Jiangsu Excellent Private Science and Technology Enterprises”, “Grade A Enterprise of Quality Credit Rating in Jiangsu”, “China Excellent Patent Award” and “China Pharmaceutical Manufacturing Industry Law-abiding Integrity Enterprise”.

山东步长制药股份有限公司

Shandong Buchang Pharmaceutical Co., Ltd.

步长的事业起步于1993年，经过二十余年艰苦奋斗，已发展成一个以医药产业为主，同时涉足高科技产业、健康产业等众多领域，多元化经营的产业集群。其医药板块“步长制药”是一家专注于中药专利药研发、生产、销售的国内知名企业。在山东、陕西、河北、吉林设有生产基地，同时在北京、上海、广东设有分公司，分支机构遍布中国主要省份。经过多年发展，公司已建成一支高素质、专业化团队，拥有十个事业部、十家药厂，销售网络交叉覆盖全国3万个医院和20万零售药店。

赵涛董事长1996年被评为全国优秀青年企业家，中国侨商投资协会副会长，并被推选为中国企业家协会常务理事。2001年中国“创业之星”，陕西“三五”人才，2003年与杨利伟等人荣膺十大中华英才称号，2004年荣获“中国十大风云人物”。2008年11月荣获“最具社会责任企业家”，2008年12月荣获“2008品牌中国年度人物”，2010年，赵步长、赵涛父子被誉为“中国特色慈善家”。2012年在第九届中国最佳企业公民评选颁奖盛典中赵涛被评为“中国最具社会责任企业家”。2012年荣获中国创业发明金奖。2013年荣获“年度慈善家”。

自2008年起，公司创始人赵步长教授、赵超博士双双当选第十一届、第十二届全国人大代表，这是党和国家给予步长的最高荣耀和最大鼓励。2010年11月，丹红注射液荣获“中国首个中药专利金奖”；“步长脑心通”荣获“中药产品品牌十强”等荣誉称号。2012年，步长制药凭借在企业社会责任方面的突出表现再次荣膺“最佳企业公民”大奖。2013年，步长蝉联中国制药工业百强中药企业第一，并荣膺“2013中国五星级企业公民”荣誉称号。

公司勇于承担社会责任，在社会公众心目中树立了良好的企业形象。公司自1997年起，连续多年位居当地民企纳税前茅；社会公益事业方面的捐款4亿多元。共铸中国心活动自2008年发起至今，共组织近5000名医生志愿者，先后走过四川、宁夏、山东、内蒙古、西藏、青海等地区的300多个乡镇，为二十多万人次进行过诊疗救治，并免费救助先心病儿童，使300多名先心病儿童手术后重获健康。 公司已连续多年荣获“中国医药卫生行业社会责任孺子牛奖”。

Buchang Pharma, established in 1993, has developed into a diversified industrial cluster after twenty-year arduous struggle, based on main pharmaceutical industry and meanwhile involved in high-tech, health, education and many industries. The pharmaceutical part, Buchang Pharma Co., Ltd. is a famous enterprise in China, engaged in the research & development, production and sales of TCD (traditional Chinese Drugs) patent medicines. Buchang Pharma has production bases in Shandong, Shaanxi and Heibei province, at the same time, set up filiales in Beijing, Shanghai and Guangdong. Branched organizations are all over China. According to years of development, the company has have owns a highly qualified and professional team, 10 business departments, 10 pharmaceutical manufacturers, and the sales network has covered 30,000 hospitals and 200,000 drug stores.

In 1996, Mr. Zhao Tao, the Chairman of Buchang, was awarded as the National Outstanding Young Entrepreneurs, vice president of China Overseas Chinese Investment Association, and was elected as the standing director of China Entrepreneurs Association. China Enterprising Star in 2001, “the third five years plan” shaanxi talent; In 2003, honored Ten Prominent Chinese award, including Yang Liwei as the same title; In 2004, won the China Top Ten Person; In November 2008, won the “most social responsibility of entrepreneurs”. In December 2008 was awarded “2008 China Brand Person of the year”. In 2010, Zhao Buchang and Zhao Tao (both father and son) were known as “China Characteristics Philanthropist”. In 2012 in the ninth China awards best corporate citizen evaluation, was named “China's most socially responsible entrepreneurs”; In 2012, won the Golden Award of Chinese Entrepreneurial Invention; In 2013, rewarded the “Annual Philanthropist”.

Since 2008, the founder of Buchang Pharma, Prof. Zhao Buchang and the President Dr. Zhao Chao, were both elected the representatives of the 11th and the 12th National People's Congress, which was the greatest honor and the biggest encouragement of the government and the country. In November 2010, Buchang Danhong Injection obtained “The First Gold Prize of Traditional Chinese Medicine”; Buchang Naoxintong Capsule got the “Top 10 Product Brand of Traditional Chinese Medicine” etc. In 2012, with outstanding performance in social responsibility, Buchang Pharma got the “Best Corporate Citizens” award again. In 2013, Buchang Pharma had continuously won the first one of National Top 100 Pharmaceutical Industry Enterprises and got the 2013 China Five-star Enterprise Citizen honorary titles.

Buchang Pharma undertakes the social responsibility valorously and sets a good corporate image in the public minds. Since 1997, Buchang company has ranked first of tax pay private enterprise continuously for many years in the local place. Donate up to 400 million Yuan in social public welfare. since launched in 2008 to now, Build China Hearts activity has organized nearly 5000 doctors volunteers, successively passed Sichuan, Ningxia, Shandong, Inner Mongolia, Tibet, Qinghai and more than 300 villages and towns regions, which has been diagnosis and treatment for more than 200,000 patients. Meanwhile, it also gives free relief to the congenital heart disease children, which makes more than 300 congenital heart disease children regain his health after the operation. Buchang Pharma has won the China Medicine and Health Industry Social Responsibility-A Willing Ox Award consecutively for many years.

悦康药业集团有限公司

Youcare Pharmaceutical Group Co., Ltd.

悦康药业集团创建于1988年，2001年在北京经济技术开发区建厂并成立集团总部，是一家集新药研发、药品生产和流通销售于一体的医药集团企业。自成立以来，集团围绕做好产品、做大产能、完善产业链的三个中心任务，在国内建立了以安徽原料药基地为基础，以北京、上海、广州、重庆四个特色制剂基地为核心的医药全产业链发展格局。2008年起集团连续多年入选中国医药工业企业百强，医药工业研发十强；2010年被科技部认定为国家火炬计划重点高新技术企业，是中国医药工业制剂国际化先导企业和北京生物医药产业跨越发展工程G20领军企业；2016年被工信部、财政部认定为国家技术创新示范企业。

创新产品是悦康的发展战略和肩负的责任。集团从仿制到创新，从普药到新药，不断研制生产出保障百姓健康需求的好药。目前，集团主要产品覆盖抗生素类、消化类、心脑血管类、抗肿瘤类、免疫调节类、抗病毒类、降糖类等十多个治疗领域，剂型囊括小水针、冻干粉针、片剂、胶囊剂、颗粒剂、栓剂、膏剂、凝胶剂等。其中，悦康头孢类粉针制剂和消化类微丸缓控释制剂等系列产品产销量连续多年稳居全国市场前列。2015、2016年连续两年获得国家科技进步二等奖，并被批为头孢药物晶型研究国家地方联合工程实验室。

悦康不仅立足国内，更瞄准国际市场。目前，集团已有70多个品规产品在德国、英国、俄罗斯、巴基斯坦、非洲、拉美等40多个国家和地区注册并销售。2011年，悦康固体片剂和胶囊剂生产线通过欧盟GMP认证后，以奥美拉唑肠溶胶囊为代表的认证产品相继打入德国、英国市场。2015年通过了再认证，为开拓欧美市场奠定了基础，同年集团广州药厂通过日本JGMP认证。

“营造全球喜悦，关爱人类健康”是悦康的企业宗旨，悦康人在“合和”文化的感召下，加强国内国际的融合，诚信勤奋，为实现“创行业名牌，建药业航母”的目标努力奋斗。

Youcare Pharmaceutical Group, was founded in 1988. In 2001, the manufacturing site and headquarter of Youcare were established in Beijing Economic-Technological Development Area. Till now, Youcare is a multi-aspect pharmaceutical enterprise integrated with new drug research, drug manufacturing, sales and distribution. Since its foundation, Youcare has always focused on the continuous improvement of product quality, capacity ramp-up to completion of industrial chains. The Group has set up an API production base in Anhui and 4 major specific core formulation manufacturing sites in Beijing, Shanghai, Guangzhou and Chongqing. Since the year of 2008, the Group has been listed in the TOP 100 China Pharmaceutical & Industrial Enterprises and the TOP 10 Pharmaceutical Enterprise in R&D for many consecutive years. In 2010, Youcare Group was also recognized by the Leap-forward Development Program for Beijing Bio-Pharmaceutical Industry (G20) as the leading enterprises. In the same year, Youcare was recognized by the Ministry of Science and Technology as the key high-tech enterprise of National Torch Plan. In 2016, Youcare was identified by the Ministry of Industry and Information and the Ministry of Finance as the National Model Enterprise for Technological Innovation.

Innovation is Youcare's development strategy and responsibility. From the production of generic drugs to the development of new drugs, the group is incessantly developing high-quality drugs for people's health. To date, Youcare’s products have covered a wide range of therapeutic fields such as antibiotics, digestive system, cardio-cerebrovascular disease, anti-tumor, regulation of the immune system, antivirus, and glucokinin. The products also exhibits a variety of dosage forms, including vial injection, freeze-dried powder for injection, tablet, capsule, granule, suppository, paste and gel. Among the abovementioned products, the cephalosporin powder for injection and the sustained release digestive pellets haven been dominant in the domestic market for years, contributing leading sales volumes in the industry. In Jan, 2016, the Omeprazole development project in which Youcare has participated was awarded the second price of the State Scientific and Technology Progress Award. Meanwhile, Youcare was also certified as the National Joint Engineering Laboratory of Crystalline Cefalosporins.

YOUCARE focuses on domestic market as well as aims at international market. By far, there are over 70 drugs of certain specification registered and sold in more than 40 countries and regions including Germany, UK, Russia, Pakistan, Africa and Latin America. Since Youcare’s production lines of tablets and capsule passed EU GMP certification in 2011, its certified products, taking Omeprazole enteric capsule as a representative, have entered German and British market in succession, which laid a foundation for the market development in Europe and America. In the year of 2015, Guangzhou Youcare manufacturing site was certified by the Japanese GMP.

“Creation of global joy, Care of human health” is the long-term concept Youcare observed. Taking “Hehe Culture (cooperation and harmony)” as root, Youcare actively integrates the home and the abroad together, and strives to create a leading famous brand within industry with its integrity and diligence.

江苏奥赛康药业股份有限公司

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

江苏奥赛康药业股份有限公司（奥赛康药业）是集医药、研发、生产、市场推广和销售为一体的国家火炬计划重点高新技术企业。公司自2010年以来持续入选“全国医药工业百强企业”，位列2015年中国化学制药行业综合实力百强排名第28位。

公司已建立现代化企业制度，拥有完善的经营管理体系、卓越的科技研发体系、顶尖的生产制造体系、稳定的质量保证体系、专业的学术推广体系、匹配的销售服务体系及药品的不良监测体系。

公司专注于质子泵抑制剂注射剂（PPI）和抗肿瘤注射剂的研发和市场推广，多个产品为国内首仿，目前是全国质子泵抑制剂（PPI）系列品种领军企业之一。公司拥有“博士后工作站”、江苏省抗消化道溃疡药物工程技术研究中心”、连续四年荣获 “中国医药企业创新力二十强” 荣誉称号（2012-2015），并连续六年获得“中国医药研发产品线最佳工业企业”殊荣（2010-2015），是国家级“守合同重信用企业”。奥赛康药业在全国医药行业中已树立了卓越的品牌影响力和领先的研发创造力。

Jiangsu Aosaikang Pharmaceutical Co., Ltd. (ASK Pharm) is a key hi-tech enterprises of the National Torch Program that integrates and streamlines innovative research and development with manufacture, marketing promotion and sales of pharmaceuticals products. Since 2010, ASK Pharm has always been listed in the “100 Top National Pharmaceutical Companies” in 2015, and ranked 28 out of the “100 Top National Chemical Pharmaceutical Companies”.

ASK Pharm has establish a modern enterprise management system, with comprehensive management system, superior R&D facility, state-of-the-art manufacturing capacity, sustainable product quality assurance, professional sales network, and after-marketing drug use monitoring and surveillance.

ASK Pharm specializes in proton pump inhibitor (PPI) products and oncology medicines. ASK Pharm has launched many first generic drugs, and ASK is one of the primary national of proprietary PPI injections. It owns a post-doctoral research station and Jiangsu Provincial engineering research center for peptic ulcer disease. It has also received the honor of “Top Ten National R&D Innovators” for 4 consecutive years (2012-2015) and “Best R&D Pipeline Pharmaceutical Manufactures” for 6 consecutive years (2010-2015). It has received the reputation of “National Class award of Honor the Contract and Keep the Promise”. ASK has become one of the most influential brands and a leading R&D innovator in national pharmaceutical industry.

重庆植恩药业有限公司

Zein Pharmaceutical Co., Ltd.

重庆植恩药业有限公司创办于2001年，是立足于重庆的一家集研发、生产和销售一体化的新兴医药企业，是一家集两江工程中心、手性工程中心和新药设计工程中心等三大研发中心、原料药生产基地、制剂生产基地和销售总部的集团公司。

植恩药业在研发方面具有丰富的经验。目前已经获得新药证书33项、临床批件32项、生产批件51项；申请国家发明专利数十项，其中已获国外专利授权3件，国内专利授权12件。公司已开展研发项目32项，承担包括国家重大新药创制项目（“11.5”和“12.5”）等70余项各类课题，并获得全国及省级奖项数十项。目前在研项目涉及神经系统药物、代谢系统药物、消化系统药物及其他类药物，其中神经系统药物已成为公司发展的主要方向，其中包括化药1类新药2项、中药5类新药1项。

植恩药业产业化能力较强，产能正逐步扩大。现有原料药生产基地年生产能力超过40吨，新建82000平方原料药生产基地将使产能提高到每年60吨-80吨，核心API品种奥利司他质量及产能达到国际先进水平，产品已热销巴西、澳大利亚、德国、波兰、新加坡和韩国，且已经在美国和印度递交上市申请，未来国际市场将进一步拓宽。现有制剂生产线可生产胶囊剂、颗粒剂、片剂、栓剂等剂型，在建制剂生产线将新增冻干剂型、小/大容量注射液等剂型，在建制剂产业化基地建筑面积33330㎡。

公司产品丰富，后续产品充足。目前主打产品有奥利司他、盐酸多奈哌齐、盐酸罗匹尼罗、甲磺司特等，即将上市的重点产品包括盐酸他利克索和盐酸兰地洛尔等。

植恩药业具有强大的一级市场到达终端市场的分销商网络。目前拥有零售终端及医院终端销售人员500余人。产品覆盖30个城市 2000 多家医院，40000家药店。外贸方面，原料药出口到全球20多个国家。

公司以“木直因心，植药为仁”为座右铭，以“创建中国医药与健康服务的领先企业”为发展目标。在强大的医药研发团队、高效的医学注册能力、广泛坚固的医药渠道网络、专业化的市场销售能力、权威的政府事务及专业机构合作能力支持下，将公司打造成行业内知名的高新技术医药企业。

Founded in 2001, Zein is a pharmaceutical enterprise in Chongqing, which focused on research, production, sales and market. As a group company, Zein owns three R&D centers which are Liangjiang Medicine Co., Ltd., Chiral Engineering Center and New Drug Design Engineering Center, an API manufacturing base, a preparation manufacturing base and a sales company.

Zein is experienced in R&D. At present, it has obtained 33 new drug certificates, 32 clinical approvals and 51 production licenses and has already applied dozens of National Invention Patents, in which 3 foreign patents and 11 domestic patents have been authorized. Zein has initiated 32 R&D projects, assumed more than 70 projects, including “Major National New Drug Development Project” (“11.5” and “12.5”) and acquired dozens of national/province awards. Zein’s understudied projects involve drugs of neural system, metabolic system and digestive system etc, in which neural drugs are the main products, including 2 State Category I New Drugs and 1 Chinese Herb Category V New Drug.

Zein is equipped with a strong capability of industrialization which is growing continually. The production capability of the API manufacturing base is more than 40 tons, and the new 82,000 m^2 API manufacturing base that is under construction will increase the capability to 60-80 tons. The quality and capability of core API, Orlistat, reaches the international advanced level and Orlistat is popular in Brazil, Australia, Germany, Poland, Singapore and Korea. The listing applications have been submitted to United States and India to explore the potential international market. The existing preparation production line meets the manufacturing requirements of capsule, granule, tablet and suppository etc. The new line under construction that covers a building area of 33,330 m^2, will add the production of lyophilized powder and large/small volume injection.

Zein owns a rich product catalog and plenty of follow-up products. Currently, the fist products are Orlistat, Donepezil Hydrochloride, Ropinirole hydrochloride and suplatast tosilate. The key products, including Talipexole Hydrochloride and Landiolol Hydrochloride will be marketed soon.

Zein also owns a strong distributor network from primary market to terminal one. There are more than 5,000 salesmen distributed from the retail terminal to the hospital terminal. Zein’s products cover 30 cities, including 2,000 hospitals and 40,000 drugstores. Zein’s APIs are exported to more than 20 countries worldwide.

Zein develops medicines with a beneficent heart and pursues to be one of the leading companies in Chinese medicine and health service. With the supporting of strong pharmaceutical research and development team, efficient medical registration ability, wide selling network, professional market-selling ability, and cooperation with government and professional institutes, Zein is growing to be a well-known and high-tech pharmaceutical enterprise.

正大青春宝药业有限公司

Chiatai Qingchunbao Pharmaceutical Co., Ltd.

在杭州西郊桃源岭下，有一座高度现代化的中药城——正大青春宝药业有限公司（以下简称青春宝），其前身杭州第二中药厂原为百年老店胡庆余堂的制胶车间。早在上世纪80年代，就被树为我国中药行业的“样板企业”和对外开放的窗口。而今青春宝，在充满生机的古树林下，鸟语花香的丛林当中续写新的故事，创造新的辉煌。

青春宝由一间只有37万元资产的落后中药作坊起步，逐步发展成为国内规模最大、设备最先进、以生产天然药物为主的集科研、生产、经营一体化的综合性制药企业之一，现为上海医药集团股份有限公司直属企业，是国家火炬计划重点高新技术企业、国家中药现代化科技产业（浙江）基地示范企业。合作完成的“中成药二次开发核心技术体系创研及其产业化”项目，荣获了2014年度国家科技进步一等奖，成为国内首个获此殊荣的单体制药企业。

青春宝以“振兴国药”为己任，致力于继承和弘扬传统中药，并进行现代化改造。1978年，青春宝搜集筛选出最为理想的一剂——明朝永乐皇帝御题“益寿永真”的宫廷秘方，加以整理后，制成中成药，命名为青春恢复片（后改名为青春宝抗衰老片），千年皇家补方再现民间。作为中国第一代保健品，“青春宝抗衰老片”近40年畅销不衰，被海内外誉为中国四大国宝之一。

青春宝品牌的知名度和美誉度已深入人心。建厂至今，前来视察、指导、参观、学习、交流的国家领导人、外国元首、社会名流以及五大洲四大洋的各界朋友已逾十万。

让人类拥有健康，拥有青春，是“青春宝”人永远的追求。

Chiatai Qingchunbao Pharmaceutical Co.,Ltd. (hereinafter to be referred as Qingchunbao) is located in Taoyuan Ling, the western suburbs of Hangzhou. It comes from a glue workshop of famous Huqingyutang and now becomes a modern traditional Chinese medicine enterprise. In 1980s, it was set as a TCM model and an opening-up window by the industry, and now is renewing its story and creating new splendor.

Beginning with RMB370,000 and a backward workshop, Qingchunbao becomes a comprehensive pharmaceutical enterprise with the largest scale and the most advanced equipment in China, mainly developing natural herbs. Being a subordinate enterprise of Shanghai Pharmaceuticals Holding Co.,Ltd., Qingchunbao integrates the research, production and management, achieves National Torch Program focused on high-tech enterprises, National modernization base of TCM technology industry (Zhejiang). Also, it achieved the first prize of 2014 National Science and Technology Progress Award for participating the program of Two development of TCM’s core tech-system and industrialization. Qingchunbao became the first single unit which won this award in Chinese pharmaceutical companies.

Taking “revitalize national medicine” as its duty, Qingchunbao not only inherits and carries forward the TCM but also reforms it. In 1978, the most ideal royal recipe, Emperor Yongle of Ming Dynasty titled “Yishouyongzhen”, was screened by Qingchunbao. It was named “Qingchunhuifu Tablets” after manufacture and later renamed “Qingchunbao anti-aging Tablets”. The tablets have been sold well for 40 years, it is the first generation of health care products and is honored as “one of the four national treasures” in China.

“Qingchunbao” brand is well known by people, more than one hundred thousand friends all over the world visited here since its foundation, including state leaders, foreign heads of state, social celebrities, etc.

Seeking health and youth for mankind is the pursuit of Qingchunbao forever.

深圳奥萨医药有限公司

Shenzhen AUSA Pharmaceuticals Ltd.

深圳奥萨医药有限公司为国家级高新技术企业，主要针对严重影响大众健康的心脑血管疾病，研究、开发安全有效的诊断和治疗产品，提供从预防、预测到治疗的系统解决方案。

奥萨已申请专利200多项，75项已经获得授权，成功研发出国家一类新药“依叶”和配套的基因诊断试剂盒，组成全球首个高血压领域“基因诊断-药品”精准医疗产品对，相关研发成果被纳入国内外多个有关脑卒中或高血压的防治指南。H型高血压治疗药物“依叶”荣获2013年中国药学发展奖创新药物奖、2015年首届最具临床价值创新药物奖、2015年中国教育部科技进步奖一等奖、2015年中华医学会中华医学科技奖一等奖、2016年国家科技进步二等奖。近三年，“依叶”疗效评价的中国脑卒中一级预防研究（CSPPT）发表SCI学术论文58篇，影响因子超过400分，其中5分以上文章20多篇。

奥萨的主营销售收入近几年来持续快速增长，复合平均增长率为68%。2016年“依叶”销售位居同类降压药全国第三名、2016年复方高血压药物销售全国第七名（前十位的其它均是外企产品）。2016年奥萨销售收入超5亿元，纳税近5千万元，获得南山区2016年度“纳税百强企业”。

Shenzhen AUSA Pharmaceutical is a national high-tech enterprise, primarily focuses on combatting cerebral and cardiovascular diseases, major public health challenges in both China and the world, through the research and development of safe and effective diagnostic and treatment products, and through the provision of systematic solutions ranging from primary prevention, prediction, to the treatment of these diseases.

AUSA has applied for over 200 patents, and has already been awarded with 75. A landmark breakthrough is the successful development of the national type-1 drug “Yiye” and its accompanying gene diagnostic kit. This is the world’s first “gene diagnostics-drug”, a precision medicine product for H-type hypertension and stroke prevention. To date, these research results have been included in numerous hypertension and stroke prevention and treatment guidelines both nationally and globally, and Yiye has helped to save numerous lives. In 2013, “Yiye” received the China Pharmaceutical Development Award and Innovative Medicine award; In 2015, “Yiye” received the first Clinical Value Innovative Medicine Award and the China Education Department Scientific Development Award; In 2016, “Yiye” received the China National Scientific Development Award, second place.

In the past 3 years, the China stroke primary prevention trial (CSPPT) evaluating the efficacy of “Yiye” treatment has made significant contribution to the field, including 58 SCI publications, including more than 20 of which have an impact factor of over 5, reaching an overall impact factor of over 400.

AUSA’s primary sales revenues have increased rapidly in recent years, with a composite growth rate of 68%. In 2016, “Yiye” sales ranked third nationally among same-type antihypertensive medication, and placed seventh among compound antihypertensive medications (All other medicines ranked within the top 10 were products by foreign manufacturers). AUSA’s 2016 sales revenues surpassed 500 million, resulting in a tax of almost 50 million, becoming one of the Shenzhen Nanshan region’s “Top 100 Tax Payer” of the year.

三生制药集团

3S Pharmaceutical Group

三生制药集团（全称：沈阳三生制药有限责任公司，股票代码：1530.HK）（以下简称“公司”）是中国迅速发展的生物制药行业的领先企业。

公司旗下拥有多家境内外子公司，包括三生国健药业（上海）股份有限公司（原上海中信国健药业股份有限公司）、浙江万晟药业有限公司、深圳赛保尔生物药业有限公司、斯通药品有限公司（意大利）等。

三生制药集团的产品处于市场领先地位并巨大的增长潜力。集团拥有近30种上市产品，特比澳是自主研发的全球唯一商业化的重组人血小板生成素（rhTPO）;益赛普是第一个在中国上市的依那西普产品;益比奥和赛博尔是中国重组人促红素市场的领导品牌;2016年，公司与阿斯利康订立独家许可协定，获得2型糖尿病药物百泌达和Bydureon在中国的商业化权利。2017年，与礼来中国订立战略合作协议，获得胰岛素产品优泌林®在中国独家经销和推广的权利。三生制药集团研发中心拥有生物药和化药双平台的4大研发中心以及抗体药物国家工程研究中心。在研产品近24种（其中15种国家一类新药），专注于治疗肿瘤、自身免疫、肾科、代谢及皮肤科等多种疾病领域。公司业务遍及国内32个省，海外覆盖23个国家。

三生制药集团始终支持与协助医务人员，解决病患临床用药难题，不断攻克疾病挑战，致力于以高品质的药品提高患者生存质量，为人类健康造福而努力。

3SBio Inc. (Shenyang Sunshine Pharmaceutical Co., Ltd., 1530.HK) (hereinafter referred to as “the Company”) is a rapidly-growing pioneer in the PRC biotechnology industry.

The Company owns a number of subsidiaries in China and overseas, including Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (formerly Shanghai CP Guojian Pharmaceutical Co., Ltd.), Zhejiang Wansheng Pharmaceutical Co., Ltd., Shenzhen Sciprogen Bio-pharmaceutical Co., Ltd., Sirton Pharmaceuticals SpA (Italy), etc.

The product portfolio of 3SBio Inc. enjoys both leading market position and huge growth potential, featuring over 30 products: TPIAO, the only commercialized recombinant human thrombopoietin (rhTPO) product in the world, which is independently developed by the Company; Yisaipu, the first-to-market etanercept product in China; EPIAO and SEPO, the dominant market leaders in the China rhEPO market; in 2016, the Company entered into Exclusive License Agreement with Astrazeneca to acquire the Chinese rights to type 2 diabetes injection medication Byetta and Bydureon. In 2017, Eli Lilly and Co. granted 3SBio Inc. exclusive rights to distribute and promote its diabetes drug Humulin in China. The Company has four R&D Centers with dual platforms combining biological medicine and medical medicine, as well as the National Engineering Research Center of Antibody Medicine. Amongst the 24 product candidates in the Company’s active pipeline, 15 have been developed as National Class I New Drugs in the PRC, targeting multiple diseases including oncology, auto-immune diseases, nephrology, metabolic area and dermatology. The Company’s business stretches over 32 provinces in China and 23 countries abroad.

3SBio Inc. has always been supporting and assisting the medical staff to resolve the clinical treatment issues of patients and perseveringly overcome the challenges of diseases, and is committed to improving patients’ life quality and human health with premium drugs.

亚宝药业集团股份有限公司

Yabao Pharmaceutical Group Co., Ltd.

亚宝药业是一家有着37年历史的集团公司。集药品和大健康产品的研发、生产、物流、销售和中药材种植于一体，下设21个分子公司，有员工近6000人，是山西省医药行业首家上市公司和首批认定的高新技术企业。

公司建有8大生产基地、3大研究基地、2大中药材种植基地。8大生产基地全部通过国家新版GMP认证，其中，北京生物制药通过了美国FDA cGMP认证，三分公司通过了欧盟GMP认证。

主要产品有中西药制剂、原料药和药用包装材料等共计300多个品种，主要为老年慢性病用药和妇女儿童用药，拳头产品丁桂儿脐贴是国家标志性名牌产品。

现有各类营销人员3000多人，建立了专业的商务、代理、临床、电子商务、国际贸易营销队伍，销售网点覆盖全国32个省市的终端市场。同时，公司还建立了药品配送中心，开展药品配送业务。

公司拥有一支国际化的专业研发队伍，各类研发人员总计410余人，其中博士22人，硕士150人。

在全国4700家医药企业中，亚宝药业综合实力排名第87名，是工信部认定的“中国医药工业百强企业”。其中，创新力居第15名，是“中国医药企业创新力20强”。“亚宝”商标为中国驰名商标。

Yabao Pharmaceutical Group Co., Ltd. has a history of 37 years, integrating R&D, production, marketing, logistics and plantation of Chinese herbal medicine with 21 subsidiary companies and about 6000 employees. Yabao is the first listed company among Shanxi Pharmaceutical enterprises and the first batch of new high-tech enterprise.

Yabao owns 8 production bases, 3 R&D bases and 2 Chinese herbal plantation bases. All the 8 production bases has passed the new GMP certification, thereinto, the production line of Beijing Yabao Bio-pharmaceutical Company has passed the FDA certification and No.3 Branch has passed EU GMP certification.

Yabao has more than 300 products in term of Chinese and western medicine, API, and pharmaceutical packaging materials, which are dominated by the medicines for the old age chronic illness and for women and children. Thereinto, “Diarrago”, is a kind of landmark product in China.

Yabao has more than 3000 marketing personnel and has established the marketing teams for professional commerce business, agents, clinic, e-commerce and international trade, with 32 provinces and cities covered by sales network. At the same time, Yabao has established drug distribution center for drug delivery.

Yabao has a internationalized research team with more than 410 research employees; thereinto, there are 22 doctors and 150 masters.

Among the 4700 pharmaceutical enterprises, Yabao took the 87th place in term of comprehensive strength, being an accredited “China Hunderd Pharmaceutical Enterprises”. Its innovation strength takes the 15th place and is one of the 20 innovative pharmaceutical enterprises in China. The trade mark of “Yabao” is a famous trademark in China.

常州方圆制药有限公司

Changzhou Fangyuan Pharmaceutical Co., Ltd.

常州方圆制药有限公司其前身是江阴方园制药有限公司，始创建于 1994年4月，仅为研发代号“8907”（后定名硫酸依替米星）的科技型孵化企业。为形成产业化生产，江阴方圆制药有限公司于2000年4月迁址常州国家高新技术产业开发区“三药”科技产业基地，更名常州方圆制药有限公司。目前，常州方圆制药有限公司已成为国家重点高新技术企业，市场营销网络已覆盖全国。

公司主导产品硫酸依替米星（商标名，“创成”）是拥有自主知识产权的抗生素类一类新药，为新一代半合成氨基糖苷类抗生素，具有高效、低毒、抗耐药菌等优点。该产品同时获得中国、英国、美国、俄罗斯、哈萨克斯坦、日本等国家专利， 2002年分别被评为国家科技进步二等奖，江苏省科技进步一等奖。

为进一步提升产品质量及满足新产品的投产需要，2011年公司在常州生命健康产业园征地96亩建设一期制剂厂区。制剂厂区采用了自动化程度高的设施设备，提高了工作效率，保障了产品质量。水针剂和冻干粉针剂车间2015年被评为江苏省示范智能车间。2015年在内蒙古赤峰市征地302亩，建设原料药生产基地（即内蒙古普因药业有限公司），建成5条原料药生产线，达产后年产22吨各类原料药。

常州方圆制药有限公司坚持“以人为本” 理念， 制定政策，鼓励、选拔和引进各类人才；建立“我以服务方圆为责任，我以方圆发展为荣誉” 的企业文化，以市场为导向，以创新为动力，以质量为中心，致力做精做强做优企业，使之具有较强创新发展能力和抗衡风险能力的优质企业。

Changzhou Fangyuan Pharmaceutical Co., Ltd. whose predecessor is Jiangyin Fangyuan Pharmaceutical Co., Ltd. was founded in April 1994. It was a technical incubated enterprise for the development of code-named “8907” (later named Etimicin Sulfate). For the industrial production, Jiangyin Fangyuan Pharmaceutical Co., Ltd. moved to Changzhou National High-tech Industrial Development Zone, “three drugs” technology industry base, renamed Changzhou Fangyuan Pharmaceutical Co., Ltd. in April 2000. At present, Changzhou Fangyuan Pharmaceutical Co., Ltd. has become a national key high-tech enterprise, marketing network has covered all the country.

The company's leading product of Etimicin Sulfate (trademark “chuangcheng”) is a class I new antibiotics with independent intellectual property rights, as a new generation of semi-synthetic aminoglycoside antibiotics, has the advantages of high efficiency, low toxicity, anti-resistant bacteria. The product owns the patents of China, Britain, the United States, Russia, Kazakhstan and Japan. In 2002, it was awarded the second prize of National Advancement in Science and Technology and the first prize of Jiangsu provincial Advancement in Science and Technology.

In 2011, to further enhance the quality of Etimicin and meet the needs of new products put into operation, the company bought 96 acres of land to build phase I preparation plant in Changzhou Life and Health Industrial Park, using high degree of automation facilities and equipment to improve the produce efficiency and assurance of product quality. The small volume injection workshop and the lyophilized powder for injection workshop were named the Jiangsu Provincal demonstration of intelligent workshop in 2015. The company bought 302 acres of land in Inner Mongolia Chefeng City in 2015, to construct the raw materials production base (Inner Mongolia Puyin Pharmaceutical Co., Ltd.), built five raw material production line, up to an annual output of 22 tons of various raw materials.

Changzhou Fangyuan Pharmaceutical Co., Ltd. adhere to the “people-oriented” concept, formulate policies to encourage, select and recruit all kinds of talents. Establish “To serve Fangyuan as our responsibility, take Fangyuan’s development as our proud” corporate culture. Insist of market-focuing, innovation as the driving force, quality as the axis, devote to make fine, stronger, excellent enterprise, make Fangyuan become a excellent enterprise who has a strong ability to innovational development and anti-risk capability.

齐鲁制药有限公司

Qilu Pharmaceutical Co., Ltd.

公司总部位于山东省济南市，是中国大型综合性现代化制药企业，专业从事治疗肿瘤、心脑血管、抗感染、精神系统、神经系统、眼科疾病的制剂及其原料药的研制、生产与销售。现有员工8000余人，其中大专学历以上人员占72.8%。

公司始终坚持创新发展战略，以市场需求为核心，以产品创新为先导，广泛拓展国内外科研开发合作，注重人才的引进与培养，建有一支高素质的科研队伍，具备专业而高效的研发能力，已先后研制成功了近百个国家级新药，为公司未来的发展建立了合理的在研产品线，多项研究被评为国家、省级科技进步奖，并创造了良好的社会效益。

公司建有占地190万平方米的制剂、化学合成、生物技术、抗生素发酵等七大生产基地以及现代化的生产车间，全自动生产线和其他主要生产设备及检测仪器均购自于世界主要专业制药设备制造商，抗生素类原料药、头孢类原料药、抗肿瘤类原料药等数个产品已具有国内乃至世界领先的生产能力和生产水平。

做最优质、最安全的产品是齐鲁人坚定的承诺和行动。公司建设了严格规范的质量控制机构和完善的质量保证体系，是首批国家食品药品监督管理局GMP认证企业。其中非无菌原料药（发酵、化学合成）、无菌原料药及多种制剂通过了美国、欧盟、澳大利亚、英国、南非以及其它国家和地区药品监管机构的认证。

公司的产品结构科学完整，已上市产品达160余种，具有治疗领域广、产品系列化特点。凭借过硬的产品质量、全心全意为客户的服务宗旨，在医药领域树立了齐鲁品牌，拥有遍布全国各大省市，远销欧洲、北美、俄罗斯、南美、东南亚、中东等地的世界级销售网络，以卓越的服务向中国和世界呈现着完全可以信赖的真诚。

Located in Jinan, Qilu Pharmaceutical is one of the leading pharmaceutical companies in China. It focuses on developing, manufacturing and marketing of generic drugs and active pharmaceutical ingredients in the therapeutic areas of Oncology, Cerebrovascular & Cardiovascular, Infections, Psychological and Neurological System, Respiratory System, Ophthalmological Diseases, etc. Qilu has 8000 employees. 72.8% of them have junior college or above educational backgrounp.

Oriented by market demands, Qilu Pharmaceutical adopts a strategy of innovation & development. The company widely cooperates with domestic and international partners on R&D projects. Qilu enrolled many qualified personnel and have a highly qualified research team. Many projects are awarded State or Provincial Scientific and Technological Progress Award and benefit greatly to the society.

Qilu Pharmaceutical has seven manufacturing sites covering an area over 1,900,000m^2 including finished dosage forms, chemical synthesis, genetic-engineering, fermentation, etc. The automatic production lines, key equipment and analytical instruments are imported from major professional vendors. Now Qilu Pharmaceutical is one of the leading global suppliers of Antibiotic APIs and Oncology APIs with huge capacity and good quality.

Thanks to the integrated and stringent system of quality control and quality assurance, the company is a leader of cGMP implementation in China. Its non-sterile APIs (fermentation and chemical synthesis), sterile APIs and comprehensive finished dosages have been respectively approved by USFDA, European Directorate for the Quality of Medicines (EDQM), Therapeutic Goods Administration (TGA) of Australia, Medicines and Healthcare products Regulatory Agency (MHRA) of UK, Medicines Control Council (MCC) of South Africa, and some other national competent authorities.

Qilu Pharmaceutical has an integrated product structure and value chain with over 160 launched products. The company has established a comprehensive domestic and overseas sales network. The global presence has covered North America, Europe, CIS countries, South America, Asia, South Africa and Middle East. The valuable brand of the company has been well built with the quality products and good services.

深圳微芯生物科技有限责任公司

Shenzhen Chipscreen Biosciences, Ltd.

微芯生物(CHIPSCREEN BIOSCIENCES)始终秉承：“原创、安全、优效、中国”——致力于为患者提供可承受的创新机制治疗药物。

2001年，微芯生物在深圳创立，专长于原创小分子药物研发，以自主创建的“基于化学基因组学的集成式药物发现及早期评价平台”为其核心竞争力，是一家“以研发为驱动力，市场为中心”的原创新药物研发领域的领军企业。目前公司已形成针对恶性肿瘤、糖尿病、内分泌及自身免疫性疾病的多条原创新药产品线，抗肿瘤原创新药西达本胺（爱谱沙®）已获国家食品药品监督管理总局（CFDA）批准上市。

微芯生物也是国家首批 “创新药物孵化基地”，独立承担多项国家“863”计划、“十五”、“十一五”、“十二五”国家重大科技专项及“重大新药创制”项目。

与此同时，公司通过对国际制药公司实施专利授权，建立国际临床联合开发以及与跨国制药企业高水准合作研究的商业模式，实现了中国原创药全球同步开发的步伐。

Chipscreen is a leading integrated biotech company specialized in discovery and development of novel small molecule pharmaceuticals. The company has utilized its proprietary chemical genomics-based discovery platform to successfully develop a portfolio of commercial, clinical and preclinical stage programs in a number of therapeutic areas including oncology, metabolic disease and autoimmune/inflammatory diseases. Our core competence is the science-driven approach in discovery, strong pipeline building capability, experience with IP, and regulatory expertise.

Chipscreen's business strategy is to generate differentiated drug candidates across multiple therapeutic areas. Drug candidates are either developed by Chipscreen or co-developed and commercialized in a partnership at the research, preclinical and clinical stages.

Chipscreen was established as Sino-foreign joint venture in 2001 by several highly regarded Chinese returnees from the United States with academic, scientific, and industrial experience. Our founders established our company out of a common vision to create the leading drug discovery and development firms, and to provide affordable innovative pharmaceuticals in China.

青岛黄海制药有限责任公司

Qingdao Huanghai Pharmaceutical Co., Ltd.

青岛黄海制药有限责任公司是中国研发、生产、销售缓控释制剂的高新技术企业。历经医药改革大潮的洗礼，现拥有全资子公司三家，控股公司两家，形成了以医药制剂生产为主业，向上覆盖药用原辅料生产，向下涵盖药品物流配送的综合性医药产业格局。

公司以打造中国缓控释制剂领军企业为战略目标，以心脑血管用药、内分泌用药、神经类疾病用药、抗肿瘤药物为产业重心，产品涵盖片剂、胶囊剂、口服液体制剂、颗粒剂、小容量注射剂等100 多个品种规格。主要产品有伲福达、伲利安、畅欣达、麦特美、元顺、复方甘草口服溶液等。其中，伲福达连续多年在全国同类品种中的产销量排名中名列第一，被多次认定为“山东名牌产品”，具有极高的社会美誉度。

公司建立了完善的生产质量管理体系，2012 年一次性通过口服制剂新版GMP 认证，产品质量名列前茅。公司以缓控释技术为核心，是国内缓控释制剂的生产基地。公司积极与国内外一流的医学院校、研发机构合作，装备有国际先进水平的研发设备和检验仪器，研发实力雄厚。公司营销以学术服务为主要特色，营销网络遍布全国各地。公司先后荣获“国家AAA 级信誉企业”、“中国医药制造业纳税百强企业”、“中国化学制药行业工业企业综合实力百强企业”、“山东省医药行业最具实力企业”等荣誉称号。公司秉承“真诚、务实、专业责任”的企业文化，不断完善，不断进取，在“呵护生命每一天”的品牌理念指引下，为人民大众的生命健康而不懈努力。

Qingdao Huanghai Pharmaceutical Co., Ltd. is a R&D based high-tech enterprise; focus on the discovery, development, manufacture and marketing of sustained and controlled release drugs. After the reform, it has three wholly-owned subsidiaries, two shareholding companies, covering not only pharmaceutical preparations, but also the upstream and downstream, including API and excipient supply, drug logistic and distribution. The company has set up a comprehensive whole industry chain management pattern.

Leading in China sustained and controlled-release preparation technology is the company strategic goal. The enterprise architecture rests on four pillars, which are four therapeutic areas, cardio-cerebral vascular, endocrine, neurology and oncology. The products cover a wide range, more than 100 varieties including granules, small volume injections, tablets, capsules, oral solutions etc., and main branded products include Nifedipine (Nifedipine Sustained-release Tablets II), Nilian (Candesartan Cilexetil Capsules), Changxinda (Isosorbide Dinitrat Sustained-release Tablets), Metformi (Metformin Hydrochloride Sustained-release Tablet), Yuanshun (Paracetamol, Caffeine, Pseudoephedrine Hydrochloride and Chlorphenamine Maleate Capsules), and Compound Glycyrrhiza Oral Solution, etc.. Among these products, Nifuda production and sales are ranked No. 1 in the country for many years. It has been repeatedly identified as “Shandong Famous Brand”, with high social reputation.

The company established an advanced production quality management system,which passed oral preparation new GMP certification in 2012. The products are of high quality and reliable. The sustained and controled-release preparation technology is company’s core competitiveness, QingDaoHuangHai is the production base of sustained and controled-release preparation technology. The company has been collaborating with domestic first-class medical institutions, research institutions. The advanced R&D equipment and testing equipment help to strengthen the R&D capability. The sales and marketing of company products is based on academic services, building a sales network throughout the country.

The company has been honored as “national AAA credit enterprise”, “Chinese medicine manufacturing tax hundred enterprises”, “Chinese industrial enterprises in the chemical and pharmaceutical industry, the overall strength of hundred enterprises”, “Shandong Province pharmaceutical industry’s most powerful enterprise”. Sincere, Pragmatic, Professional and Responsible are the key of company culture. Qingdao Huanghai will continuously improve its products and services through continuous innovation to contribute to life and healthcare. “Caring For Life every day” is not only brand philosophy, but also the actions.

江苏豪森药业集团有限公司

Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

江苏豪森药业集团有限公司，成立于1995年，经过21年的持续稳健的发展，已成为集化学、生物药物研究，医药中间体、原料药合成，制剂生产和产品销售于一体的现代化创新型医药集团。豪森连续多年位居“全国医药工业百强”前30强，“中国创新力十强医药企业”前3强。豪森被国家工信部、财政部认定为“国家技术创新示范企业”。

从美国新泽西、上海到连云港，豪森建立了完整的药物研发体系。3万平米的研发中心、近千人的专业技术人员、上千台国际先进的研发设备和检测仪器、每年数亿元的研发投入，豪森已成为行业内技术集聚、人才集聚、资金集聚的研发高地！

在抗肿瘤、精神、糖尿病、心血管等6大疾病领域，豪森已有近50个品种正在服务于患者。盐酸吉西他滨荣获国家科技进步二等奖；近20个研发项目列入国家“重大新药创制”科技重大专项。历经十多年的研发，两个自主创新药物吗啉硝唑和甲磺酸氟马替尼将率先投放市场，还有10多个1.1类创新药物正在进行临床研究。

药品质量事关患者的生命安全。豪森坚持“全员、全过程、持续改进”的质量方针，以“质量源于设计”等先进理念为引导，建立了从研发、生产至销售全过程的质量管控体系。

豪森的所有产品已全部通过新版GMP认证，抗肿瘤注射剂率先通过美国FDA认证，这是世界对豪森品质的肯定。

面向未来，豪森将以创新为发展的主旋律，在产业高端构建研发优势、品质优势、人才和管理优势，做响豪森品牌，做优民族医药，做强中国创造！

Jiangsu Hansoh Pharmaceutical Group, established in 1995, through 21 years of sustained and steady development, has grown into a modern innovative pharmaceutical group covering chemical & biological drug research, pharmaceutical intermediates & active pharmaceutical ingredients synthesis, finished dosage formulation manufacturing and sales. Hansoh ranked among Top 30 in 100 of National Pharmaceutical Industry and Top 3 in 10 Innovative Pharmaceutical Enterprises in China for many years. Additionally, Hansoh is awarded National Technology Innovation Model Company by National Ministry of Industry and Information Technology and National Ministry of Finance.

Hansoh has a complete R&D system for drugs, with the R&D centers located in New Jersey of U.S.A., Shanghai and Lianyungang. With 30,000 square meters of R&D center, nearly 1000 professional technical personnel, thousands of international advanced R&D equipments and testing instruments, and hundreds of millions of R&D investment every year, Hansoh has become an R&D highland attracting technology, talents and capital in the pharmaceutical industry.

Nearly 50 kinds of products, covering six major disease fields, such as Oncology, Psychotropic, Diabetic and Cardiovascular, Hansoh’s products are serving patients in need. Among them, one product named Gemcitabine HCl, was granted the second prize of National Scientific and Technological Progress, and nearly twenty R&D projects are listed in Major New Drug Discovery and Manufacture of National Major Scientific Special Project. Through more than ten years research and development, two innovative drugs, which are developed and researched by Hansoh independently, named Morinidazole and Flumatinib Mesylate will take the first lead and be launched on the market. Besides, over 10 Class 1.1 drugs are under clinical research.

Quality of a drug is connected to the safety of patients’ lives. Sticking to the quality policy of “All staff, The whole process, Continuous Improvement”, and lead by the advanced concept of “Quality by Design”, Hansoh has established the quality control system covering the whole area from R&D, manufacture to sale.

All the products of Hansoh have been granted with new GMP certificates, and the anticancer injectables have been approved by US FDA ahead of the peers, which to some certain extent, is the global affirmation to Hansoh’s product quality.

Confronted with the future, Hansoh will still prioritize innovation, trying to build superiority in R&D, quality, talents and management. Standing at the high-point of the pharmaceutical industry, we firmly believe Hansoh people will further promote their brand and strengthening China creation.

深圳信立泰药业股份有限公司

Shenzhen Salubris Pharmaceuticals Co., Ltd.

深圳信立泰药业股份有限公司成立于1998年，是集高端处方药、介入医疗器械等产品研发、生产、销售于一体的综合性医药上市公司（股票代码：002294），主营业务集中于心血管、生物医疗工程、创新生物药等高端医药医疗领域，市值位列国内医药工业企业前茅。公司荣获“国家火炬计划重点高新技术企业”、“国家级创新型试点企业”，技术中心被评为“国家级企业技术中心”，已稳步发展成为以心血管产品为主，拥有核心知识产权的国内自主创新龙头企业。

公司主营产品均为国内创新或首家上市的高端处方药，已在心脑血管领域形成产品体系和领先优势。同时，公司在抗肿瘤、抗感染、降血糖、骨科、自身免疫性疾病等多领域、多层次布局，实现全方位发展。

ShenZhen Salubris Pharmaceuticals, established in 1998, is a comprehensive medicine listed company (Stock code: 002294) integrated with R&D, manufacturing and distribution for the product of High-end prescription drugs, interventional medical device etc. & mainly marketing in the high-end medical field of Cardiovascular, Bio-medical engineering, Innovative biological medicine etc. Market value among the forefront of the domestic pharmaceutical industry enterprises. Company won the honor of “Key high-tech enterprises of China Torch Program”, “National innovative pilot enterprises”. Technology center was regarded as “National Enterprise Technology Center”. Company has steadily developed cardiovascular products, and become domestic independent innovation leading enterprises with the core intellectual property rights.

The company has formed a product system in the field of cardiovascular and cerebrovascular and now in a leading position. Almost all company’s main products are domestic innovative or first to markets. At the same time, in anti-cancer, anti-infection, hypoglycemic, orthopedics, autoimmune diseases and other fields company has multi-level layout and achieve all-round development.

正大天晴药业集团股份有限公司

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

正大天晴药业集团是集科研、生产和销售为一体的创新型医药集团企业，是国内最大的肝健康药物研发和生产基地，为国家重点高新技术企业、国家火炬计划连云港新医药产业基地重点骨干企业，2015年位列中国医药工业百强企业榜第17位，在江苏省医药行业中位列第二。2016年，肝病用药在国内医院市场占有率达22.5%，肝病用药市场占有率连续多年稳居行业第一。2016年初，正大天晴与美国强生公司签署独家许可协议，将一款肝炎治疗创新药的国际开发权许可给强生公司，协议总额达2.53亿美元，标志着公司进军国际化的步伐加快。

正大天晴始终将科技创新作为企业发展的重要战略，是国内创新药物研究投入最多的药企之一，研发投入占比逐步从销售收入的8%提高到15%，向跨国公司看齐。正大天晴以研究院为创新载体，“江苏省新型肝病药物工程技术研究中心”、国家博士后科研工作站、国家级企业技术中心、“江苏省抗病毒靶向药物研究重点实验室”等高层次研发平台相继建立，自主创新能力不断增强。目前，研究院在研项目200多个，其中一类新药20多个，生物药近30个。截止2016年底，公司有效专利及专利申请582项，其中发明专利547项；授权公告的专利259项，其中发明专利228项；国际授权专利32项。

“十三五”期间，公司将持续强化核心竞争力的打造，在保持肝健康国内龙头地位的基础上，重点打造肿瘤及肿瘤辅助用药等治疗领域，推动企业从“聚焦肝病”向“两核多强”转变，从化学药向“化学药与生物药并举”转变、从“仿创结合”向“创仿结合”转变、从“专注国内”向“国内外协调发展”转变，同时创新技术路径和商业模式，带动产品研发、生产技术和营销模式的转型升级，以及产业体系的提质换档，向创新型、国际化的医药集团稳步迈进。

CTTQ is an innovative pharmaceutical group that engages in drug R&D, manufacturing, and marketing. It has the largest R&D and manufacturing base for liver disease drugs in China, is honored as one of the National Key High and New Tech Enterprises, and ranked 17th in National Top 100 Medical and Pharmaceutical Powers in 2015.

CTTQ currently has 10 subsidiaries, 3 manufacturing plants, 2 R&D centers (in Nanjing and Lianyungang), 4 joint labs (in Shanghai and Chengdu), and 1 business development office in California, USA. CTTQ has passed multiple EU and US GMP inspections, and it is the first company that obtained the national new version of GMP certification in 2011. Its customer base spans over 30 countries. With more than 8000 employees, CTTQ has 2014 sales totaled RMB 10 billion.

Innovation and cooperation are CTTQ’s core values. Its R&D investment on innovative drugs takes the leadership among domestic counterparts. In recent years, it has developed several high level R&D platforms, including Jiangsu Province Liver Disease Innovative Drugs Technology Research Center, Jiangsu Province Antiviral Targeting Drug Research Key Laboratory, National Postdoctoral Research Fellow Station, and State-level Enterprise Technology Center. More than 10 projects were designated as National Key New Drug Innovation Science and Technology Project. Its R&D Institute has a highly capable research team of over 700 employees, with about 60% holding post-graduate degrees or senior technical certificates.

CTTQ invests over 10% of its annual sales revenue as R&D budget every year. At present, it manufactures 70 prescription medicines in China in 5 main therapeutic categories, including liver diseases, oncology, respiratory diseases, diabetes, and antibiotic. It has more than 200 projects in its product pipeline, in which State Category I innovative drug projects make up more than 10%.

CTTQ attaches great importance to intellectual property and patent protection. It has filed 582 patents, including 547 inventions by the end of 2016. Among them, 259 patents we have been granted, including 228 inventions and 32 patents granted in foreign countries. Tian Qing Gan Mei, one of our top-selling products, won China Golden Patent Award.

As a responsible corporate citizen, CTTQ is driven by a strong desire to improve Chinese medical treatment and promote public health, through both Tianqing Liver Disease Research Fund and CR-HepB Program. It donated RMB 10 million to establish the former in 2011, which was designed for healthcare professionals in under-developed areas to study liver diseases, and overall national improvement of liver disease prevention and medication. CR-HepB Program is a unified registry system in China, forming an important data resource for government and medical institutions to achieve standardized management of HBV patients. CR-HepB data have been published in EASL, AASLD, and APASL.

In the future, CTTQ aims to increase R&D investment from 8% to 15% of sales revenue to match international standards. This will significantly strengthen CTTQ’s core competitiveness and optimize its R&D system. In addition to maintaining the leading position in the domestic liver health market, CTTQ will expand its focus on oncology, and other therapeutic areas. CTTQ will also improve its strength of R&D and manufacturing capabilities in protein drug and therapeutic antibodies. In addition, CTTQ will enter into markets outside China to develop and commercialize high valuable generics and innovative medicines for unmet therapy.

北京泰德制药股份有限公司

Beijing Tide Pharmaceutical Co., Ltd.

北京泰德制药股份有限公司成立于1995年，是一家研发、生产和销售化学药物及生物制剂的高新技术企业，是国内最大的靶向药物研制、生产基地。现有员工2500人。

泰德制药经过20年的发展，先后被国家科技部和北京市认定为国家重点高新技术企业、北京市高新技术企业，入选中关村国家自主创新示范区创新型试点企业和“十百千工程”等。先后获得北京市生物医药产业跨越式发展工程（G20工程）杰出贡献企业、中国医药企业制剂国际化先导企业、中国医药工业最具投资价值企业、中关村最具影响力信用企业等荣誉称号。根据国家工业和信息化部统计数据，公司已连续四年位列中国医药行业工业企业主营业务收入全国百强。

泰德制药的产品质量真正达到国际水平。公司全部生产线通过国家2010版GMP认证。2008年，公司通过日本厚生劳动省无菌注射剂GMP认证，成为中国第一家向日本出口注射剂的制药企业，截至目前，累计销售注射剂产品近千万支，在国内制药行业起到重要的示范作用，并被评为北京市药品质量管理示范企业。

政府和行业也对泰德制药的产品给予了高度评价并授予多项荣誉，公司主导产品前列地尔注射液（凯时®）和氟比洛芬酯注射液（凯纷®）均被评为国家重点新产品、国家火炬计划项目、北京市自主创新产品和北京市科学技术奖，还被北京市评为G20工程突出贡献大品种。2014年，公司产品凯时®被评为北京市著名商标。

目前，公司拥有注射剂、片剂、胶囊、颗粒剂、外用贴剂、冻干制剂、生物制剂等多个剂型产品。泰德制药秉承“关怀生命、精益创新”的宗旨，以开发具有独立知识产权的创新药为目标，以独立创新、自主研发和引进吸收再创新为发展方向，立足国内，放眼世界，为社会提供更优质的新药产品、为改善大众的健康水平而不懈努力！

Beijing Tide Pharmaceutical Co., Ltd. established in 1995, is a new high-tech enterprise integrating research, development, production and sale of chemicals and biologics and is the biggest domestic base for development and production of targeted drugs, with 2500 employees at present.

After 20 years of development, Tide Pharmaceutical Co., Ltd. has been rated as the national high-tech enterprise, Beijing new high-tech enterprise, the selected innovative pilot enterprise in national independent innovation demonstration zone in Zhongguancun and “Ten Hundred Thousand Project” by Ministry of Science and Technology and Beijing City successively, and obtained honorary titles such as outstanding contribution enterprise of great-leap-forward development project of Beijing bioengineering and pharmaceutical industry (G20 Project), the leading international enterprise for medicine preparation enterprise in China, the most valuable investment enterprise in China medical industry, the most influential credit enterprise in Zhongguancun. According to statistical data of Ministry of Industry and Information, the company has been listed in Nationwide Top Hundred for main business income of China pharmaceuticals industry for four years continuously.

The product quality of Tide Pharmaceutical has reached international level. All production lines of the company have passed GNP certification of national version 2010. In 2008, the company passed sterility injection GMP certification of MHLW, becoming the first Chinese pharmaceutical enterprise of exporting injection to Japan. Up to now, injection products have been sold accumulatively for nearly ten million injections, playing an important role in domestic pharmaceutical industry. The company is rated as the demonstration enterprise in Beijing City on pharmaceutical quality management.

The government and the industry also highly praise products of Tide Pharmaceutical Co., Ltd, and grant it many honors. Alprostadil Injection (Kaishi®) and Flurbiprofen Axetil Injection (Kaifen®), the leading products of the company, are rated as National Key New Products, national Torch Program project, Beijing Independent Innovation New Product and Beijing Science and Technology Award. They are also rated as Large Category with Outstanding Contributions in G20 Project by Beijing City. In 2014, the companys product Kaishi® was rated as a famous trademark of Beijing City.

At present, the Company possesses many dosage forms of products such as injection, tablet, capsule, granule, external-use patch, freezing-dry preparation, biologics and so on. The Company adheres to the tenet of caring for life, seeking for innovation, aiming at development of innovative drugs with independent intellectual property, focusing on independent innovation, independent research and development, introduction, absorption and re-innovation. The Company will make use of domestic and international markets to provide more superior new drugs for society and make unremitting endeavor to improvement of public health level.

鲁南制药集团股份有限公司

Lunan Pharmaceutical Group Co., Ltd.

鲁南制药集团是集中药、西药、生物制药的生产、科研、销售于一体的国家大型综合制药集团、国家重点高新技术企业，成员企业包括鲁南厚普制药有限公司、鲁南贝特制药有限公司、山东新时代药业有限公司、鲁南新时代医药有限公司等八家子公司，位列中国大企业集团竞争力500强，连续七年荣登山东省纳税100强榜。

鲁南制药集团高度重视科技创新，设有国家手性制药工程技术研究中心、哺乳动物细胞高效表达国家工程实验室、中药制药共性技术国家重点实验室、国家级企业技术中心、博士后科研工作站、“泰山学者”岗位等科研平台。在加强自主创新体系建设的同时，企业与100余所国内外知名院所建立了长期合作关系， 成功地完成了400多项研究课题，多次承担国家科技支撑计划、国家863计划、国家重大新药创制专项、国家火炬计划、国家重点新产品计划，100多个项目获得科技奖项。其中获得山东省科技进步一等奖4项，国家科技进步二等奖6项。多个产品顺利通过美国FDA认证、欧盟CEP认证。公司积极开拓国际市场业务，目前公司产品已出口美国、德国、韩国、日本等60多个国家和地区。公司高度重视环保工作，坚持科学发展，着力建设“资源节约型”、“环境友好型”企业。公司高度重视知识产权保护工作，截止目前已申报国际、国内发明专利900多项，已获授权专利500多项。国家知识产权局举办的第十七届中国专利奖颁奖大会上，鲁南制药舒尔佳（奥利司他）获得2015年度中国专利金奖。

鲁南制药集团始终坚持“造福社会、创造美好生活”的经营宗旨，以“创新引领、服务推动”为指导方针，秉承“不怕困难、挑战困难、战胜困难”的企业精神，坚持“以改革为动力、以市场为中心、以科技为先导”的指导思想。风华正茂、立志全球的鲁南制药集团正以“保持化学制药的优势，大力发展中药，做强生物制药”为目标，大力加强以企业自主创新为主体、市场为导向、产学研协同创新的科技创新体系建设，在为成为国内领先、世界一流的国际化综合制药集团而不懈奋斗！

Lunan Pharmaceutical Group Corporation is a comprehensive, major national hi-tech enterprise that produces, researches and sells traditional Chinese medicine, chemical medicine and bio-pharmaceutical medicinal products. The group is comprised of eight subsidiary companies including Lunan Hope Pharmaceutical Co., Ltd., Lunan Better Pharmaceutical Co., Ltd., Shandong New Time Pharmaceutical Co., Ltd., Lunan New Time Bio-Tech Co., Ltd. etc.. It was selected into the top 500 enterprises of China and Shandong top 100 taxpayer in seven consecutive years.

Lunan Pharmaceutical Group Corp. pays high attention to technology innovation and it is equipped with National China Pharmaceutical Engineering Technology Research center, National Mammalian Cells Efficiently Express Engineering Laboratory, New Technology of TCM State Key Lab, National Enterprise Technology center, Postdoctoral Scientific Research workstation, Mount Taishan Scholars Post etc. The group builds its own technology innovation system and is collaborated with more than 100 foreign and domestic famous institutes. The company has finished more than 400 research subjects, including National Science and Technology Support Plan, National 863 Plan, National Key New Drugs Special Formulate, National Torch Project, National Key Product Plan, more than 100 projects received Science and Technology Progress Award, Provincial Science and Technology Progress First Prize 4 and National Scientific and Technological Progress Second Prize 6. Several products have already finished the registration and authentication of FDA and EU. The company explore the international market continuously and its products export to more than 60 countries, including America, Germany, Korea and Japan. Lunan Pharmaceutical Group pays high attention to environment protection, insists on develop scientifically and build Resource-efficient and Environment-friendly type enterprise. Also the company pays high attention to the protection of intellectual property, until now the company already apply more than 900 items of international and domestic invention patent. In the 17th Chinese Patent Award Presentation Ceremony holding by State Intellectual Property Office of the P.R.C, Shu Erjia (orlistat) by Lunan was awarded the Gold Prize of Chinese Patent in 2015.

Lunan Pharmaceutical Group Corp. insist on the principle of “benefit society and create a better life”, “innovation leads, service promotes”, “no fear of difficulties, challenge difficulties and overcome difficulties” and following the strategic guiding ideology: taking reform as the power, market as the center, science and technology as the guide. With the goal of “Keep the advantage of chemical pharmaceutical industry, strive to develop traditional Chinese medicine, make biological pharmacy stronger”, the flourishing & globalizing Lunan Pharmaceutical Group Corp. is developing the enterprise innovation ability and a scientific innovation system of production and research collaboration, it will turn into a leading domestic level, world class and comprehensive pharmaceutical group.

江苏康缘药业股份有限公司

Jiangsu Kanion Pharmaceutical Co., Ltd.

江苏康缘药业股份有限公司成立于1996年，2002年在上海证券交易所上市，是集中药材种植、中药研发、生产、贸易为一体的大型中药企业，已成为中国中药行业领军企业之一，先后被评为国家重点高新技术企业、国家创新型试点企业、国家技术创新示范企业、中国制药工业百强企业（34位），是中国中药行业获新药证书最多、拥有发明专利最多的企业以及推进中药国际化最为深入的企业之一。

公司秉承“精品国药、康缘创造”的宗旨，立足创新发展，以中药现代化、国际化为己任，着力打造科技制高点，形成了“以国家级科研平台建设为依托，体制创新和机制创新为手段，高层次人才引进与培养为核心，产学研协同创新为重要补充”的创新模式，建有中药制药过程新技术国家重点实验室和中成药智能制造国家地方联合工程研究中心等国家级科研机构，拥有一支博硕士比例在60%以上的300多人的科研队伍，建成我国第一个中药数字化智能制造工厂，列入国家工信部智能制造试点示范项目（中药行业唯一），推进中药制造技术和装备水平逐步达到国际药品制造先进水平。

Jiangsu KANION Pharmaceutical Co., Ltd. was established in 1996 and listed on the Shanghai stock exchange in 2002. It is a large enterprise of traditional Chinese medicine which includes planting of Chinese herbal medicines, researching and developing, producing, and trading of traditional Chinese medicine. It has become one of leader enterprises among traditional Chinese medicine industry. It has been honored as National Key High-tech Pharmaceutical Enterprise, National Pilot Enterprise of Innovation, National Model Enterprises of Technological Innovation, top 100 Pharmaceutical Enterprise In China (34th). In addition, it is one of the enterprises which acquire the most new drug certificates, owning most invention patents and pushing forward the internationalization of traditional Chinese medicine at the deepest level.

Jiangsu KANION Pharmaceutical Co., Ltd. adheres to the purpose of ‘high-quality Chinese medicine, made in KANION’. It is based on innovation and development and regard modernization and internationalization of traditional Chinese medicine as its own responsibility. It focuses on promoting science and technology. Thus it has formed an innovation model that rely on the construction of scientific research platform at the national level, using institutional innovation and mechanism innovation as the means, focusing on introducing and training of high-level talents, supplying with collaborative innovation of production, education and research. It has built many scientific research institutions, such as a national key laboratory for new technique in the manufacturing process of traditional Chinese medicine and a national local joint engineering research center on the intelligent manufacturing of Chinese patent medicine. What’s more, it has a scientific researching team of 300 people in which there are over 60 percent of them own doctor and master degree. We build the first intelligent manufacturing factory for digitalization of traditional Chinese medicine which is listed in the intelligent manufacturing pilot project by Chinese Ministry of Industry and Information Technology (the only one in the Chinese medicine industry). Thus, we improve manufacturing technology and equipment of traditional Chinese medicine to gradually reach the most advanced level of international drug manufacturing.

成都百裕制药股份有限公司

Chengdu Baiyu Pharmaceutical Co., Ltd.

成都百裕制药股份有限公司（简称百裕制药）注册成立于2005年，是一家专业从事药品研发、生产和销售为一体的科技型高新技术企业。下设5家子公司，成都百裕制药股份有限公司、成都百裕金阁莱药业有限公司、成都金百裕医药有限责任公司、四川上善银杏农业开发有限公司、白果裕康信息服务有限公司等。目前公司多条生产线已通过国家GMP认证。主营产品为银杏内酯注射液、依诺肝素钠注射液、兰索拉唑等多个新特药品。

百裕制药是具有国际技术领先性的生物医药制造企业，也是推动中药现代化和国际化进程中的先锋者。公司先后获得相关荣誉或奖励有：“国家高新技术企业”、四川省“成长性”中小企业、“四川省知识产权试点企业”、“四川省创新型企业”、“四川省企业技术中心”等。

公司秉承“百年济世，裕享安康”为企业使命；坚持以“创新、执着、求实、利他”作为企业的核心价值观，把人才视为公司的可持续发展的宝贵财富，把专注于独立知识产权的高科技产品的开发作为企业发展的核心竞争力。公司先后开发上市新特药品近10个，在研产品约50余个，申请国内外发明专利约80项目，其中获得国内发明专利授权29项，美国发明专利1项。相关项目先后获得“国家重大科技专项重大新药创制专项”、“国家科技型中小企业技术创新基金”、“四川省重大成果转化项目”、“四川省科技创业领军人才专项”、“四川省战略性新兴产品计划专项”、“四川省专利实施与促进专项资金专项”、“四川省战略性新兴产业发展专项”等立项。

Incorporated in 2005, Chengdu Baiyu Pharmaceutical Co., Ltd. (referred to as Bai Yu Pharmaceutical) is a new high-tech enterprise engaged in research and development, production and sales of drugs. It has five subsidiaries including Chengdu Baiyu Pharmaceutical Co., Ltd., Chengdu Baiyu Jingelai Pharmaceutical Co., Ltd., Chengdu Jinbaiyu Pharmaceutical Co., Ltd., Sichuan Shangshan Ginkgo Agricultural Development Co., Ltd. and Baiguo Yukang Information Service Co., Ltd. At present, a number of production lines of the company have passed the national GMP certification. The main products include Ginkgo Biloba Injection, Enoxaparin Sodium Injection, lansoprazole and other new drugs.

Baiyu Pharmaceutical, as a pharmaceutical manufacturing enterprise with leading international technology as well as a pioneer in advancing modernization and internationalization of traditional Chinese medicine, has successively won many honors like ‘National High-tech Enterprise’, ‘The Growing Small And Medium-Sized Enterprise In Sichuan Province’, ‘Pilot Enterprise of Intellectual Property Rights in Sichuan Province’, ‘The Innovative Enterprise in Sichuan Province’, ‘The Enterprise Technology Center in Sichuan Province’.

The company adheres to the enterprise mission of “Benefit the Society, Enjoy Good Health”, follows the core value of “Innovation, Dedication, Truth-Seeking and Altruism”, regards the personnel as wealth for the sustainable development of the company, and takes the development of high-tech products with independent intellectual property rights as the core competitiveness for company development. The company has developed and marketed nearly 10 new and specific drugs, more than 50 products under research, applied for invention patents of about 80 items at home and abroad, of which 29 have won domestic invention patent authorization, one has won the patent of the United States. The relevant projects have won the “Special Major New Drug Discovery of National Major Science and Technology”, “Technology Innovation Fund for National Science and Technology Small and Medium-Sized Enterprise”, “Major Achievements Transformation Project in Sichuan Province”, “Science and Technology Leader in The Entrepreneurial Talent in Sichuan Province”, “Strategic New Product Plan in Sichuan Province”, “Patent Implementation and Promotion of Special Funds in Sichuan Province”, “Special Development of Strategic Emerging Industries in Sichuan Province” and other awards.

浙江华海药业股份有限公司

Zhejiang Huahai Pharmaceutical Co., Ltd.

浙江华海药业股份有限公司创立于1989年，是一家集化学药、生物药、医药包装及贸易流通为一体的制药企业，并于2003年在上交所上市。目前，公司拥有注册资本10.4亿元，总资产67亿元，占地面积150多万平方米，并在美国、香港、上海、江苏、浙江等地设有30多家分子公司，共有员工5600多人。

公司是国家重点高新技术企业、国家创新型企业、中国医药工业百强企业，设有“国家级企业技术中心”、“博士后科研工作站”、“院士工作站”、“企业研究院”，拥有一支1600多人的高学历、高技术、具有丰富研发经验的科研队伍，其中10人入选国家“千人计划”，14人入选省“千人计划”，博士40多人，教授级高工、高级工程师20多人，在绿色合成、工业结晶、药物新剂型、新工艺研发等方面已形成强大的创新实力，并积极布局高端新剂型、生物制药和新药领域，为华海实现一次次跨越发展提供了不竭动力。

通过多年的转型升级和产业结构调整，公司建立了完善的原料药和制剂产业链，形成了以心血管类、精神类、抗病毒、抗肿瘤等药物为主导的产品系列，不仅是世界前10大制药企业的主要原料药供应商，更是在美国规模化销售制剂产品的首家中国药企。公司产品远销全球200多个国家和地区，制剂产品已基本覆盖美国所有大中型药品采购商，同时以欧美高端市场为起点，逐步向南美、俄罗斯、中东等市场拓展，深度融入国际制药产业链。

Zhejiang Huahai Pharmaceutical Co.,Ltd. was initially founded in 1989, engaging in developing, manufacturing, packaging and marketing of Chemical drugs and biopharmaceuticals. The company’s stock was successfully listed in Shanghai Stock Exchange in 2003. With a registered capital of RMB 1.04 billion and total asset of 6.7 billion, the company has more than 30 branches (subsidiaries) in the United States, Hong Kong, Shanghai, Jiangsu and Zhejiang of China. It occupies an area of 800,000 square meters, and has over 5,600 employees.

As High-Tech Enterprise, National innovation-driven Enterprise and Top 100 pharmacy industry of China, The company has a highly-educated, skilled and experienced R&D team, which have more than 1,600 technicists. Well established technology of green chemistry, industrial crystallization, designing new dosage forms and new processes, Huahai is now trail-blazing into for the realm of modified-release technology, biopharmaceuticals and new drug discovery, which underpin the Second Transformation and Upgrading.

After years of upgrading and restructuring, Huahai has become a leading vertically integrated pharmaceutical manufacturer for both APIs and formulations. Cardiovascular, neurological, antiviral and anti-tumor drugs has become main series of products. These products are sold to over 200 countries and regions, finished drug products sells to almost all major distributors of U.S. And we take European and American markets as a start point, gradually expanding to South America, Russia, and Middle East etc. Huahai is becoming part of the global pharmaceutical supply chain.

武汉禾元生物科技股份有限公司

Wuhan Healthgen Biotechnology Corp.

武汉禾元生物科技股份有限公司（禾元生物，证券代码：833101）创立于2006年，是一家专门从事分子医药技术研究与产品开发的国家高新技术企业。公司始终坚持原始创新和市场导向，在董事长、国家“千人计划”、武汉大学教授杨代常先生的带领下，建立了国际领先的水稻胚乳细胞生物反应器技术平台和国际先进的重组蛋白质纯化技术平台，建立了我国首个植物表达技术的新药研发平台，较好地解决了国际植物生物反应器的表达量低、纯化工艺复杂、规模化困难和痕迹量宿主蛋白检测技术难题，具有表达量高、安全性好、规模化容易、成本低和绿色环保等优势。开创性地利用植物表达体系，自主研发的生物制品I类重磅新药“植物源重组人血清白蛋白注射液”，是我国首个获得的重组白蛋白注射液临床批件，现已进入临床研究，标志着我国在植物生物反应器领域达到了世界领先水平。

公司具有雄厚的技术研发团队，在“十一五”、“十二五”和“十三五”期间，承担并完成多项国家重大科技专项，获得了国家授权发明专利8项和国际授权发明专利16项；公司的植物表达技术平台被列入“十二五”期间的重大突破性科技前沿技术，获得国家科学技术发明二等奖、湖北省科学技术发明一等奖两项和国家优秀专利奖等。公司致力于为全世界人民提供绿色、安全、廉价、充足的生物医药产品，为中国医药的“智能制造”进向国际做出努力和贡献。

Healthgen Biotechnology Corp. (Healthgen Biotech, stock code: 833101), a private company dedicating to plant-based molecular pharming was founded in 2006. Under the leadership of President and Chief scientist Daichang Yang, who also gained the “Thousand Talents program” of the National Central Organization Department, Healthgen Biotech has being developed series peptides and proteins with in-house R&D pathways using OryzHiExp. Our first major potential candidate in clinical development is recombinant human serum albumin derived from Oryza sativa (OsrHSA), which has been approved by CFDA for clinical trial. It marks a milestone of plant-based molecular pharming around the world. Healthgen Biotech owned the largest facilities for processing of plant-based biopharmaceuticals in the world and has established GMP-compliance facilities and quality control system. Healthgen Biotech’s state-of-arts technology, OryzHiExp, is protected by 8 granted patents in China and 16 granted patents in international-wide. OryzHiExp has the advantages of high expression level, easy scale-up of processing, more safety and environment-friendly with low cost. Healthgen Biotech has R&D team who has capacity to undertaken the major national Scientific Research Projects. The state-of-arts technology honored Invention Award of National Science and Technology, Invention Award of Hubei Province government. Its mission is providing the biopharmaceuticals with environment-friendly, safety, inexpensive and adequate supply for people all over the world.

西藏易明西雅医药科技股份有限公司

Tibet AIM Pharm. INC.

西藏易明西雅医药科技股份有限公司（以下简称“公司”或“易明医药”），创始于2003年，是一家集新药研发、中藏药材种植、药品生产、经营销售、产业投资为一体的全产业链新型医药企业。经过10余年的发展，公司于2016年成功登陆A股市场，股票代码SZ002826。

公司拥有拉萨和成都两个实验中心，实验室面积近2000平米，已引进waters-EMPOWER 和岛津-Lab Solutions CSLite数据管理系统等先进实验设备，使得公司在实验数据管理方面达到行业领先水平。公司固定职工约400人，95%以上研发人员拥有药学相关专业本科及以上学历，核心技术人员均拥有15年以上药物研发经验，与国内多家科研院所建立密切合作关系，并聘请了10余名国际、国内著名专家为技术顾问。

公司先后承担并完成了国家科技部火炬计划项目、科技型中小企业创新基金项目、西藏（成都）科技孵化器项目、西藏自治区重点科技项目等一系列科技项目；获得“中国心脑血管病诊疗产业技术创新战略联盟理事单位”、“中国专利优秀奖”、“国家火炬计划·产业化示范项目证书”、“自治区工程技术研究中心”等一系列荣誉；多个产品获得四川省名牌称号。

公司采用Q-marker研究理念建立的一整套药品全程质量控制及质量溯源体系已经推广使用，口服制剂一致性评价、中药注射剂再评价等工作进展顺利，一些战略领域和品种的新药开发已经启动，原料及制剂的国际注册申请陆续获批。随着这一系列项目的实施和落地，易明医药将在中国医药创新及国际化之路迈向新的里程碑。

Tibet AIM Pharm. INC.(hereinafter referred to as the Company or AIM Pharm.) was founded in 2003. It is a new industry chain pharmaceutical corporation which integrates R&D, TCM and Tibetan medicine plantation, drug manufacture, sale and industrial investment. After a decade development, the Company is listed on the main board of the A share market in 2016 (SZ002826).

The Company owns two laboratory center in Lhasa and Chengdu which covers an area of 2000 square meters and introduced advanced experiment installations like waters-EMPOWER and Shimadzu-Lab Solutions CSLite. This makes the Company achieved an industry-leading position in laboratory data management. The Company has fixed staff of 400 people, among which more than 95% had a pharmaceutical related bachelor degree or above. The core technical staff owns more than 15 years of pharmaceutical R&D experiences, and have built a close cooperation with many domestic scientific institutions. The Company has employed more than 10 domestic and international experts as technical consultant.

The Company has finished a series programs including Torch Program of National Ministry of Science and Technology, Science and Technology SME Innovation Fund Project, Tibet (Chengdu) Technology Incubator Project, Tibetan Autonomous Region Key Science and Technology Projects; The Company has also been honored as “Member of China Cardiovascular and Cerebrovascular Disease Diagnosis and Treatment Industry Technology Innovation Strategic Alliance Governing”, “China Patent Excellence Award”, “National Torch Plan-Certificate of Industrial Demonstration Project”, “Autonomous Regional Engineering Technology Research Center”, etc.. Many products of the Company received Famous Brand in Sichuan Province

The Company adopted Q-marker research concept to build a complete all-phase drug quality control and tracing system to be promoted and implemented. Projects including Consistency evaluation of oral preparations and Reevaluation of TCM injections progressed smoothly. Some of the strategic products and new drug R&N has been initiated, whilst the registration for raw material and preparation have been successively approved. With the implementation of this series of projects, AIM Pharm. will target toward a new milestone in the journey of innovation and internationalization of Chinese pharmaceutics.

山东罗欣药业集团股份有限公司

Luoxin Pharmaceutical Group Co., Ltd.

山东罗欣药业集团股份有限公司于1988年在山东临沂成立，并于2001年改制为股份制企业，是一家集药品研发、生产、贸易和健康服务为一体的大型医药企业集团。公司现有员工4000余人，其中科研人员占总人数的12%。罗欣集团自2011年起连续被评为中国医药研发产品线最佳工业企业，是国家重点高新技术企业、国家技术创新示范企业。此外，公司拥有国家企业技术中心、国家地方联合工程实验室、国家博士后科研工作站等研发机构，形成了强势的国家级科研技术中心；并承担了国家“重大新药创制”科技重大专项、国家火炬计划项目、国家重点新产品计划等多项科技项目；荣获国家科技进步奖二等奖 1 项。

罗欣药业集团坚持实施“展望长远、兼顾当前、创仿同步”的产品研发战略，并于2014年在上海张江高科园区设立了罗欣上海科研中心——罗欣生物科技（上海）有限公司，与集团和各科研院校形成了三位一体的科研体系。目前，公司主要致力于消化系统、呼吸系统、心血管系统、抗感染、抗肿瘤等领域药品的开发，已开展的创新药研发项目达到 7 项；其中，创新药LXI-15028作为一种新型的钾离子竞争性酸抑制剂（P-CAB），已于2017年6月通过CFDA评审进入临床试验研究；创新药LXI-15029作为mTORC1和mTORC2的双重抑制剂，也已进入临床试验阶段，并将有望成为同机制治疗肿瘤疾病的第一个有效化合物。

2016年罗欣药业集团股份有限公司在工信部发布的中国医药工业百强榜单中位列第37位，实现营业收入65亿元。未来，罗欣药业集团将持续对研发的投入,不断推出高科技含量、高质量、高附加值的“三高”产品，为企业持续发展奠定坚实的产品基础。

Luoxin Pharmaceutical Group Co., Ltd. is a large-scale pharmaceutical enterprise group dedicated to integrating medicine R&D, production, trade and health services. Originally established in Shandong Linyi in 1988, Luoxin successfully restructured into a joint-stock enterprise in 2001. The company currently boasts more than 4000 employees, of which 12% are R&D personnel. Since 2011, Luoxin Pharmaceutical Group has been rated “the best industrial enterprise in Chinese Pharmaceutical Industry with R&D pipeline,” among numerous other awards like the “National Key High-tech Enterprise” and “Technological Innovation Model Enterprise”. The Group has also established research institutes such as National Enterprise Technology Center, National and Local Engineering Laboratory, and National Postdoctoral Programme, through which the company has undertaken a number of award-winning projects under nationally-recognized scientific and technological programs including the Major New Medicine Development, National Torch Plans and the National New Products Program.

Luoxin Pharmaceutical Group adheres to its R&D vision of “Looking into the Future, Focusing on the Present and Parallel Advancement on Generic and Innovative Products”. Most recently, in June 2014, Luoxin Pharmaceutical Group established its Shanghai R&D Center in Shanghai Zhangjiang Hi-Tech Park, to drive innovative medical research with the group and the other Research Institutes. The company focuses on the R&D of pharmaceutical products of several therapeutic areas including gastrointestinal disease, respiratory disease, cardiovascular disease, infectious disease and cancer. So far, we have launched seven R&D projects on innovation drugs; among them, the innovation drug LXI-15028, a new potassium ion competition inhibitor (P-CAB), received permission from CFDA to initiate clinical trials in June 2017. The innovation drug LXI-15029, a double-inhibitor of mTORC1 and mTORC2, also received permission to initiate clinical trials, and is expected to become a First-in-Class drug of this mechanism for the treatment of tumors.

In 2016, Luoxin Pharmaceutical Group ranked thirty-seventh in the Top 100 List of Chinese Pharmaceutical Industries, and achieved 6.5 billion RMB operating income. In order to lay a solid product foundation for the enterprise’s sustainable development, the company will continue to pursue its 3 guiding fundamentals for all products: high-tech, high-quality, high value.

信达生物制药（苏州）有限公司

Innovent Biologics (Suzhou) Co.,Ltd.

信达生物制药(苏州)有限公司（www.innoventbio.com）由中组部“千人计划”国家特聘专家俞德超博士于2011年8月创立，致力于做国内最好、国际一流的高端生物药制药公司，开发、生产老百姓用得起的高端生物药。公司已获得全球知名创投高达4.9亿美元的投资，形成了利用全球资本支持创新的新格局。

经过五年的发展，信达生物公司立足创新，建立起了一条包括13个新药品种的产品链，覆盖肿瘤、眼底病、自身免疫疾病、心血管病等四大疾病领域，承担国家科技项目7项，其中5个品种入选国家“重大新药创制”专项，1个品种入选国家重点研发计划“精准医学研究”专项；建成大规模的产业化基地，包括2条1,000L（已建成）、6条3,000L（建设中）、4条15000（建设中）产业化生产线，符合CFDA、FDA和EMA的GMP标准。2条1000升生产线已于2016年9月通过了合作方国际制药集团的GMP审计，这是中国第一条符合美国FDA GMP标准的生物药生产线；组建了一支具有国际先进水平的高端生物药开发、产业化人才团队，其中有50多位海外归国专家。

2015年，信达两次与美国礼来达成全面战略合作，获得首付及潜在里程碑款等33亿美元，创造了“中国人发明的生物药海外市场第一次转让给世界500强药企”、“中国造创新药第一次卖出了国际价”等多个“中国第一”。2015年6月，作为中国优秀创新型企业代表，应国务院邀请参加了“第六次中美创新对话”，俞德超博士在大会上发表了关于中国创新的演讲。《人民日报》和《华尔街日报》九次对信达生物公司自主创新的成果和国际合作的成功案例进行了深度报道。信达生物的创新成果成功入选2015年度“中国医药与生物技术十大进展”，并于2016年6月作为“十二五”重大成果受邀参加由中组部、科技部等15个部委组织的国家“十二五”创新成果展，受到国家领导人的肯定。2017年1月，公司总裁俞德超博士荣获由中国科学院、中央电视台、科学技术部等八部委共同评选的国家“2016年度科技创新人物”。同时获奖的还有“长征五号”和“天宫二号”、“神舟十一号”载人飞行任务研制团队等。最近，中国中央电视台（CCTV）的《经济半小时》长篇报道了公司开发的抗肿瘤创新药物，点赞信达人为患者谋福、为一个个家庭谋福的努力和这份真正的中国制造。

A leading biotech company in China, Innovent Biologics (Suzhou) Co., Ltd. was founded in August 2011. Innovent aims to produce highly complex biopharmaceutical products that will be affordable to people in China and around the world. Backed with investments from world-class leading financial institutions totaling $490M, Innovent has established a solid foundation for growth.

From its onset, Innovent has been focusing on innovation. In its first five years, Innovent built up a portfolio of 13 molecules targeted towards indications in cancer, ophthalmology, autoimmune disorders, and cardiovascular diseases. Five of Innovent’s pipeline products have been granted “National Mega Innovative Program” status. From a manufacturing perspective, Innovent has built a large-scale manufacturing base, which includes two 1,000-liter bioreactors that have been in operation since 2014. Innovent also has six 6,000-liter and four 15,000-liter bioreactors that are currently in the design phase. The entire facility is in compliance with GMP Standards from the CFDA, FDA and EMA. Innovent has also been fortunate to have attracted over 50 overseas returnees, most of whom are high level professionals and talented people from across the industry, having not only deep China expertise but also having meaningful global experience as well. These high quality and knowledgeable professionals form the backbone of Innovent talent pool.

In March and October of 2015, Innovent and Eli Lilly signed two collaboration agreements to co-develop and cocommercialize six antibody drugs over the next decade. The transaction not only brings upfront and potential milestone payments to Innovent well above $3.0 B, but also sets several industry precedents for Chinese biotech companies. This was the first time a biopharmaceutical product invented by a Chinese company was licensed to a Global Top 20 company while also commanding the largest upfront payment a Chinese company has received to date from a global partner.

In recent months, Innovent has been recognized by outside organizations for its significant contributions. In June 2015, Innovent CEO Michael Yu was invited by the China State Council to attend the “Sixth U.S. – China Innovation Dialogue” in Washington DC., Michael Yu represented the best innovative Chinese companies as he delivered a speech on the state of biopharmaceutical innovation in China. Also, Innovent’s R&D prowess was voted as one of the “Top Ten Breakthroughs in the China Biopharmaceutical Industry” in 2015 and in June 2016, Innovent was selected to attend the national “12th Five-Year” Science and Technology Innovation Accomplishment exhibition, where Innovent was widely recognized by national leaders. In January 2017, Innovent founder and CEO Michael Yu, was selected as State’s “Person of the Year in Innovation for Science and Technology in China in 2016”. The event was jointly organized by CCTV Technology, the Ministry of Education, and the Chinese Academy of Engineering. Other co-winners of the award include “Long March 5”, “Tiangong 2”, and “Shenzhou 11”.

华领医药技术（上海）有限公司

Hua Medicine (Shanghai) Ltd.

华领医药是中国新药研发创新的领军企业，目前专注于2型糖尿病和神经退行性疾病的个性化治疗创新药物研究。这家由国际顶尖的医药研发专家和投资团队创办的公司目前拥有两个创新药物的国际开发权。其中最为领先的是全球首创、用于治疗2型糖尿病的口服药物，目前已经在中国进行III期临床试验。公司另外还有两个早期阶段的化合物，分别针对代谢疾病和中枢神经系统紊乱。华领医药的策略是凭借公司内部的强大药物研发能力和管理能力，引入海外先进的技术和产品资源，以“中西合璧、联合创新”运营模式，研发、生产和销售重大疾病领域的创新产品和服务。公司致力于成为中国向全球药物研发创新中心迈进的重要推动力。

Hua is a leading, innovative drug development company in China focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by an experienced group of entrepreneurs and international investment firms, Hua currently has world-wide rights to two novel assets. The most advanced program is a first-in-class, oral drug for the treatment of Type 2 Diabetes currently in Phase III trials in China. The company has also internally developed earlier-stage compounds focused on a highly validated CNS target for multiple indications including Parkinson’s Disease associated dyskinesia and Depressive Disorder. Hua’s strategy is to leverage the cost-efficient and high-quality drug discovery capabilities available in China, while partnering or licensing the most promising drug assets from the US and abroad. Through these efforts, Hua intends to be the driving force behind China's evolution into a global innovation center for drug development.

歌礼生物科技（杭州）有限公司

Ascletis Bioscience Co., Ltd.

歌礼是一家由海归团队创立的创新型医药企业。歌礼立足中国，面向世界，致力于癌症和传染性疾病领域创新药物的研发、生产和销售，为中国患者提供最佳的、具有自主知识产权的创新药物，满足他们的医疗需求。歌礼生产基地位于浙江绍兴滨海新城，占地23亩，建筑面积1.8万平方米，规划建设固体制剂车间、原料药车间、检验中心及相应配套设施等，用于公司创新药物的生产。

歌礼通过自主开发和战略合作，开发、引进最优秀、最适合中国市场的一流产品和技术，充分利用中国现有的研发能力和资源，进行临床中晚期开发，以中国患者可以承受的价格将领先的创新药物推向市场。截至目前，歌礼共拥有四个临床阶段的1类创新药物：丙型肝炎病毒（HCV）NS3/4A抑制剂丹诺瑞韦（ASC08）；HCV NS5A抑制剂瑞维达韦（ASC16）；RNAi靶向治疗肝癌药物ASC06；HIV蛋白酶抑制剂ASC09。

慢性病毒性丙型肝炎（丙肝）是歌礼当前的重点研究领域。以丹诺瑞韦和瑞维达韦等直接抗病毒药物为核心，歌礼提供三联疗法和全口服无干扰素疗法等两个完全与国际临床前沿接轨的丙肝治疗方案，并形成不同产品梯次，为中国数以千万计的丙肝患者提供更多、更佳的治疗选择。

歌礼核心产品丹诺瑞韦已在中国大陆地区、台湾地区、韩国及欧美等国家和地区完成了37个临床试验，受试者超过2600人。中国大陆地区III期临床试验结果显示，以丹诺瑞韦为核心组成的三联疗法对占中国丙肝患者总数60%的基因1型患者治愈率达到97%。歌礼现已提交丹诺瑞韦新药上市申请，预计可于2017年年中获批上市。

在推进现有各项产品的开发和上市的同时，给病人带来突破性新药的承诺也推动歌礼不断探索外部的合作机会。在相继与罗氏、杨森等国际药业巨头建立广泛的战略合作关系之后，歌礼将继续在全球范围内寻找处在不同开发阶段的创新产品，以灵活、开放的合作心态和形式，与国内外同行建立合作，加快研发出新型和有效的产品交付到中国以及全球市场。

Ascletis is an emerging biotechnology company, dedicated to discovering, developing and commercializing important new treatments for infectious diseases and cancer. Ascletis' GMP commercial manufacturing facility is located in BinHai New City, ShaoXing, Zhejiang. The 18,000 m2 state-of-art facility houses various modules such as formulation, active pharmaceutical ingredient (API), QA/QC etc.

To date Ascletis has four clinical stage drug candidates in its product pipeline: Danoprevir (ASC08), a NS3/4A HCV protease inhibitor partnered with Roche; Ravidasvir (ASC16), a phase IIa HCV NS5A inhibitor licensed from Presidio Pharmaceuticals; ASC06, a clinical stage, first-in-class, systemically delivered RNAi therapeutic for the treatment of liver cancers licensed from Alnylam Pharmaceuticals; and ASC09, a next-generation HIV protease inhibitor licensed from Janssen, a pharmaceutical company of Johnson & Johnson.

Chronic hepatitis C (CHC) is currently the primary disease focus of Ascletis. With its two direct-acting antiviral agents (DAA), Danoprevir and Ravidasvir, Ascletis provides two regimens for 25 million CHC patients in China, an interferon (IFN)-containing triple therapy and an all-oral IFN-free therapy. Both of the regimens offer comparable efficacy and safety profiles to the current leading regimens for HCV treatments in USA.

Ascletis' lead product, Danoprevir, is a second generation HCV NS3/4A protease inhibitor. It has been evaluated in 37 clinical trials with a total of approximately 2600 healthy volunteers and patients tested. Phase III Study results show that after 12-week treatment of Danoprevir in combination with PEG-IFN and ribavirin, the cure (SVR12) rate observed in genotype 1 non-cirrhotic patients in China was 97%. Ascletis has filed NDA for Danoprevir and will launch Danoprevir into market in the second half of 2017.

While conducting drug development for existing drug candidates, Ascletis is engaged in a continued globally search for innovative medicines at various stages of development, with a clear goal to accelerate the delivery of novel and effective products to the China marketplace as well as markets worldwide.

江苏亚盛医药开发有限公司

Ascentage Pharma Group Corp., Limited

亚盛医药是一家立足中国、面向全球的原创新药研发企业，在肿瘤、乙肝及与衰老相关的疾病治疗领域已成功布局，尤其在细胞凋亡和自噬双通道调控抗肿瘤药物领域的研发领先全球，所有在研项目均为新化合物结构的原创1类新药，并旨在进军国际高端医药市场。

公司在基于靶向蛋白结构的药物设计与优化领域形成了多项核心技术，拥有一百多项国际发明专利，已成功开发近10项原创小分子靶向抗肿瘤药物进入临床前或不同阶段国际临床研究，其中6项已分别进入到中国、美国及澳大利亚的I-II期临床开发阶段。

亚盛医药专注于已为临床验证的癌症靶点，其研发产品管线主要为细胞凋亡路径关键蛋白的抑制剂，通过抑制BCL-2/ Bcl-xL、IAP和MDM2-p53等，重启肿瘤细胞的凋亡程序；第二代和第三代的针对癌症治疗中出现的激酶突变体的抑制剂；与肿瘤治疗的有密切相关性的表观遗传学靶点的抑制剂等。

此外，亚盛医药已与美国领先的生物技术公司UNITY Biotechnology建立合作，旨在全球范围内共同合作开发基于清除衰老细胞的新型抗衰老治疗药物；公司的主要合作伙伴还包括密西根大学及美国默克等。

公司现有研究人员100多人，其中中组部“千人计划”国家特聘专家入选者3人，具有多年海外原创药物研发经验高层次人才10余人，硕士及博士人数占公司总人数一半以上。

Ascentage Pharma is a global, clinical-stage biopharmaceutical company, dedicated to discovery and development of “first-in-class” and “best-in-class” small-molecule targeted therapeutics for addressing unmet medical needs in cancers, hepatitis B and age-related diseases.

Ascentage has world-leading proprietary Protein-Protein Interactions (PPIs)-targeting drug discovery technologies and holds over 100 international patents. Ascentage currently has six small molecule drugs in phase I-II trials in US, Australia and China and additional programs in preclinical stages.

The established R&D pipeline of Ascentage includes the inhibitors to a number of key proteins, including IAP, Bcl-2/Bcl-XL and MDM2-p53, that regulate programmed cell death process; 2nd and/or 3rd generation of kinase inhibitors that overcome mutant resistance in cancer therapy; and inhibitors of epigenetics.

Ascentage is partnering with UNITY Biotechnology to co-develop senolytic therapies addressing the age-related diseases. The other major partners of Ascentage include University of Michigan and Merck.

再鼎医药（上海）有限公司

ZAI Lab (Shanghai) Co., Ltd.

再鼎医药是一家总部位于上海的高科技生物制药公司。公司拥有一支具有全球创新药物研发背景及丰富经验的新药研发团队，公司立足中国，致力于研制世界一流的创新药物。

公司采用自主创新与合作开发并举的研发策略，一方面自主研发“全球新”的创新药，为全球患者解除病痛提供治疗手段；另一方面，基于对中国患者现有的及不断增长的治疗需求的深刻洞察，积极与领先的跨国制药公司或高度创新的生物技术公司进行战略合作，将国内急需的全球领先的创新药物早日引入中国，惠及于中国患者。通过这种双轮驱动的创新策略，再鼎医药已经打造了一个遍布研发各阶段、极具竞争力的新药产品线。未来，公司将继续通过积极的外部合作和内部研发策略不断扩大产品线。

Zai Lab is a Shanghai-based biopharmaceutical company. Our globally-experienced drug development team is passionate about bringing transformative medicines to China and discovering and developing our own therapeutics for patients worldwide.

Our vision at Zai Lab is to create a premier drug discovery, development, manufacturing and commercialization organization built on a foundation of world-class expertise and insights into the existing and expanding needs of Chinese patients. We have assembled a team of leaders who have a collective track record in all aspects of our business, including pioneering success in the regulatory process in China. We have established a pipeline of best-in-class biopharmaceuticals at different stages of development by securing partnerships with leading multinational pharmaceutical and highly innovative biotechnology companies. Our pipeline will grow through additional collaborations and from our internal discovery and development efforts.

北海康成（北京）医药科技有限公司

CANbridge Life Sciences Ltd.

北海康成是一家总部设在中国北京的创新型医药科技企业，通过对接世界最大的生命高科技医药产品线与全球增长最快、潜力最大的应用市场，以加速高端、特效的医药产品在中国和亚洲的市场化。

公司的创建人和首席执行官薛群博士(James Xue, PhD, MBA)，曾任美国健赞公司(Genzyme)高管及健赞中国区第一任总经理，是集美、中研发、营销、创业和企业管理经验于一身的优秀高端海归人员。

北海康成的核心竞争力不仅表现在世界级一流的顾问和管理团队上，与同行业其他企业相较，北海康成筛选、评估、获取优质项目的能力，项目执行及管理能力，临床开发的科研实力均表现出其超群的优越性。

CANbridge Life Sciences Ltd. is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan). CANbridge develops partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical device or diagnostic products that are either unavailable in China/North Asia or address medical needs that are underserved in the region. CANbridge also licenses or obtains exclusive rights to commercialize drug and device products that are approved in their home markets for commercialization in China and North Asia.

Its founder and CEO, James Xue PhD, MBA was a former Genzyme executive and founding general manager of Genzyme China.

With its world-class management and advisory team, CANbridge has the capability to select, acquire, develop and deliver future therapeutics and diagnostics with high potential to meet seriously unmet medical needs among Chinese and Asians.

和记黄埔医药（上海）有限公司

Hutchison MediPharma Limited

和记黄埔医药（上海）有限公司于2002 年9 月成立，总部位于中国上海张江高科技园区。公司立足于中国本土创新，专注研发具有自主知识产权保护的治疗癌症和自身免疫性疾病的创新靶向药物，以满足全球医药市场的需求，是国际先进、国内最为领先的新药研发企业之一。

和记黄埔医药拥有一套完整的药物研发体系和一流的研发平台，拥有最先进的仪器配置、国际AAALAC 认证的试验动物中心、激酶筛选平台、转化医学中心、 计算机辅助化学结构设计平台、药代动力学评估中心、初步毒性评估平台等。并设置有肿瘤研究部、免疫研究部、化学部、药代部、药物安全评价部、分析及质量部、药学部、临床与法规事务部、商务开发部等完备研究开发部门，协同研发、无缝衔接。

和记黄埔医药的十几位高级管理层均留学美国等著名高等院校和研究机构，在世界知名医药及生物科技公司工作数十年，并先后参与多个国际重磅炸弹药物的研究开发工作，拥有丰富的专业知识和成功研发新药的从业经验。以资深管理层为核心，公司组建了一支由330余名拥有丰富中西药研发经验的科学家所构成的队伍，90%的科研人员拥有硕士或博士学位，其中约10%的员工曾留学欧美，在国外著名院校或研究机构接受过系统的专业学习和前沿科学研究工作。同时，公司还拥有一批富有经验且熟知中国临床开发及药事法规的本土研究人员。另外，公司拥有近8000 平米的研发中心和一个近4500 平米的GMP 制剂生产基地，建立了集研发、中试和产业化生产于一体的完整产业链条。

深耕创新15年，现如今，和记黄埔医药取得了极为瞩目的成绩。公司目前共有8个1类小分子新药，在欧美、澳洲、中国同步进行共计31项临床研究。其中有4个已经处于临床关键三期的晚期开发阶段。值得一提的是，和记黄埔医药携手合作伙伴阿斯利康近期启动了沃利替尼治疗乳头状肾癌(PRCC)的临床三期、国际多中心研究，这不仅是全球史上首个具有伴同诊断，遴选携带MET基因驱动的PRCC患者的三期注册研究，也是中国民族药企研发的靶向创新药物第一次在全球范围内开展以上市为目的的注册性临床研究。沃利替尼有望成为首个由中国民族药企为全球市场研发的重磅炸弹式药物，彻底改变中国生物医药研发在国际上的形象，掀开中国新药研发史的全新篇章。更值得一提的是，和记黄埔医药与合作伙伴礼来共同开发的小分子靶向药物呋喹替尼在治疗晚期结直肠癌的临床三期中达到所有的研究终点，体现了同类最优的疗效和安全性，并完成新药申报，即将获批上市造福广大晚期结直肠癌患者。这也标志着和记黄埔医药从生物创新公司到生物制药公司的成功转型。

Hutchison MediPharma Ltd. (“HMP”) was established in September, 2002, located in Zhangjiang Hi-Tech Park, Shanghai, China. HMP is an innovative biopharmaceutical company based in China aiming to become a global leader in the discovery, development and commercialization of targeted therapies for oncology and immunological diseases.

HMP has built a large-scale and first-class fully integrated drug R&D platform with the state-of-the-art equipment configuration, the experimental animal center with AAALAC international certification, the kinase screening platform, the translational science center, the computer aided chemical structure design platform, the pharmacokinetic evaluation center, the preliminary toxicity evaluation platform, etc., covering chemistry, biology, pharmacology, toxicology, chemistry and manufacturing controls for clinical and commercial supply, clinical and regulatory and other functions, which work seamlessly together.

The leadership team members in HMP comprise mainly of returnees trained in USA and other western countries, with an average 20-year experience in multinational pharma & biotech companies, and participated in the discovery & development of numerous blockbusters. There are more than 330 scientists and staffs in HMP, 90% of the scientific research personnel have a master or doctoral degree, and about 10% of them were educated in well-known colleges, universities or research institutions in Europe or USA, and joined HMP with rich experience in innovative drug R&D. Meanwhile, HMP also has a group of locally trained researchers that are familiar with China's clinical development and regulations. In addition, HMP has nearly 8000 square meters of R&D center and approximately 4500 square meters of GMP formulation production base for industrialization and production of the new drugs.

HMP has made remarkable achievements since it was established in 2002. HMP has built a rich pipeline with 8 clinical candidates in 31 active trials (including 4 candidates in Phase III pivotal registration trials) in United States, Europe, Australia and China. It's worth to mention that HMP and its partner AstraZeneca initiated a global, Phase III registration trial of savolitinib in Papillary Renal Cell Carcinoma (“PRCC”) recently. This is the first pivotal study ever conducted in MET-driven PRCC and the first molecularly selected trial in renal cell carcinoma worldwide, and also the first innovative anti-cancer drug candidate, discovered in China, entering a global pivotal registration trial to date. Savolitinib has the potential to become a blockbuster drug for global market, which could set a landmark in the history of Chinese innovation for drug R&D. Moreover, the novel drug fruquintinib, discovered independently by HMP and being co-developed with Eli Lilly, convincingly met all primary and secondary endpoints in its Phase III pivotal study for advanced colorectal cancer, and showed best-in-class potential. The NDA submission to CFDA has been completed and is pending for approval. We believe that the launch of fruquintinib will not only transform HMP into a biopharmaceutical company with commercial products, but also offer the Chinese cancer patients a choice for better treatments.

苏州康宁杰瑞生物科技有限公司

Suzhou Alphamab Co., Ltd.

苏州康宁杰瑞生物科技有限公司是从事生物大分子药物研发的生物技术制药公司，由国家千人计划特聘专家徐霆博士于2009 年归国创建。

至目前为止公司已累计投入研发经费4 亿多人民币，拥有6000 余平方米的专业实验室与符cGMP标准的中试车间。建立了从大分子药物的早期筛选、工程化、细胞株构建、工艺开发、质量研究到临床试验及申报注册的完整研发功能链，产品涵盖肿瘤、抗凝、不孕不育及重大传染性疾病诸领域。

公司建立了拥有自主知识产权的多个技术平台， 其中包括蛋白质工程及单域抗体、双特异性抗体、混合抗体生产平台。提出技术及产品专利50余项 ，获授权6项， 进入PCT 阶段的9 项，其中三个专利已经获得国际专利授权。目前共有8 个新药申报临床，其中一类新药长效卵泡刺激素、国内首个PDL1 单域抗体和Nulojix生物类似药已获批进入临床研究。

康宁杰瑞在立足自主研发的同时还积极开展与外界的科研协作，建立起开放共赢的研发模式。通过与包括芝加哥大学，哈佛大学、中科院以及东南大学、上海交大、浙江大学等著名学府及机科研机构的合作来培养人才及提升自身的研发能力。公司成立有江苏省研究生及博士后工作站；与东南大学成立校企共建技术中心；与美国Thermo Fisher公司合作建立技术平台。

同时我们也正着力推动研发品种的产业化进程。总投资二十亿元、位于苏州工业园区核心地带的康宁杰瑞江苏产业化基地的建设已经启动，一期工程预计将建成具有12000升能力的多个大分子药物生产线，以期在不久的将来实现在研产品的工业化生产。

我们期待通过研发及产业化体系的不断建设和持续创新，将康宁杰瑞打造成国内领先、国际一流的创新型、综合性、国际化大型生物制药企业。为国内患者同步提供可获得的、国际领先的先进治疗药物，从而满足临床需求、造福社会。

Suzhou Alphamab Co., Ltd. is a clinical-stage innovative biotech based in BioBAY China.

Founded in 2009, Alphamabis a leading biotechnology company focusing on the discovery, development and manufacture of innovative biologics therapeutics. With multiple in-house proprietary platforms, includingantibody screening, bi-specifics, mix-mAb production, protein engineering, and CMC development, Alphamab and its subsidiaries have developed a robust pipeline of over 20 innovative biologics programs in immune-oncology, infertility, infectious diseases and several other areas, such as KN035 PD-L1 domain antibody (the first subcu PD-L1/PD-1 mAb) under clinical development in the US and China, and the best-in-class long-acting FSH in phase I.

Alphamab is striving to develop 1st-in-class or best-in-class biologics medicine to address unmet medical needs globally.

基石药业（苏州）有限公司

CStone Pharmaceuticals Co., Ltd.

基石药业是一家总部设于中国苏州，以创新药研发为驱动的生物制药公司，致力于肿瘤免疫药物的开发，拥有丰富的产品线。公司于2016年7月完成A轮融资，共募集到1.5亿美元（约9.75亿人民币）资金，由三家颇具声望的投资公司参与，分别是元禾原点、博裕资本及毓承资本。

公司的领导团队均来自国际知名药企管理层，已成功构建起以临床研发和转化医学为核心竞争力的团队，并且将以国际标准开展高质量的临床研究。特别是在广受瞩目的肿瘤治疗领域，基石药 业以其出色的肿瘤免疫药物为核心，凭借其世界级的研发团队，最前沿的药物研发项目， 以及开放式创新的策略有望引领国内新药研发行业走向全球， 并成为跨国药企与国际生物制药公司在中国以及亚太地区进行产品共同开发的最佳合作伙伴。

公司重组抗PD-L1全人源单克隆抗体注射液CS1001于2017年6月27日获得国家食品药品监督管理总局（CFDA）颁发的临床试验批件，标志着我国首个自然全长、全人源抗PD-L1单克隆抗体成功进入临床研究开发阶段。这是公司发展的重要里程碑，并为基石药业后续进行具有开创性的，以PD-L1为骨架的多种联合治疗开发奠定了坚实的基础. 目前，全球已有五个PD-1/PD-L1新药获得批准上市，涉及10余种适应症，中国尚无同类产品成功开发上市。基石药业独立开发的CS1001未来有望满足中国患者对此类药物的迫切需求。

CStone Pharmaceuticals, headquartered in Suzhou, is a biopharmaceutical company devoted to the development of a new generation of innovative drugs. CStone has a rich oncology pipeline with a strategic focus on immuno-oncology. In July of 2016, CStone Pharmaceuticals announced the completion of its $150 million Series A financing, led by three prestigious VC/PE funds: Oriza Seed Venture Capital, Boyu Capital and WuXi Healthcare Ventures.

All members of the management team are seasoned executives from top multinational pharmaceutical companies. CStone has successfully built up an industry leading team with clinical development and translational medicine as its core competence. This enables CStone to accelerate the drug approval timeline while applying global standard practices to ensure clinical trial quality. The unique advantages in pipeline, clinical development, and funding also positions CStone as the partner of choice for multinational pharmaceutical / biotech companies to develop drugs in China and the Asia Pacific region.

CStone received Clinical Trial Application (CTA) approval from the China Food and Drug Administration (CFDA) on June 27th, 2017 for its investigational agent CS1001. This is China's first fully human, full-length anti-PD-L1 monoclonal antibody to successfully enter the clinical development stage. This event is a significant milestone for the company, which lays a solid foundation for subsequent development of multiple combination therapies using anti-PD-L1 as the backbone treatment. Currently, five anti-PD-1/PD-L1 drugs are approved by the U.S. FDA in more than 10 indications, but none has been approved in China. As such, CStone’s CS1001 has the potential to address the urgent needs of Chinese patients for this class of drugs.

上海药明巨诺生物科技有限公司

JW Therapeutics (Shanghai) Co., Ltd.

上海药明巨诺生物科技有限公司成立于2016年2月，是以科技创新为先导的细胞免疫治疗公司，拥有一支在全球制药企业和研发机构富有经验的顶尖创业团队。公司致力于研发，转化及应用领先的精准细胞免疫疗法，并引进了全球公认的肿瘤细胞免疫治疗领军企业 Juno Therapeutics的核心技术（Juno是纳斯达克上市公司，也是当前全球研发储备最深厚，研发进度最为领先的行业内翘楚），并在中国最大的药物研发服务企业药明康德全力支持下，建立起的一家独立的立足于中国，世界一流,中国领先的细胞治疗公司，服务于中国肿瘤患者，成为中国和世界细胞治疗领域的领导者。

药明巨诺依托国际化的技术资源和团队的多年积累，发挥中国优势，力争在中国做出具有全球影响力的世界级创新。我们也希望与中国和世界各地合作伙伴展开多种形式的合作，为肿瘤患者带来更多变革性的治疗解决方案。

李怡平(James Li)先生担任药明巨诺公司首席执行官，李先生是药明巨诺联合创始人，之前曾担任凯鹏华盈合伙人以及安进中国公司总经理。李革博士担任药明巨诺公司董事长，公司董事会成员包括李怡平先生，Hans Bishop先生 （Juno CEO），Steve Harr先生 (Juno CFO)，以及药明康德首席财务官兼首席投资官胡正国先生。

Established in Feb 2016, JW Therapeutics (Shanghai) Co, Ltd. is an innovation driven cellular immunotherapy company, led by a group of industry veteran with extensive global bio-pharmaceutical and R&D experiences. Supported by the R&D and technology from Juno Therapeutics (a NASDAQ listed global leader in the field) and the expertise of Wuxi Aptec (the largest bio-pharma CRO/CMO in China), the company aims to become a leader in the immune-cell therapy field in China and globally, focusing on research, translational, development, quality manufacturing, and commercializing of the best cell therapy solutions for the Chinese patients.

JW Therapeutics will capitalize on its global R&D assets and intellectual resources, leverage the unique opportunities in China, and become a global innovator and leader in the immune-cell therapeutics space. We are open to collaboration and partnership opportunities in China and globally to provide the transformative therapeutic solutions to patients.

Mr. James Li is the CEO and co-founder of JW Therapeutics; previously he was a partner of KPCB China and General Manager of Amgen China. The board of directors includes Dr. Li Ge (Chairman, Chairman & CEO of Wuxi), James Li, Hans Bishop (Juno CEO), Steve Harr (Juno CFO), and Ed Hu (Wuxi CFO).

北京加科思新药研发有限公司

Beijing Jacobio Pharma Co., Ltd.

北京加科思新药研发有限公司成立于2015年，是一家致力于创新药物研发的高新技术企业。注册资本金1.6亿元，由王印祥博士、胡邵京博士、王晓洁女士、周文来博士等组成的留美海归博士团队领军，他们具有数十年的新药创制和研发管理实践经验，在中国有数个有影响力的创新药上市。

公司位于开发区生物医药园5号楼，拥有4000平米实验室，下设合成、分析、制剂、药理、QA、注册、医学等专业功能平台，拥有顶尖的科研团队。

由加科思所管理的创新引导基金-屹唐加科思基金，首期规模2亿元，定位于天使投资，全部投资于加科思新药研发助推器遴选出的项目公司以及部分开发区内新药研发的初创企业。

加科思致力于为重大疾病治疗提供突破性创新产品，公司的内部研发专注于小分子肿瘤免疫和分子靶向药物研发。同时，加科思建立“平台+基金”的“捆绑式创新工场”模式拓展外部研发，吸引海外科学家带着有开发潜力的项目回国创业，致力于成为新药研发创业者的助推器，发掘并帮助创业者在北京亦庄创业并成长为细分领域内的行业标杆乃至全球具有影响力的生物医药企业。

Beijing Jacobio Pharma Co., Ltd, founded in 2015, is dedicated to innovative drug discovery and development. The registered capital of 160 million yuan, by the United States Dr. team leader, Such as Dr. Wang Yinxiang, Dr. Hu Shaojing, Ms.Wang Xiaojie and Dr Zhou Wenlai. they have decades of drug discovery research and management experience, in China several influential listed drug innovation.

Jacobio is located in Beijing Yizhuang Biomedical Park, with 4000 square meters of experimental buildings, under the synthesis, analysis, preparation, pharmacology, QA, registration, medical and other professional function platform, with the top team.

By the management of Jacobio about innovation guide capital–ET-Jacobio Capital, the first phase of the scale of 200 million yuan, aimed in angel investment.The total investment Jacobio drug development boosters selected item company as well as part of the development zone of new drug research and development of start-ups.

Jacobiois committed to providing groundbreaking innovative products for the treatment of major diseases, the company's internal research and development focus on small molecular tumor immunology and molecular targeted drug research and development. At the same time, the establishment of Jacobio’s “platform+fund” “bundled Innovation workshop” model to expand the external development, attract overseas scientists with potential for the development of the project Returning to business, is committed to become a booster for new drug research and development of entrepreneurs, to explore and to help entrepreneurs in BDA and grow to the benchmark and the world influential biological medicine business segments within the industry.

北京诺诚健华医药科技有限公司

Beijing InnoCare Pharma Tech Co., Ltd.

诺诚健华是一家植根于中国且具全球视野的新药创制公司。公司的核心团队都具有丰富的新药研发经验，曾成功开发出超过100个新药专利和候选新药。公司的科学顾问委员会由来自清华、北大的生命科学带头人、跨国公司新药研发专家以及国内顶尖医院的医疗专家组成。他们与公司的研发团队一起，构成公司的核心竞争力。

面对在中国发病率居高不下且缺乏有效治疗的肝癌、胃癌及类风湿关节炎、系统性红斑狼疮等自身免疫疾病，诺诚健华自创立之日起，就把“利用最新的科学技术与发现驱动新药研发，提供患者治疗所需的新药，为改善公众健康而努力”作为自己的使命。为达成这一使命，我们专注于国际一类新药与新技术产品开发，通过“自主研发、外部引进与国际合作”等途径，有效整合各方资源并加快新药研究在中国从实验室到医院的进程，在帮助中国患者尽早用到国际一类新药的同时，把公司打造成国内外生物医药行业的领军企业。

InnoCare is a biopharmaceutical company rooted in China with the global vision to discover and develop novel treatment for cancer and autoimmune diseases. InnoCare' s core scientific team members have strong educational backgrounds and rich drug innovation experiences in the U.S. and China. InnoCare also has an elite Scientific Advisory Board (SAB) comprising of professionals from leading universities, hospitals, academic institutions and pharmaceutical industry. InnoCare is forging forward on the critical path of defeating diseases and pushing the boundaries of innovation into unchartered territories.

The mission of InnoCare is to become a global leader in providing patients with safe, effective and affordable treatments to address the unmet medical needs in cancer and autoimmune diseases. We pay special attention in targeting Chinese populations because of their high incidence rates yet insufficient effective treatments or cures for diseases such as liver cancer, gastrointestinal cancer, and autoimmune diseases including lupus and rheumatoid arthritis. To achieve our goal, we have employed numerous synergistic approaches including internal research and development, licensing-in, and international collaborations to accelerate the development process of the First-and/or Best-in-Class drugs.

百济神州（北京）生物科技有限公司

BeiGene (Beijing) Co., Ltd.

百济神州是一家根基于中国，走向全球布局的生物制药公司，由美国科学院院士及中国科学院外籍院士王晓东院士，联合美国资深创业家欧雷强先生共同创立。我们致力于成为具有创新性的分子靶向与免疫抗肿瘤药物研发领域领导者。我们相信，下一代癌症治疗方法将同时着重单一制剂和联合疗法的开发，从根本上冲击癌细胞生长和存活的多重机制。

我们拥有四个完全自主研发且获得临床概念验证的在研新药，每个均显示出潜在差异化特性。

BGB-3111是一种在研的小分子布鲁顿酪氨酸激酶(BTK) 抑制剂。与目前唯一通过美国食品和药物管理局（FDA）和欧洲药品管理局（EMA）批准的BTK抑制剂Ibrutinib相比，BGB-3111在生化试验中表现出对于BTK更高的选择性，二者I期报告的数据比较，BGB-3111显示了更高的药物暴露量，也对血液和淋巴结中靶点显示了完全的、24小时的持续抑制效果。

BGB-A317是一种针对免疫检查点受体PD-1的人源化单克隆抗体。BGB-A317 与目前获批的 PD-1 抗体不同，通过生物工程技术，去除了和 Fc g受体 I的结合能力，并通过抑制 PD-1、解除免疫系统的激活障碍，恢复 T 细胞的肿瘤杀伤能力。BGB-A317正在开发作为单一疗法以及与其它治疗组合的疗法用以治疗实体瘤和血液系统恶性疾病。百济神州与新基公司在BGB-A317的实体瘤领域存在全球战略合作关系。

BGB-290是一种强效的高选择性PARP1及PARP2抑制剂，在临床前模型中展现了例如血脑屏障穿透和PARP-DNA复合体捕获等药理特性。BGB-290正在作为单药疗法及组合疗法在各种实体恶性瘤中进行临床开发。

BGB-283由百济神州科学家发现，作为一种新型RAF抑制剂，具有独特的RAF二聚体和EGFR抑制活性。BGB-283在临床前模型和癌症患者中均显示有抗肿瘤活性，不仅对BRAF-V600E突变的肿瘤有活性，对非V600E-BRAF突变和KRAS/NRAS突变的肿瘤也有活性。

我们拥有由超过400名员工和顾问组成的全球团队，其中包括超过200名科学家及临床医学专家。他们具有深入科学知识、广泛制药经验，并致力于提高全球癌症患者生活。我们在全球多地设有办公地点和设施，包括位于美国加州三藩市的全球临床总部（分设于Emeryville和San Mateo），在澳大利亚、新西兰、北京及上海的临床开发团队，在北京建立的研发中心，在苏州、广州设有的生产基地，以及在美国波士顿和北京设有的营运部门。

BeiGene is a China-based, globally focused biopharmaceutical company, co-founded by Member of United States National Academy of Sciences, Foreign Member of the Chinese Academy of Science Dr. Xiaodong Wang and senior American entrepreneur Mr. John Oyler. BeiGene is dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer. We believe the next generation of cancer treatment will utilize therapeutics both as monotherapy and in combination to attack multiple underlying mechanisms of cancer cell growth and survival.

We have four internally developed assets, each with demonstrated proof-of-concept and a potentially differentiated profile.

BGB-3111 is a potent and highly selective investigational small molecule inhibitor of BTK (Bruton's Tyrosine Kinase). BGB-3111 has demonstrated higher selectivity against BTK than ibrutinib (the only BTK inhibitor currently approved by the U.S. Food and Drug Administration and the European Medicines Agency) based on biochemical assays, higher exposure than ibrutinib based on their respective Phase I experience, and sustained 24-hour BTK occupancy in both the blood and the lymph node.

BGB-A317 is a humanized monoclonal antibody against the immune checkpoint receptor PD-1. It is believed to be differentiated from the currently approved PD-1 antibodies with the ability to bind Fc gamma receptor I specifically engineered out, and has the potential to restore a T-cell's cancer killing ability by inhibiting PD-1 and removing the blockade of immune activation against cancer. BGB-A317 is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. BeiGene and Celgene have entered into a global strategic collaboration on BGB-A317 for solid tumors.

BGB-290 is a potent and highly selective inhibitor of PARP1 and PARP2 with brain penetration and PARP–DNA complex trapping for improved cytotoxicity. BGB-290 is being developed as a monotherapy and in combination with other agents for a variety of solid tumor malignancies.

Discovered by BeiGene scientists, BGB-283 is a novel RAF inhibitor with unique RAF dimer and EGFR inhibition activities. BGB-283 has shown antitumor activities in preclinical models and in cancer patients not only in tumors with BRAF V600E mutations but also those with non-V600E BRAF mutations and KRAS/NRAS mutations.

We have a global team of 400+ employees and consultants, including more than 200 talented scientists and clinicians, with deep scientific knowledge, extensive pharmaceutical experience, and a commitment to improving the lives of cancer patients globally. We have offices and facilities established around the world, including global clinical headquarter in San Francisco (Emeryville and San Mateo) and additional clinical facilities in Australia, Beijing, and Shanghai, R&D center in Beijing, manufacturing sites in Suzhou and Guangzhou, and operations in Boston and Beijing.

前沿生物药业（南京）股份有限公司

Frontier Biotechnologies Inc.

前沿生物药业（南京）股份有限公司（前沿生物）由海归“千人计划”专家创立于2002年，是一家立足中国、面向全球，在抗病毒及长效制剂领域，具有核心国际竞争力的生物医药企业。致力于研究、生产、商业化针对未满足的重大临床需求的创新药物。历经十几年的磨砺与积累，建立了一支具有国内外药品开发经验的优秀团队，拥有全球自主知识产权的长效多肽药物开发平台和多个原创在研产品。

主研产品艾博卫泰是全球艾滋病治疗领域首个长效新药，拥有全球自主知识产权。该药由前沿生物潜心耕耘15年，填补了中国在抗艾药研发领域的空白。目前Ⅲ期临床试验已提前达到主要终点指标，已于5月提交新药申请，并获药审中心提供绿色通道，给予快速审评。

重磅级产品3BNC117，为全人源广谱高效中和性HIV抗体，由美国洛克菲勒大学顶级科研成果，前沿生物授权引进。公司计划将艾博卫泰与3BNC117联合使用，组成拥有全新作用机制的两种长效药物全注射配方，为全球首个长效抗艾配方，将颠覆性的改变艾滋病治疗模式。

另一主打产品AB001为第三代新型透皮贴片制剂，用于治疗急性和慢性骨骼、肌肉、关节疼痛，为中国首创，将打破中国非甾体抗炎药贴片剂的治疗格局、安全有效，使用方便，市场潜力巨大。

在自主研发项目的同时，前沿生物不断寻求机会，与业界领先的科研机构合作，加速创新药物的研发，通过授权和收购等形式增强产品线，为医生和患者提供多元化的治疗选择。在未来，前沿生物药业将尽心竭力，为中国及世界医药事业的发展做出贡献。

Frontier Biotech is a research-based, clinical stage pharmaceutical company founded in 2002 by a group of Returnees. We are dedicated in the discovery, development and commercialization of innovative therapeutic products for unmet medical needs and under-served patients.The management team have extensive business and development experiences in the US and China pharma/biotech industry. Frontier Biotech leverages China's large patient population, and rapid growing economy and pharmaceutical market, develops innovative pharmaceutical products with worldwide IP protection and to be marketed in the near future.

Our lead product candidate, Albuvirtide, is a treatment-paradigm shifting long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. An NDA was accepted by Chinese FDA in July 2016 and selected for priority review. Albuvirtide could become the first long-acting anti-HIV new drug worldwide.

Another blockbuster candidate, 3BNC117, is a novel broad-spectrum high-potent HIV neutralizing antibody. It was discovered and developed by The Rockefeller University and licensed by Frontier. Combining 3BNC117 with albuvirtide, we will form an all-injectable, long-acting, two-drug regimen that has novel mechanism of action for the treatment and prophylaxis of HIV infection and AIDS.

A third candidate, AB001, is designed as a best-in-class topical patch product for the treatment of acute and chronic muscle and joint pain and inflammation. It's a third-generation patch product with patent-protected and non-hydrogel based matrix formulation for superior skin penetration and tissue permeability, anti-inflammation and pain relief potency.

Frontier Biotech has built up its product pipeline through internal discovery and in-licensed drug candidates. Collaborating with top research institutes, Frontier Biotech will expedite innovative drug discovery and development to provide differentiated therapies for patients in need.

珐博进（中国）医药技术开发有限公司

FibroGen (China) Medical Technology Development Co., Ltd.

珐博进（中国）医药技术开发有限公司（“珐博进（中国）”）是一家于2011年在北京经济技术开发区成立的生物医药科技公司，致力于研发创新性生物技术、化学药品，以解决中国患者亟需满足的临床需求。目前，珐博进（中国）注册资本为1.5亿元，投资总额4.5亿元，现有员工90人。

目前，珐博进（中国）的在研产品包括的在研产品包括用于治疗慢性肾病相关贫血的罗沙司他和用于治疗因角膜功能障碍引起的视力缺陷的创新医疗器械生物合成角膜。

罗沙司他是具有全新作用机制的1类创新药。珐博进（中国）计划2017年下半年完成罗沙司他在中国开展的治疗慢性肾病患者相关贫血的两项III期临床试验并提交上市申请。罗沙司他有望成为首个口服治疗、无需注射、无需静脉铁剂补充的抗贫血新药，为中国数百万慢性肾病贫血患者提供革命性的创新疗法。

生物合成角膜是一种基于全新生物材料制作的创新型III类医疗器械，具有国际领先水平，是以高纯度生物合成人胶原蛋白制成的透明生物合成角膜，有望通过再生医学的原理置换眼角膜，治疗因角膜功能障碍引起的视力缺陷。

珐博进（中国）在北京经济技术开发区投资建设了高水准的中试研发基地，于2014年取得《药品生产许可证》，并以卓越的研发实力被先后评定为“中关村高新技术企业”、“北京市级企业科技研究开发机构”和“北京生物医药产业跨越发展工程（G20工程）- 后备企业”。

珐博进（中国）在上海和河北沧州设有分公司，上海分公司主要开展临床研究和医学事务活动，沧州分公司正在建设的原料药工厂，投产后将为北京的罗沙司他制剂工厂供应原料药。

FibroGen (China) Medical Technology Development Co., Ltd. (“FibroGen China”), a biopharmaceutical company established in Beijing Economic Technology Development Area (“BDA”), Beijing in 2011, is committed to researching and developing innovative drugs to address urgent unmet medical needs for patients in China. As of August 31, 2017, FibroGen China had a registered capital of RMB 150 million, a total investment amount of RMB 450 million, and 90 employees.

Currently, FibroGen China has two product candidates under development, including Roxadustat for the treatment of anemia in chronic kidney disease (“CKD”) patients, and biosynthetic cornea for the treatment of visual impairment caused by corneal dysfunction.

Roxadustat is a Class 1 innovative drug with a novel mechanism of action. FibroGen China plans to complete two phase III clinical trials of Roxadustat for the treatment of CKD anemia in China and file a new drug application in the second half of 2017. Roxadustat is expected to be the first oral anemia therapy that does not require injection or IV iron supplementation, offering millions of CKD anemia patients in China with a revolutionary novel therapy.

The biosynthetic cornea is an internationally advanced Class III innovative medical device based on a type of novel biomaterial. This transparent biosynthetic cornea is made of high-purity biosynthetic human collagen, and intended to treat visual impairment caused by corneal dysfunction by replacing human corneal tissues based on regenerative medicine.

FibroGen China invested in and built an advanced pilot plant in BDA that has been granted the Pharmaceutical Production Permit in 2014. Due to its significant R&D capabilities, FibroGen China has been recognized as a “ZhongGuanCun High-tech Enterprise”, a “Beijing Municipal Enterprise Technology Research and Development Institute” and a “Reserve Enterprise of the Beijing Leap-Forward Development Program (G20 Program) for Biopharmaceutical Industry”, successively.

FibroGen China has established branch offices in Shanghai and Cangzhou, Hebei Province. Shanghai branch mainly carries out activities in relation to the clinical development and medical affairs, whereas the Cangzhou branch is building out an active pharmaceutical ingredients (“API”) plant to supply API to FibroGen China’s Roxadustat drug production facility located in Beijing.

荣昌生物制药（烟台）有限公司

RemeGen, Ltd.

荣昌生物制药（烟台）有限公司由荣昌制药与房健民教授于2008年7月共同发起创办。公司专注于生物药物的研发及产业化，拥有国际水平的研发和运营管理团队，配备多规格的全球最先进的可弃式生物反应器及相关的纯化、制剂设备，具有符合欧美及中国GMP管理标准的生产、物控、质量、项目、验证等管理体系，确保实验室和生产车间严格按照美国FDA、欧盟EMA、中国CFDA的GMP要求建设和运营。

荣昌生物自成立以来，针对自身免疫及恶性肿瘤等人类重大疾病，先后自主研发了抗体融合蛋白药物“RC18”，双靶标抗体融合蛋白药物“RC28-E”、“RC28-T”，抗体-药物偶联（ADC）新药“RC48”等创新生物药物，这些新药上市后将给无数患者带来新的希望。

系统性红斑狼疮、类风湿性关节炎、干燥症、视神经脊髓炎、多发性硬化症等自身免疫疾病是威胁人类健康的严重疾病，传统治疗手段无法满足病人的需要。荣昌生物研发的“RC18”是攻克这一类顽疾的“新型武器”，已经进行到Ⅲ期临床研究阶段，预期在2019年取得新药证书。“RC18”具有自主知识产权，药物分子结构获得全球专利保护。

在癌症治疗领域，荣昌生物研发出了抗体-药物偶联（ADC）新药“RC48”，用于治疗Her2过度表达的胃癌、乳腺癌、肺癌、卵巢癌、膀胱癌等多种癌症。“RC48”通过“精确制导”直达癌细胞内部，达到治疗肿瘤的目的，是我国首个进入临床研究的ADC新药，现已展开Ⅱ期临床，预期2019年取得新药证书。

荣昌生物的研发管线中还有多个具备自主知识产权的生物一类新药，承担国家“863”和重大新药专项10余个。荣昌生物将“用科学提高生命质量”作为自己神圣的使命，放眼全球，在技术、人才、产品、服务、管理等方面不断提高竞争力，在自身免疫疾病、肿瘤等疾病领域持续保持领先优势，通过各种形式和途径为全球客户提供技术、产品和服务，为人类的健康事业做出贡献。

RemeGen., Ltd. (hereinafter referred to as “RemeGen”) was founded by Rongchang Pharmaceutical Manufacturing Co. and Dr. Fang Jianmin in July, 2008. Company focused on the R&D and industrialization of biological drugs, with the international level of research and development and operating management team, equipped with many specifications of the world's most advanced disposable bioreactor and related equipment of purification and filling, has production, material control, quality, project, validation, etc. management system in accordance with EU, US and Chinese GMP management standards, to ensure that the laboratory and production workshops strictly comply with GMP requirements of US FDA, EU EMA and Chinese CFDA to construct and operate.

Since the company’s establishment, has focused on autoimmunity and malignant tumor and so on the major human diseases, has independently researched and developed the “RC18” antibody fusion protein, dual-targeting antibody fusion protein “RC28–E” and “RC28–T”, antibody–conjugate (ADC) “RC48”, etc. innovative biological drugs, these new drugs will bring new hopes to millions of patients after marketing.

Systemic lupus erythematosus, rheumatoid arthritis, xerosis, optic myelitis, multiple sclerosis, etc. autoimmune diseases are serious threats to human health, and traditional treatments cannot satisfy the patients’ needs. “RC18” that researched and developed by RemeGen is a “new weapon” for conquering this kind of diseases, has been underway to Ⅲ period clinical phase, expected to obtain new drug certificate in 2019. “RC18” has proprietary intellectual property rights and its drug molecular structure is protected by global patent.

In the field of cancer therapy, RemeGen developed antibody–conjugate (ADC) “RC48”, is used to treat Her2 excessive expression of gastric cancer, breast cancer, lung cancer, ovarian cancer, bladder cancer and other cancers. “RC48” through “Precision Guidance” straight to the inside of cancer cells, in order to treat tumor, it is China's first ADC new drug that went into the clinical research, has begun Ⅱ period clinical, expected to obtain new drug certificate in 2019.

There are multiple first-class new drugs with proprietary intellectual property rights in the development pipeline of RemeGen, and more than 10 national “863” and major new drugs projects. “Science enhances the quality of life” is the mission of RemeGen, to think globally, to improve competitiveness in technology, personnel, products, services, management, etc. aspects, to continue to lead in the field of autoimmune diseases, cancer and other diseases, through various forms and channels to provide technology, products and services for global customers, and to contribute to human health.

北京泛生子基因科技有限公司

Genetron Health (Beijing) Co., Ltd.

泛生子基因科技有限公司是世界领先的精准医疗专家，致力于以覆盖癌症全周期诊疗各个环节（风险评估、早期筛查、分子病理诊断、用药指导和预后监测）的健康管理产品，将基因组学有效应用，协助医疗专家、科研机构等，为癌症患者、癌症高危人群及健康人群，提供可靠的分子诊疗方案、专业的癌症遗传风险评估。

自2013年成立以来，泛生子已成立了美国北卡、中国北京双研发中心，并先后在北京、上海、杭州、重庆建成了总面积超过10,000平米的临床医学检验中心，同时，泛生子建成国际上最先进、全面、多元的检测平台，具有自主知识产权信息分析软件的世界级生物信息分析平台，符合美国病理学家协会（CAP）等最高要求标准的临床样本处理平台。

泛生子聚焦癌症精准医疗，与美国最权威的两大癌症研究中心——杜克大学和约翰霍普金斯大学，建立长期合作伙伴关系，并拥有来自世界顶级大学和科研机构的专家团队，学术背景覆盖癌症遗传学、癌症基因组学、生物信息学、药理学、临床病理等多领域，凭借多年科研工作经验和转化医学开发经验保障企业核心科研实力。

根据中国市场特点，泛生子确立了服务与产品并驾齐驱的业务模式，业务范围现已覆盖全国数百家科研机构和临床医院，并与上下游产业积极联动。

未来，泛生子将继续以自身强大的癌症基因组学基础和高效的临床转化能力，专注科学研究、技术创新、产品服务，持续拓展产品销售网络，联通整合上下游产业资源，以最科学、最专业、最个性化的服务和产品，成为行业发展的驱动力。

As a world-leading expert in precision medicine, Genetron Health is committed to developing health management products that cover all elements of full-cycle cancer clinical treatment (including risk assessment, early screening, molecular pathology diagnosis, medication guidance and prognosis monitoring) and effectively applying genomics to assist medical experts and research scientists to provide cancer patients, high-risk and healthy individuals with reliable molecular clinical services and professional cancer genetic risk assessment.

Since its establishment in 2013, Genetron Health has set up joint research and development centers in Beijing, China and North Carolina, USA, building clinical medicine testing centers successively in Beijing, Shanghai, Hangzhou, and Chongqing, with overall 10,000 square meters areas. In the meanwhile, with world's most advanced, most comprehensive and most diverse testing platform, Genetron Health develops world-class bioinformatic analysis platform that has information analysis software with independent intellectual property rights, and clinical samples processing platform that meets the highest requirements and standards of College of American Pathologists (CAP).

Genetron Health focuses on cancer precision medicine, establishing a long-term partnership with two most authoritative cancer research centers in the United States, namely Duke University and Johns Hopkins University, having teams of experts from top universities and scientific research institutions all over the world, covering many academic fields including cancer genetics, cancer genomics, bioinformatics, pharmacology, and clinical pathology. The company secures its core scientific research strength by its years of scientific research experience and translational medicine developing experience.

Based on the features of Chinese market, Genetron Health has established a business model of developing services and products at the same time, with diverse business scope covering hundreds of scientific research institutions and clinical hospitals nationwide, and actively cooperating with upstream and downstream firms.

In the future, on the basis of its own strong background in cancer genomics and efficient clinical and translational abilities, Genetron Health will continue to focus on scientific research, technological innovation, and product service, expanding products sales network, cooperating with and integrating industrial resources of upstream and downstream firms, becoming the driving force of the industry's development with the most scientific, professional, and personalized services and products.

赛生医药江苏有限公司

SciClone Pharmaceuticals (Jiangsu) Company., Ltd.

赛生医药江苏有限公司（下称“公司”）系由美国赛生药业公司（SciClone Pharmaceuticals, Inc.,下称“美国赛生”）全资所属管理型公司——赛生医药（中国）有限公司初期投资人民币4500万元（注册资本人民币3000万元）设立的内资企业。

公司是一家以中国为中心的专业制药公司。赛生的产品进入中国超过20年，具有相当的商业规模和国际业务。旗舰产品日达仙®（胸腺法新或胸腺肽阿尔法1）在中国免疫调节剂市场份额超40%，长期占领导地位，是中国进口量最大的药物之一，2003年被列为国家储备药。除自研药物外，赛生还通过海外合作将大量国际领先药物、医疗器械引入中国。2014年8月，治疗肝癌的新型产品 DC Bead®经国家食品药品监督管理总局注册并已上市。预计在2020至2023年，我公司将有3个三类新药（Loramyc, Angiomax, Cleviprex）和1个一类新药（PT-112抗肿瘤药）在中国上市。

在研发方面，我公司拥有一支专业的研发团队，致力于抗肿瘤领域1.1类国产新药的研发。目前已有数个在研项目，其中一个已经进入CFDA的IND程序。

2015年9月24日，我公司注册成立。于2016年3月22日取得了《药品经营许可证》，并于2016年8月3日取得了《药品经营质量管理规范》认证证书。

公司的经营范围为药品研发、批发，医疗器械销售等。公司现有员工78人，设有质量部、采购部、销售部、人事行政部、财务部5个部门。注册地址为泰州市药城大道1号科技大厦502、503室，办公面积253.5平方米。

公司组织架构健全，人员配备齐全，制定了质量管理制度、操作规程，岗位职责等质量体系文件，能够满足药品研发，销售等质量管理的需求。

SciClone Pharmaceuticals (Jiangsu) Company Limited (hereinafter referred as “Our Company”) is a local company invested by SciClone Pharmaceuticals (China) Co. Limited. The registration capital is 30 million RMB.

Our company is a China focused specialty pharmaceutical company. SciClone’s products have been listed in China market for more than 20 years and are widely accepted by the local market. Our flagship product Zadaxin® (Thymofalsin or Thymosin α1) covers 40% market share in the China immunomodulatory market. It is also one of the largest imported products in China which was listed as “national reserve drug” in 2003. On top of the in-house development programs, SciClone also works with overseas companies to introduce the world-leading drugs and medical devices into China. Back in Aug 2014, our innovative medical device “DC Bead® was approved by CFDA for treating HCC. It is estimated that, between 2020 to 2023, we will commercially launch another 3 Class III new drugs (Loramyc, Angiomax, Cleviprex) and 1 Class I new drug (PT-112).

On the research and development side, we have a specialized professional R&D team that focus on Class I anti-tumor drugs. We have several new drug development projects and one of them is now in the CFDA IND process.

Our company was registered on September 24, 2015 and obtained our “Drug Trading License” on March 22, 2016. We also received our GSP license on Aug 3, 2016.

Our business scope includes but not limited to drug development, drug and medical device selling. We have now a total of 78 employees. Our registered address is Suite 502 &503, 1 CMC avenue, Taizhou, Jiangsu Province, China.

Our company is fully compliant with local quality laws and regulations and is fully capable of conducting drug development and selling.

海捷投资控股集团

Hiyield Investment Holding Group

海捷投资控股集团是在长沙、上海设有公室的全国性投资机构，成立于2002年。公司业务涵盖风险和股权投资、上市及并购重组、定增与市值管理等多个领域。其中，管理人民币股权投资基金七支，分别为海捷先进装备产业基金（国家创业引导基金）、海捷津杉创投基金、海捷医药产业基金、海捷慕士创投基金、宁波智能产品创新发展基金、湘江新区产业基金和厦门时尚创意基金；公司还设立了新三板投资基金两支和海捷领投系列基金数支；股权投资基金管理规模168亿元人民币。

公司股权投资专注于新材料、高端装备、医疗健康、文娱体育、教育传媒及大数据等行业，创立以来共投资70多家企业，其中A股上市10家，香港上市5家，新三板挂牌10家（创新层3家），IPO在会审核1家。公司凭借精深的专业能力和在资本市场的良好关系，推动所投资企业达到业务发展，上市融合或并购重组之目的。

公司资产管理业务行业领先，先后参与了67家上市公司定向增发，累计管理定增基金145亿元人民币，管理资产规模创造了优异的业绩，树立了卓越的品牌。

公司九位资深合伙人在证券、投资及金融领域具有丰富的经验。自1996年始，作为中国证券业投资银行先行者之一，核心团队先后主持了三一重工、电广传媒、酒鬼酒、华数传媒、隆平高科、华天酒店、华帝股份、振华重工等超过30家上市公司的股改、发行、上市、再融资、重组等工作，深度参与了中国资本市场的变革与成长，见证了中国投资银行及上市公司的飞速发展。

公司在医疗/大健康产业先后发起设立有两只医疗产业基金，投资涉足 医药、医疗器械、移动医疗、精准医疗、医疗大数据等多个领域，在肿瘤、 精准医疗产业有深度布局，并与千山药机、尔康制药、云南白药等多家上市 公司等形成战略联盟，在产业培育、资产并购、市值管理等层面展开深度合作。

公司投资理念——时间见证诚信，专业创造价值。

Hiyield Investment Holding Group, found in 2002, is a national investment agency launched offices in Changsha and Shanghai.

The company's business covers a variety of capital models, including equity investments, mergers and acquisitions, IPO, capitalization. In charge of 7 RMB funds, respectively, the Hiyield Advanced Equipment Industrial Fund (National Fund for Entrepreneurship boot), Hiyield Jinshan Venture Capital Fund, Hiyield HealthCare Industrial Funds, Hiyield Mousse Venture Capital Funds, Hiyield New Materials Industrial Funds and series of Hiyield Leader Investing Founds. Until now, there is 16.8 billion RMB of assets under management.

Our funds primarily invested in those companies have excellent managementteams, in developing or have the potential to become the leaders of theindustries. Investment fields contain with TMT, consumption and culture, newmaterials, manufacturing and healthcare industry. So far our company has invested more than 70 enterprises, in which 10 have IPO in China A share market, 5 have IPO in Hong Kong stock market, 10 have listed in new third board market, 1 have IPO reviewed listing. Typically, those enterprises Hiyield invested in could get convenience in finance and management consulting from Hiyield Croup.

The company participated in 67 additional directions on public companies, the total asset in charge is 14.5 billion RMB, which created a good profit and brand reputation.

Our nine senior partners have extensive experience in securities, investment and finance. Since 1996, as one of China's securities industry pioneer Investment Bank, our core team has presided over 30 public companies, such as Sany Group. (600031), TV and Broadcast media Culture Development Co(000917), Jiu Gui Jiu (000799), Hua-Tian Hotel (000428), Vatti Corporation Ltd. (002035), Shanghai Zhenhua Heavy Industry Co. (600320) and so on.

In HealthCare Industry, we has initiated and established two HealthCare Industrial Investment Funds, investment involved in medicine, medical equipment, mobile healthcare, precision medical fields, medical big data,etc., especially in tumor and precision medical industry we programed plentyof potential startups. Meanwhile we has formed strategic alliances of public companies in healthcare industry, such as China Sun Pharmaceutical Machinery (300216), Er-Kang Pharmaceutial (200267), Yunnan Baiyao Group (000538),we has cooperated on industry incubation, asset acquisition and market value management.

Our investment idea–Time attest integrity, profession create value.

高瓴资本管理有限公司

Hillhouse Capital Management, Ltd.

高瓴资本集团是一家专注于长期结构性价值投资的公司，以其卓越的投资业绩在全球投资界享有盛誉。高瓴资本由张磊先生于2005年创立，经过十余年的发展，高瓴现已成为亚洲地区资产管理规模最大的基金之一，管理资金规模超过300亿美金。高瓴资本受托管理的资金主要来自于目光长远的全球性机构投资人，包括全球顶尖大学的捐赠基金、医疗基金会、主权财富基金、养老基金及家族基金等。

作为具有全球视野的长期价值投资者，高瓴资本始终坚持独立思考、深入研究，通过深刻理解行业和业务的发展规律，同时寻找具有伟大格局观的企业家，将长期资本投资于优质企业成长的关键阶段。投资之后，高瓴通过自身丰富的全球资源，协助企业不断提升战略及运营管理水平，从而帮助企业创造长期价值。

截至2016年底，高瓴资本的投资领域涵盖了生命健康、消费与零售、科技创新、金融、企业服务等行业。代表性的互联网和消费行业投资案例包括：腾讯、百度、京东、携程、Airbnb、Uber、美的、格力、百丽国际、普洛斯物流、中通快递、蓝月亮、滴滴出行、美团、蔚来汽车、孩子王、摩拜、Grabtaxi等。

生物医药和医疗健康领域始终是高瓴的重点战略投资方向。高瓴已经投资了一批国内外优质医药企业，其中包括：百济神州、药明康德、甘李药业、君实生物、信达生物、惠每医疗（梅奥在华合资公司）、Moderna等。

在创新药行业，高瓴立志成为全球优质企业的超长期合伙人，与被投资企业一起共担风险，共创价值。以百济神州为例子，高瓴在百济神州还未崭露头角的早期阶段就开始投资，参与了百济神州从成立以来的每一轮融资，是百济神州在中国唯一的全程投资人。从2014年的A轮，2015年的B轮，到2016年纳斯达克上市及之后的增发，高瓴是百济神州每一轮股权融资的主要投资人。并且，高瓴在投资之后将内部的研究和经验完全分享给百济神州，帮助公司在每一个关键时点做出最恰当的战略决策。

高瓴资本始终坚持长期价值投资理念，矢志不渝的为中国医药企业带来最优质的资本支持，并不遗余力地帮助企业家实现他们的梦想，共享成功！

Founded in 2005 by Mr. Zhang Lei, Hillhouse Capital Group is an investment firm focused on long-term opportunities backed by structural tailwinds. It is now one of the largest investment funds in Asia, with a global reputation and track record. The firm manages more than US$30 billion for long-sighted global institutional clients, including endowment funds for world-class universities, foundations, sovereign wealth funds, pensions and family offices.

As a value oriented investor with a global vision, Hillhouse relies on independent thinking and thorough research to pinpoint investable trends and look for entrepreneurs with strategic vision. We partner with and support good companies by channelling funds to where they are needed, when they are needed most. Drawing on the strengths of our global resources, proprietary research, and network of operating advisors, we also assist companies in creating long-term value by helping them optimize strategies and operations.

Hillhouse invests in areas such as healthcare, consumer, TMT, advanced manufacturing, financials and business services. As of mid-2017, Hillhouse has invested in many leading consumer and TMT companies. These include Tencent, Baidu, JD.com, Ctrip, Airbnb, Uber, Midea, Gree, Belle Int'l, GLP, ZTO, Blue Moon, Kidswant, Didi, Meituan, NIO, Mobike and Grabtaxi. In the healthcare and biotech sectors, a particular area of focus for Hillhouse, we have partnered with BeiGene, Wuxi AppTec, Ganlee, Junshi, Innovent, Huimei (JV with Mayo Clinic in China) and Moderna, amongst others.

In supporting industry-leading drug developers, Hillhouse is dedicated to sharing risks and creating value together with portfolio companies, with an aim of building long-term cooperative partnerships with exceptional entrepreneurs worldwide. In the case of BeiGene, a biopharmaceutical company focusing on immuno-oncology area, Hillhouse made its first investment to BeiGene well before it achieved industry-wide prominence, and provided it with steady capital support and resources throughout its entire journey. As a major investor in each and every one of BeiGene's funding rounds, Hillhouse participated in BeiGene's series A and series B funding in 2014 and 2015, its listing on the Nasdaq in 2016 and a follow up public placement. In addition to providing capital, Hillhouse also supports BeiGene by sharing its internal research insights and experiences to assist BeiGene with making crucial strategic decisions.

Adhering to the principles of long-term, value-oriented investment, Hillhouse is determined to bring the best funding support to pharmaceutical companies in China. We help entrepreneurs reach for their dreams and together travel the path to success.

上海醴泽投资管理有限公司

LYZZ Capital Advisors Management, Ltd.

上海醴泽投资管理有限公司（以下简称“醴泽资本”）是一家致力于中国医药健康产业投资的专业基金。由成功科学家、企业家等行业资深人士组成的投资团队，依靠企业管理经验和海内外行业资源为被投企业提供增值服务，力求通过中国医药创新为患者带来福音，同时努力让中国创新走向国际。

醴泽资本具有成功的人民币基金和外资基金管理经验，并拥有众多的优质项目投资和退出案例，成功投资过微芯生物、方恩医药、西安新通、诺康生物、天津赛诺、Neurelis等十余家医药行业创新型企业。同时通过增值服务，为企业引入行业优质资产和创新标的，从而实现共赢。

醴泽资本围绕中国市场对医药创新的渴求，在全球范围内选择优质标的，充分发挥投资与产业化的协同效应，并为投资标的提供多赢的退出方式。通过与国内外知名行业机构和企业合作，引进国际先进技术，结合国内实际情况进行开发，成为国际企业进中国和国内创新企业走出去的优选合作伙伴。同时拥有强大的海内外行业顾问团队参与被投企业的运营，从而为企业、投资人和基金创造价值，实现共赢。

LYZZ Capital Advisors is a leading healthcare-dedicated investment management firm in China. The LYZZ management team is composed of highly experienced scientific and medical professionals who’ve been senior executives in pharmaceutical and biotech companies, and have worked together for many years. They take pride in their ability to add value to their portfolio companies with their operational experience and global network, helping their portfolios to develop innovative medicines for unmet medical conditions, and become internationally recognized innovators.

The LYZZ Capital team has successful managed several USD and RMB funds with a strong portfolio of invested companies and excellent returns. They search for talents, assets and technologies globally, with an emphasis on unmet medical needs and market potential in China. Their partners include some of the top global pharma companies, leading Chinese pharma companies, global top venture firms and many prominent professional organizations.

Notable investments by the LYZZ team in pharmaceutical innovation include Shenzhen Chipscreen, Fountain Medical Development, China Nuokang Biopharma, Xi’an Xintong, Tianjin Sainuo, Neurelis, etc.

深圳市倚锋投资管理企业（有限合伙）

Efung Venture Capital Co., Ltd.

创立于20世纪末的倚锋，是我国第一批专业的创投机构。自2012年来专注于原创药及高端医疗器械的VC和PE投资业务。倚锋致力于以资本推动科技成果产业化，协助企业快速成长，并带给投资人丰厚回报。在逾十年的积累中，倚锋打造了专业的管理团队并建立了完备的风控策略，旨在用资本的力量带动并引领国内医疗健康产业，尤其是原创药及高端医疗器械领域的发展。

截止2017年7月，倚锋管理基金总规模逾10亿元，并于2017年5月获得了深圳市政府引导基金的注资。在团队的努力下，倚锋于2009年起连续获得了“深圳十佳创投机构”的称号。倚锋的创始合伙人、董事长朱晋桥先生，已根植医疗健康投资行业十余年，有着丰富的投资经验和精准的投资眼光。另一方面，倚锋的核心管理团队均由来自全球知名院校的医药、生物、化学等相关领域的博士组成，这也保证了倚锋在项目选择上的专业性。在精准的投资决策和专业的投资判断下，倚锋的管理团队曾投资了迈瑞医疗、和佳医疗、微芯生物、亚盛医药、前沿生物及Aridis Pharmaceuticals等国内外业界知名企业，创造了巨大的经济效益和社会影响力。

经过逾十年的积累，倚锋形成了“以创业者为中心，以价值创造者为本”的理念，并坚持投资、融资、风控、管理、服务的“五位一体”系统化运营，致力于用专业的经验和丰厚的资源与投资人一起参与和分享医疗健康行业的升级盛宴，并进一步打造以人为本、基业长青的卓越创投企业。

Founded by the end of the 20th century, Efung Capital is one of the pioneers in the professional investment industry. Efung Capital was established in 2007 and has been focusing on VC and PE investment of original drug and high-end medical device since 2012. Efung is committed to promote the industrialization of scientific and technological achievements by allocating the right capital at the right time. Our purpose is to help high-tech companies to grow rapidly and bring satisfactory returns to our investors. During more than a decade accumulation, Efung has created a professional management team, established a comprehensive risk management strategy, and intend to promote and lead the development of the domestic healthcare industry, especially in the original drug and high-end medical device area.

As of July 2017, Efung is managing a fund with more than one billion RMB, and qualifying for the Government guide fund of Shenzhen City in May 2017. Due to the team’s efforts, Efung was granted “top ten venture capital in Shenzhen” title continuously since 2007. Mr. Jinqiao Zhu, the founding partner and chairman of Efung, has been rooted in the medical and health investment industry for more than ten years; he has rich experience in investment and accurate investment insights. On the other hand, the core management team of Efung is composed of PhDs in medicine, biology, chemistry and related fields from globally well-known institutions, which also ensures the professionalism of the project selections. In the precise investment decision-making and professional investment judgment, Efung management team has invested prestigious domestic and international companies such as Mindray, Hokai, Chipscreen, Ascentage Pharma and Aridis Pharmaceuticals, etc, which has created huge economic benefits and social influence.

After more than ten years accumulation, Efung has formed a concept which called “entrepreneurs as the center, value creators as the base”. Also, Efung keeps the faith on investment, financing, risk management, management, service “five in one” systematic operation, commits to participating and sharing the feast of health care industry upgrading with professional experience and rich resources, and this comcept will further build into a people-oriented and long lasting venture capital enterprise.

红杉资本股权投资管理（天津）有限公司

Sequoia Capital Equity Investment Management (Tianjin) Co., Ltd.

红杉是全球最高大的树种之一，以此命名的红杉资本自1972年在美国成立以来，作为第一家机构投资人投资了众多创新公司，包括苹果、思科、甲骨文、雅虎、谷歌产业潮流的领导者。红杉资本中国基金成立于2005年9月，始终视「创业者背后的创业者」为其企业精神，一直致力于发掘和培育产业界的参天大树——基业长青的伟大公司。十年来在中国投资了约300家具有鲜明技术和创新商业模式、具备高成长性和高回报潜力的成长型公司，包括阿里巴巴、唯品会、新浪网、滴滴出行、京东商城、掌趣科技、奇虎360、聚美优品、陌陌、光环新网、大众点评网、美团网、美丽说、今日头条、高德软件、赶集网、DJI大疆创新、文思创新、诺亚财富、万达院线、阿里影业、铂涛酒店集团、德邦物流、中通快递、贝达药业、新产业生物、华大基因、威高集团、鱼跃医疗等众多国内知名企业。红杉作为长期的价值投资者，我们最大的梦想是挖掘并培育出「百年老店」。

Sequoia Capital was founded in 1972 in Menlo Park, California, taking its name from one of the largest and longest-lived tree species in the world. In keeping with its motto “The Entrepreneurs Behind The Entrepreneurs”, and in keeping with its legendary namesake, Sequoia Capital has always been devoted to building great companies that stand the test of time. Formed in September 2005, Sequoia Capital China has an impressive and diverse portfolio comprising about 300 dynamic companies that deliver high returns on investment using differentiated technologies and innovative business models. Particularly, in the healthcare sector, portfolio includes Beta Pharma, Snibe Diagnostic, BGI, Yuwell, WEGO, and Guahao.com.

启明维创创业投资管理（上海）有限公司

Qiming Weichuang Venture Capital Management (Shanghai) Co., Ltd.

启明创投成立于2006年，以其卓越的投资业绩在中国风险投资界享有盛誉。先后在上海、北京、苏州、香港和西雅图设有办公室。2016年，启明在美国募集了一支投资医疗健康的基金，并在西雅图成立了启明美国公司。目前，启明创投旗下管理五支美元基金，四支人民币基金，管理资产总额达27亿美金。

启明创投致力于成为中国优秀创业家们的首选投资伙伴。自成立至今，专注于投资互联网消费（Intersumer）、医疗健康（Healthcare）、信息技术（IT）以及清洁环保技术（Clean Technology）等行业早期和成长期的优秀企业。截止目前，启明已投资超过210家企业，其中有超过30家分别在美国纽交所、纳斯达克、香港联交所、台湾柜买中心、上交所A股及深交所上市或通过并购方式赢得投资回报。其中有大批知名企业包括：小米、大众点评、iTutorGroup、蘑菇街、美图公司、哔哩哔哩弹幕网、泰格医药、甘李药业、再鼎药业、微医集团、海博思创、Face++、优必选和摩拜单车等。就投资回报率而言，启明创投始终占据中国风险投资行业的领先位置。

启明创投始终秉持促进中国企业创新与成长，推动社会产业进步与发展为己任，凭借其投资团队丰富的行业经验和全球资源网络以及在业界卓越的声誉，不遗余力地帮助创业家和他们的企业突破自我、不断创新，与之共创事业，共享成功！

Founded in 2006, Qiming is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou and Hong Kong. In 2016, Qiming raised a US healthcare fund, and set up Qiming US office in Seattle. Currently Qiming manages five US Dollar funds and four RMB funds with US$2.7 billion assets under management.

Qiming strives to be the investor of choice for top entrepreneurs in China. Since our debut, we have backed over 210 young, fast-growing and innovative companies across China in the internet and consumer (“Intersumer”), healthcare, information technology and clean technology sectors. Over 30 of them are already listed on NYSE, NASDAQ, HKEx, Gretai Securities Market, Shanghai Stock Exchange, and Shenzhen Stock Exchange or achieved exit through M&A. Many of our portfolio companies are today’s most influential brands in their respective sectors, including Xiaomi, Dianping, iTutorGroup, Mogujie, Meitu, Bilibili, Tigermed, Gan & Lee, Zai Lab, We Doctor Group, HyperStrong, Face++, UBTech and Mobike. Qiming consistently ranks among the top venture firms in terms of returns to its investors.

Qiming drives innovation and growth of business enterprises and promotes overall industry advancement and social development. With access to our partners’ experience and global network as well as our excellent industry background, we spare no efforts in helping our entrepreneurs and their companies succeed!

深圳前海元明资产管理有限公司

Shenzhen Qianhai YuanMing Asset Management Co., Ltd.

元明资本由熟悉中美两国的企业家和资深金融医药投资专家创立，专注于对中美两国医药研发、创新医疗器械研制、高端医疗服务行业先进企业的投资，成立于2015年1月。

元明资本的创始合伙人为在中美商界拥有成功创办企业经历、丰富社会资源与卓越领导力的田源博士和姜明博士。

元明资本拥有优秀的管理团队，团队成员具有世界顶级学府的专业背景，国际知名医药研发机构的资深经历以及数十年行业耕耘的精专从业经验，在北美、中国及全球其他地区主导与参与过具有国际领先水平的新药研发与投资。

元明资本将国内外医药资源优势、资金优势与资本市场相结合，充分进行资源整合，在中美两国医药市场和资本市场的高度互动和交流中寻找战略性成长机会。

元明资本高度重视与医药及医疗产业具有国际化视野和一流专业水准的创始人及团队合作。元明资本关注具有发展前景和成长价值的医药和医疗项目，通过控股权收购、行业整合投资、夹层投资及其他法律法规允许的投资方式进行并购投资，通过对目标公司进行业务重组及改善，挖掘并提升企业价值，通过多层次的退出方式最终获取基金超额收益。

Yuanming Capital was founded in January 2015 by entrepreneurs and senior medical investment experts who are familiar with the market of China and America. This cross-border investment company seeks to invest in pharmaceutical research, creative medical instruments development and advanced medical service companies in China and America.

The partners of Yuanming Capital are Dr. Yuan Tian and Dr. Ming Jiang. They have wide network, prominent leadership and successful experience in starting business.

Yuanming Capital possesses an outstanding management team. The team members have strong academic background in top-class universities, extensive working experience in world-famous medical R&D institutes and profound expertise in pharmaceutical business. They have successfully led or participated in the research and investment of new medicine with international advanced level in North America, China and other areas around the globe.

Yuanming Capital combines domestic and foreign medical resource advantages and financial advantages with capital market, and seeks to find strategic growth opportunity through the highly interactive communication of China and America's medical and capital market.

Yuanming Capital pays high attention to cooperate with founders and teams with international vision and first-class professional standard in pharmaceutical and medical industry. The firm focuses on pharmaceutical and medical programs that have promising future and great potential growth value. Buyout is made through stake purchase, industrial consolidation investment, mezzanine investment and other investment ways within the scope allowed by relevant laws and regulations. The firm exploits and promotes the potential value of the target companies by business reconstructing and improvement. The firm applies multi-level exits of capital and achieves excess profits.

上海浦东科技投资有限公司

Shanghai Pudong Science and Technology Investment Co., Ltd.

上海浦东科技投资有限公司（以下简称“浦东科投”）成立于1999年，改革前是一家国有综合投资管理公司。

公司注册资本1.56亿元；投资了15个科技项目和6个科技服务平台，包括复旦张江、杏灵药业、透景医疗等高科技及医疗项目。

前期多元化投资业务为公司培养了一批投资领域的人才并积累了一批优质资产。利用境内境外资本市场估值落差，调动市场资源，围绕IC产业开展并购业务。

注重并购与整合的联动；在与上海、北京、浙江等地发起设立多支投资基金；投资并购了一批优质项目；2015年下半年，公司作为发起人，联合相关方面，在北京设立规模8亿元的北京高精尖产业（健康诊疗）并购投资基金，并通过竞争性遴选，成为基金的管理公司。

为支持国家“双创”战略，积极布局一批具有发展潜力的中小微企业，公司正在发起设立首期规模20亿元的上海浦东小微企业成长基金（正在设立中）。

Shanghai Pudong Science and Technology Investment Co., Ltd. (PDSTI), established in 1999, was a comprehensive state-owned investment management company prior to the reform.

Registered capital: RMB 156 million; invested in 15 projects in high technology and healthcare sector.

Adjusted investment strategy to shift the focus onto cross border M&A opportunities. Took advantage of valuation gap between domestic and foreign capital market in the IC industry.

Invested in and acquired some quality assets; Established a number of M&A investment funds in Shanghai, Beijing and Zhejiang; Invested in a listed company and became its largest shareholder.

In the second half of 2015, the company, acting as the promoter and together with the relevant parties, established the Beijing sophisticated industry (healthcare clinics) M&A investment fund with the size of RMB 8 million, and became the manager of the fund after a competitive selection.

In order to support the State’s “Entrepreneurship and Innovation” strategy by proactively establishing a batch of middle, small and mirco businesses with development potential, the company is promoting to establish the Shanghai small and micro businesses development fund with the initial size of RMB 2 billion, which is under the process of establishment.

淡马锡投资咨询（北京）有限公司

Temasek investment Management

淡马锡成立于1974年，是一家设立在新加坡的投资公司。得益于全球10个办事处的支持，截止于2015年3月31日，淡马锡拥有的投资组合价值高达2，660亿新元，主要集中在新加坡和亚洲地区。

淡马锡的投资着眼于四大主题：转型中的经济体、增长中的中产阶级、强化中的比较优势和新兴的龙头企业。它的投资组合涵盖面广泛，行业包括金融服务、电信、媒体与科技、交通与工业、生命科学、消费与房地产，以及能源与资源。

自1974年成立以来，淡马锡复合年化股东总回报率为16%。自2004年我们首次获得评级，淡馬锡每年都分别获得评级机构穆迪和标准普尔所授予的Aaa /AAA整体企业信贷评级。

作为一家机构，我们关心社会福祉，因为这与我们的发展息息相关。我们意识到，无论是涉及社会、环境和公司治理的因素，还是公司和业务的长期可持续性，都会对他们带来影响。

作为一个负责任的企业公民和资产管护者，我们通过相关教育、医疗和研究的计划、支持人才的培育和社群的构建；我们也通过更深入的人员交流和交往，搭建起人与人之间的桥梁；并通过讲求诚信和追求卓越的企业文化，建立更完善的公司治理制度。此外，我们还协助受灾地区的民众进行重建，恢复正常生活。

自淡马锡于1974年成立以来，我们已经设立了 16 个社会捐助项目，目的是为新加坡和亚洲培育人才、建设社群、培养能力和重建生活。我们的捐助项目和公益机构已经援助超过 24 万人。

Incorporated in 1974, Temasek is an investment company based in Singapore. Supported by 10 offices globally, Temasek owns a S$266 billion portfolio as at 31 March 2015, mainly in Singapore and Asia.

Temasek's investment themes centre on: Transforming Economies; Growing Middle Income Populations; Deepening Comparative Advantages; and Emerging Champions. Its portfolio covers a broad spectrum of industries: financial services; telecommunications, media and technology; transportation and industrials; life sciences, consumer and real estate; as well as energy and resources.

Total shareholder return for Temasek since its inception in 1974 was 16% compounded annually. Temasek has had an overall corporate credit rating of “Aaa” by Moody’s and “AAA” by Standard & Poor’s since our inaugural rating in 2004.

As an institution, we have a stake in the well-being of our larger community. We recognise that environmental, social and governance factors can impact them as well as the long term sustainability of companies and businesses.

We practise our commitment as a responsible corporate citizen and steward by supporting efforts that build people and communities through education, healthcare and research; build bridges between peoples through deeper understanding and friendship; build better governance through a culture of integrity and excellence; and rebuild lives and livelihoods devastated by major natural disasters.

Since our inception in 1974, we have established 16 endowments, aimed at building people, building communities, building capabilities and rebuilding lives, in Singapore and Asia. Our endowments and philanthropic entities touched the lives of more than 240,000 people.

深圳市高特佳投资集团有限公司

Shenzhen GTJA Investment Group Co., Ltd.

2001年高特佳投资集团在深圳成立，率先在业内提出“主题行业投资”的投资模式，专注医疗健康产业投资，以战略性股权投资为主导，覆盖并购、PE、VC、天使等全阶段的投资业务，聚集了国内规模最大的拥有10年以上医疗投资经验的专业化团队，对产业有深刻理解和准确判断，构建了医疗健康产业投资生态平台，目标成为具有全球影响力的医疗健康投资机构。

资产管理规模近200亿元，医疗健康产业基金16支，先后投资130余家企业，其中医疗健康企业60余家，并推动了20余家企业成功上市，其中高特佳控股投资国内血液制品龙头企业博雅生物，并助推其成功上市（股票代码：300294）。

国内领先的投后管理体系，根据被投企业的发展阶段和实际需求，为被投企业提供战略梳理、运营管理、品牌建设等服务，与被投企业共同成长。

集团业务立足中国，面向全球，并建立了深圳、上海、北京、南京等运营中心。

Founded in 2001 in Shenzhen, The GTJA Investment Group (GIG) is the first asset manager that started the “Theme-Based Industry Investment Approach ”. Focusing on healthcare industry, GIG has expanded from its roots in strategic investment to become a diverse asset management platform covering Merges & Acquisitions, Private Equity, Venture Capitaland Angel Rounds of investment. GIG has assembled the largest professional team in China, with over 10 years of industry experience and deep understanding as well as accurate judgment of the healthcare industryand has built a healthcare industry investment eco platform to become one of the world's highly influential healthcare investment institutions.

With ¥20 billion Yuan of assets under management across 16 healthcare industry funds, The GTJA Investment Group has invested in over 130 companies-60 of which are from the healthcare industry-and has taken more than 20 companies public. Amongst all, Boya Bio-Pharmaceutical (300294), still a holding company of GIG, is the leading enterprise in the domestic blood products industry.

GIG boosts one of the best portfolio management infrastructures in China. Based on the stage of development and actual need of the portfolio companies, GIG provides services ranging from strategic support and operation management all the way to brand building and strives to grow together with the portfolio companies.

Operating in 8 offices including Shenzhen, Shanghai, Beijing and Nanjing, GIG has established a firm foothold in China, and is growing into an investment group with global vision and impact.

上海建信股权投资管理有限公司

Shanghai Jianxin Capital Management Co., Ltd.

上海建信股权投资管理有限公司是专注于医药健康产业的风险投资基金，致力于生物医药、医疗器械、诊断试剂、医疗服务等医药健康领域的投资。基金总部位于上海，同时在北京、杭州、苏州、烟台等地设有分支机构。公司已于2014年5月备案于中国证券投资基金业协会。

公司拥有一支近20人的专业投资人才队伍，他们分别来自于国内外一流的医疗和金融机构。团队成员在医药健康行业有丰富的投资、管理和创业经验，并积累大量的成功案例。在产品开发、临床试验、申报注册、市场拓展、并购上市等方面为被投项目提供专业的增值服务，推动项目快速发展，为投资人创造良好的业绩。

自公司成立以来，参与投资国内和海外的医药健康项目近30个。在生物医药领域，投资企业深圳微芯生物、中山康方生物、上海和誉生物、厦门力品药业、Quartet Medicine、Marauder Therapeutics、武汉海特生物、山东步长制药、陕西康惠制药等。

Jianxin Capital is a venture capital firm focusing on the healthcare industry including biotech, medical device, IVD etc. Headquartered in Shanghai, Jianxin has branches in Beijing, Hangzhou, Suzhou and Yantai. Jianxin Capital has filed with Asset Management Association of China from May 2014.

Jianxin has nearly twenty professionals who are from top healthcare and financial institutions. The team members have enriched experience in investment, management and entrepreneurship of healthcare industry. The company provides the value-added services to the portfolio company in the fields of products development, clinical trial, registration application, market expansion and M&A.

The company has invested in more than 30 domestic and overseas deals in healthcare industry since its establishment. Jianxin has invested in Chipscreen, Akeso Biopharma, Abbisko Therapeutics, LP Pharma, Quartet Medicine, Marauder Therapeutics, Wuhan Hiteck, BUCHANG PHARMA(code: 603858), Shaanxi Kanghui Pharmaceutical(code: 603139),etc.

北京德福悦安投资顾问有限公司
GL Capital Group

德福资本(GL Capital Group) 由创始人李振福先生于2010年合资成立，总部设立于北京，旗下管理美元以及人民币基金，资产管理规模总共8亿美元。德福中国机遇基金(GL China Opportunities Fund)是德福资本管理的一支以医疗医药产业投资为核心， 并积极探求符合其投资理念并能充分利用其团队经验的其他行业。 2013年，德福资本正式成立人民币基金，丰富其投资方式以及机会。人民币基金目前已投资5个项目，包括2个医院项目，德福资本中国团队由具有丰富投资和管理经验、具备国际视野又了解中国市场的专业投资管理人士组成。拥有丰富的行业资源，能够为被投资企业提供专业性的增值服务。

德福资本重点关注处于成长期/成熟期、或有独特技术优势的创新型企业，投资类型多样，退出方式灵活。德福资本已在中国成功投资26个医疗企业和一个拥有台湾知名品牌的百货零售型企业。26家医疗企业包括制药公司、医院以及诊所、中成药、医药推广服务商、移动医疗、服务、医疗器械等不同领域，其中11家为上市企业。

GL Capital Group, headquartered in Beijing, was founded by Jeffrey Li in 2010 and manages both USD and RMB funds, currently with US$800 million AUM combined. GL Capital focuses on healthcare in which the team can leverage its experience and resources to maximize investment opportunities. GL Capital has a strong brand in China's healthcare investment industry for the proprietary resources, value-add and experience the Fund brings to portfolio companies GL Capital team consists of investment and industry professionals with extensive China market experience. The team brings expertise from various backgrounds and is regarded by portfolio companies as a high value-add investor GL Capital invests in growth and late-stage companies and innovative enterprises with high growth and barrier to entry. GL Capital is flexible in both deal structuring and exit channels.

GL Capital has a strong deal pipeline and already successfully invested in 26 healthcare companies in China and one notable retail brand in Taiwan. The 26 healthcare companies cover sectors including pharmaceuticals, distribution, TCM, clinics and hospitals, CRO, mobile health, medical device and drug marketing/promotion. 11 of the companies are listed companies.

中投海外直接投资有限责任公司

CIC Capital Corporation

中投公司成立于2007年9月29日，是依照《中华人民共和国公司法》设立的国有独资公司，组建宗旨是实现国家外汇资金多元化投资，在可接受风险范围内实现股东权益最大化。公司总部设在北京，注册资本金为2,000亿美元。

中投公司下设三个子公司，分别是中投国际有限责任公司（以下简称“中投国际”）、中投海外直接投资有限责任公司（以下简称“中投海外”）和中央汇金投资有限责任公司（以下简称“中央汇金”）。

中投公司的境外投资和管理业务分别由中投国际和中投海外承担。中投国际和中投海外均坚持市场化、商业化、专业化和国际化的运作模式。

中投海外于2015年1月成立，是中投公司对外直接投资业务平台，开展直接投资和多双边基金管理。中投海外下设投资一部、投资二部和运营管理部门。其中，投资一部职责包括基础设施、矿业以及油气能源方面的直接投资；管理相关多双边平台基金以及项目跟投等；投资二部职责包括除投资一部三个行业以及农业以外行业的直接投资；管理相关多双边平台基金以及项目跟投等。

Headquartered in Beijing, China Investment Corporation (CIC) was founded on 29 September 2007 as a wholly state-owned company incorporated in accord with China's Company Law, with registered capital of $200 billion. The company was established as a vehicle to diversify China's foreign exchange holdings and seek maximum returns for its shareholder within acceptable risk tolerance.

CIC has three subsidiaries, CIC International Co., Ltd. (CIC International), CIC Capital Corporation (CIC Capital) and Central Huijin Investment Ltd. (Central Huijin).

The overseas investment and management activities of CIC are undertaken by CIC International and CIC Capital. Both CIC International and CIC Capital are market-oriented commercial entities with a specialized mandate and global reach.

CIC Capital was incorporated in January 2015 with a mandate to specialize in making direct investments to refine CIC's overall portfolio management and enhance investment on long-term assets. CIC Capital encompasses two investment departments and operational and management departments. Investment Department I is responsible for direct investments in infrastructure, mining, and energy (oil and gas) and for managing related bilateral, multilateral, and platform fund investments, and co-investments. Investment Department II is responsible for direct investments in sectors other than agriculture and the three sectors managed by Investment Department I and for managing related bilateral, multilateral, and platform fund investments, and co-investments.

平安银行医疗健康文化旅游金融事业部

Finance SBU of Healthcare Industries of Ping An Bank

平安银行医疗健康文化旅游金融事业部是平安银行贯彻平安集团“大医疗健康战略”成立的总行级医疗健康专营金融机构，于2015年8月成立。作为全国银行业首个总行级健康产业专营机构，事业部致力于打造“专业银行+垂直银行+综合银行”三位一体的行业银行，以“商行+投行+投资”的理念搭建行业化综合价值平台，作为平安集团大金融资产、大医疗健康产业布局（商业健康险、互联网医疗、线下诊所联盟、医保管理等）与医药行业战略客户的连接枢纽，以成为行业龙头的BD、财务、投资等一站式服务平台为愿景，从战略、资本、运营、财务、品牌等维度为企业创造价值。目前，事业部管理资产规模千亿元、人均创利过千万、实现医药行业龙头70%覆盖、与113家医药上市公司实现业务合作。

事业部汇聚顶尖名校金融、医学、法律等人才，具备商业银行、券商、国际投行、PE机构等各业精英，形成行业研究、产业开发、投资银行、交易银行、跨境金融、审批六大团队。事业部成功打造“平安医药通”服务品牌，以“做医药、更轻松”为理念，为行业客户提供“医药跨境通”、“医药交易通”、“医药投行通”三大解决方案，提供“全产业链+全生命周期+全流程”的综合化金融服务。

自2015年以来，事业部与药明康德、绿叶、迈瑞医疗、康哲、海王星辰、罗欣、人福、九州通、爱尔眼科、美年大健康、乐普医疗、老百姓、天士力等多家上市公司，在美股、港股私有化、跨境并购资金离岸、并购基金、产业基金等领域合作近30单有影响力的案例，业务涵盖A股40%医疗健康类上市公司，遍布美、英、法、澳等全球范围城市，参与跨境并购项目130亿元，私有化融资460亿元。凭借在跨境并购领域的出色表现，荣膺2016年中国并购公会“并购专项奖—年度最佳并购融资奖”。同时在交易银行产品、大股东、管理层需求方案等各层面服务客户，总交易金额达100亿美元!

事业部正联合医药产业领袖、全球金融巨头，共同发起成立“平安健康荟”——服务于行业资源整合和并购重组的专业化开放式平台，为医药企业提供集“并购标的推荐+并购融资设计+并购联合投资+并购顾问服务”一体的闭环解决方案，共同建立国内医药产融合作新生态。

Finance SBU of Healthcare Industries of Ping An Bank was established in according to the “Healthcare Strategy” of Ping An Group in August 2015, which is focus to the finance of healthcare industry specialized institutions of the head office level. As the first head office level healthcare industry specialized institution of the domestic banks, the SBU is committed to create a “professional bank+ vertical bank+integrated bank” three-in-one industry bank. With the concept of “commercial bank + investment bank+invest”, building integrated industry value platform, the SBU connects Ping An Group great financial assets, great healthcare industry layout (commercial health insurance, internet medical, offline clinic alliance, etc.) and the pharmaceutical industry strategic customers. The aim of the SBU is to create value for the enterprise from the strategic, capital, operations, finance, and other dimensions. At present, the asset size of the SBU is 100 billion Yuan, per capital profit is over 10 million Yuan, coverage to the leading pharmaceutical companies is over 70%, and builds business cooperation with 113 listing pharmaceutical companies.

The SBU gathers finance, medicine and law elites from top schools, as well as elites from commercial bank, brokerage, and international investment bank, PE industry, who are divided into six groups of industry research, industry development, investment bank, trading bank, cross-border finance and approval.

With the concept of easier medical, the SBU successfully creates Ping An Medical Pass, which provides three solutions of medical cross-border pass, medical trading pass and medical investment pass, as well as integrated financial services of whole industry chain+whole life cycle + whole process.

Since 2015, the SBU has nearly 30 influencing financial cases in US/Hong Kong privatization, cross-border M&A, M&A funds, industries funds, etc. with listed companies such as Wuxi App Tec, Luye, Mindrey, CMS, Nepstar, Luoxin, Humanwell, Jointown, Aier Eye, Health-100, Lepu Medical, Lbx Drugs, Tasly, ect. The business of the SBU covers 40% healthcare listed companies of A shares, throughout the United States, Britain, France and Australia and other global city, involving in cross-border M&A 13 billion Yuan, private financing 46 billion Yuan.

With the outstanding performance in cross-border M&A, it won “M&A Award-the best M&A financing Award” in 2016 of CMAA. At the same time, the total transaction amount is of $10 billion Yuan in providing the transaction banking products and satisfying the needs of major shareholders and management level!

The SBU tries it best effort to co-found the professional open platform of Ping An healthy Club with the pharmaceutical industry leaders and global financial giants, which focuses on professional open platform of industry resource integration and M&A, providing solutions for pharmaceutical enterprises with M&A targets recommendation, M&A finance design, M&A joint investment, and M&A advisory, thus establish new ecological cooperation with the domestic pharmaceutical companies.

天津博信鑫元资产管理股份有限公司

Tianjin Boxin Xinyuan Asset Management Co., Ltd.

天津博信鑫元资产管理股份有限公司（以下称“博信资产”）创立于2007年12月，是国内最早从事股权投资管理的专业机构之一，注册资本约10,028万元人民币。成立10年来，博信资产凭借丰富的行业经验、精湛的专业能力、广博的政府及社会人脉资源、庞大的企业信息数据库、严谨的风控决策流程、多元化的企业增值服务，跻身国内知名股权投资基金之列，并荣膺专业评测机构清科集团及投中集团评选的“2010年中国私募股权投资机构10强”、投中集团“2011年中国最佳新锐私募股权机构”、CLPA中国有限合伙人联盟2011-2012年度颁奖榜单“最具LP投资价值GP50强”、清科集团“2013年中国私募股权投资机构50强（本土）”、清科集团“2014年中国私募股权投资机构50强”等。2015年11月23日，博信资产成功登录新三板挂牌交易，股票代码为834395，股票简称为博信资产。

经过10年的发展，博信资产以严格的管理、优良的业绩和一流的服务，树立了良好的品牌形象，赢得了投资者和业界的广泛认可。

博信资产旗下人民币基金和美元基金规模合计超过30亿元人民币，资管计划规模超过260亿元人民币。截至目前，博信资产累计投资项目42个，其中，8个项目成功IPO（其中5个已完全退出），5个项目成功并购转换为A股股票（其中3个项目已完全退出），8个项目成功登陆新三板（其中1个项目已申报IPO，在会审核）。根据博信挂牌时券商按照市场通用方法所做估值，博信基金所投项目退出IRR高达31.59%，处于同行业领先水平。

Established in Dec.2007 and with RMB 100.28 million of registered capital, Boxin Xinyuan Asset Management Co., Ltd. (“Boxin AMC”, formerly as “Boxin Capital”) is one of the first equity investment managers in China. In the past decade, Boxin AMC has evolved into one of the most prominent equity investment funds in China, thanks to its extensive industry experience, strong professional capabilities, broad government and social network, comprehensive sector database, prudent risk management protocols and diversified value-added services. Based on its professional excellence, Boxin AMC has won numerous awards including “2010 Top 10 Private Equity Investors in China” (Zero2IPO Group and ChinaVenture), “2011 Best New Private Equity Investor” (ChinaVenture), “2011-2012 Top 50 Domestic Private Equity Investors for LP Value Creation” (CLPA) and “2014 Top 50 Private Equity Investors in China” (Zero2IPO Group). On Nov 23rd, 2015, Boxin AMC (834395) became successfully listed on the National Equities Exchange and Quotations (NEEQ).

After 10 years of dedicated development, Boxin AMC has earned a stellar reputation among investors and peers through its stringent management schemes, strong performance profile and high-quality services.

Currently, Boxin AMC manages over RMB 3 billion under its RMB and USD private equity funds and over RMB 26 billion of other asset management business. As of today, Boxin AMC has invested in 42 companies, among which 8 have successfully sought IPO (5 clean exits), 5 have been acquired by public companies (3 clean exits) and 8 have become listed on the NEEQ (1 currently seeking IPO). According to valuation via commonly used methodologies, Boxin’s exit-IRR upon its NEEQ-listing reached 31.59%, ranking among the highest of its peers.

成都博远嘉昱创业投资合伙企业（有限合伙）

Biotrack Capital

博远资本创始合伙人是陈鹏辉先生，在创立博远医疗基金之前担任红杉资本中国基金合伙人，负责医疗领域的投资。之前任职于光大控股，组建了光大控股首期医疗基金，担任基金负责人，全面负责基金的管理和投资。代表性的投资项目包括华大基因 (300676)，浙江贝达医药（300558）,鱼跃医疗（SZ002223），再鼎医药（Nasdaq ZLAB）,美中宜和等近二十多家国内医疗领域的领先企业。在进入医疗投资领域之前，在国内领先的医药研发外包公司尚华医药研发服务集团担任总裁，COO,CFO.领导了公司的快速发展，并于2010年领导公司在纽约证交所上市。曾任美国圣地亚哥生物技术公司Ligand Pharmaceuticals（NASDAQ LGND）的研究员，从事新药研发工作。本科毕业于南京大学化学系，是美国杜兰大学药物化学硕士和美国西北大学凯洛格商学院MBA。

Biotrack Capital founding partner is Kevin CHEN. Previously, he was a partner at Sequoia Capital China, responsible for healthcare investment. Before Sequoia, Mr. Chen set up the first healthcare fund at Everbright Holdings and served as head of Everbright Healthcare Fund. Mr. Chen has led investments in over 20 leading healthcare companies in China such as BGI, Betta Pharma, Yuwell Medical, Zai Lab, and Amcare Hospital etc. Before Everbright, he was the President, COO & CFO of ShangPharma Corporation between 2008 and 2011 and took the company public at NYSE in 2010. Mr. Chen also worked as research scientist at Ligand Pharmaceuticals in San Diego, California. Mr. Chen holds a bachelor degree in chemistry from Nanjing University, master degree in medicinal chemistry from Tulane University and an MBA from Kellogg School of Management, Northwestern University.

上海景旭创业投资有限公司

Shanghai Prosperico Venture Co., Ltd.

景旭创投是一家专注于医疗健康领域的风险投资机构，拥有专业的投资团队丰富的行业资源整合能力，致力于围绕医疗健康产业链发掘优质企业并助力企业快速成长的价值投资。自创立至今，景旭创投不断完善在创新医疗器械、连锁医疗服务和生物制药等细分领域的投资布局，迄今已完成对逾20家高成长性医疗健康企业的投资，其中包括：生物制药领域的博威生物、安特金生物；创新医疗器械领域的莱诺医疗、金仕生物、BioNano；医疗服务领域的友睦口腔（NEEQ：870486）、中国脐带血库（NYSE：CO）、美中嘉和（NEEQ：835660）等。

A venture investment company with profound industiral insights and an global exposure, Prosperico Ventures specializes in healthcare investments with focus on innovative diagnostics, medical devices and drug discovery & development. Since 2015, Prosperico Ventures has invested in more than 20 life sciences and healthcare companies across China and US. Major protfolios of Prosperico Ventures include Mab-Ventures, Nano Technology, U-Dental, China Chord Blood Baning Corporation, BioNano, Xynomics Pharmaceuticals, etc.

华融证券股份有限公司
Huarong Securities Co., Ltd.

华融证券股份有限公司（以下简称“公司”）是经中国证监会批准，由中国华融资产管理股份有限公司（以下简称“中国华融”）作为主发起人，联合中国葛洲坝集团有限公司共同发起设立的全国性证券公司。2007年9月，公司在北京正式挂牌成立。目前，公司注册资本51.42亿元。

公司下设上海和深圳2家业务总部，北京、上海、深圳、湖南等16家分公司，66家营业部，控股华融期货有限责任公司和华融瑞泽投资管理有限公司。公司紧紧依托中国华融在资产管理、银行、信托和金融租赁等方面的综合优势，可为客户提供证券经纪、融资融券、证券承销与保荐、与证券交易及证券投资活动有关的财务顾问、证券投资咨询、证券自营、证券资产管理、投资顾问等综合化的财富管理服务。公司2011-2016年连续六年被中国证监会评为A类券商，其中2015年获评为A类AA级券商。

公司创立适逢我国资本市场全面大发展之际，将坚持高标准、高起点，以规范经营、诚实守信、开拓创新为经营宗旨，在社会各界的支持下，努力发展成为一个对国家有贡献、对社会负责任、对客户有价值的证券公司。公司将坚持以市场为导向，以客户为中心，以诚信、专业、稳健、共赢为经营宗旨，在社会各界和投资者的大力支持下，努力打造一家有尊严、有价值、有内涵、有实力、有责任的“五有”现代一流投资银行!

Huarong Securities Co.,Ltd (hereinafter to be referred as ‘HuaRong Securities’), with China Huarong Asset Management Co., Ltd. (hereinafter referred to as China Huarong) as the initiator and China Gezhouba Group Co., Ltd. as its partner, is a nationwide securities company which is approved by China Securities Regulatory Commission. It was inaugurated in Beijing in September 2007. Currently, its registered capital is 51.42 billion yuan.

I.Profile

In Huarong Securities, there are two business headquaters respectively in Shanghai and Shenzhen, 16 branches in Beijing, Shanghai, Shenzhen, Hu’nan and other divisions, and 66 offices. It’s also the controlling shareholder of Huarong Futures and Huarong Ruize Investment Management Co., Ltd. By relying on China Huarong’s advantages in assets management, banking, trust and financial leasing, Huarong Securities provides clients with comprehensive wealth management services including stock brokerage, margin trading, securities underwriting and sponsoring, financial advice related to securities trading and investment, securities investment consultation, securities proprietary business, securities assets management, and investment consultation. It’s rated by CSRC as Class A brokerage company for 6 consecutive years from 2011 to 2016 and Class AA brokerage company in 2015.

II.Objectives

The establishment of Huarong Securities coincided with the rapid development of China’s capital market. So it will endeavor to be a securities company that makes contribution to China’s development, takes its corporate social responsibilities and helps to increase clients’ values with the support of all communities by sticking to its operation aims of regulated operation, integrity and innovation. As a market-oriented and client-centered company, it will aim at integrity, professionalism, moderation and win-win results and build itself into a world-class investment bank with respect, values, connotations, capabilities and responsibilities with the support of all communities concerned.

第一创业证券股份有限公司

First Capital Securities Co., Ltd.

第一创业证券股份有限公司（以下简称“第一创业”）是经中国证监会批准，由华熙昕宇、首创集团等多家实力雄厚的股东投资设立的全国性证券公司，前身是1993年4月成立的佛山证券公司。公司注册资本21.89亿元，总部设在深圳，员工总数超过2800人。2016年5月11日，公司首次公开发行股票并在深圳证券交易所上市交易，证券简称“第一创业”，证券代码“002797”。

齐全的业务牌照与资质

第一创业（含各子公司)拥有齐全的证券业务牌照，业务体系覆盖交易所、银行间等场内、场外市场，可为广大投资者和客户提供固定收益、投资银行、资产管理、证券经纪、研究咨询、直接投资、私募股权基金、公募基金、期货、另类投资等一站式综合金融服务。

网点覆盖全国主要城市

目前，第一创业在全国设有40余家营业部，并在北京、上海、深圳、河北设立了分公司；拥有3家全资子公司：第一创业期货有限责任公司、第一创业投资管理有限公司、深圳第一创业创新资本管理有限公司；控股第一创业摩根大通证券有限责任公司、创金合信基金管理有限公司；参股银华基金管理有限公司、证通股份有限公司、中证机构间报价系统股份有限公司；并与国家高端智库——国家金融与发展实验室联合发起设立了“深圳市第一创业债券研究院”。

致力于成为“有固定收益特色的业绩优良的”的上市证券公司

第一创业多年来一直坚持“追求可持续发展，努力打造具有独特经营模式、业绩优良、富有竞争力的一流投资银行”的公司愿景，以客户为中心，以创新为动力，致力于为客户提供专业的金融中介服务。经过20多年的发展，公司建立了完善的公司治理结构和稳定的核心管理团队，并形成了优秀的企业文化，在固定收益、资产管理、私募股权基金管理、投资银行、证券经纪等业务领域已形成了差异化竞争优势，实现了可持续发展。

First Capital Securities Co., Ltd. (hereinafter referred to as “First Capital”) is a nationwide securities company approved by the China Securities Regulatory Commission, and established by Huaxi Xinyu Investment Co, Beijing Capital Group and numerous other shareholders of great strength. Formerly known as Foshan Securities Company, it was incorporated in April 1993. The Company, headquartered in Shenzhen, has registered capital of RMB2,189 million, and more than 2,800 employees. The Company launched its initial public offering on May 11, 2016, and its shares are listed and traded on the Shenzhen Stock Exchange. Its securities abbreviation is “First Capital” and its stock code, “002797”.

A complete set of business licenses and qualifications

First Capital (including its subsidiaries) has a complete set of securities business licenses, and its scope of business encompasses exchange and interbank as well as other exchange-traded and over-the-counter markets, providing fixed income, investment banking, asset management, securities brokerage, research inquiry, direct investment, private equity funds, publicly offered funds, futures, alternative investments and other integrated one-stop financial services to all investors and our customers.

Nationwide network covers major cities

Currently, First Capital has more than 40 sales offices nationwide, and has set up branches in Beijing, Shanghai, Shenzhen and Hebei. It has three wholly-owned subsidiaries: First Capital Futures Co., Ltd., First Capital Investment Management Co., Ltd., and First Capital Innovative Management Corporation LTD.; controlling stakes in JP Morgan First Capital Securities Co., Ltd. and Truvalue Asset Management Co., Ltd..; equity stakes in Yinhua Fund Management Co., Ltd., E-Capital Transfer Co., Ltd., and China Securities Internet System Co., Ltd.. It has also teamed up with National Institution for Finance & Development, a top national-level think tank in China, to establish “Shenzhen First Capital Bond Research Institute”.

Committed to becoming a listed securities company “with fixed income characteristics that excels”

First Capital has always upheld its vision of the “pursuit of sustainable growth, diligently creating a competitive first class investment bank with a unique business model and excellent performance”. It is customer-oriented, innovation-driven, and committed to providing professional financial intermediary services to customers. Having developed for more than two decades, the Company has established good corporate governance, a stable core management team, as well as excellent corporate culture. It has created competitive differentiation advantages in fixed income, asset management, private equity fund management, investment banking, securities brokerage and other business areas, achieving sustainable growth.

上海东富龙科技股份有限公司

Shanghai Tofflon Science and Technology Co., Ltd.

上海东富龙科技股份有限公司（中文简称：东富龙；外文简称：Tofflon）是一家为全球制药企业提供制药工艺、核心设备、系统工程整体解决方案的综合化制药装备供应商，产品广泛应用于无菌注射剂、固体制剂、化学原料药、生物工程、中药提取等药物制造科学领域。东富龙成立于1993年，经过20载艰苦奋斗，锐意进取，东富龙已有超过8000多台制药设备和制药系统服务于全球40多个国家和地区的2000家知名制药企业，并已成功进入到西欧、北美等高法规市场，2011年2月1日，东富龙正式在深圳证券交易所创业板上市（股票名称：东富龙；股票代码：300171）。

今天东富龙专注于药物制造科学和药机制造科学的研究，践行制药装备与制药工艺的融合、创新，致力于智慧药厂的开发与建设。汇聚全球技术，在上海总部建立了综合研究所，逐步在欧洲、美国、印度建立全球设计所和技术中心，与美国、欧洲、日本合作伙伴成立合资企业和开展技术合作，拥有具有全球竞争力的五大现代化的制药装备生产基地，先后通过了德国TUV ISO9001、ISO14001、OHSAS 18001、CE、UL、PED、ASME等国际认证，拥有中外员工2000多名，对接各国制药标准（USFDA / MHRA / WHO / TGA / MCC等），提供具有全球竞争力的注射剂解决方案、固体制剂解决方案、原料药解决方案、生物工程解决方案、中药解决方案、检查包装解决方案等，致力于成长为全球制药装备整体解决方案的主流供应商。

未来东富龙秉承“专业技术服务于制药工业”的使命，聚焦制药工业关注的挑战和压力，从药物创新、制药工艺、核心设备、系统工程方面提供系统整体解决方案，成为智慧药厂的交付者，服务于全球制药工业。从“中国的东富龙成长为世界的东富龙”，从“单一设备供应商成长为系统方案解决者”。在做强制药主业的同时，积极布局和发展医疗器械和食品工程，为实现社会、客户、股东、员工及其家庭幸福的最大化而不懈努力，为服务于人类大健康事业做出新的贡献！

Shanghai Tofflon Science and Technology Co., Ltd. (Short for “Tofflon”, Stock Code: SZ 300171) was founded in 1993. It is a comprehensive pharmaceutical equipment supplier to provide process support, core equipments, integrated system and pharma engineering for the pharma and biotech industry in the world. Since its foundation, Tofflon has supplied more than 8000 equipments and systems for 2000 pharmaceutical companies across over 40 countries and regions in the world which have been widely applied in the fields of liquid and lyo injectables, chemical API, bio engineering and pharma packaging, etc.

Today Tofflon focuses on studying drug manufacture science and process equipment manufacture science, practices drug process knowledge integration with pharma equipment knowledge. Taking “Synergy Global Advanced Technologies” strategy, Tofflon builds comprehensive development institute in Shanghai headquarters, is building design houses and technical centers in USA, Europe and India, establishes joint ventures and technology collaboration with the technical partners from USA, Europe and Japan. Furthermore Tofflon has built five modern pharmaceutical equipments manufacturing bases with global competitiveness. It has been approved with all the international regulatory certifications like German TUV ISO9001, ISO14001, OHSAS 18001, CE, UL, PED, ASME, etc. Thanks to 2000 Chinese and foreign employees professional works, it can provide competitive pharmaceutical equipment and system solutions valuable for today and future’s competence improvement of the pharma and biotech companies.

In the future to commit to its mission “Expertise in Pharmaceutical Industry”, Tofflon will continuously work with pharmaceutical industry to face and meet the challenges and pressures in the industry through developing “innovative drug manufacturing science” and building “advanced drug manufacturing platform”. In the following years, Tofflon will dedicate itself to grow from “China Tofflon to Global Tofflon”, from “Equipment Supplier to Solution Provider” so as to grow up to a total solution provider of pharmaceutical manufacturing systems and engineering for the global pharma and biotech industry to contribute to the maximum benefits and welfare of its served society, customers, stockholders, employees and their families.

北京科信必成医药科技发展有限公司

CoSci Med-Tech Co., Ltd.

北京科信必成医药科技发展有限公司总部位于北京中关村国家自主示范区海淀核心区，成立于2003 年，是一家拥有多项国内外自主知识产权的国家高新技术企业，是“中关村国家自主创新示范区创新型企业”，全国企事业知识产权试点单位，国家技术转移示范机构，北京市专利示范单位，中关村20 周年突出贡献企业，2010 年~2012 年连续三年获得德勤高科技、高成长中国50 强及亚太500 强。

科信必成先后承担了国家“十一五”、“十二五”重大新药创制项目，多项国际化合作项目列入中关村科技园区海淀园专项发展资金。研发中心建立可达到FDA、EMA 药物制剂标准的化学药物速释、缓释、控释口服固体制剂技术平台。开发品种涵盖心脑血管、呼吸系统、神经系统、退行性疾病、解热镇痛等多个领域，在每个领域均有系列产品满足不同治疗时期的需求。科信必成拥有13 项具有独立自主知识产权可产业化的围绕控缓释共性关键技术平台，主要包括掩味颗粒技术、精准微片技术、渗透泵控释片给药系统技术、群控释放渗透泵控释片技术、固体分散物工业化制备技术、醋酸纤维素水分散体微囊包合技术、水为润湿剂制备凝胶骨架片技术、蜡质骨架材料双层缓释片制备技术等，截至目前申请药物制剂国家发明专利169 项，获得83 项授权；申请国际PCT 专利6 项，1 项已获得美国和欧洲13 国授权。

科信必成是专注于口服固体制剂产业化的药品研发机构，已为国内60 多家制药企业提供服务，其中包括42 家上市公司以及2014 年度中国医药工业百强榜前100 强中的20 家。近年公司加大与国际制药企业的合作力度，将最先进的创新理念和制剂技术引进，并消化吸收再创新，推进国内制药技术研发与工业化水平的进步，从而真正的打造具有国际先进水平的药物制剂技术平台，实现口服药物速、缓、控释等制剂技术和产品达到国际水平，助推中国医药产业实现国际化。

CoSci Med-Tech Co., Ltd. is an technology driven innovative pharmaceutical service enterprise located in Beijing Zhongguancun Science and Technology Park. Its focus is the R&D and industrialization of oral solid modified-release formulations, with its own patented innovative Drug Delivery Technologies.

During the last 15 successful business years, CoSci has filed 169 patent applications and granted 83 by the Chinese Office of Intellectual Properties. We’ve also filed 6 international PCT applications and 1 was approved by EU Office and US office.

CoSci’s 13 technology platforms were positively assessed by domestic and global partners:
1) Milti-Porous Osmotic Pump Controlled-Release Tablet
2) Complete Dissolution of Drug Content From Osmotic Pump Formulations
3) Enteric-Coated Pellet
4) Tablet Matrix Using Water as Wetting-Agent
5) Double-Layer Wex-based Matrix
6) Sustained-Release Pellet
7) Industrial Production of Solid Dispersions
8) Microencapsulation of Cellulose Acetate Dispersables
9) Extended-Release Drug Delivery System Oral Dipersable Pellets
10) Mirco-Tablet
11) Colon-Release Formulations
12)Multi-Unit Sustained-&Controlled-Release Formulations (Mirco-Pellet Compression)

Well accepted is also the philosophy of CoSci: we realize products rather than technology, which lead to marketing value of our partners. Currently we have 118 valuable products in our pipeline.

方恩（天津）医药发展有限公司
Fountain Medical (Tianjin) Co., Ltd.

方恩（天津）医药发展有限公司是一家能够提供全方位与国际标准接轨的临床开发服务的CRO（合同研究组织）公司。方恩以天津为中心分别在美国、北京、上海、南京、广州、成都、香港、台湾、韩国、亚美尼亚及日本建立了分支机构。方恩现有员工1200 多位，中国大陆的临床运营团队分布在全国36 个城市，目前还在不断的发展壮大中，致力于为国内外生物制药或医疗器械客户提供高质量低成本的全方位的临床研究服务。

方恩自成立以来，参与并承担了“十一、五”及“十二、五”重大新药创制项目，通过了国内外大中型制药企业的数十次稽查，为许多国内外领先的医药企业及全球一些非盈利机构和一些新兴的生物医药公司提供临床研究服务。至今为止，方恩已支持提交国内外15 个新药证书并有11 个已经批准； 承接了200 多项临床试验项目包括多个治疗领域下的入组10000 例的上市后研究；与亚洲300 多家临床试验机构保持着良好的合作关系；目前已经为分布于中国大陆、香港、台湾和韩国的各阶段临床试验入组了近60000 例受试者。

相信丰富的临床经验、对合作需求的敏锐触觉、顺应合作伙伴需求及对细节的专注性将成为方恩成功发展的基石。

Fountain Medical Development Ltd. (FMD) is a Contract Research Organization (CRO) offering a full range of ICH GCP compliant clinical research services, these services target multinational pharmaceutical and medical device companies looking to establish their medical product (s) in the US, Europe, and parts of East Asia (including China, Hong Kong, Taiwan, and South Korea; Japan). Our extensive global experience in multiple therapeutic areas, is comprehensive and transcends other local and global CRO’s.

Our competitive costs and rich clinical experience allow us to pass significant savings onto our clients. Our extensive clinical experience and high sensitivity for cooperation not only satisfies the detail oriented requirements of our partners, but also establishes a solid foundation for FMD to thrive. In the course of our steady growth and expansion, we have successfully completed more than 200 clinical trial projects and enrolled more than 60,000 patients in clinical trials; in addition, we have maintained stable partnerships with more than 300 sites in Asia. As a global CRO, FMD has completed many pivotal international studies, the results of which can be used in FDA and EMA applications, ensuring that FMD is your trustworthy CRO of choice.

药明康德新药开发有限公司

WuXi AppTec Co., Ltd.

药明康德是国际领先的开放式能力与技术平台公司，为全球制药、生物技术以及医疗器械等领域提供从药物发现、开发到市场化的全方位一体化的实验室研发和生产服务。药明康德目前有14,000名全球员工，其中12,000名从事研发工作，全球27个研发基地共60万平方米研发基地和生产厂房。本着以研究为首任，以客户为中心的宗旨，药明康德通过高性价比、高效率的服务平台帮助全球客户缩短药物及医疗器械研发周期、降低研发成本。药明康德平台涵括小分子药物研发及生产、细胞疗法与基因疗法研发生产、医疗器械测试等，正承载着来自全球30多个国家的近3000多家创新合作伙伴的数千个研发创新项目，致力于将最新和最好的医药和健康产品带给全球病患，实现“让天下没有难做的药，难治的病”的梦想。药明康德荣获了诸多荣誉，包括2015弗若斯特沙利文“2015年度亚洲最佳CRO”， “2015开放式研发技术领军企业奖”，SCRIP2014“新兴市场最佳企业”等。2015年美国FDA批准的45个新药中，有33个来自于药明康德的合作伙伴；2016年美国FDA批准的22个新药中，有16个来自于药明康德的合作伙伴。

WuXi AppTec is a leading pharmaceutical, biopharmaceutical, and medical device capability and technology platform company with 14,000 employees globally, including more than 12,000 dedicated scientists. Through its 26 R&D sites worldwide, and a total of 6.0 million square feet of office, laboratory and manufacturing space, WuXi provides comprehensive platform capabilities in small molecule R&D and manufacturing, biologics R&D and manufacturing, cell and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics. Today, WuXi platform is enabling more than 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients. Our vision is to become the most comprehensive capability and technology platform to fulfill WuXi’s dream that “every drug can be made and every disease can be treated.” WuXi has received many distinguished recognitions, including the “Company of the Year Award” (2016), “Asian CRO Company of the Year” Award (2015), the “North American Open-Access R&D Technology Leadership” Award (2015), “Best Company in an Emerging Market” (2014). In 2016, 16 from the 22 US FDA approved drugs are from WuXi's collaborators; in 2015, 33 from the 45 US FDA approved drugs are from WuXi's collaborators.

药渡经纬信息科技（北京）有限公司

Pharmacodia (Beijing) Co., Ltd.

药渡经纬信息科技（北京）有限公司，成立于2013年，公司以“助力药物创新，加速价值创造”为使命，全力打造生物医药垂直领域“一站式信息服务”平台。

药渡致力并专注于药物大数据的研究与应用，已逐渐形成以“药物数据”为核心展开的四大业务版块，包括“数据—全球药物研发信息与数据平台”、“咨询—药学专业咨询和投融资服务平台”、“商城—优质研发资源的物联平台”、“头条—药物研发生态圈学习和交流平台”，为生物医药行业提供最有价值的创新产品和专业服务。

药渡产品用户已覆盖140多个国家，广泛服务于政府专业机构、高校科研院所、药物研发企业、投融资机构等。并分别于2015年、2016年获评“中关村医药研发大数据平台”、“国家高新技术企业”。

今后，药渡将继续探索和深化IT技术在医药垂直领域的深度结合和运用，加速和深化药渡专有技术的研发，不断提升自身产品体系的时效性、精准性和前瞻性。同时，整合医药行业的资源优势，打造“数据驱动”的医药全产业链“互联网化”平台。

Established in 2013, Pharmacodia Information Technology (Beijing) Co., Ltd. taking “promoting drug innovation and accelerating value creation” as its mission, aims to build a vertical “one-stop information service” platform in the pharmaceutical and biomedicine field.

Pharmacodia focuses on the research and application of drug big data. With “drug data” as the core, the company has established four major business sections, including “Data-Global Drug R&D Information and Data Platform”, “Consulting-Pharmacy Professional Consultation and Investment and Financing Service Platform”, “Mall–High-quality R&D Resources Platform”, “Headline-Drug R&D Learning and Communication Platform”, providing the most valuable innovative products and professional services for the pharmaceutical industry.

Pharmacodia products have covered more than 140 countries and are widely used in government agencies, university research institutes, drug research and development enterprises and investment and financing institutions. The company was awarded “Zhongguancun Pharmaceutical R&D Big Data Platform” and “National High-tech Enterprise” in 2015 and 2016 respectively.

In the future, Pharmacodia will continue to explore and deepen the integration and application of IT technology in the field of pharmaceutical and biotech, accelerate the research and development of proprietary technology of Pharmacodia, and constantly improve the timeliness, precision and forward-looking of its own services. At the same time, Pharmacodia will integrate the advantages of resources to build “Data-driven” Internet platform for the pharmaceutical industry.

缔脉生物医药科技（上海）有限公司

dMed Biopharmaceutical Company Limited

缔脉生物医药科技（上海）有限公司是一家临床合同研究组织（CRO），旨在为中国及全球生物医药公司和医疗器械公司提供高水准全方位的服务，包括为客户就临床开发的各个方面以及产品注册申报出谋划策，也提供与临床试验相关的各种支持。致力于提高研发产品的成功率。

服务对象及主营业务

服务于中国生物医药和医疗器械公司，以及在中国开展临床研究的国外中小型生物医药 和医疗器械公司：临床试验设计及执行，试验数据分析及报告，注册文件及提交，系统 支持，功能性服务， 以及咨询服务（临床研发及注册策略咨询，技术咨询，国外开展临 床试验及注册的咨询）。

服务于跨国生物医药和医疗器械公司（立足于中国，服务于全球临床试验）： 生物统计，临床试验数据管理，临床编程，医学报告撰写，药物不良反应事件评估及风险管理，注册文件支持及运作，质量监控及稽查。

合作模式

战略合作 – 提供长期、多维度、跨地区的服务与战略合作伙伴关系。

业务流程服务外包 -- 提供高效率的、有成本优势的、灵活方便的业务流程外包服务。

咨询服务 -- 依照客户需求，提供各种灵活快捷的科学和战略方面的咨询性服务。

质量监督--代表客户或者与客户紧密合作，使用高质量的系统和关键评价指标，确保其他供应商为客户提供的服务是高质量的和有一致性的。

风险共担 – 与客户携手共同投资和开发，共同承担风险。

dMed Biopharmaceutical Company Limited is a clinical Contract Research Organization (CRO), providing high-end services to innovative biopharmaceutical and medical device companies. dMed is committed to increasing the probability of success of R&D products. Its services include scientific, strategic, regulatory and quality assurance related consultation for clinical development and product registration; clinical trial design and execution; clinical data management, statistical analysis, medical writing; pharmacovigilance and risk management; and clinical trial quality system and assurance.

Our Clients and Services

Provide service for domestic biopharmaceutical and medical device companies and small and medium-sized biopharmaceutical and medical device companies interested in China market End-to-End Services including Clinical Trial design and conduct, clinical trial data Analysis and Report, Regulatory submission, Systems support, Functional Services, comprehensive Consultation Services (clinical development plan and regulatory strategies, scientific consultation, international facilitation for clinical trial execution and registration).

Provide service for multinational biopharmaceutical and medical device companies (In China for China & In China for Global), such as Statistics, Data Management, Programming, Medical Writing, Pharmacovigilance and Risk Management, Regulatory documentation support and operations, Quality Assurance & Audit.

Our Solutions

Strategic partnership–a mid to long term relationship in broad spectrum of services, processes or geographic scopes.

Full Service–provide holistic solution and services from development planning to regulatory submission as well as post-marketing support.

Functional Service–Business process outsource with cost-effectiveness, or strategic resource flexibility.

Consulting Service–Scientific and strategic consultation in flexible way upon client needs.

Oversight–Partner with or act on behalf of client to ensure consistency with quality system and key metrics.

Risk Sharing partnership–Co-invest in drug development process and share risks.

零氪科技（北京）有限公司
LinkDoc Co., Ltd.

零氪科技于2014年11月成立，作为全球领先的人工智能与医疗大数据平台，拥有国内最大规模和体量的医疗大数据资源库和最具优势的技术支撑服务体系，目前已在全国范围内为政府部门、各级医疗机构、国内外医疗器械厂商、药企等提供高质量的临床与科研数据整体解决方案。

零氪科技凭借在医疗大数据整合、处理和分析上的核心技术优势，依托先进的医疗人工智能工具，致力于为社会和行业提供大数据辅助决策（辅助管理、辅助科研、辅助临床诊疗）、医院舆情监控及品牌建设、药械研发、保险控费、患者全流程管理等一体化服务。

公司创始人团队来自腾讯、百度、麦肯锡、阿斯利康等五百强企业高管以及政府和行业协会，具有多年行业从业经验。公司总人数已达800人，其中，有200人的技术团队专注人工智能及大数据技术的开发，专业涵盖：人工智能、技术架构、产品设计、数据安全、数据挖掘、系统工程、计算机视觉、临床医学等多个领域。同时在全国31个省市及自治区拥有专业医学临床服务团队300余人，服务全国近500家三甲医院。

Founded in November of 2014, as a world leading AI and medical big data platform, LinkDoc has processed the largest scale and volume medical data and provided the most advantageous technical solutions in China. LinkDoc has been providing solutions integrated with high quality clinic and scientific research data to governments, various levels of medical institutions, domestic and foreign medical device manufacturers, pharmaceutical companies, etc. throughout the country.

With the advantages of core technologies in medical big data integration, processing and analysis, and advanced medical AI tools, LinkDoc is committed to providing integrated service as big data aided decision-making (management, scientific research, clinical diagnosis and treatment), hospital media coverage monitoring and brand building, medical device research and development, insurance cost control, patient whole-process management, etc.

The founders of the company are experienced entrepreneurs and professionals from top 500 enterprises such as Tencent, Baidu, McKinsey, AstraZeneca as well as government and industry associations, with years of experience in the field. The total number of staff has reached 800, including a team of 200 technicians focusing on AI and big data technology development in such fields as artificial intelligence, technical architecture, product design, data security, data mining, system engineering, computer vision and clinical medicine. In addition, the company has a clinical service team of more than 300 professionals in 31 provinces and municipalities around China, which servers nearly 500 top hospitals in China.

中国药科大学

China Pharmaceutical University

中国药科大学是一所历史悠久、在药学界享有盛誉的教育部直属“211工程”重点建设的大学，坐落于历史文化名城古都南京。前身为始建于1936年的国立药学专科学校（四年制），是我国历史上第一所由国家创办的高等药学学府。

学校学科涵盖理学、医学、工学、经济学、管理学、文学、法学7个学科门类。药学一级学科为国家重点学科。2015年，学校药理与毒理学、化学以及临床医学三个学科领域的ESI排名进入全球前1%。药理与毒理学学科发文量居国内高校之首。学校现有25个本科专业、5个专科（高职）专业、 药学、中药学2个一级学科博士点、24个二级学科博士点、5个一级学科硕士点、36个二级学科硕士点，5个专业学位授权点；药学、中药学2个博士后流动站。23个学科专业可招收博士后研究人员。

学校是全国医药院校中唯一一所连续三次获得国家级教学成果一等奖殊荣的高校。2014年，学校推荐申报的3项教学成果全部荣获第七届国家级教学成果二等奖，囊括该届国家级药学教育类教学成果奖所有奖项。学校就业率一直位列教育部直属高校及江苏省高校前茅。2014届本科毕业生就业率位列教育部直属高校第一名。

学校推进科研创新，研发普惠良药。建有“天然药物活性组分与药效”国家重点实验室和省部级重点实验室、工程技术中心、创新平台18个。与海外40多个国家和地区的院校及科研机构建有学术联系。“十二五”以来，获国家“重大新药创制”科技重大专项课题26项，经费资助达1.78亿元，获批项目数、经费数均居全国高校之首。获国家科技进步二等奖2项，获国家新药证书2本、新药临床批文6个、授权发明专利410件；发表SCI论文3919篇。

截止2015年底，学校全日制在校生15000余人，其中：研究生3600余人，本专科生近12000人。专任教师910人，其中：中国工程院院士2人、德国科学院院士1人、“国家杰出青年科学基金”获得者5人、“长江学者”6人、“千人计划”入选者2人、“万人计划”入选者3人。学校现有玄武门、江宁2个校区，占地近2100亩。

今天的中国药科大学，正朝着建设国际知名的高水平研究型大学的目标努力迈进。

China Pharmaceutical University (CPU), situated in the historical and cultural city of Nanjing, is one of the “211 Project” key universities affiliated to the Ministry of Education (MOE) of China. It has been known for its long history and high reputation in China’s pharmaceutical field. CPU was founded in 1936 as China’s first independent four-year National College of Pharmacy and the first public institution for higher pharmaceutical education in the country.

CPU provides a wide variety of disciplines in sciences, medicine, engineering, economics, management, arts and law. Its first-level discipline of pharmacy is enlisted as the National Key Discipline. In 2015’s ESI ranking, its pharmacology and toxicology, chemistry as well as clinical medicine entered the world’s Top 1%. Its publications in pharmacology and toxicology ranked top among all universities in China. CPU offers 25 bachelor’s degree programs, 5 associate (polytechnic) programs, 24 research-oriented doctoral degree programs under the two first-level disciplines of pharmacy and traditional Chinese pharmacy, 36 research-oriented master’s degree programs under its 5 first-level disciplines, 23 post-doctoral research programs under its two first-level disciplines of pharmacy and traditional Chinese pharmacy as well as 5 professional degree programs at the master’s level.

CPU is the only one among all medical and pharmaceutical colleges & universities that has won first prizes of the National Outstanding Teaching Achievements for three times consecutively. In 2014, all its three recommended projects for the National Outstanding Teaching Achievement Awards won the second prizes, covering all the awards for pharmaceutical education. The employment rate for its graduates has always been ranking on the top among all universities affiliated to MOE and all the local colleges and universities in Jiangsu Province. In the Year 2014, its undergraduate employment rate ranked No. 1 among all universities directly under MOE.

The University promotes innovation in research and aims to develop effective medicines for public health. It has 18 key laboratories, engineering centers and innovation platforms, including the State Key Laboratory of Natural Medicines. The university has established academic collaboration with universities and institutions in over 40 countries and regions. In China’s National Key High-Tech Innovation Project for the R&D of Novel Drugs, the university has undertaken 26 major projects with a total fund of 178 million RMB, No.1 among all universities in China in terms of either the total number of projects or the total amount of funds. Our researchers won two second prizes of the National Science & Technology Progress Award and obtained 2 new drug certificates, the approval documents for clinical trials of 6 new drugs as well as 410 authorized patents. We published 3919 papers in SCI-indexed journals.

By the end of Year 2015, CPU hosts more than 15,000 full-time students, including around 12,000 undergraduates and over 3,600 postgraduates. It has 910 full-time faculty, including 2 members of the Chinese Academy of Engineering, 1 member of the German Academy of Sciences, 5 winners of research funds for the “National Outstanding Youths”, 6 “Changjiang Scholars”, 2 scholars in China’s “Two Thousand Talents Program" for returned high-level talents from overseas and 3 scholars in China’s “Ten Thousand Talents Program". The University is composed of two campuses, namely the Xuanwumen Campus and the Jiangning Campus, which cover a total area of about 2100 mu (or 140 hectares).

Today, CPU is striving forward to build itself into a world-famous, high-level and research-oriented university.

沈阳药科大学

Shenyang Pharmaceutical University

沈阳药科大学是一所具有光荣革命传统的学校，前身为1931年诞生于江西瑞金的中国工农红军卫生学校，是我国历史最悠久的综合性药科大学。学校总占地面积143.45万平方米，总建筑面积70.4万平方米。

学校目前已发展成为多学科、多层次、多形式教育的高等药学学府，设有药学院、制药工程学院、中药学院、生命科学与生物制药学院、工商管理学院、医疗器械学院、功能食品与葡萄酒学院、社科与文体学院、继续教育学院和亦弘商学院10个学院。在1154名教职工中，专任教师657名，其中教授114名，副教授228名。现有中国工程院院士1人，长江学者特聘教授1人，中组部“千人计划”国家特聘专家1人，国务院药学学科评议组成员1人，新世纪百千万人才工程国家级人选3人，现有在校研究生2419名（博士443、硕士1976）、本科生8522名、成人函授生4985名。

学校始终以医药及相关行业发展需求为导向，围绕学校办学定位、突出药学学科优势、坚持药学教育主线，适度拓展本科专业布局，持续优化本科专业结构，逐步形成了以药为主，跨医、工、理、管、经5个学科门类10个专业类的本科专业结构布局。共设置20个本科专业，其中国家级特色专业5个。学校是国家批准有权授予博士学位、硕士学位和招收港、澳、台地区学员及外国留学生、国内高中保送生的院校。现有博士后流动站2个（药学、中药学），一级学科博士学位授权点2个，二级学科博士学位授权点19个，一级学科硕士授权点7个，二级学科硕士授权点51个，硕士专业学位授权点4个。药剂学科为国家级重点学科，中药分析学为国家中医药管理局“十二五”中医药重点学科，药学和中药学为辽宁省高等学校一流特色学科。“十一五”以来，学校共主持承担国家、省、市等各级各类课题945项，其中国家“863”、“973”、国家重大科技专项、国家科技支撑计划、国家自然科学基金等国家级课题288项，经费到款4.26亿元。与企业签订技术贸易合同、协议1733份，成交额4.49亿元，到款额1.95亿元。

学校积极开展国内外学术交流与合作，与美国、日本、英国、俄罗斯等19个国家和地区的63所高等院校及科研机构建立了合作关系。

面向未来，学校坚持“团结、勤奋、求实、创新”的校训精神，并在“立足药学，突出特色，注重质量，创新发展”的理念指导下，持续提升学校的核心竞争力和国际化办学水平，加快建设成为药学教育领域特色鲜明、国内一流、国际知名的高水平大学。

Shenyang Pharmaceutical University is a school has a glorious revolutionary tradition, the predecessor was born in 1931 in Jiangxi Ruijin Chinese Red Army of Workers and Peasants Health School, is the oldest comprehensive pharmaceutical university in our country. The school covers an area of 1.4345 million square meters, with a total construction area of 704,000 square meters.

The university now has developed into a multi-disciplinary, multi-level, multi-forms of education in higher medicine university. It contains 10 schools,including school of pharmacy, school of pharmaceutical engineering, school of traditional Chinese medicine, school of life science and biological pharmaceutical, school of industrial and commercial management, school of medical apparatus and instruments, school of functional food and wine, school of social sciences and literary style, school of continuing education, and also Hong Business school. In 1154 faculty members, there are 657 full-time teachers including 114 professors, 228 associate professors.Existing Chinese Academy of Engineering 1, the Yangtze River scholar Professor 1, the Central Organization Department, “thousands of plans,” National Distinguished experts, the State Council pharmacy disciplines 1, New Century Talents Project national candidates 3, existing school graduate 2419 (443 Doctoral, Master 1976), undergraduates 8522, adult students of correspondence 4985.

School has always been guided by the demands of pharmaceutical and related industries development, around the school running orientation, prominent medicine discipline advantage, adhere to the pharmacy education the main line, moderately expand the undergraduate professional layout, continuous optimization of the structure of undergraduate majors, gradually formed is given priority to with medicine, across the medical, engineering, science, management, the five disciplines ten undergraduate professional class structure layout. A total set up 20 undergraduate programs, including five national professional characteristics. School is the national approval shall have the right to grant doctorate, master's degree and recruit students in Hong Kong, Macao, and Taiwan and foreign students, high school unripe domestic colleges and universities. Existing post-doctoral flow station 2 (Pharmacy and Traditional Chinese medicine), first level discipline doctorate authorization 2, the second level discipline doctorate authorization 19, level discipline master's degree authorization point 7, secondary discipline master's degree authorization points 51, authorized professional master degree 4. Pharmacy disciplines as national key disciplines, medicine analytics for the State Administration of Traditional “second five” key disciplines in medicine, pharmacy and Traditional Chinese medicine Liaoning Province Academic Discipline class characteristics. “Eleventh Five-Year”, the school presided over the commitment to national, provincial and municipal levels of 945 and other topics, including the national “863”, “973”, a major national scientific and technological projects, the State Science and Technology Support Program, the National Natural Science Foundation 288 national issues, funding models to 426 million yuan. And technology trade enterprises signed contracts, agreements parts 1733, and turnover of 449 million yuan, to the amount of 195 million yuan.

The University actively carries out academic exchanges and cooperation with 63 universities and research institutions. The areas containthe United States, Japan, Britain, Russia and other 19 countries.

For the future, the school adhere to the “unity, diligence, truth-seeking, innovative” spirit of school motto, and “based on medicine, prominent characteristics, pay attention to quality, innovation and development”, under the guidance of the concept of core competitiveness and continued ascension school education internationalization level, speed up the construction become a pharmaceutical education field characteristic, high level of domestic first-class, internationally renowned university.

北京大学药学院

Peking University School of Pharmaceutical Sciences

北京大学药学院始建于1941年，是国家重点药学院之一，在学科建设、师资培养、教学、科研等方面做出了重要贡献，为我国培养了大量药学高级人才。

药学院由六系（化学生物学系，药物化学系，天然药物学系，药剂学系，分子与细胞药理学系，药事管理与临床药学系）、一室（天然药物及仿生药物国家重点实验室）、一所（应用药物研究所）、一中心（药学实验教学中心）组成。北京大学药学学科于2007年被认定为国家一级重点学科，在教育部2012年学科评估中排名第一。

学院的科学研究主要集中于心脑血管疾病、肿瘤、老年病等重大疾病，以天然药物及仿生药物国家重点实验室为核心，药物化学、生药学、药理学等重点学科为依托，在核酸药物、糖类药物、中药及天然药物等领域积累了较雄厚的基础，取得了国内领先、国际上有影响的成绩，有些研究成果已达到国际先进水平。学院承担国家自然科学基金、“973”、“863”、国家科技支撑计划、国家科技重大专项等国家级及省部级重要科研项目，参与北京大学“211”及“985”工程建设。学院获得国家自然科学二等奖4项，省部级奖励45项；近五年获得发明专利135项，发表研究论文1824篇（其中SCI收录1236篇）。2009年以来，药学院积极面向国家重大需求，承担了国家“重大新药创制”科技重大专项课题“北京大学综合性创新药物研究开发技术大平台的建设”，构建了完整的创新药物发现与研发体系，新药研发自主创新能力明显加强，目前有1个抗肿瘤一类新药被SFDA批准进入II期临床研究，另外2个一类新药进入临床研究。

药学院与国内外知名大学、科研机构、制药企业有着广泛的合作与交流，促进了国际学术影响力与科研水平的稳步提升。

北京大学药学院今后几年的奋斗目标是：逐步发展为一所学科齐全、具有国际一流水平的药学院。

Peking University School of Pharmaceutical Sciences (SPS), established in 1941, is a national key pharmaceutical school. In the past decades, SPS has made great achievements in discipline construction, faculty training, teaching, and scientific research, and has nurtured a large number of high-level pharmaceutical scientists and professionals.

SPS is composed of six academic departments (Chemical Biology, Medicinal Chemistry, Natural Medicine, Pharmaceutics, Molecular and Cellular Pharmacology, Pharmacy Administration and Clinical Pharmacy), one key laboratory (State Key Laboratory of Natural and Biomimetic Drugs), one institute (Institute of Applied Pharmaceutical Research), and one center (Pharmaceutical Teaching Laboratory Center). The pharmaceutical science discipline of Peking University became an accredited national key discipline in 2007, and was ranked the first in discipline evaluation by Chinese Ministry of Education in 2012.

The scientific research of SPS is mainly focused on major diseases including cardiovascular and cerebrovascular diseases, tumor, and senile diseases. With the State Key Laboratory of Natural and Biomimetic Drugs as the core, and with the support from key disciplines (Medicinal Chemistry, Pharmacognosy, and Pharmacology), SPS has built up a solid foundation in the scientific research of nucleic acid drugs, saccharide drugs, and natural medicines (including traditional Chinese medicines). Some research achievements have reached international top level. SPS undertakes national key research programs, including projects from National Natural Science Foundation of China (NSFC), “973” and “863” projects, and National Key Technologies R&D Programs, as well as provincial and ministerial research projects. SPS also participates in the “211” and “985” project of Peking University. SPS has won 4 National Natural Science Award (class two), and 45 awards at provincial and ministerial levels. In the past five years, SPS has obtained 135 issued patents, and has published 1824 research papers (1236 cited by SCI). To meet the primary demands of the nation, SPS has been establishing the Peking University Comprehensive Center for Drug Discovery and Development (CCDDD) since 2009, which is supported by the Primary Drug Innovation Program of National Science and Technology Mega Projects. Thus far, SPS has built up an integrated research and technology system for the discovery and development of innovative drugs. One class I anti-tumor innovative drug (IND) has entered phase II clinical trial, and two other class I INDs have been approved for clinical trial by SFDA.

SPS has extensive cooperations and communications with top universities, research institutes, and pharmaceutical enterprises at home and abroad. The international impact and academic strength of the School has been increasing in the past years.

In the coming years, Peking University School of Pharmaceutical Sciences aims to develop into a comprehensive and international top-level pharmaceutical school.

复旦大学药学院

School of Pharmacy Fudan University

复旦大学药学院创建于1936 年，是我国最具影响力的五所高等药学院校之一。现有教职员工131人，其中：正高职称37人，副高职称45人；博士生导师37名，硕士生导师67名。拥有国家“千人计划”特聘教授3名、国家“青年千人计划”人才1名、入选上海市“千人计划”特聘教授2名、973项目首席科学家2名、国家“杰出青年基金获得者”3名和“优秀青年基金获得者”1名、教育部“长江学者”特聘教授1 名、教育部新世纪优秀人才10名、上海市领军人才1 名、上海市优秀学术和技术带头人6名等。

药学院下设药物化学、药剂学、药理学和临床药学四大学科群，按药学一级学科专业招收本科生，分为药学和临床药学方向。2012年以来，已培养本科生639名、硕士生314余名、博士生84余名，受到了社会和用人单位普遍欢迎。在列年培养的学生中，有6人成为中国科学院和中国工程院院士、1人成为美国科学院院士。目前在读研究生405名、本科生（含留学生）384余名。获得国家精品课程1项（药理学）、全国百篇优秀博士学位论文2篇（药剂学）。

学院以药学基础及应用基础研究为主，兼顾新药开发，侧重于抗感染药物、抗肿瘤药物、心脑血管药物的新理论、新技术、新方法、新产品等研究。拥有智能化递药教育部和全军重点实验室、上海药物创制产业化开发中心、上海市小分子药物重点实验室、国家中医药管理局三级实验室（中药制剂、中药生药分析）等。设有仪器分析测试、计算机辅助药物设计、动物实验、药物筛选与药效评价、分子影像与示踪、药物制剂中试等多个技术支撑平台。

2012年以来，承担国家重大科学研究计划（973）、国家重大创制新药技术专项、863计划项目、国家自然科学基金等国家及省部级项目162项，到位科研经费约达1.5亿元；授权专利113项；年均发表SCI论文150篇以上；获得国家科技进步奖二等奖2项（第二和第三完成人）、教育部自然科学奖二等奖（第二完成人）和上海市科技进步二等奖（第五完成人）各1项等。

Founded in 1936, School of Pharmacy Fudan University (SPFDU) has a long history and now is one of five most influential pharmacy schools in China.The SPFDU has 131 faculties, with 37 professors and 45 associate professors, which include 37 doctoral supervisors and 67 master supervisors. There are 3 “Thousand Person Plan” distinguished professors from the national project and 1 “Thousand Youth Person Plan” professor, 2 elected “Thousand Person Plan” distinguished professors from Shanghai project, 2 chief scientists of national key scientific research project (973), 1 Yangtze Distinguished Professor recognized by the Ministry of Education, 3 National Outstanding Youth Foundation Winners, 1 National Excellent Youth Foundation Winner and other 10 cross-century talents recognized by the Ministry of Education, 1 leading figure in Shanghai,and 6 outstanding academic leaders in Shanghai.

SPFDU is organized into four main academic departments: PharmaceuticalChemistry, pharmaceutics, Pharmacology and Clinical Pharmacy. SPFDU has undergraduates majored in pharmacy and clinical pharmacy. Since 2012, about 639 undergraduate students, 314 masters and 84 PhD have graduated from SPFDU.6 of the undergraduate students have been awarded as national Academicians. Currently students of SPFDU consist of almost 405 graduate students and over 384 undergraduates including foreign students. Besides, Pharmacology was awarded as national excellent course and 2 theses about pharmaceutics were selected as the national excellent Ph.D. Thesis.

Based on pharmaceutical basic research and applied basic research, and taking account into the development of new medicine, SPFDU focuses on research about the new theories, new technologies, new methods and new products of anti-infective drugs, antineoplastic drugs and cardiovascular drugs. The School has Smart Drug Delivery laboratory, Key Laboratory of Ministry, Moleculesand Three-level laboratories of Traditional Chinese Medicine (TCM) and the TCM crude drug analysis of the State Traditional Chinese Medicine Administration. It also includes several supporting technical platforms: Specialized Integrated Platform of National New Drugs Development, Screening and Efficacy Evaluation Platform for Antivirals, Technology Platform for the development of New Formulation and New Drug Delivery System, GLP Laboratory Animal Center, Instrument Test Center.

Since 2012, SPFDU has accomplished national key scientific researches (973), major projects of national development of new drugs, 863 and national and provincial projects of the national natural science foundation162 terms. Also, SPFDU achieved funding about 1.5 billion, 113 patents, over 150 publications on SCI annually and 2 second national prize of science and technology progress, 2 first prize of natural science from the Ministry of Education, 1first prize of science and technology progress from the Ministry of Education, 1 second prize of natural science from the Ministry of Education and 1 second prize of science and technology progress from shanghai government.

中国人民解放军军事医学科学院毒物药物研究所

Institute of Pharmacology and Toxicology Academy of Military Medical Sciences

毒物药物研究所是1958年5月由军事医学科学院毒物、化学、药理三系合并而成。成立以来，研究所牢记使命，始终围绕国家和军队重大需求，走过了辉煌的历程。

历经几代科学家50多年的奋斗，针对外军装备的6类14种制式化学战剂，我所建立了完备的防化医学体系，带领我国防化医学实现了从无到有，从弱到强的历史性转变。目前全军装备的14种防化药品全部由我所研制，特别是抗神经性毒剂特效药是我国药物发展史上结构全新药物研发的典范。以抗神经性毒剂防治药物研究作为重要组成部分的“战时特种武器防害医学防护”获得了医药卫生领域迄今为止唯一的国家科技进步特等奖。

21世纪以来，我国生物安全形势面临严峻考验。2005年，我国各地禽流感频发，有演变为当年SARS危机可能。时任国务院总理温家宝亲临我所召开应急防控会议，要求尽快研制抗流感特效药。我所临危受命，在短时间内突破国外技术壁垒，创新建立了磷酸奥司他韦生产工艺按时完成国家战储任务。2011年，全球最大磷酸奥司他韦原料药生产线通过国家验收，标志我国流感防控药物生产和储备不再依赖国外。

我所建立以来，共获得国家和军队新药证书73个，其中国家一类新药证书7个，形成了以抗毒、抗神经精神疾病、抗病毒及超级菌研究为优势特色的创新药物研发体系。研究所目前拥有国家重点实验室、国家工程技术研究中心、国家战略药品研发基地、国家药品安全评价和食品安全风险评估等五个国家级创新药物研发平台，是我国创新药物研究的一支重要力量。

Institute of Pharmacology and Toxicology, Academic Military Medical Sciences established in 1958, is a comprehensive institute composed of a good variety of disciplines, including pharmaceutical chemistry, pharmaceutical analysis, pharmaceutics, drug metabolism, pharmacology, hygienic toxicology, experimental pathology and biochemistry.

Orienting to the studies of novel medications, BIPT has advanced instruments and facilities as well as the advanced means and techniques in all the fields of research and development (R&D) of new drugs, and it has been able to complete independently the whole process of preclinical researches concerning the development of a new drug. It usually involves the drug design, synthesis, pharmacological evaluation, safety evaluation and supply of preparations for clinical trials. Several new drugs involved in antihypertensive, analgesics, diabetes mellitus, antiviral, has been developed successfully.

中国医学科学院北京协和医学院医药生物技术研究所

Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College

中国医学科学院北京协和医学院医药生物技术研究所（原名抗生素研究所）成立于1958 年，是我国抗感染药物的主要研发单位，也是我国第一支青霉素的诞生地，为我国抗生素的研发、人才培养及工业化生产起到了奠基的作用，在我国重大疾病、尤其是传染病的防控中作出了突出贡献。随着生物学理论与技术进步和社会的发展，药物研究的范围扩展至肿瘤、心血管、免疫调节等领域，1986 年研究所更名为医药生物技术研究所。

研究所现有在职人员约300人，包括中国工程院院士，国家（部）级“突出贡献中青年专家，长江学者特聘教授，国家自然基金委创新群体、杰出青年和优秀青年基金获得者，研究生导师，客座教授等。在读博士、硕士学位研究生约150人。

进入21 世纪后，研究所被国家确立为公益性研究机构，加强了药学基础研究平台的建设和国际合作，研究所的“微生物与生化药学”成为国家重点学科，是我国药物研究、硕博研究生教学和科学技术产业化的核心基地之一。

The Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, was founded in 1958 as the Institute of Antibiotics, a national key institute for developing drugs to combat infectious diseases in China. As the place of giving birth to the first ampule of penicillin in China, the Institute laid a solid foundation for discovery and development of antibiotics, nurturing professional talents and industrial production of antibiotics. The institute has also made great contribution to the prevention of cancer, cardio-vascular system disease and immune system disease, etc. In 1986, the institute was changed name as Institute of Medicinal Biotechnology.

Today, there are about 300 employees in the institute including Academicians of the Chinese Academy of Engineering, National Outstanding Scientists, Cheung-Kong Scholars, Creative Research Groups of the National Natural Science Foundation of China (NSFC), Distinguished Young Scholars and Excellent Young Scientists of NSFC, Postgraduate Student Supervisors, and Visiting Professors, etc. There are about 150 doctoral degree and master degree candidates.

In the 21st century, as the social commonwealth research institute, the institute has strengthened platform building for basic research of pharmacology and international cooperation. Meanwhile, microbial and biochemical pharmacy in the institute was evaluated and authorized as national key subject by Ministry of Education, P.R.China. Now the institute becomes as one of the central primary base for drug research, postgraduate education and industrialization of scientific and technology in China.

首都医科大学附属北京天坛医院

Beijing Tiantan Hospital, Capital Medical University

首都医科大学附属北京天坛医院始建于1956年，是一所以神经外科为先导，神经科学为特色，集医、教、研、防为一体的大型现代化三级甲等综合教学性医院。经过半个多世纪的艰苦创业和奋发努力，医院实现了跨越式发展，医疗技术水平以及医院的知名度跻身于国内一流医院的行列。

目前医院现有床位1150张，设有30余个临床科室和11个医技科室，年门诊量达百万以上、年住院病人近3万人次，拥有各类先进的医疗设备。

Founded in 1956, Beijing Tiantan Hospital affiliated to the capital medical university, a quaternity consisting of medical treatment, scientific research, medical education and disease especially associated with neurosurgery serving as a precursor. Through hard work and strenuous efforts for more than half a century, the hospital has already achieved leap-and-bound development and ascended into the top-level hospitals in China in terms of medical technology and hospital fame.There are 1150 beds over 30 clinical departments and 11 adjunct departments at present in hospital equipped with various advanced medical equipments, and furthermore, patient visits steadily increased tallying up to over 1,000,000 outpatient visits per year and 30,000 inpatient admissions per year.

北京市纳微化结构药物工程技术研究中心

Beijing Nanostructured Drug Engineering & Technology Center

北京市纳微化结构药物工程技术研究中心依托北京化工大学有机无机复合材料国家重点实验室和北京万生药业有限公司，利用具有自主知识产权的超重力技术和理论，完成难溶性药物及靶向药物的纳微化制备，进而形成新药研发产业化级技术，实现纳米药物产业化规模，增强生物医药领域创新能力，提升新药开发水平和制药行业的产业技术进步。

中心通过药物纳微化关键技术的研究，突破了纳米药物产业化技术的瓶颈，创制了高性能低成本的纳微结构药物颗粒的超重力制备新方法，并实现了工业示范生产，与华药集团倍达制药有限公司、浙江新和成股份有限公司合作，分别开发建成了40吨/年的纳米头孢呋辛酯和5000吨/年纳微结构维生素A颗粒超重力法制备工业生产线，成为国际上首次实现超重力过程强化技术在生物药物材料领域应用的工业化事例，产生了良好的经济和社会效益。

中心自成立以来，以市场需求为导向，已取得突破性进展，研制的纳米降血脂药物非诺贝特完成全部临床前研究工作，2015年获得SFDA临床批件（2015L06032）。目前中心正与多个世界著名前十强制药大公司合作，进行药物颗粒纳米化技术的研究和开发。纳微结构药物颗粒超重力法制备新工艺获得2008年教育部技术发明一等奖。

Beijing Nanostructured Drug Engineering & Technology Center was established backed by State Key Laboratory of organic-inorganic composites of BUCT and Beijing Wansheng Pharmaceutical Co., Ltd. The center aims to complete the nanofabrication of poorly water-soluble drugs and targeted drugs by utilizing the independent intellectual property rights of HIGEE technology and theory, in order to format the industrialized technology of new drugs' research, to achieve the scale of industrialization of nano-drugs, to enhance the ability of innovation in the field of biomedical drug, to promote the level of new drug development and the progress of industrial technology in pharmaceutical industry.

The center has conquered the bottleneck of nano-drug industrialization technology and created a new method of HIGEE for high-performance and low-cost nanostructured drug particles and successfully brought industrial demonstration production into reality in the process of solving crucial technology of nano-drug fabrication. Through the cooperation with North China Pharmaceutical Group Beta Pharmaceutical Co., Ltd. and Zhejiang NHU Company Ltd., a 40 tons/year of nano-CEFUROXIME AXETIL production line and a 5000 tons/year of nanostructured vitamins A particles production line were developed by HIGEE technology, respectively. The production lines have become the first industrialized case in the world to be applied in pharmaceutical materials by using the technology of HIGEE, additionally good economic and social benefits has emerged.

The center has made some breakthroughs by following the market demands since its establishment. A lipid-lowering drug, Fenofibrate Nanotablets, all it's preclinical research has been completed and SFDA clinical approval (No.2015L06032) was obtained in 2015. The center is currently working in conjunction with a number of the world's top-10 pharmaceutical companies in research and development of drug nanoparticle. The New HIGEE Technology for Nanostructured Drug won the first prize of the Technological Invention Award of the Ministry of Education in 2008.

中国药促会大事记（2016年12月–2017年10月）

2016年

12月3日

中国药促会药物研发专委会和药物临床研究专委会2016年年会在广东顺德举行。此次会议促进了创新企业与临床研究机构的深入交流，为推动企业积极开展创新药物研发，提高临床试验质量，提供了难得的宝贵经验。

2017年

1月16日

中国药促会“关于药品管理法知识产权保护相关条款的研究”研讨会在北京举行。

1月17日

中国药促会“我国药品价格管理体制改革研究”课题结题会在北京召开。

2月19日-22日

中国药促会受邀参加亚太经合组织生命科学创新论坛和监管协调指导委员会会议。为中国参与亚太区监管融合、创新与发展提供建议与支持。

2月25日

中国药促会在杭州召开了2017年会长会议扩大会议。会议总结了十届会员大会第三次会议以来的重点工作、审议通过了2017年重点工作安排，参会代表围绕创新药医保谈判遴选原则与标准和药品管理法等法规修订相关问题进行了讨论并提出了建议。

2月25日

经2017年会长会议扩大会议审议通过，北京市纳微化结构药物工程技术研究中心、江苏康缘药业股份有限公司和成都百裕制药股份有限公司正式加入中国药促会。

3月11日

由中国药促会主办的新药创制科技重大专项十二五、十三五重大成果项目暨第六届凯美纳中国经验分享会SUCCESS & 瑞普基因二代测序新品发布会在海南召开。

3月12日

由中国医学科学院、中国中医科学院、中国药促会和人民网联合主办的“第二届（2016）中国医药创新品牌系列评选活动”颁奖典礼在京隆重举行。经业界专家推荐，汇总网络公众投票和专家评审结果，本届评选活动评出的17个奖项分别代表了中国医药创新领域的人物、企业和产品，弘扬了民族企业精神、塑造了中国医药品牌。

3月31日

中国药促会执行会长宋瑞霖一行走访了会员单位正大天晴药业集团股份有限公司，参观了正大天晴研究院、异甘草酸镁（天晴甘美）制剂车间、恩替卡韦原料生产车间和制剂生产车间，并与正大天晴总裁王善春及相关企业负责人进行了座谈。

4月1日

中国药促会执行会长宋瑞霖一行走访了会员单位江苏康缘药业股份有限公司，并参观了康缘药业现代中药研究院。

4月5日-6日

中国药促会执行会长宋瑞霖与副会长刘殿波应JPMA邀请，出席第6届亚洲制药协会合作会议，并会见了JPMA国际委员会委员长平手晴彦等代表。

4月7日

中国药促会执行会长宋瑞霖、副会长刘殿波一行考察波士顿咨询研究机构、日本卫生和全球政策研究所、日本最大的医药CRO公司CIMIC、TMI律师事务所等相关机构，就日本医疗保障体系、药品知识产权及药政管理等有关问题进行深入了解。

4月12日

中国药促会“我国创新药品医保准入路径研究”课题开题会在北京召开。

4月20日

中国药促会收到福建省有关部门对我会提出的《关于对福建药品限价阳光采购相关问题的建议》的答复。

5月4日

中国药促会组织撰写的以“从仿制到创新”为主题的系列文章在施普林格·自然集团（Springer Nature）旗下出版的《Nature》杂志刊登，系统展示了近十年来中国医药从仿制向创新转型取得的显著成果。

5月17日

北京加科思新药研发有限公司、北京诺诚健华医药科技有限公司正式加入中国药促会。

5月18日

中国药促会执行会长宋瑞霖会见了到访的国际药品制造商协会联合会副总干事布莱登·肖博士，双方就未来多领域深度合作等重要议题进行了热烈讨论，并达成广泛共识。

5月19日

中国药促会执行会长宋瑞霖作为受邀专家参加国务院汪洋副总理主持召开的国务院部门协调会议，就改革药品知识产权制度发言，为促进中央认可在我国建立药品专利链接、专利期补偿等制度可行性提供了行业参考意见。

5月20日

中国药促会主办的“康弘药业‘朗沐’上市3周年庆典活动”在北京举办。

5月23日

中国药促会执行会长宋瑞霖会见了到访的世界知识产权组织北京办事处高级代表，双方就知识产权保护包括药品专利保护、药品

专利链接制度研究等方面的合作进行了卓有成效的会谈。

5月24日

中国药促会与施普林格·自然集团（Springer Nature，）签署了战略合作意向书，以推动双方在中国医药重大创新成果展示、学术交流、学术会议以及品牌推广等领域的深入合作。

5月25日

中国药促会药物研发专业委员会主任委员张丹，候任主任委员王印祥会见了日本制药工业协会药物开发联盟工作组组长武田制药高级总监Atsushi Hasuoka博士一行，双方就两协会如何在未来共同促进亚洲医药创新与投资、满足亟待解决的临床需求等议题展开了深入的交流。

6月9日

中国药促会在烟台召开了“药品专利链接和专利期补偿制度研讨会”。会议就中国引入药品专利链接制度与专利期补偿制度的可行性以及如何落地等热点问题进行了讨论。国家食品药品监督管理总局、国家知识产权局、卫生计生委等部门相关领导及会员单位代表和专业委员会专家近70人出席了会议。

6月10日-11日

由中国药促会、中国心血管健康联盟、中国抗血栓药物治疗联盟共同主办的“第二届中国临床研究质量管理（GCP）暨创新药研发大会”在山东省烟台市召开。大会围绕如何建立符合国际标准的临床多中心药物临床试验研究体系，推动国内创新药物研发与国际接轨等问题展开了深入讨论。来自药品审核查验机构、医疗机构和医药企业的多位专家，还有来自本土创新型企业和跨国医药企业的医药专家，以及临床研究机构和企业的相关工作人员共计300余人出席了会议。

6月10日

中国药促会医药政策专业委员会、药物临床研究专业委员会、药物研发专业委员会换届会议暨第二届第一次工作会议在烟台顺利召开。会议选举产生了第二届专委会委员、副主任委员、主任委员；总结了第一届专委会的工作成果并研究探讨了第二届重点工作安排。来自国内知名临床医院、高等院校和科研院所的临床、药学和医药政策研究专家，以及来自会员单位的行业药物研发专家等一百余人出席了专委会工作会议。

6月20日

中国药促会“我国基层医疗机构慢性病治疗药物管理制度研究”课题开题会在北京召开。

6月26日-7月4日

中国药促会2016-2017年度会长丁列明率团赴欧进行访问。期间，中国药促会代表团受邀出席了IFPMA会长会议和理事会会议，并先后访问了世界卫生组织总部、法国制药企业协会、法国赛诺菲公司总部、世界贸易组织、世界知识产权总部、德国研究型制药企业协会、德国拜耳公司、德国工业联合会、绿叶制药集团德国分公司等多家机构。

7月21日

中国药促会和中国药师协会共同主办的以“发挥药师服务能力，助力健康中国”为主题的第八届中国医院药学政策论坛在银川召开。来自人社部、中国药促会、中国药师协会等单位的相关领导

和各医疗机构的药剂科主任、临床专家，以及来自全国各地药学领域的代表近400人参加了会议。

7月28日

浙江华海药业股份有限公司、缔脉生物医药科技(上海)有限公司和北京德福悦安投资顾问有限公司正式加入中国药促会。

8月8日

中国药促会“美国医药产业的创新发展政策及对中国医药产业发展借鉴研究”结题会在北京召开。

8月25日

第二届“中国医药创新与投资大会”组委会在京召开媒体见面会，向媒体记者介绍了第二届大会的筹备情况和工作进展。中国药促会执行会长宋瑞霖等主办方领导、部分支持单位及国际机构代表出席了见面会。

9月15日

中国药促会在山东烟台召开2017年度会员单位联络秘书工作会议。

9月16日-17日

由中国药学会、中国药促会和烟台市政府共同主办的以“创新、合作、投资、发展”为主题的2017医药创新与发展国际会议在烟台隆重召开。“千人计划”生物医药专家、中国医药工业百强企业负责人和跨国公司高管等400人出席了会议。

9月16日

中国药促会与烟台市人民政府在“2017医药创新与发展国际会议”上签署了共建国际生命科学创新示范区合作协议。

9月20日

百济神州（北京）生物科技有限公司、前沿生物药业（南京）股份有限公司、武汉禾元生物科技股份有限公司、珐博进（中国）医药技术开发有限公司、西藏易明西雅医药科技股份有限公司、华融证券股份有限公司正式加入中国药促会。

10月9日

中国药促会提名的9名专家全部通过审核并正式成为IFPMA ICH专家工作组成员。受CDE委托，中国药促会已派出专家进入CDE工作组参与相关指导原则的讨论工作。

10月10日

由IFPMA、中国药促会和RDPAC共同主办的IFPMA实践伦理准则培训会议在北京亮马河饭店举行。会议旨在通过开展以IFPMA实践准则为基础的商业伦理培训的方式，推动中国医药行业伦理准则的建设与实践，优化市场竞争环境与秩序。

10月13日

中国药促会“创新药品医保支付标准形成机制研究-以日本经验为研究重点研究项目”开题会在北京召开。

10月28日

由中国药促会主办、沈阳药科大学承办的国家创新药物产学研战略联盟第五次会议暨医药政策解读与科技成果推介会在苏州召开。

10月28日

中国药促会正式成为亚洲制药组织合作会议（APAC）成员，并受邀参加即将召开的第7届APAC会议。

10月28日

中国药促会与苏州工业园区管理委员会就“中国医药创新与投资大会”的背景、内容、意义及相关配套政策达成共识并签署了合作协议。2018、2019年“中国医药创新与投资大会”将继续在苏州工业园区举办。

10月29日

由中国药促会等协会主办的第二届“中国医药创新与投资大会”在苏州工业园区盛大开幕。大会开幕式紧紧围绕医药创新政策、投资走向、创新模式与投资的交互影响等问题展开讨论。共有9个重磅新药的最新临床研究数据在开幕式后的临床数据首发专场进行了发布。CFDA副局长孙咸泽和国家卫计委副主任曾益新等领导及来自国内外投资、医药创新企业与研究院所等700余家机构、约2000名代表出席了开幕式。

10月29日

中国药促会、台湾-生技医疗产业策进会、香港生物医药创新协会、澳门-国际中药质量研究会在第二届“中国医药创新与投资大会”开幕式上共同签署了《两岸四地生物医药创新合作协议》。宣告四家协会将发挥民间协会平台优势，共同促进中国生物医药创新的发展繁荣。

10月29日

中国药促会与美国癌症研究基金会（NFCR）在第二届“中国医药创新与投资大会”开幕式上签订了合作备忘录，双方将建立长期的“中美肿瘤医药创新合作机制”，共同搭建中美肿瘤医药创新合作平台推动抗肿瘤药物的研发与创新。

10月29日

中国药促会主办的以“贯彻十九大精神，落实两办意见”为主题的创新企业座谈会在苏州金鸡湖会议中心召开，国家卫计委副主任曾益新及科教司、药政司负责同志出席会议，并听取了企业及研究所的具体情况介绍，表示在下一步的工作中充分吸取意见与建议。

10月29日

中国药促会第十届会员大会第四次会议在江苏省苏州市召开。国资委、中国工业经济联合会等有关部门领导及中国药促会88家会员单位160多位代表参加了会议。大会听取并审议了中国药促会年度工作报告、《中国药促会2016-2017年度会费收支情况报告》、《关于设立中国医药创新促进会创新研发服务专业委员会的议案》，并以无记名投票的方式通过了《关于修订<中国医药创新促进会章程>的议案》和《关于修订会费标准的议案》、选出了2018-2019年度候任会长和副会长。

10月29日

经中国药促会第十届会员大会第四次会议审议通过，中投海外直

接投资有限责任公司、平安银行医疗健康文化旅游金融事业部、天津博信鑫元资产管理股份有限公司、成都博远嘉昱创业投资合伙企业（有限合伙）、上海景旭创业投资有限公司、第一创业证券股份有限公司、荣昌生物制药（烟台）有限公司、北京泛生子基因科技有限公司、山东罗欣药业集团股份有限公司、赛生医药江苏有限公司、零氪科技（北京）有限公司正式加入中国药促会。

10月29日

中国药促会邀请部分会员企业代表与香港交易所召开闭门座谈会，就香港交易所即将设立的创新板展开讨论。

10月30日-31日

第二届“中国医药创新与投资大会”举行了上市公司路演、非上市公司路演、医疗器械项目路演、美国肿瘤药项目路演、台湾项目路演及澳大利亚与加拿大项目路演。经过前期踊跃报名和大会组委会的精心筛选，为国内外优质创新企业及极具发展潜力的项目提供了向投资界集中展示的高端平台，涵盖多个治疗领域并涉及医药全行业。

10月31日

第二届“中国医药创新与投资大会”政策论坛在苏州召开。中国药促会执行会长宋瑞霖、CFDA药品化妆品注册管理司副司长杨胜、CFDA药品审评中心副主任周思源出席会议，并做专题报告。来自医药创新与投资界的400多位代表出席会议，聆听了药品审批与审评主管部门领导及专家对深化药品制度改革、实施ICH指南的具体政策与措施的详细解读。

10月31日

第二届“中国医药创新与投资大会”投资人经验分享论坛在苏州召开。再鼎医药、元明资本、红杉资本、高瓴资本、启明创投、高特佳投资、倚锋创投等多家医药界知名投资机构的资深专家和合伙人受邀出席论坛，围绕医疗健康行业投资的热点、估值、投资者与创业者关系等业界关注的话题进行了剖析和讨论。来自医药创新与投资界的300多位代表出席了会议。

Remarkable Events of PhIRDA
(December 2016-October 2017)

Year 2016

December 3

2016 Annual Meeting of PhIRDA Drug R&D Specialty Committee and Clinical Research Specialty Committee was held in Shunde, Guangdong Province. The meeting promoted the in-depth exchange of innovative enterprises and clinical research institutes, and provided precious experience in promoting enterprises to actively carry out new drug R&D, and improve the quality of clinical trials.

Year 2017

January 16

Seminar on “Research on Drug Administration Law Concerning Intellectual Property Protection” was held in Beijing by PhIRDA.

January 17

Closing Seminar on “Research on the Reform of Drug Price Management System in China” was held in Beijing by PhIRDA.

February 19-22

PhIRDA was invited to attend APEC Life Science Innovation Forum and Regulatory Coordination Steering Committee Meeting. It provided suggestions and support for China to participate in regulatory convergence, innovation and development in Asia Pacific.

February 25

2017 PhIRDA President Board Meeting was held in Hangzhou. The meeting summarized the main works after the Third Meeting of 10th PhIRDA General Assembly, and reviewed and approved key work arrangements for 2017; all attendees discussed and made recommendations on the negotiation and selection principles and standards for medical insurance of innovative drugs, and revision-related issues of Drug Administration Law and other laws and regulations.

February 25

Reviewed by 2017 PhIRDA President Board Meeting, Beijing Nanostructured Drug Engineering & Technology Center, Jiangsu Kanion Pharmaceutical Co., Ltd. and Chengdu Baiyu Pharmaceutical Co., Ltd. officially joined PhIRDA.

March 11

PhIRDA hosted the National Major New Drug Innovation Project during the Twelfth and Thirteenth Five Year Plan–The 6th Conmana Experience Sharing Conference and SUCCESS & Repugene NGS New Product Release Meeting in Hainan.

March 12

CAMS, CACMS, PhIRDA and People's Daily Online co-hosted the Award Ceremony of “The Second (2016) Innovation Brand Selection in Chinese Pharmaceutical Industry” in Beijing. With the recommendation of industry experts, and online public voting and expert review results, the activity appraised and selected 17 awards, which represent the figures, enterprises

and products in the field of pharmaceutical innovation in China respectively, and carry forward the spirit of national enterprises and shape the Chinese pharmaceutical brands.

March 31

Led by Executive President Song Ruilin, PhIRDA work team went to the member Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and visited Research Institute, Magnesium Isoglycyrrhizinate preparation workshop, Entecavir API production workshop and preparation workshop; Executive President Song Ruilin also had a productive meeting with President Wang Shanchun and the relevant responsible persons.

April 1

Led by Executive President Song Ruilin, PhIRDA work team went to the member Jiangsu Kanion Pharmaceutical Co., Ltd. and visited Kanion Modern Chinese Medicine Institute.

April 5-6

Invited by JPMA, PhIRDA Executive President Song Ruilin and Vice President Liu Dianbo attended the 6th Asia Partnership Conference of Pharmaceutical Associations, and met with Chairman Haruhiko Hirate of JPMA International Committee and other representatives.

April 7

PhIRDA Executive President Song Ruilin and Vice President Liu Dianbo visited Boston Consulting Research Institute, Japan Health and Global Policy Institute, the largest pharmaceutical CRO company CIMIC in Japan, TMI law firm and other relevant agencies, to have a deep understanding of the medical security system, pharmaceutical intellectual property and drug administration in Japan.

April 12

Opening seminar on “Research on the Access for Medical Insurance of Innovative Drugs in China” was held in Beijing by PhIRDA.

April 20

PhIRDA received the reply to Suggestions on Relevant Issues of Drug Sunshine Procurement of Restrictive Priced Medicines in Fujian Province proposed by the related departments of Fujian Province.

May 4

The serial articles themed “From Imitator to Innovator” organized and written by PhIRDA have been published on Nature of Springer Nature, to systemically show the remarkable achievements of transformation from generic drugs to innovative drugs of the pharmaceutical industry in China over the past decade.

May 17

Beijing Jacobio Pharma Co., Ltd. and Beijing InnoCare Pharma Tech Co., Ltd. officially joined PhIRDA.

May 18

PhIRDA Executive President Song Ruilin met with Brendan Shaw, Deputy Executive Director of IFPMA and had a fruitful discussion on multidisciplinary and in-depth cooperation in the near future and reached an extensive consensus.

May 19

PhIRDA Executive President Song Ruilin attended the State Council Coordination Conference hosted by Vice Premier Wang Yang as an invited expert. Executive President Song made a speech on the reform of the pharmaceutical intellectual property system, and also provided industrial reference comments for the feasibility of promoting the central government to approve the establishment of drug patent linkage, patent term restoration and other systems in China.

May 20

PhIRDA hosted "The 3rd Anniversary Celebration of Marketing of 'Conbercept' produced by Kanghong Pharmaceutical" in Beijing.

May 23

PhIRDA Executive President Song Ruilin met with the senior representative of Beijing Office of WIPO, and had a productive meeting on intellectual property protection, including the cooperation in the research of drug patent protection and drug patent linkage system.

May 24

PhIRDA signed the Strategic Cooperation MOU with Springer Nature, to promote the in-depth cooperation in fields of demonstration of major pharmaceutical innovation results in China, academic exchanges, academic conferences and brand promotion.

May 25

Chairman of PhIRDA Drug R&D Specialty Committee Zhang Dan and Elect Chairman Wang Yinxiang met with Atsushi Hasuoka, Leader of JPMA DA-EWG and Senior Director of Takeda Pharmaceutical and other representatives, and had an in-depth discussion on how to jointly promote Asian pharmaceutical innovation and investment and meet the clinical needs to be addressed urgently in the future.

June 9

PhIRDA held "Conference on Drug Patent Linkage and Patent Term Restoration System" in Yantai, and the attending leaders and enterprise representatives conducted in-depth discussions on establishing the drug patent linkage and patent term restoration system in China. Almost 70 delegates including leaders from CFDA, SIPO, and NHFPC etc., representatives from members and experts of specialty committees attended the conference.

June 10-11

The Second China Cardiovascular Disease Clinical Research Quality Management Standard (GCP) Conference was co-hosted by PhIRDA, China Cardiovascular Association and China Anti-thrombotic Drug Treatment Alliance in Yantai, Shandong Province. Representatives conduct in-depth discussions on how to establish a clinical multi-center drug clinical trial research system that meets the international standard and how to bring pharmaceutical innovation in China in line with international practice. More than 300 people attended this conference, including experts from inspection sectors, clinical institutions, pharmaceutical companies and R&D institutions and senior representatives from domestic and foreign innovative enterprises attended this event.

June 10

The General Election of Medicinal Policy, Drug R&D, Clinical Research Specialty Committee and the First Meeting of the 2nd General Assembly was successfully held in Yantai. The Conference selected the members, Vice Chairman and Chairman of the 2nd General Assembly of Specialty Committee; it also summarized the work achievements of the first Specialty Committee Conference and studied and discussed the arrangement of major works of the 2nd Specialty Committee. More than 100 participants attended this event including the clinical, pharmaceutical and medical policy research experts from well-known clinical hospitals, universities and research institutes and drug R&D experts from members.

June 20

Opening Seminar on "Research on Chronic Disease Treatment Drug Management System of Primary Medical Institutes in China" was held in Beijing by PhIRDA.

June 26-July 4

Led by PhIRDA Chairman 2016-2017 Ding Lieming, PhIRDA Delegation was invited to Europe to attend the President Meeting and Council Meeting

of IFPMA, and successively visited the WHO headquarter, LEEM, Sanofi headquarter, WTO, WIPO, VFA, Bayer AG, BDI and Luye Pharma AG (Miesbach) etc.

July 21

The 8th China Hospital Pharmacy Policy Forum co-hosted by PhIRDA and Chinese Pharmacists Association was successfully held in Yinchuan on July 21st, 2017. Nearly 400 people attended the forum, including relevant leaders from MOHRSS, PhIRDA and Chinese Pharmacists Association, and pharmacy directors from medical institutions, clinical experts and representatives in pharmacy field from all over the country.

July 28

Zhejiang Huahai Pharmaceutical Co., Ltd., dMed Biopharmaceutical Co., Ltd., and GL Capital Group officially joined PhIRDA.

August 8

Closing seminar on “Policies Encouraging Pharmaceutical Innovation in U.S. and Its Reference for the Development of Chinese Pharmaceutical Industry” was held in Beijing by PhIRDA.

August 25

The press-conference of 2017 China BioMed Innovation and Investment Conference was held in Beijing to introduce the preparations and work progress of the conference to the journalists. PhIRDA Executive President Song Ruilin, leaders of sponsors, and representatives of some support organizations and international agencies attended this event.

September 15

The 2017 PhIRDA Contact Representative Meeting was held in Yantai, Shandong Province.

September 16-17

Co-hosted by CPA, PhIRDA and Yantai Municipal Government, 2017 International Conference on Pharmaceutical Innovation and Development themed “Innovation, Cooperation, Investment and Development” was held in Yantai. Over 400 participants attended this event, including biomedical experts of “Thousand Talents Program”, senior managers of top 100 pharmaceutical enterprises in China, and executives of multinational corporations.

September 16

The Cooperation Agreement of Co-Building International Life Science Innovation Demonstration Zone by PhIRDA and Yantai Municipal Government at the 2017 International Conference on Pharmaceutical Innovation and Development.

September 20

BeiGene (Beijing) Co., Ltd., Frontier Biotechnologies Inc., Wuhan Healthgen Biotechnology Corp., FibroGen (China) Medical Technology Development Co., Ltd., Tibet AIM Pharm. Inc. and Huarong Securities Co., Ltd. officially joined PhIRDA.

October 9

9 experts proposed by PhIRDA passed the review and formally became the members of IFPMA ICH Expert Working Group. Entrusted by CDE, PhIRDA recommended experts to CDE Working Group to participate in the discussion on the relevant guiding principles.

October 10

IFPMA, PhIRDA and RDPAC co-hosted the IFPMA Code Capacity Workshop Ethics & Business Integrity Training in Landmark Towers Hotel in Beijing. The meeting aimed to promote the construction and practice of codes of ethics in China’s pharmaceutical industry and optimize the market competition environment and order through organizing business ethics training based on the practical guidelines of IFPMA.

October 13

Opening Seminar on “Research of Formation Mechanism of Innovative Drug Insurance Payment Standards–Taking Japan's Experience as the Research Focus” was held in Beijing by PhIRDA.

October 28

Hosted by PhIRDA and organized by Shenyang Pharmaceutical University, the 5th National Innovative Drugs Industry-University-Research Cooperation Alliance & Medical Policy Interpretation and Scientific Achievements Promotion Conference was held in Suzhou.

October 28

PhIRDA officially became a member of APAC and was invited to attend the 7th APAC Conference held next year.

October 28

PhIRDA and Suzhou Industrial Park Management Committee reached a consensus and signed an agreement on the background, contents, significance and related supporting policies of China BioMed Innovation and Investment Conference. This event will also be held in Suzhou Industrial Park in 2018 and 2019.

October 29

2017 China BioMed Innovation and Investment Conference was co-hosted by PhIRDA, SAC, CAMDI and HKEX. Policies on encouraging pharmaceutical innovation, investment trend and innovative model and interactive influence of investment were the main topics and 9 new drugs released their latest clinical-trial data on the conference. Sun Xianze, the Vice Minister of China Food and Drug Administration (CFDA), Zeng Yixin, the Vice Minister of National Health and Family Planning Commission (NHFPC) and over 700 investment institutions, R&D institutes and pharmaceutical innovation companies, more than 2000 delegates participated in this event.

October 29

PhIRDA (China Mainland), Institute for Biotechnology and Medicine Industry (IBMI) (Chinese Taipei), HK Bio-Med Innotech Association (Hong Kong) and International Association of Quality Research in Chinese Medicine (Macao) jointly signed Cooperation Agreement on Pharmaceutical Innovation at the opening ceremony of 2017 China BioMed Innovation and Investment Conference, announcing that the four associations will play the platform advantages of folk associations to jointly promote the development and prosperity of biopharmaceutical in China.

October 29

PhIRDA and NFCR signed a MOU at the opening ceremony of the 2017 China BioMed Innovation and Investment Conference, and will jointly establish a long-term “Sino-US Cooperation Mechanism of Oncology Pharmaceutical Innovation”, and build a cooperation platform for oncology pharmaceutical innovation to promote the R&D and innovation of anti-tumor drugs.

October 29

PhIRDA hosted the Innovation Enterprise Seminar themed “Implementing the spirit of the 19th National Congress and document issued by the general office of central committee of CPC and the general office of the state council” at Jinji Lake Conference Center in Suzhou. Zeng Yixin, vice minister of NHFPC and principals of Division of Science and Education and Medical Policy Division attended this event, and listened to the instruction of specific situations of enterprises and research institutes; they expressed that they would fully absorb the advice and suggestions in the following work.

October 29

The Fourth Meeting of 10th PhIRDA General Assembly was held in Suzhou, Jiangsu Province. Leaders of SASAC, CFIE and other departments, and more than 160 representatives from 88 PhIRDA members attended this event. The meeting approved PhIRDA Annual Work Report, PhIRDA’s

Annual Financial Report for Year 2016-2017, and Proposals to Establish PhIRDA Innovative R&D Services Specialty Committee. The Proposal to Revise the Constitution of PhIRDA and Proposal to Revise the Membership Fee Standard were passed with secret ballots, and the President and Deputy President were elected for 2018-2019.

October 29

Approved at the Fourth Meeting of 10th PhIRDA General Assembly, CIC Capital Co., Ltd., Ping An Bank Company Ltd. Finance SBU of Healthcare, Culture & Tourism Industry, Tianjin Boxin Xinyuan Asset Management Co., Ltd., Biotrack Capital, Shanghai Prosperico Venture Co., Ltd., First Capital Securities Co., Ltd., RemeGen, Ltd., Genetron Health (Beijing) Co., Ltd., Luoxin Pharmaceutical Group Co., Ltd., SciClone Pharmaceuticals (Jiangsu) Inc. and LinkDoc Co., Ltd. officially joined PhIRDA.

October 29

PhIRDA invited representatives of some members to conduct the closed-door meeting with HKEX on the innovation board to be set up.

October 30-31

The 2017 China BioMed Innovation and Investment Conference held the roadshows of listed companies and non-listed companies, medical device projects, U.S. oncology drug roadshows, Taiwan company roadshows, and Australia and Canada company roadshows. Through the registration and careful selection by the Organizing Committee, a high-level platform was provided for domestic and foreign high-quality innovative enterprises and projects with high development potentiality, and the platform covered many therapeutic fields and the entire pharmaceutical industry.

October 31

Policy Forum on the 2017 China BioMed Innovation and Investment Conference was held in Suzhou. PhIRDA Executive President Song Ruilin, Yang Sheng, Deputy Director-General of Department of Drug and Cosmetics Registration of CFDA, and CDE Deputy Director Zhou Siyuan attended this event and made a keynote speech. More than 400 representatives from pharmaceutical innovation and investment field attended the Forum and listened to the detailed interpretation of policies and measures for deepening drug regulatory reform and implementing ICH guidelines by the leaders and experts of drug approval and review authorities.

October 31

Investor Experience Sharing Forum of the 2017 China BioMed Innovation and Investment Conference was held in Suzhou. Senior experts and partners of ZAI Lab, Yuanming Capital, Sequoia Capital, Hillhouse Capital, Qiming Venture Capital, GTJA Investment, Shenzhen Efung Venture Capital Co., Ltd. and other well-known investment institutes in the pharmaceutical industry were invited to attend this event, and conduct in-depth discussion on investment hot spots in healthcare industry, valuation, and relationships between investors and entrepreneurs. More than 300 representatives from pharmaceutical innovation industry and investment attended this event.